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ABSTRACT 
 
Janus kinases (JAKs) and Signal Transducer and Activators of Transcription 
(STATs) are essential for signalling in response to the Interferons (IFNs) and most 
cytokines. Aberrant activation of JAKs and/or STATs has been observed in many human 
cancer cells, and several recent studies have suggested that STAT3 oncogenic pathways 
are also associated with intrinsic drug resistance.  
Chemoresistance is a major cause of failure of cancer treatment. In lung cancer 
cells chemoresistance can be mediated by Fibroblast Growth Factor 2 (FGF-2). In small cell 
lung cancer (SCLC) cell lines FGF-2 induces the expression of anti-apoptotic proteins via a 
MEK-ERK-dependent mechanism, which involves the formation of a multi-protein 
complex constituted by B-RAF, PKCε and S6K2. We investigated the generality of this 
phenomenon by analysing additional types of cells. Since there have been reports 
suggesting that activation of JAKs and/or STATs can occur downstream of FGF-2 we 
hypothesised that JAKs and/or STATs may also play a role in FGF-2 mediated 
chemoresistance pathway(s). 
In U2OS osteosarcoma cells, FGF-2 offers protection against cisplatin-induced cell 
death. As with SCLC cells this involves B-RAF, PKCε, S6K2, MAPKs and, most notably, 
JAKs (JAK1, JAK2, or TYK2), but not the STATs. Whereas the non-small lung cancer cells 
(NSCLC) HCC95 respond to FGF-2, HCC78 do not. In neither case, however, did FGF-2 
mediate chemoresistance against cisplatin. 
Using RNA interference (RNAi), we have observed that ERK2 knockdown caused 
a concomitant reduction of STAT3 levels. The data suggest that ERK2, but not ERK1, 
levels can regulate STAT3 expression, and that ERK1 and ERK2 have non-overlapping 
functions. It also indicates that ERK2 protein levels can regulate STAT3, an important 
signal transducer and activator of transcription.  
The identification of a novel inter-play between the JAKs and MAPKs in the 
context of chemoresistance opens new avenues for treatment, which urgently warrant 
additional studies. 
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INTRODUCTION 
 
 
 
 
 
1.1. CANCER 
In many countries more than a quarter of deaths are attributable to cancer. In 
the year 2000, malignant tumours were responsible for 12 per cent of the nearly 56 
million deaths worldwide from all causes. According to the World Cancer Report the 
main cancer risk factors are tobacco consumption, infectious agents, late diagnosis in 
developing countries, and the Western lifestyle (World Health Organisation, 2003). 
Cancer control is the aim of many institutions and government policies whose main 
strategies and goals include prevention, early diagnosis and treatment. Breast cancer is 
the most prevalent type of cancer in the world (4.4 million survivors up to 5 years 
following diagnosis) (Parkin et al., 2005). Lung cancer is the most frequently diagnosed 
type of cancer (1.35 million worldwide per year) and the most common cause of death 
from cancer (1.18 million deaths worldwide per year) (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The twenty most common causes of death from cancer in the United Kingdom in 
2008. Chart obtained from the Cancer Research UK (CR UK) website (http://info.Cancerreseachuk.org 
/cancerstats/motality/cancerdeaths/). 
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In the present study, we have focused on lung cancer and aimed to understand 
some aspects of the molecular basis of the resistance to chemotherapy. Furthermore, 
we investigated these mechanisms in another type of cancer, namely bone cancer. 
 
 
 
1.1.1. CHEMOTHERAPY 
The discovery of chemotherapeutic agents began at the start of the 20th century 
with the development of models to screen chemicals that could treat cancer (reviewed 
by DeVita and Chu, 2008). Today, chemotherapy is standard clinical practice in 
conjunction with surgery and/or radiation to treat cancer patients. Successful 
treatment has been achieved in subsets of patients with a variety of tumour types such 
as lymphoma, small cell lung cancer (SCLC), ovarian cancer, and choriocarcinoma. 
Over the past decade chemotherapy has been widely used for rectal, bladder, breast, 
gastroesophageal, head and neck cancers, and sarcomas (DeVita and Chu, 2008). 
Two commonly used chemotherapeutic drugs used to treat many cancer types 
are cisplatin and etoposide. Due to their relevance for the present study their 
mechanism of action is briefly described in this section. 
Cisplatin’s primary target is DNA and it acts by inducing the formation of DNA 
adducts (Pinto and Lippard, 1985). Cisplatin’s platinum atoms form covalent bonds 
with the N7 positions of purine bases of DNA promoting the formation of DNA-
protein and/or DNA-DNA inter- and intra-strand crosslinks (Jamieson and Lippard, 
1999). The formation of these lesions activates several signal transduction pathways, 
including pathways that lead to the activation of apoptosis by mechanisms that are not 
fully understood (Siddik, 2003). For example, cisplatin was shown to be able to induce 
apoptosis by promoting the clustering of the death receptor Fas in a Fas ligand-
independent fashion on the cell surface (Micheau et al., 1999). Many cells are, however, 
resistant to Fas-induced apoptosis (e.g. O'Connell et al., 2000; Mizuno et al., 2003; Yang 
et al., 2007; Bertrand et al., 2009) and thus additional death activating pathways must be 
triggered by cisplatin. Cisplatin can also induce changes in the fluidity of cellular 
membranes (Dimanche-Boitrel et al., 2005) and, in addition, interact with the plasma 
membrane, reducing the activity of certain ion channels and transport proteins 
(Grunicke and Hofmann, 1992).  
The main target of etoposide is DNA-topoisomerase II (Bromberg et al., 2003). 
Topoisomerase II is a DNA-strand passing enzyme that is able to create a transient 
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double-strand break in a DNA molecule, allowing the ATP-dependent passage of one 
DNA strand through another (Wang, 2002). This enzyme participates in several cellular 
processes such as DNA replication and transcription by reducing DNA superhelicity 
through the removal of DNA intertwines that naturally arise from these processes. 
Topoisomerase II can resolve intertwines between two catenated DNA molecules, 
which is a prerequisite for proper chromosome segregation. Indeed, in several 
organisms, mutations or drugs that block topoisomerase II decatenating activity 
severely affect chromosome segregation as the concatamers between sister chromatids 
physically constrain their segregation (Holm et al., 1985; Uemura et al., 1987; Clarke et 
al., 1993; Gorbsky, 1994; Gimenez-Abian et al., 1995). Etoposide was shown to stabilise 
the enzyme-cleaved DNA complex that is normally a transient intermediate in the 
catalytic cycle of topoisomerase II (reviewed by Baldwin and Osheroff, 2005). The 
accumulation of these cleavage complexes is thought to induce permanent DNA 
breaks. This, in turn, can trigger programmed death pathways (Kaufmann, 1998; Li 
and Liu, 2001). The precise mechanisms of action of etoposide, however, remain to be 
fully elucidated.  
The use of cisplatin and etoposide, as well as many other chemotherapeutic 
drugs, in the clinic aims to activate, by and large, cell death pathways (apoptosis) in 
cancer cells. 
 
 
 
1.1.2. LUNG CANCER 
Lung cancer is nowadays the leading cause of cancer mortality (Jemal et al., 
2008). The main causal agent is smoking and the disease has no particular symptoms or 
signs that can allow for its detection at an early stage (Spiro and Silvestri, 2005). 
Although surgery offers the best chance of cure in lung cancer, only a small proportion 
of patients are ever suitable for curative resection and the majority must rely on non-
surgical and adjuvant therapies. Lung cancer has a median survival period of 6-12 
months from the time of diagnosis, with an overall 5-year survival rate of 5-10% (Spiro 
and Porter, 2002). The cure rate is extremely low largely because the disease readily 
metastasises and because the tumour eventually becomes resistant to available 
chemotherapy. 
Lung tumours arise from cells of the respiratory epithelium that become 
malignant. Histopathologically, lung cancer comprises two main tumour types: non-
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small cell lung cancer (NSCLC), observed in 75-80% of the cases, and SCLC, which 
comprises 20-25% of all lung cancer cases (Spiro and Porter, 2002). Although the 
incidence of NSCLC is higher, SCLC remains the most aggressive form of the lung 
cancer types, with a median survival time without treatment of 2-4 months (Ihde, 
1995). Surgical resection or radical radiotherapy is able to cure only 10% of all patients 
with NSCLC. Since SCLC is characterised by the early development of metastases, this 
type of tumour is usually unsuitable for surgical resection. The cure of many lung 
cancer patients tends, therefore, to rely on alternative approaches. Chemotherapy has 
been evaluated as neoadjuvant and adjuvant treatment around surgery, neoadjuvant 
and adjuvant upon radiotherapy, and as the primary treatment for advanced 
inoperable disease (Spiro and Porter, 2002). Standard chemotherapy for lung cancer 
consists of a combination of two or more drugs. Although etoposide and cisplatin are 
two of the most potent anti-tumour agents, cells often find a means to attenuate DNA 
damage-mediated apoptotic signals, which can result in the development of 
chemoresistance. Chemoresistance is, thus, a major limitation in the treatment of lung 
cancer patients.  
Over the last decade newer chemotherapeutic agents have emerged and 
provided slightly better survival rates in lung cancer. For patients with NSCLC 
chemotherapy offers only a modest survival improvement. Agents such as navelbine, 
gemcitabine and taxanes combined with platinum were shown to be better tolerated, 
resulting in an improved quality of life for patients with advanced NSCLC (Buter and 
Giaccone, 2005). The management of SCLC, which appeared so promising at the 
beginning of the 1970s, has advanced very little in outcome over the last 15 years. 
Indeed, SCLC remains one of the most frustrating cancers to treat (Thatcher et al., 
2005). Etoposide, cisplatin, carboplatin, cyclophosphamide, ifosfamide, doxorubicin, 
vincristine and, more recently, topotecan, irinotecan and paclitaxel are drugs that are 
being used, or have been trialled, in SCLC patients. Initial treatment of SCLC is often 
effective but patients usually relapse within a very short period of time (Fig. 2). 
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Figure 2. Relapse following successful chemotherapy in a patient with SCLC. Images from a 
positron emission tomography (PET) scan of a lung cancer patient treated with chemotherapeutic drugs. 
Pictures correspond to a latitudinal section of the chest showing the lung cavity. After treatment with 
chemotherapeutic drugs the tumour (indicated with red arrows) was substantially reduced. The patient 
relapsed just a few months after treatment. Images were courtesy of Professor Michael Seckl. 
 
 
 
 
 
Although initial chemotherapeutic treatment appears to be effective against 
lung cancer, treatment with second-line chemotherapy at relapse has a disappointing 
effect, with few responses and the almost inevitable development of resistance. 
Continued efforts to understand the biology of the disease and the mechanism by 
which tumour cells are, or become, resistant to chemotherapy are, however, driving the 
discovery of new therapies. 
Because smoking is the main casual agent of lung cancer in 80-90% of cases, the 
most important and cost-effective management for this disease is smoking cessation. 
Nevertheless, for those with the disease, unravelling chemoresistance mechanisms for 
the development of effective treatment strategies is still a priority. 
 
 
 
1.1.3. BONE CANCER 
Bone cancer is classified in different types based on its histology: osteosarcoma 
is the most frequently diagnosed primary sarcoma of bone, followed by 
chondrosarcoma, Ewing's sarcoma, chordoma and malignant fibrous histiocytoma, 
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which includes fibrosarcoma (Dorfman and Czerniak, 1995). Osteosarcoma and 
Ewing's sarcoma may arise at any age but are typically found in children and 
adolescents. Classical chondrosarcoma typically presents later in adulthood (Bielack 
and Carrle, 2008). Exposure to radiation is known to be an exogenous risk factor but 
just occurs in adults and is very rare (Longhi et al., 2003). The majority of 
osteosarcomas occur without a familial predisposition or a history of exposure to 
radiation. A number of rare inherited syndromes were linked to this type of cancer and 
indeed several genetic alterations have been found to be associated with osteosarcoma 
(Hansen, 1991). Viruses can also induce bone sarcomas in animals and humans (Finkel 
et al., 1966; Ganem, 2006). 
Osteosarcoma can develop anywhere in the skeleton, but the most common 
places are in the legs or upper arms. It is generally a highly aggressive tumour that 
metastasises primarily to the lung (Longhi et al., 2006). The application of 
chemotherapy substantially improved the 5-year survival rate that was only 10% until 
30 years ago (Bacci et al., 2000; Longhi et al., 2006; Bielack et al., 2009). Cisplatin, 
doxorubicin, methotrexate and ifosfamide are considered the most active agents 
against osteosarcoma (Bielack et al., 2004; Ta et al., 2009). Usually successful treatments 
involve the combination of two or more drugs. As for many cancers, poor response to 
chemotherapy is associated with a lower survival rate (Bacci et al., 2000). Second line 
treatments have been extremely discouraging and local or metastatic recurrences have 
poor outcomes, with overall survival rates of only 10-20% (Bielack and Carrle, 2008). 
Nowadays, at relapse, surgery is still the main option when possible. Accordingly, for 
relapsing patients new strategies must be explored. 
 
 
There are currently various different ways to treat cancer, which include 
surgery, radiotherapy, chemotherapy, hormone therapy, immunotherapy, and gene 
therapy (the latter still being the object of intense research) (Cancer Research UK, 2002). 
Chemotherapy is one of the most commonly used cancer treatments, but its success is 
largely affected by some important factors including systemic toxicity (resulting in 
unpleasant side effects), rapid drug metabolism (resulting in the reduction of drug 
action duration) and resistance, to mention just a few.  
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1.1.4. CHEMORESISTANCE 
Resistance to chemotherapeutic drugs is probably the major obstacle to the 
successful treatment of many tumour types. Chemotherapeutic agents were developed 
based on the observation that tumour cells proliferate faster than normal cells 
(Johnstone et al., 2002). Therefore, chemotherapeutic treatments used often induce cell 
cycle arrest and/or cell death through the upregulation of apoptosis, senescence 
and/or mitotic catastrophe.  
Defects in apoptotic pathways or acquired resistance to apoptosis (resistance 
that occurs as a result of an alteration, such as a mutation in the cell, which favours cell 
survival) can, however, lead to expansion of a population of tumour cells and/or 
increase the escape from surveillance by the immune system. This can ultimately lead 
to resistance to chemotherapeutic agents and treatment failure (Igney and Krammer, 
2002). Chemoresistance was initially linked to reduced drug concentrations due to the 
action of efflux pumps and to detoxifying enzymes. It is now clear that tumour cells 
also escape cytotoxic treatments by several other mechanisms including enhanced 
DNA repair activity and reprogramming of survival signalling pathways (e.g. 
O'Driscoll, 2009). It has been proposed that oncogenes may provide cancer cells with 
intrinsic resistance capacity (“natural” resistance that is inherent to a cell as a result of 
the cell’s genetic makeup) and that inhibition of apoptosis may confer cells with the 
ability to survive better in a stressful environment (Johnstone et al., 2002).  
Chemoresistance can arise through a number of different molecular 
mechanisms and, unsurprisingly, evasion from apoptosis is a prominent hallmark of 
cancer (Hanahan and Weinberg, 2000). Inappropriate control of cell death has also been 
implicated in the pathogenesis of a number of other human diseases including viral 
infections, autoimmune diseases, neurodegenerative disorders and acquired immune 
deficiency syndrome (AIDS) (Thompson, 1995). 
 
 
 
1.1.5. APOPTOSIS 
Apoptosis is a cell death mechanism that can be induced by exogenous (e.g. 
radiation and chemotherapeutic agents) and endogenous (e.g. DNA damage, oxidative 
stress, ATP deprivation) stimuli. Some apoptotic processes are actually “programmed” 
and part of normal cellular homeostasis. For this reason, apoptosis is sometimes 
referred to as programmed cell death (PCD). This process is, in fact, crucial for the 
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development, health and integrity of multicellular organisms contributing to the fine 
balance between cell proliferation and cell death, thereby allowing the maintenance of 
a constant total number of cells in the body (Kerr et al., 1972; Wyllie et al., 1980; Kerr, 
2002). It is generally accepted that the apoptotic program is the default cellular setting 
present in a latent form in virtually all the cells in the body, which must be actively 
suppressed for the cells to survive. Morphologically it is characterised by several 
cellular modifications such as membrane blebbing, cell shrinkage due to the extrusion 
of water and chromatin condensation. Intracellular events include fragmentation and 
loss of DNA content, cytoskeletal alterations and protease activation (reviewed 
by(Danial and Korsmeyer, 2004). 
PCD is a multistep process that can be initiated by many different stimuli. The 
subsequent effector phase converges into a few common pathways that inevitably lead 
to the loss of cell viability (Kroemer et al., 1995). In mammalian cells, pathways leading 
to apoptosis converge on the selective proteolytic cleavage of a particular family of 
proteins termed cysteine-aspartic acid proteases (caspases) (Earnshaw et al., 1999). 
Caspases are regulated at the post-translational level, which helps to ensure they can 
be quickly activated following an appropriate stimulus. They are found in the cytosol 
as inactive pro-enzymes that become activated upon cleavage thereby activating 
downstream effectors such as other caspases and the nuclear proteins poly(ADP-
ribose) polymerase (PARP) and lamin B, which were shown to be useful markers of 
apoptosis (Lazebnik et al., 1993; Lazebnik et al., 1994). Caspases also play key roles in 
the regulation of the immune system by virtue of being required for the maturation of 
cytokines (e.g. caspase 1) and skin development (e.g. caspase 14) (Kuida et al., 1995; Li 
et al., 1995; Denecker et al., 2008). 
 
 
 
1.1.5.1. REGULATION OF APOPTOSIS 
Mitochondria play an important role in the regulation of cell death signals, 
activating caspases and triggering other cell death events (Breckenridge and Xue, 
2004). An example of important pro-apoptotic factors released by these organelles is 
cytochrome c. The latter activates caspases through cytosolic apoptotic protease 
activating factor-1 (APAF-1) (Li et al., 1997) and second mitochondria-derived activator 
of caspase/direct inhibitor of apoptosis-binding protein with low pI 
(SMAC/DIABLO), which in turn promote caspase activation by binding to inhibitor of 
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apoptosis proteins (IAPs) and block their caspase inhibitory activity (Du et al., 2000; 
Verhagen et al., 2000). IAP family members control apoptosis by regulating the activity 
of caspases either by inducing their degradation or by directly inhibiting their 
enzymatic activity (Salvesen and Duckett, 2002; Riedl and Shi, 2004; Vaux and Silke, 
2005). The most intensively studied IAP family member, X-linked IAP (XIAP), is a 
potent inhibitor that directly blocks caspase activity (Eckelman et al., 2006). 
There are two main apoptotic pathways: the intrinsic pathway (also called the 
mitochondrial pathway as these organelles play a pivotal role in the execution of 
apoptosis) and the extrinsic pathway (also called the death receptor pathway as it is 
initiated by cross-linking of death receptors) (Green and Evan, 2002). The intrinsic 
pathway is initiated from within the cell in response to cellular signals that result from 
severe cell stress, such as DNA damage, viral infection, detachment from the 
extracellular matrix and hypoxia. It predominantly leads to the activation of caspase 9 
(Hakem et al., 1998; Jiang and Wang, 2004). The extrinsic pathway is triggered by death 
receptors, such as the tumour necrosis factor (TNF) receptor or the TNF-related 
apoptosis inducing ligand (TRAIL) receptor (reviewed by Papenfuss et al., 2008). These 
receptors contain an intracellular death domain, which can recruit and activate caspase 
8 or 10 through the adaptor protein Fas-associated death domain (FADD), and 
subsequently downstream effector caspases (Ashkenazi and Dixit, 1998; Debatin and 
Krammer, 2004). A simplified diagram of the main events involved in intrinsic and 
extrinsic pathways of apoptosis is shown in Figure 3. 
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Figure 3. Simplified diagram of the main events in the intrinsic and extrinsic apoptotic 
pathways. The extrinsic pathway of apoptosis is triggered by death receptors while the intrinsic pathway 
is initiated from within the cells in response to cellular signals resulting from severe cell stress. Both 
pathways activate initiating caspases followed by downstream activation of effector caspases to trigger cell 
death. Pro-apoptotic BCL-2 family members such BAX and BAK induce permeabilisation of the outer 
mitochondrial membrane and subsequent release of apoptotic molecules. The anti-apoptotic family 
members repress apoptosis by inhibiting pro-apoptotic proteins and the mitochondrial release of apoptotic 
molecules. (Figure adapted from Papenfuss et al., 2008). 
 
 
 
 
The B-cell leukaemia/lymphoma-2 (BCL-2) family of proteins, which reside in 
the mitochondrial membrane, regulate the permeability of the mitochondrial outer 
membrane and the release of pro-apoptotic proteins from the intermembranar space 
(reviewed by Youle and Strasser, 2008). Different family members of the BCL-2 family 
can have opposing apoptotic activities. Accordingly, BCL-2 proteins can be classified 
into three classes based on their functions and the presence of BCL-2 homology (BH) 
domains: i) the anti-apoptotic subfamily includes members such as BCL-2, BCL-2-like 1 
protein (BCL-XL) and myeloid cell leukaemia sequence 1 (MCL-1), which are 
characterised by the presence of four BH domains; ii) the pro-apoptotic subfamily 
encompasses members such as BCL-2-associated X protein (BAX) and BCL-2-
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antagonist/killer (BAK), which have three BH domains; and iii) the divergent class 
BH3-only proteins subfamily includes the pro-apoptotic proteins BCL-2-associated 
agonist of cell death (BAD) and BCL-2-interacting killer (BIK). The interplay between 
the different classes of BCL-2 family proteins is fundamental in determining the 
mitochondrial response and thus cellular outcome. Pro-apoptotic family members such 
as BAX and BAK are crucial for inducing permeabilisation of the outer mitochondrial 
membrane, and the subsequent release of apoptotic molecules (Wei et al., 2001; Zong et 
al., 2001). The anti-apoptotic family members such as BCL-2, BCL-XL and MCL-1 
repress apoptosis by inhibiting BAX, BAK and/or BH3-only proteins (e.g. Gross et al., 
1999; Cheng et al., 2001). Activation of BCL-2 proteins can occur by different 
mechanisms, which include i) phosphorylation: for example, BAD is activated by loss 
of phosphorylation in response to growth factor deprivation (Zha et al., 1996); ii) 
proteolysis: for example, BID is activated by caspase 8-mediated cleavage (Li et al., 
1998; Luo et al., 1998); or iii) regulation of their expression levels: as examples, BCL-XL 
can be transcriptionally, or translationally induced by growth factors (Grad et al., 2000; 
Pardo et al., 2002), and MCL-1 is rapidly degraded by the ubiquitin–proteasome 
pathway in response to death stimuli (Cuconati et al., 2003; Zhong et al., 2005). 
 
 
 
1.1.5.2. APOPTOSIS AND CANCER 
Every cell in a multicellular organism has the potential to die by apoptosis, but 
tumour cells often use alternative pathways that allow them to escape death. 
Modifications of apoptotic pathways can not only lead to an increase in tumour 
volume, but also have the potential to confer resistance to therapy (Igney and 
Krammer, 2002). For example, mutations and over-expression of anti-apoptotic BCL-2 
family members has been shown to contribute to tumour progression and to increase 
resistance to chemotherapeutic drugs. Not surprisingly, such molecular alterations 
have been identified in numerous types of cancer (Ayhan et al., 1994; Coustan-Smith et 
al., 1996; Kaiser et al., 1996; Krajewska et al., 1996; Gobe et al., 2002). Because cancer cells 
often exhibit a dependency on particular pathways for survival through an active 
process previously described as “oncogene addiction” (Sharma et al., 2006), the 
identification of oncogenes and a more detailed understanding of the mechanisms 
involved in cancer cells’ intrinsic resistance capacity is crucial to develop more effective 
cancer therapies.  
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1.2. THE MAIN SIGNALLING PATHWAYS OF CANCER 
A number of pathways have been reported to be involved in determining life 
and death at the cellular level by regulating components of the apoptotic machinery. 
Oncogenic signalling pathways such as the ras viral oncogene homolog (RAS)/ raf 
murine leukaemia viral oncogene homolog (RAF)/ mitogen-activated protein kinase 
kinase (MEK)/ extracellular regulated kinase (ERK) pathway, the phosphoinositide 3-
kinase (PI3K)/ phosphatase and tensin homologue deleted on chromosome 10 
(PTEN)/ protein kinase B (PKB)/ mammalian target of rapamycin (mTOR) pathway 
and janus kinase (JAK)/ signal transducer and activators of transcription (STAT) 
pathway have been studied in great detail (Bowman et al., 2000; Bromberg and Darnell, 
2000; Hanahan and Weinberg, 2000; Ballif and Blenis, 2001; Cantley et al., 2002; Vivanco 
et al., 2002; Yu and Jove, 2004; Steelman et al., 2008). As these pathways are particularly 
relevant to this study they will be described in some detail below. 
 
 
 
1.2.1. THE RAS/RAF/MEK/ERK SIGNALLING PATHWAY 
The RAS/RAF/MEK/ERK signalling pathway is an evolutionarily highly 
conserved pathway that can control several fundamental cellular processes, such as 
proliferation, differentiation, survival and apoptosis (reviewed by Kolch, 2000; Ballif 
and Blenis, 2001). This pathway can be activated by many stimuli and can have distinct 
biological outcomes depending on a variety of factors that determine the environment 
in which the signal is generated and received (e.g. concentration of molecules involved; 
negative feedback mechanisms; particular mutations). Spatial distribution and kinetics 
of ERK activation are, in fact, critical to the cellular outcome of RAS/RAF/MEK/ERK 
pathway (Murphy and Blenis, 2006). 
RAS proteins are small GTPases that function as molecular switches controlling 
the signals from cell surface receptors to a panel of intracellular cascades. Upon ligand 
binding (e.g. growth factors, or cytokines), membrane-bound RAS is activated by the 
exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) by 
guanine nucleotide-exchange factors (GEFs). This results in a conformational change 
that reveals an effector interaction site (Omerovic and Prior, 2009). RAS-GTP recruits 
RAF to the plasma membrane where it becomes phosphorylated on tyrosine residues 
by membrane-bound or receptor-associated tyrosine kinases (Marais et al., 1995). RAF 
is a multigene kinase family that comprises A-RAF, B-RAF and C-RAF (Chong et al., 
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2003). These three proteins play distinct functions (Hagemann and Rapp, 1999; 
Wellbrock et al., 2004). Knockout mice showed that the three proteins have non-
redundant roles in development. Thus, a-raf-/- animals are viable but the mice die 7-21 
days after birth due to neurological and gastrointestinal defects (Pritchard et al., 1996). 
In contrast, b-raf-/- and c-raf-/- embryos die, the first due to growth retardation, and 
vascular and neuronal defects and the second due to massive liver apoptosis 
(Wojnowski et al., 1997; Wojnowski et al., 1998; Mikula et al., 2001). RAF proteins are 
composed of three conserved regions (Fig. 4): CR1 that contains a RAS binding domain 
(RBD) and a cysteine-rich domain (CRD); CR2, which can be phosphorylated and 
serves as a regulatory domain controlling the localisation and activation of RAF; and 
CR3, the catalytic kinase domain that is also regulated by phosphorylation (Morrison et 
al., 1993; Vojtek et al., 1993; Nassar et al., 1995; Morrison and Cutler, 1997; Cutler et al., 
1998; Zhang and Guan, 2000; Chong et al., 2001).  
Regulation of RAF kinases is a complex process involving membrane 
recruitment, dimerisation or oligomerisation, interactions with other proteins, 
conformational changes, and phosphorylation of regulatory and catalytic domains of 
the protein (Chong et al., 2003). The three RAF isoforms have different repertoires of 
phosphorylation sites (Fig. 4) and the phosphorylation of different sites results in 
differences in their regulation (reviewed by Wellbrock et al., 2004). Phosphorylation 
residues are conserved in A-RAF and C-RAF, and these two proteins are activated by 
similar mechanisms (Marais et al., 1997). B-RAF shares some phosphorylation sites 
with the other two members but has unique features. In the negative-charge regulatory 
region (N-region), located in the CR2 domain, B-RAF has a constitutively 
phosphorylated serine (highlighted with a yellow star in Figure 4) and an aspartic acid 
instead of a tyrosine residue (highlighted with a blue box in Figure 4) (Mason et al., 
1996; Brummer et al., 2006). This latter residue confers a constant negative charge in the 
N-region and thus B-RAF has an elevated basal kinase activity compared to other RAF 
isoforms. Although B-RAF has a conformation typical of active kinases, an interaction 
between a glycine-rich loop and the activation segment displaces the activation 
segment (Wan et al., 2004). The phosphorylated threonine and serine residues required 
for B-RAF activation are located in this segment (Zhang et al., 2000).  
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Figure 4. Structural organisation of RAF proteins. Three conserved regions are shared by RAF 
family members: the CR1 (yellow) that contains a RAS-binding domain (RBD) and a cysteine-rich domain 
(CRD), the CR2 (orange) that contains a negative-charge regulatory region (N-region) and the CR3 (red) 
that contains an activation segment (purple). Known phosphorylated sites – tyrosine (Y), serine (S), 
threonine (T) and aspartic acid (D) – are indicated. The serine in the N-region is conserved among 
isoforms but is constitutively phosphorylated in B-RAF (highlighted with a yellow star). In the same 
region, the tyrosine identified in A-RAF and C-RAF is replaced by an aspartic acid in B-RAF (highlighted 
with a blue box). (Figure adapted from Wellbrock et al., 2004). 
 
 
 
 
The activation of RAF leads to the phosphorylation of MEK on two serine 
residues (Seger et al., 1992; Alessi et al., 1994; Papin et al., 1995; Schaeffer and Weber, 
1999; Kolch, 2000). B-RAF was shown to be the RAF family member that more 
efficiently phosphorylated MEK (Papin et al., 1996; Marais et al., 1997) and it was 
therefore proposed to be its main activator (Wellbrock et al., 2004). The expression of an 
inducible form of B-RAF promoted a more rapid and robust activity of both MEK and 
ERK than did the equivalent C-RAF and A-RAF forms (Pritchard et al., 1995). In 
addition, ERK activation can fully occur in mouse embryonic fibroblasts (MEFs) from 
mice that lack a-raf and c-raf (Mikula et al., 2001; Huser et al., 2001; Mercer et al., 2002), 
whereas the same cell type from b-raf-null mice have compromised ERK activity 
(Wojnowski et al., 2000). 
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Activated MEK phosphorylates ERK1 and ERK2 on specific threonine and 
tyrosine residues within their activation segments (Boulton et al., 1991). ERK1/2 are 
serine/threonine kinases that have 83% homology with most differences being 
mapped to the kinase domains (Chen et al., 2001). Although they are activated by the 
same upstream kinases, display identical kinetics of action and seem to have the same 
substrate specificities (Yoon and Seger, 2006), some studies suggest that ERK1 and 2 
have critical functional differences that result in non-overlapping functions. For 
example, mutation of the erk2 gene in mice causes early embryonic lethality (Saba-El-
Leil et al., 2003), while erk1-/- mice are viable and reproduce normally, presenting only 
minor defects such as a deficit in thymocyte maturation (Pages et al., 1999). It has been 
suggested that erk2 can compensate for most of the functions of erk1, but the 
contrasting phenotypes seem to indicate that the two kinases also have distinct 
functions (Aouadi et al., 2006). Interestingly, significant differences between the two erk 
proteins were found in the control of cell proliferation. While the silencing of erk1 
facilitated cell growth, silencing of erk2 caused severe cell-proliferation deficits as 
demonstrated in MEF cells, liver cancer cell lines and murine hepatocytes (Vantaggiato 
et al., 2006; Bessard et al., 2008; Fremin et al., 2009). 
Once activated, ERK1/2, which are also called mitogen-activated protein 
kinases (MAPKs), can phosphorylate numerous substrates in all cellular compartments 
including phospholipases, transcription factors, cytoskeletal proteins and protein 
kinases termed MAPK-activated protein kinases (MKs). MKs include, for example, 
ribosomal S6 kinases (RSKs) and mitogen- and stress-activated kinases (MSKs) 
(reviewed by Roux and Blenis, 2004). Upon stimulation a significant population of 
ERK1/2 accumulates in the nucleus (Khokhlatchev et al., 1998; Lenormand et al., 1998). 
It has been demonstrated that ERKs continuously shuttle between the cytoplasm and 
the nucleus depending on their activation status (Ando et al., 2004; Costa et al., 2006; 
Fujioka et al., 2006). The maintenance of a pool of nuclear active kinases therefore 
requires continuous activation of the MEK pathway (Costa et al., 2006). ERK1 shuttling 
through the nuclear membrane was found to be slower than ERK2, which was caused 
by the presence of a unique region located at the N-terminal (residues 8-39) of ERK1 
(Marchi et al., 2008). This difference may explain some of the putative non-redundant 
roles of ERK1 and ERK2. 
In the nucleus, activated ERKs can control transcription at several levels by 
phosphorylating transcription factors. These transcription factors, once activated, bind 
to the promoters of many genes required for cell growth and survival and/or initiate 
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chromatin modifications along inducible genes thereby modulating the transcriptional 
response (Edmunds and Mahadevan, 2004).  
The RAS/RAF/MEK/ERK pathway is tightly regulated through the 
coordinated action of positive and negative regulators. Activation and deactivation of 
this signal transduction cascade is regulated by kinases as well as phosphatases. These 
act at different levels of the signalling cascade, at different times and on different 
cellular compartments. For example, the regulation of RAF proteins activation is 
tightly controlled by phosphorylation and dephosphorylation events. The 
phosphorylation of the residues Ser259 (within the CR2 domain) and Ser621 (within the 
CR3 domain) of C-RAF provides docking sites for 14-3-3 proteins, which regulate its 
activation through complex mechanisms (Morrison et al., 1993; Muslin et al., 1996). It 
was proposed that 14-3-3 dimers can maintain C-RAF in a inactive conformation 
(binding to both Ser621 and Ser259), as well as stabilise an active form upon stimulation 
(binding to Ser621) (Tzivion et al., 1998; Hekman et al., 2004). Accordingly, the 
phosphorylation of Ser259 of C-RAF was shown to inhibit C-RAF activation (Morrison et 
al., 1993; Dhilon et al., 2002; Kubicek et al., 2002), while the phosphorylation of Ser621 
seems to be essential for its activation (Tzivion et al., 1998; Hekman et al., 2004). In 
addition, inactivation of C-RAF can also be mediated by protein phosphatase 5 (PP5) 
that selectively dephosphorylates the essential activating residue Ser338 (within the N-
region) (von Kriegsheim et al., 2006). Adaptor/scaffold proteins have an important role 
in modulating the RAS/RAF/MEK/ERK pathway (Kolch, 2000). Scaffold proteins 
interact with components of the pathway, stabilising and coordinating interactions 
between them thus increasing the efficiency and fidelity of signal transduction 
(Morrison and Davis, 2003; Pouyssegur et al., 2003). One example of such a scaffold 
protein is the kinase suppressor of RAS (KSR) that coordinates the assembly of MEK 
with C-RAF at the plasma membrane, and then recruits ERK to be subsequently 
phosphorylated by MEK (Morrison, 2001).  
Deregulated RAS/RAF/MEK/ERK signalling has been associated with many 
human cancers (Hoshino et al., 1999). In particular, oncogenic mutations in RAS and 
RAF were identified in a significant percentage of cancers. These mutations are 
believed to contribute to tumourigenesis and cell growth (Bos, 1989; Davies et al., 2002). 
B-RAF in particular was found mutated in a wide range of human cancers, including 
66% of malignant melanomas and in a smaller percentage of lung cancers (3%) and 
sarcomas (9%) (Davies et al., 2002). Over 45 mutations have been identified in B-RAF 
and, most importantly, the mutation of the residue 599 (V599E) has been found to 
account for over 90% of B-RAF mutations and approximately 86% of all mutations in 
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cancer (reviewed by Garnett and Marais, 2004). In addition, the RAS/RAF/MEK/ERK 
pathway is absolutely required for the control of cell survival as it modulates the 
activity of many proteins involved in apoptosis, including BCL-2 family members and 
caspases (Chang et al., 2003; Troppmair and Rapp, 2003). For example, ERKs can 
phosphorylate MCL-1 on a threonine residue located at its proline, glutamic acid, 
serine and threonine (PEST) sequence, a sequence that confers proteins a signal for 
degradation. This then results in slower turnover of this anti-apoptotic protein, which 
is normally rapidly degraded (Domina et al., 2004).  
 
 
 
1.2.2. THE PI3K/PTEN/PKB/MTOR SIGNALLING PATHWAY 
The PI3K/PTEN/PKB/mTOR signalling pathway also plays a central role in 
the control of cell growth, proliferation and survival and is therefore involved in the 
pathology of cancer and other disorders including metabolic, inflammatory and 
cardiovascular diseases (Wymann et al., 2003). 
Multiple forms of PI3Ks were identified in higher eukaryotes and these are 
classified into three classes (I-III) according to their sequence homology and substrates 
(Wymann and Pirola, 1998). In response to growth factors and hormones, class Ia 
PI3Ks phosphorylate plasma membrane-located phosphatidylinositol lipids at the 3-D 
position of the inositol ring converting phosphatidylinositol bisphosphate (PIP2) into 
phosphatidylinositol triphosphate (PIP3) (Hawkins et al., 1992). PIP3 provides an 
anchor for the assembly of signalling proteins with pleckstrin-homology (PH) domains 
such as PKB, phosphoinositide-dependent kinase-1 (PDK1) and phospholipase Cγ 
(PLC-γ) amongst others (Wymann and Pirola, 1998; Cantley, 2002). The PH domains 
specifically bind to D-3 phosphorylated phosphoinositides. PIP3 levels are tightly 
regulated in unstimulated cells by phosphatases such as PTEN (Maehama and Dixon, 
1998). Loss of the tumour suppressor PTEN protein or function contributes to 
uncontrolled signalling though PI3K and leads to increased cell survival (Maehama 
and Dixon, 1999).  
Proteins containing a PH domain are located in the cytoplasm of unstimulated 
cells and when PIP2 is converted into PIP3 they are recruited to the plasma membrane. 
This brings PKB and PDK1 into proximity and promotes the phosphorylation of a 
threonine residue (Thr308) of PKB by PDK1 (Alessi et al., 1997; Lawlor and Alessi, 2001). 
The phosphorylation of a serine residue (Ser473) by another kinase has also been shown 
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to be required for the full activation of PKB (Alessi et al., 1996). PKB, also called AKT, is 
a member of a multigene family that, following activation by PI3K, can activate 
numerous downstream targets and exert a wide range of cellular functions (Kandel 
and Hay, 1999). Most known protein targets of PKB are inhibited by phosphorylation 
(Cantley, 2002). One such example is the phosphorylation of the pro-apoptotic protein 
BAD. BAD phosphorylation creates a binding site for the evolutionary conserved 
inhibitory proteins 14-3-3, which prevent BAD from binding to anti-apoptotic BCL-2 
family members (Datta et al., 1997; del Peso et al., 1997). 
Activation of PKB has been postulated to phosphorylate over 9000 proteins and 
plays an important role in cellular metabolic control, proliferation and growth (Lawlor 
and Alessi, 2001; Hay, 2005; Manning and Cantley, 2007). PKB can transduce anti-
apoptotic signals via activation of mTOR and ribosomal protein kinases such as p70 S6 
kinase (S6K) (e.g. Mahalingam and Templeton, 1996; Jonassen et al., 2004; Edinger and 
Thompson, 2004). mTOR belongs to the family of phosphatidyl inositol kinase-like 
proteins, a group of serine/threonine kinases involved in cellular growth and survival, 
and also in cancer (reviewed by Hay, 2005; Sabatini, 2006). mTOR nucleates two 
distinct multi-protein complexes. When mTOR associates with the regulatory-
associated protein of mTOR (Raptor) it forms a rapamycin- and nutrient-sensitive 
multiprotein complex [mTOR complex (mTORC) 1] and when it associates with the 
rapamycin-insensitive companion of mTOR (Rictor) it forms a growth-factor-sensitive 
but nutrient-insensitive complex (the mTORC2) (reviewed by Guertin and Sabatini, 
2007). These two complexes also include other proteins that regulate their function. 
Activated PKB can induce the activation of mTORC1 contributing to cell growth and 
proliferation (Laplante and Sabatini, 2009). PKB activates mTORC1 by catalysing the 
phosphorylation (which leads to the inhibition) of proteins such as tuberous sclerosis 
complex (TSC) 2 and proline-rich AKT substrate 40 kDa (PRAS40) that are components 
of the complex and suppressors of its function (Inoki et al., 2002; Potter et al., 2002; 
Sankat et al., 2007; Vander Harr et al., 2007; Wang et al., 2007a). mTOR when associated 
to mTORC2 was shown to be the kinase that directly phosphorylated PKB Ser473 
residue contributing for its full activation (Sarbassov et al., 2005). Activated mTOR can 
catalyse the phosphorylation of many other downstream targets including S6Ks 
(Isotani et al., 1999).  
Two S6K proteins were identified, α and β (S6K1/2), which share 
approximately 70% of homology in their protein sequences (Gout et al., 1998; Shima et 
al., 1998; Koh et al., 1999; Lee-Fruman et al., 1999). These proteins show a conserved 
domain structure consisting of four main regions: an acidic N-terminal, a catalytic 
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domain, a linker domain and an auto-inhibitory C-terminal domain (reviewed by 
Jastrzebski et al., 2007) (Fig. 5). Both S6K genes code for two isoforms resulting from 
alternative splicing at the N-terminal, giving rise to the p70 and p85 isoforms of S6K1 
and to the p54 and p60 isoforms of S6K2 (Reinhard et al., 1992). The longer isoforms of 
S6K1/2 have a N-terminal extension that includes a nuclear localisation sequence 
(NLS) (Reinhard et al., 1994; Minami et al., 2001). The shorter S6K2 isoform can also 
localise to the nucleus due to the presence of an additional NLS in its C-terminal 
regions (Gout et al., 1998; Lee-Fruman et al., 1999). S6K2 is also distinguished by a 
proline-rich domain, which is not present in S6K1 (Gout et al., 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Structural organisation of S6K proteins. The domain structure of S6K1 and S6K2 is 
depicted in the figure. S6K main domains include a N-terminal (N-term) domain (dark grey), a catalytic 
domain (yellow), a linker domain (blue) and a C-terminal (C-Term) domain (light grey). Key activating 
phosphorylation sites – serine (S) and threonine (T) – are indicated. Pro-rich – Proline rich domain, NLS – 
nuclear localisation sequence. (Figure adapted from Jastrzebski et al., 2007). 
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Both S6K1/2 can phosphorylate the 40S ribosomal S6 protein thereby 
promoting an increase of mRNA translation and protein synthesis, which are necessary 
for growth and proliferation (Dufner and Thomas, 1999). Despite their high homology 
and apparent similar substrate specificity for S6, several lines of evidence indicate that 
S6K1 and S6K2 have distinct biological roles. Indeed, knockout mice studies showed 
that s6k1-null mice are small (Shima et al., 1998), whereas s6k2-null mice have no 
obvious phenotype (Pende et al., 2004). Some mechanisms of regulation of S6K1 and 
S6K2 activity are highly conserved (Martin et al., 2001a; Phin et al., 2003). S6Ks are 
regulated in a complex manner involving sequential phosphorylation at multiple sites 
(reviewed by Jastrzebski et al., 2007). Activation of S6K1 requires an initial calcium-
dependent priming event that releases the interaction between the autoinhibitory C-
terminal and the N-terminal domains exposing four sites (Ser411, Ser418, Tyr421 and 
Ser424), which are then phosphorylated by mTOR (Isotani et al., 1999; Hannan et al., 
2003). This allows the phosphorylation of two residues in the linker domain by mTOR 
and one residue on the catalytic domain by PDK1 resulting in maximal activation of 
S6K1 (Alessi et al., 1998; Burnett et al., 1998; Pullen et al., 1998; Isotani et al., 1999). S6K1 
and S6K2 were also shown to have some distinct substrates and functions. For 
example, S6K1 (but not S6K2) phosphorylates S6K1 Aly/REF-like target (SKAR) 
(Richardson et al., 2004), which contribute for an increase of translation efficiency of 
spliced mRNA (Ma et al., 2008). In addition, in SCLC cells, S6K2 was shown to play a 
central role unshared by S6K1 in promoting cell survival and contributing for 
chemoresistance (Pardo et al., 2006). 
S6Ks are mainly regulated by the PI3K pathway but RAS/RAF/MEK/ERK 
signalling can also contribute to their regulation. Activation of S6K1 was shown to 
occur downstream of RAS in the absence of PKB activation thought the activation of 
RSK1 that phosphorylates TSC1, inhibiting its ability to suppress mTOR signalling 
(Roux et al., 2004). S6K2, but not S6K1, was also shown to be a downstream target of 
MEK signalling as MEK inhibitors impaired its activity (Martin et al., 2001b; Pardo et 
al., 2001; Wang et al., 2001).  
PI3K-induced cell survival is mainly mediated by its downstream effector PKB. 
Amplification of the gene encoding for PKB have been reported in many cancers 
including ovarian, breast and pancreatic (e.g. Bellacosa et al., 1995; Cheng et al., 1996). 
PKB can block apoptosis by phosphorylating BAD, as previously mentioned, or for 
example, by inducing the phosphorylation of caspase 9, which inhibits its activity 
(Cardone et al., 1998). PKB has also been shown to be involved in RAS-mediated 
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inhibition of apoptosis (Khwaja et al., 1997) and linked to an increased expression of the 
anti-apoptotic protein BCL-2 (Ahmed et al., 1997). 
The PI3K/PTEN/PKB/mTOR pathway is unique in that all of the major 
elements of the pathway have been found mutated, or amplified, in many cancers 
(reviewed by Yuan and Cantley, 2008). Indeed, over-activation of oncogenes, such 
PI3K and PKB, or the loss of tumour suppressors, such PTEN are known to contribute 
to oncogenic transformation (Aoki et al., 1998; Salmena et al., 2008). 
PI3K targets also include protein kinases C (PKCs) (Toker and Cantley, 1997). 
Due to their relevance to the present study, the structure and function of PKCs will be 
described in detail next. 
 
 
 
1.2.2.1. PKCS 
PKC represents a family of serine/threonine kinases that transduce signals 
triggered by various growth factors, cytokines and hormones. They are classified based 
on the structural motifs that determine their requirements for activation. They are thus 
divided into three subfamilies that are structurally and functionally different: classic 
PKCs (PKCα, PKCβI, PKCβII, PKCγ), novel PKCs (PKCδ, PKCε, PKCη, PKCµ, PKCθ), 
and atypical PKCs (PKCζ, PKCι/λ) (reviewed by Parker and Murray-Rust, 2004). 
PKCα, δ and ε are widely expressed, whereas expression of the other PKCs is largely 
cell-type specific. 
PKCs are constituted by four conserved domains (Fig. 6): the C1 domain 
includes one or two cysteine-rich motifs that form a binding site for diacylglycerol 
(DAG) and phorbol esters (compounds that are analogues of the endogenous ligand); 
the C2 domain contains a calcium binding site; and the C3 and C4 domains form the 
catalytic domain with ATP and substrate binding sites (Mackay and Twelves, 2007). 
Classical PKCs can be activated by calcium, DAG and phorbol esters, whereas novel 
PKCs can only be activated by DAG and phorbol esters as they lack a calcium binding 
site. Atypical PKCs are insensitive to both calcium and DAG (Parker and Murray-Rust, 
2004). 
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Figure 6. Structural organisation of PKC proteins. Four conserved regions (CR1-4) are shared by 
PKC family members. The C1 domain (green) includes one or two cysteine-rich motifs that constitute a 
binding site for diacylglycerol (DAG) and phorbol esters. The C2 domain (blue) contains a calcium binding 
site. The C3 (red) and C4 (yellow) domains bind ATP and substrate thereby providing catalytic activity to 
these enzymes. (Figure adapted from Mackay and Twelves, 2007).  
 
 
 
 
 
Activation of classical and novel PKCs typically involves their recruitment and 
interaction with DAG. This interaction induces a conformational change that exposes 
binding sites for substrates and scaffolding proteins (Parekh et al., 2000; Newton, 2003). 
In the case of classical PKCs, binding of calcium increases the rate of translocation to 
the plasma membrane where they bind DAG (Schaefer et al., 2001). PKC activation, 
maturation and stability require the phosphorylation of both serine and threonine 
motifs. For example, activation of PKCε involves the phosphorylation of the residues 
Thr566, located within the activation loop of the kinase domain and Ser729, located in the 
C-terminal (Parekh et al., 1999; Cenni et al., 2002). The phosphorylation of the threonine 
residue within the activation loop appears to be required for optimum activity (Parekh 
et al., 2000) and is catalysed by PDK-1 through a mechanism similar to that leading to 
PKB activation previously described (Chou et al., 1998; Le Good et al., 1998). 
Phosphorylation of residues within the C-terminal loop is critical for stabilising the 
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kinase core, as it locks this domain in an active conformation (Newton, 2003). In this 
open conformation, mature PKC binds to substrates and triggers downstream 
signalling events. Upon stimulation, PKCs can redistribute to the nuclear membrane or 
to organelles such as the mitochondria or the Golgi apparatus (Wang et al., 1999; 
Garcia-Bermejo et al., 2002). Their location is determined by scaffold proteins and also 
by information intrinsic to individual isoforms (such as the presence of NLS) (Parker 
and Murray-Rust, 2004). Interaction with other proteins not only regulates PKC 
localisation but also brings it into closer contact with substrate proteins, thereby 
determining appropriate specificity of action of the different family members (Jaken 
and Parker, 2000). 
PKC isoforms have been shown to regulate a broad range of biological 
functions including cell growth, differentiation and apoptosis (Dempsey et al., 2000). 
Different isoforms can play opposing roles. For example, PKCε mediates cell survival 
in many cell types and it achieves this by different mechanisms, which can involve the 
activation of PKB (Lu et al., 2006) or be independent of the PI3K pathway (Pardo et al., 
2002). In accordance with this, the silencing of PKCε was shown to induce apoptosis of 
glioma cells and to sensitise melanoma cells to TRAIL-induced apoptosis in melanoma 
cells (Gillespie et al., 2005; Okhrimenko et al., 2005). In contrast, PKCδ responds to 
many apoptotic stimuli that induce its translocation to the mitochondria, leading to the 
release of cytochrome c and caspase activation (Li et al., 1999; Majumder et al., 2000; 
Denning et al., 2002). Atypical PKCs (PKCι and PKCζ), for example, were found to be 
involved in the activation of S6K1, playing an important role in cell cycle progression 
(Akimoto et al., 1998; Romanelli et al., 1999). 
PKCs have also been implicated in drug resistance, as well as in invasion and 
metastasis of many types of cancer cells (reviewed by(Griner and Kazanietz, 2007; 
Mackay and Twelves, 2007). Increased PKC expression has been, in fact, linked to 
chemoresistance in various cell types, including ovarian and lung cancer cells (Basu 
and Weixel, 1995; Ding et al., 2002). In particular, PKCε was shown to mediate 
prosurvival/chemoresistance in NSCLC cells by preventing the activation of caspase 9 
and 3, and mitochondrial cytochrome c release (Ding et al., 2002). 
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1.2.3. THE JAK/STAT SIGNALLING PATHWAY 
One of the most studied and best understood signalling pathways are those 
involving JAKs and STATs (Murray, 2007). JAK/STAT signalling pathways are 
universal and essential to cytokine receptor signalling. About 40 cytokine receptors 
signal through combinations of four JAKs and seven STAT family members. These 
operate in the regulation of expression of many genes that control fundamental 
biological processes in cells, including cell proliferation, apoptosis, angiogenesis and 
immune responses and, therefore, play crucial roles in the biology of most organisms 
(Stark et al., 1998).  
 
 
 
1.2.3.1. BIOLOGICAL ROLE OF JAKS AND STATS  
Evolutionarily conserved in eukaryotic organisms, JAK/STAT signalling 
pathways appear to be an early adaptation used to facilitate intercellular 
communication. These pathways may have co-evolved to give rise to highly adapted, 
ligand-specific signalling pathways that are able to control gene expression (Aaronson 
and Horvath, 2002). The evolutionary expansion of JAKs in higher animals is thought 
to have occurred concurrently with the evolution of innate and adaptive immune cells 
in fish, which is consistent with the multiple roles that these proteins now have in 
immune cells (Yamaoka et al., 2004). Chromosomal distribution and homologues in 
model eukaryotes suggest that the STAT family arose from a single primordial gene as 
the need for cell-to-cell communication increased (Kisseleva et al., 2002). JAK/STAT 
signalling pathways are activated and regulated by an infinite number of intrinsic and 
environmental stimuli, and this can add great plasticity (and presumably speed) to the 
response of a cell or tissue to any given cue.  
 
 
 
1.2.3.1.1. THE JAKS 
The four known mammalian family members, JAK1, JAK2, JAK3 and tyrosine 
kinase 2 (TYK2), are ubiquitously expressed with the exception of JAK3, which is 
preferentially expressed in leukocytes (reviewed by Schindler and Plumlee, 2008). 
These kinases feature seven conserved domains, termed JAK homology domains (JH) 
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1-7 (Fig. 7), where only one has catalytic activity (JH1). JH2, a pseudo kinase domain, is 
devoid of catalytic activity but critically regulates the activity of the kinase domain (c.f. 
Section 1.2.3.3) (Chen et al., 2000; Saharinen et al., 2000; Yeh et al., 2000). JAKs also have 
a predicted SRC-homology (SH) 2-related domain. In JAK1, this domain does not 
perform the classical SH2 function of binding specific motifs containing a 
phosphorylated tyrosine residue, as it was shown to be structurally important for 
binding to the oncostatin M receptor (OSMR) and efficient OSMR surface expression 
(Radtke et al., 2005). In the N-terminal region, JAKs have a four-point-one, ezrin, 
radixin and moesin (FERM) domain that is crucial for the association of JAKs with 
membrane-proximal receptor motifs (Hilkens et al., 2001; Zhou et al., 2001). As with 
other kinases, JAK activation is driven by the phosphorylation of critical tyrosine 
residues, which releases the blockade of the catalytic site (reviewed by Rane and 
Reddy, 2000; Heinrich et al., 2003; Schindler and Plumlee, 2008). Phosphorylation 
within the activation loop is predicted to disrupt the interaction between JH1 and JH2, 
consequently relieving the JH2 domain inhibition of JAK’s kinase activity (Saharinen et 
al., 2003). The phosphorylated tyrosines are adjacent to each other (residues 1022/1023 
in human JAK1, 1007/1008 in human JAK2, 980/981 in human JAK3, and 1054/1055 in 
human TYK2) and are often referred to as the pYY motif (Gauzzi et al., 1996; Feng et al., 
1997; Liu et al., 1997; Zhou et al., 1997). The first of these tyrosine residues was shown to 
be absolutely required for the catalytic function of JAKs (Liu et al., 1997; Feng et al., 
1997; Zhou et al., 1997). Unlike what is observed for the other JAKs, the 
phosphorylation of JAK3 pYY motif can have opposing effects on the regulation of its 
catalytic activity: the phosphorylation of Tyr980 has a positive effect on kinase activity 
while the phosphorylation of Tyr981 negatively regulates it (Zhou et al., 1997). Besides 
these two, many other tyrosine residues that play a role in JAKs regulation were 
identified (e.g. JAK2 has 49 tyrosine residues but functions have not yet been attributed 
to all of them). These additional tyrosine residues are both positive and negative 
regulators of JAK function. For example, the phosphorylation of Tyr221 increases the 
kinase activity of murine jak2, while the phosphorylation of Tyr570, located in the 
inhibitory JH2 domain, inhibits jak2-mediated cytokine signalling (Argetsinger et al., 
2004; Feener et al., 2004). The phosphorylation of JAK2 Tyr972 was also shown to play a 
role in the stabilisation of an active conformation necessary for its maximal function 
(McDoom et al., 2008). Importantly, the phosphorylation of particular JAK residues was 
shown to provide binding sites for other signalling molecules necessary for particular 
biological functions mediated by the JAKs. As an example, JAK2 Tyr201 was shown to 
be required for the interaction of JAK2 and SHP-2, an important tyrosine protein 
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phosphatase (Godeny et al., 2007). The Tyr813 of JAK2 and the correspondent Tyr785 of 
JAK3, located within the pseudokinase domain, were identified as 
autophosphorylation sites required to create a binding site for the SH2 domain-
containing adapter protein SH2B-β that, in the case of JAK2, increases JAK2-mediated 
phosphorylation of STAT5B (Kurzer et al., 2004). 
JAKs play a critical role in many biological responses. jak1 and jak2 are essential 
genes as jak1 knockout mice die perinatally due to a failure to nurse (Rodig et al., 1998) 
and jak2 knockout mice exhibit earlier lethality, presumably because of the critical role 
that jak2 plays in erythropoiesis (Neubauer et al., 1998; Parganas et al., 1998). jak3 and 
tyk2 knockout mice survive but have defective cytokine responses. jak3 knockout mice 
exhibit severe combined immunodeficiency (SCID)-like defects (Nosaka et al., 1995; 
Park et al., 1995; Thomis et al., 1995). JAK3 mutations were also identified in patients 
with autosomal SCID (Russel et al., 1995; Macchi et al., 1995). TYK2-deficient humans 
exhibit a severe allergic phenotype that has been attributed to an impaired anti-
microbial response (Minegishi et al., 2006). In addition, mutations in JAKs are often 
found in patients with haematological diseases, which are described in Section 1.2.3.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Structural organisation of JAK and STAT proteins. JAKs comprise seven conserved JAK 
homology domains (JH1-7) that form four main regions: the four-point-one, ezrin, radixin and moesin 
(FERM) domain (green), the potential SRC homology 2 (SH2) domain (yellow), and the pseudo kinase 
(orange) and tyrosine kinase domains (red). STATs are composed by seven conserved domains: the N-
terminal (NH2) domain (dark grey), a coiled-coil domain (dark blue), a DNA binding domain (DBD) 
(green), a linker domain (light blue), a SH2 domain (yellow), a tyrosine activation motif (purple) and a 
transcriptional activation domain (TAD) (light grey). Relevant phosphorylation sites – tyrosine (Y) and 
serine (S) – are indicated. (Figure adapted from Heinrich et al., 2003; Schindler and Plumlee, 2008).  
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1.2.3.1.2. THE STATS 
STATs are a family of latent cytoplasmic proteins that are activated by several 
stimuli, which include interferons (IFNs), most cytokines and a number of growth 
factors. In mammalian cells, seven members have been identified, namely STAT1, 
STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6 (Levy and Darnell, 2002). 
Different STATs are activated by a distinct set of cytokines and growth factors and are, 
therefore, implicated in different gene expression programmes (Horvath, 2000).  
STATs share seven structurally and functionally conserved domains (Fig. 7): 
the well conserved N-terminal domain promotes the formation of unphosphorylated 
STAT homotypic dimers; the coiled-coil domain consists of a potentially dynamic four-
helix bundle that protrudes laterally from the core and not only associates with 
regulatory proteins but is also implicated in controlling the process of nuclear import 
and export; the well conserved DNA binding domain (DBD) mediates binding to 
gamma IFN-activated site (GAS) elements and is also involved in the regulation of 
nuclear import and export; the linker domain structurally translates active 
dimerisation to the DNA binding motif and regulates a process of continual basal 
nuclear export; the highly conserved SH2 domain mediates specific recruitment to the 
receptor chains, as well as the formation of active STAT dimers; the tyrosine activation 
motif that, along with 5–7 specific C-terminal amino acids is exposed on the surface of 
the inactive homodimer, facilitating its JAK-dependent phosphorylation during 
receptor recruitment; and the transcriptional activation domain (TAD), which is 
located at the C-terminal and is highly variable in length and sequence between 
different STAT family members (reviewed by(Schindler and Plumlee, 2008). 
STAT activity is predominantly regulated by post-translational modifications 
(PTMs) (reviewed by Levy and Darnell, 2002). Activation of STATs involves the 
phosphorylation of a single tyrosine located at the carboxyl end of the molecule (Fig. 
7). The phosphorylation of this residue induces a conformational change that promotes 
the formation of STAT dimers via reciprocal phosphotyrosine and SH2 domain 
interactions (Chen et al., 1998; Becker et al., 1998). The dimer conformation gives STATs 
the ability to recognise specific DNA promoters of target genes. The phosphorylation 
of a serine residue located within the C-terminal (Fig. 7) was also shown to be required 
for maximal activation of transcription of STATs (Wen et al., 1995; Varinou et al., 2003). 
STATs can carry out distinct functions. STAT1 plays a fundamental role in the 
biological response to type I (IFNα subtypes and IFNβ) and type II (IFNγ) IFNs 
(Durbin et al., 1996; Meraz et al., 1996) and it induces, by and large, the transcription of 
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target genes associated with the suppression of cellular proliferation (Schindler et al., 
2007) and the regulation of different types of immune responses. In marked contrast, 
STAT3 mediates the transcription of genes that are involved in proliferative and both 
anti- and pro-inflammatory responses. STAT3 plays an important role in transducing 
signals elicited by members of the interleukin (IL)-6 and IL-10 families, granulocyte 
colony-stimulating factor (G-CSF), leptin, IL-21 and IL-27 (reviewed by Schindler and 
Plumlee, 2008). stat3 is an essential gene as stat3 knockout mice exhibit an early 
embryonic lethal phenotype (Takeda et al., 1997). Constitutive activation of STAT3 can 
prevent cell cycle arrest and apoptosis, and it has been associated with immune 
suppression and transformation (e.g. Catlett-Falcone et al., 1999; Kujawski et al., 2008; 
Bollrath et al., 2009; Grivennikov et al., 2009). Therefore, STAT3 has been reported to be 
a proto-oncogene (Bromberg and Darnell, 2000) and the encoded protein has been 
shown to be constitutively phosphorylated in a variety of tumours. STAT1, on the 
other hand, can play a key role in promoting apoptosis and/or inducing an anti-
proliferative effect in a variety of cell types (Stephanou and Latchman, 2005). 
Paradoxically, it can also play a role in tumour development and drug resistance, 
depending on cellular context (Kovacic et al., 2006; Patterson et al., 2006). STAT5 has 
two highly homologous isoforms, STAT5A and STAT5B that derive from closely linked 
genes and play a critical role in driving both erythropoiesis and lymphopoiesis (Yao et 
al., 2006). STAT5 mediates the signalling response of members of the IL-3, single-chain 
and γC receptor families (Schindler et al., 2000; Murray, 2007). Like STAT3, STAT5 was 
also shown to play an important role in the inhibition of apoptosis (Onishi et al., 1998). 
STAT4 and STAT6 play more restricted and specific roles in lymphocyte function. 
STAT4 is implicated in IL-12- and IL-23-dependent polarisation of naïve CD4+ T-cells 
and activation of IFN-γ secretion by natural killer (NK) cells (TH1 response). STAT6 
plays a critical role in driving IL-4/IL-13 dependent T helper (TH)2-cell polarisation 
(TH2 response); B-cell function and mast cell activity (Wurster et al., 2000). STAT2 is the 
most divergent STAT in sequence and function (Park et al., 2000). It responds 
exclusively to type I and type III (IFNλ) IFNs and it thus operates primarily in immune 
responses. 
The vast range of functions played by different STATs and, in some cases by the 
same STAT depending on the stimuli, demonstrates the intricate nature of the cellular 
and molecular regulation of these proteins. 
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1.2.3.2. JAK/STAT ACTIVATION AND SIGNALLING  
JAK/STAT signalling pathway(s) can be activated by diverse stimuli. Ligand 
binding to cytokine receptors (e.g. IFN and IL receptors) triggers a change in their 
conformation that promotes sequential phosphorylation events (reviewed by(Levy and 
Darnell, 2002). Unlike many growth factor receptors that have intrinsic tyrosine kinase 
activity, cytokine receptors do not. Instead, the required tyrosine kinase activity is 
provided by receptor-associated cytoplasmic proteins, which are often members of the 
JAK and v-src sarcoma viral oncogene homolog (SRC) family kinases. These are 
usually non-covalently bound to the membrane-proximal region of the cytokine 
receptors via their FERM domains (Chen et al., 1997; Gauzzi et al., 1997; Yamaoka et al., 
2004). Receptors with intrinsic tyrosine kinase activity, such as the epidermal growth 
factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR), can 
directly phosphorylate STAT proteins thereby bypassing JAK activation (Bowman et 
al., 2000; Levy and Darnell, 2002). Furthermore, G protein-coupled receptors (GPCR) 
can also activate the JAK/STAT pathway (Mellado et al., 1998; Wong and Fish, 1998; 
Vila-Coro et al., 1999). 
The JAK/STAT signalling canonical pathway is relatively simple, with only a 
few main components being required for the response (reviewed by Rawlings et al., 
2004). In fact, depending on the stimuli, the receptor-associated JAK can process the 
signal or, following receptor oligomerisation, other JAKs can be recruited to it. Homo- 
or heterodimerisation of JAKs is followed by their activation resulting in the 
propagation of the initial signal (reviewed by Rane and Redi, 2000). Rapid 
phosphorylation and activation of JAKs has been observed in response to many 
cytokines and growth factors (Novak et al., 1995; Leaman et al., 1996; Vignais et al., 
1996; Gual et al., 1998). For example, IFNγ-induced activation of JAK1 and JAK2 was 
observed within a few minutes of treatment (Silvennoinen et al., 1993a; Silvennoinen et 
al., 1993b; Watling et al., 1993; Muller et al., 1993). JAK activation occurs through 
reciprocal interaction and trans-phosphorylation on tyrosine residues within the kinase 
activation loop (pYY motif). Several cytokine receptor complexes contain at least two 
different JAKs and receptor aggregation and transphosphorylation are both important 
for the activation of the JAKs in response to ligand. For example, IL-2 cannot activate 
JAK1 in the absence of JAK3 (Oakes et al., 1996) and IFN-γ cannot activate JAK1 
without JAK2, which was shown to be the initiating kinase of the cascade (Watling et 
al., 1993).  
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Activated JAKs phosphorylate the receptor tail, which provides docking sites 
for the SH2 domain of STAT proteins. The STAT proteins are recruited to the receptor, 
whereupon they become phosphorylated on a single tyrosine located at the carboxyl 
end of the molecule around the residue 700 (cf. Fig. 7). This enables them to form 
homo- or heterodimers, which leads to the formation of a dimer-specific NLS that 
permits the subsequent translocation into the nucleus (Meyer et al., 2002).  
Nuclear import of activated STATs occurs through the nuclear pore after the 
binding of STAT dimers’ NLS to specific importins (for example, STAT1 binds to 
importin α5 and β1, and STAT3 binds to importin α3 or α6 and β1) (Reich and Liu, 
2006). All STATs can form homodimers and STAT1 can form heterodimers with STAT2 
or with STAT3 depending on the nature of the stimuli (Levi and Darnell, 2002). For 
example, IL-6 stimulation induces the formation of STAT1 and STAT3 homodimers, as 
well as STAT1:STAT3 heterodimers and the different dimers bind to different DNA 
sequences thus activating distinct sets of genes (Guschin et al., 1995). The dimer 
conformation gives STATs the ability to recognise different specific DNA promoters of 
target genes. 
The initial dogma that inactive STATs are present in the cytoplasm as 
monomers that only dimerise upon tyrosine phosphorylation has been replaced by the 
understanding that unphosphorylated (and presumably inactive) STATs can also exist 
as dimers, or in higher order complexes, in the cytoplasm (Ndubuisi et al., 1999; Wenta 
et al., 2008). Unphosphorylated STAT dimers interact through different domains (N-
terminal and core domains) and these interactions are weaker than the interactions that 
occur between phosphorylated STAT dimers (Mao et al., 2005).  
Initial reports suggested that mutations that prevent phosphorylation of the C-
terminal key tyrosine residue, or mutations on the SH2 domain that prevent 
dimerisation, also prevent STAT translocation to the nucleus, showing that these 
events are critical for the nuclear import of STATs (Shuai et al., 1993, Shuai et al., 1994). 
Although STAT nuclear accumulation is triggered by dimerisation in response to 
tyrosine phosphorylation, the phosphorylation of this residue per se is not required for 
nuclear translocation, as “artificially” dimerised unphosphorylated STATs can also 
accumulate in the nucleus (Milocco et al., 1999). In fact, unphosphorylated STATs have 
been found in the nucleus (McBride et al., 2000). Unphosphorylated STATs can shuttle 
between the cytoplasm and nucleus in a constitutive manner (Vinkemeier, 2004) 
raising questions regarding their nuclear import, as monomeric STATs do not possess 
a canonical NLS.  
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Several authors have shown that unphosphorylated forms of STAT1, STAT3 
and STAT6 are able to transcriptionally activate target genes, although these are 
distinctive from those activated upon stimulation with cytokines or growth factors 
(Chatterjee-Kishore et al., 2000; Yang et al., 2005; Cui et al., 2007). Unphosphorylated 
STAT1 supports the constitutive transcription of the low molecular mass polypeptide 2 
(LMP2), a protein involved in the processing of viral and tumour antigens for 
presentation in the context of major histocompatibility complex (MHC) class I 
molecules (Chatterjee-Kishore et al., 2000). Importantly, over-expression of 
unphosphorylated STAT3 was shown to promote the expression of oncogenes such as 
muscle RAS oncogene homolog (MRAS), found elevated in many cancers and which is 
believed to contribute to cellular transformation and differentiation (Yang et al., 2005). 
Unphosphorylated STAT6 can directly bind to the cyclooxygenase-2 (COX-2) 
promoter, a protein that catalyses the production of prostaglandins, which are 
involved in inflammation and are often found over-expressed in tumours (Cui et al., 
2007). In Drosophila melanogaster, unphosphorylated STATs can associate with 
transcriptionally repressed heterochromatin thereby maintaining its stability (Brown 
and Zeidler, 2008).  
As mentioned above, following dimerisation, STATs quickly accumulate in the 
nucleus where they bind to specific promoter elements of target genes and regulate 
transcription (e.g. Pranada et al., 2004; Vinkemeier, 2004; Meyer et al., 2007) (Fig. 8). 
STATs can both activate and repress gene expression. One example of negative 
regulation of transcription is the inhibition of c-myc expression in response to IFN-γ, 
which induces binding of STAT1 homodimers to consensus GAS elements in the c-myc 
promoter. This leads to the inhibition of cell proliferation (Ramana et al., 2000). It is 
widely accepted that STATs mostly regulate transcription positively (Der et al., 1998). 
For example, cyclin D1 is upregulated in response to prolactin through the binding of 
STAT5 to GAS sites in the cyclin D1 promoter in mammary epithelial cells (Brockman et 
al., 2002) and also following IL-6 stimulation of most cells as a consequence of STAT3 
binding to the cyclin D1 promoter on v-Sis inducible elements (SIE) sites. 
Consequently, as cyclin D1 participates in the transition from G1 to S phase of the cell 
cycle, this results in enhanced proliferation (reviewed by Fu et al., 2004). 
Phosphorylation of a serine residue located within the C-terminal of most 
STATs (Fig. 6) was also shown to be required for STAT maximal activation of 
transcription (Wen et al., 1995). Phosphorylation of STAT1 Ser727 was shown to occur 
when the protein is assembled on transcriptional complexes bound to chromatin 
(Sadzak et al., 2008). Importantly, phosphorylation of this serine residue in response to 
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IFN-γ is dependent on the previous phosphorylation of Tyr701 (Kovarik et al., 2001). 
Other PTMs are known to regulate STAT transcriptional activity (Levy and Darnell, 
2002). These will be presented in the next section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Mechanisms of STAT signalling. Activation of STATs can occur in response to cytokine 
stimulation of their receptors through JAKs or through receptors with intrinsic tyrosine kinase activity. 
Latent STAT proteins are recruited to the activated receptors and phosphorylated at a tyrosine residue. 
Activated STATs translocate into the cell nucleus where they can bind to specific promoter elements of 
target genes. Grey arrows indicate direct activation. Dashed arrows indicate indirect activation. The dotted 
curved arrow indicates translocation. (Figure adapted from(Levy and Darnell, 2002). 
 
 
 
 
 
In addition to their function as transcription factors, there is some evidence that 
STATs also have nontranscriptional roles. STAT3 can affect cell motility through its 
direct interaction with components of the central machinery for cell motility (reviewed 
by Gao and Bromberg, 2006). For example, activated STAT3 was found to directly bind 
components of focal adhesions, such as focal adhesion kinase (FAK) and paxillin and 
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was thus proposed to have an adaptor or a sensor role in mediating cell motility (Silver 
et al., 2004). Furthermore, JAK2/STAT3 may play a role in the phosphorylation of these 
components of focal adhesions (Gao et al., 2009). Another novel, non-canonical, 
function of STAT3 was recently revealed. STAT3 was found localised in the 
mitochondria and was demonstrated to regulate metabolic functions (Gough et al., 
2009). The accumulation of STAT3 in these organelles supported RAS-dependent 
malignant transformation, which was associated with sustained altered glycolytic and 
oxidative phosphorylation activities, two known properties of cancer cells. 
Although STATs are the main transcription factors through which the JAKs 
commonly exert their effects, some responses can be mediated by the JAKs 
independently of STAT activation. For example, JAK2 can mediate the up-regulation of 
BCL-XL in response to erythropoietin (Epo) in cells expressing an Epo receptor 
defective in activation of the STAT pathway (Packham et al., 1998). In addition, JAK3 
was reported to be involved in the regulation of members of the BCL-2 family in stat5-
null mice (Wen et al., 2001). Recently, a completely novel role for JAKs was identified in 
haematopoietic cells (Dawson et al., 2009). JAK2 was found in the nucleus where it was 
shown to mediate phosphorylation of histone H3 and to prevent its association with 
heterochromatin protein 1 (HP1), suggesting that JAK2 is able to regulate chromatin 
architecture around specific promoters. An example of a JAK-regulated gene identified 
by theses authors is LIM domain only 2 (LMO2). Interestingly, LMO2 is an important 
regulator of transcription in erythropoiesis. It was initially discovered in association 
with a chromosomal translocation, and consequently aberrantly expressed, and was 
shown to play a key role in leukaemia’s aetiology (Nam and Rabbitts, 2006). 
 
 
 
1.2.3.3. REGULATION OF JAK/STAT SIGNALLING PATHWAYS 
JAK/STAT signalling pathways, albeit being able to do so, do not usually 
function autonomously. Rather they cross-talk with many other signalling pathways, 
such as p38 MAPK (Goh et al., 1999), calcium/calmodulin kinase II (CamKII) (Nair et 
al., 2002), PI3K (Nguyen et al., 2001) and PKCδ (Deb et al., 2003). These kinases can 
phosphorylate STATs on particular serine residues within the TAD domain on a 
conserved PMSP motif (cf. Fig. 7). This additional phosphorylation event increases the 
transcriptional activation potential of STATs and it is necessary for the transcription of 
particular subsets of genes (Decker and Kovarik, 2000). Similarly, it is possible that 
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additional unrecognised phosphorylation sites, or other PTMs, may also regulate STAT 
activity (Levy and Darnell, 2002). Indeed, STAT1 has been shown to be methylated on 
Arg31 which was shown to increase its transcriptional activity (Mowen et al., 2001) and, 
although this finding is somewhat controversial, it is still plausible that methylation 
may regulate STAT activity (Meissner et al., 2004; Komyod et al., 2005). 
Lysine acetylation has also been reported in STAT1, STAT3 and STAT6. 
Acetylation of STAT1 residues Lys410 and Lys413 was shown to be required for 
interaction with the anti-apoptotic nuclear factor of kappa light polypeptide gene 
enhancer in B-cells (NF-κB), reducing its DNA binding, nuclear localisation and target 
gene expression (Kramer et al., 2006). Acetylation of STAT1 is, however, a controversial 
issue after two other groups, leaders in the JAK/STAT field (D. Levy and U. 
Vinkemeier Groups), have disputed the validity of these results (A. Costa-Pereira, 
personal communication). In contrast, acetylation of STAT3 Lys685 (within the TAD 
domain) was shown to be required for STAT3-mediated NF-κB processing (processing 
of pro-apoptotic p100 into the anti-apoptotic p52 form) and consequently for cell 
proliferation and survival (Nadiminty et al., 2006). Acetylation of STAT3 also improves 
the homodimer stability and increases its DNA binding ability (Wang et al., 2005; Yuan 
et al., 2005). Acetylation of STAT6 was shown to enhance its transcriptional activity 
(Shankaranarayanan et al., 2001). 
Additionally, STATs are known to interact with proteins that serve as bridges 
between transcription factors and RNA polymerase II. STATs can interact with 
members of the evolutionarily conserved eukaryotic minichromosome maintenance 
(MCM) family (Zhang et al., 1998). The same group showed that STAT1 and MCM 
proteins are recruited to STAT1 target genes promoters in response to cytokines and, 
furthermore, that they move along the chromatin with RNA polymerase II during 
transcription elongation (Snyder et al., 2005). As another example, IFN-α induces the 
activity of the IFN-stimulated gene factor 3 (ISGF3) transcription complex that is 
composed of a STAT1:STAT2 heterodimer and a weak DNA-binding protein, IFN-
regulatory factor (IRF)-9 (Horvath et al., 1996). IRF-9 binds to STAT1 through a region 
within the coiled-coil domain (residues 153-239). In response to the same type of IFN, 
STAT2 can directly bind transcription adaptors such as p300 and CREB-binding 
protein (CBP) (Bhattacharya et al., 1996). 
The duration and degree of gene activation are, unsurprisingly, under strict 
regulation by a series of negative regulators (reviewed by(Greenhalgh and Hilton, 
2001; Schindler and Plumlee, 2008). Negative regulation of JAK/STAT pathways can 
occur by receptor internalisation to endocytic vesicles and subsequent receptor 
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degradation, and/or by more specific inhibitory signals that lead to the activation of 
protein tyrosine phosphatases (Aaronson and Horvath, 2002). Protein phosphatases 
can act at the level of the membrane-associated receptor-kinase complex or in the 
nucleus, by dephosphorylating activated STAT dimers and promoting the recycling of 
latent STAT monomers to the cytoplasm. Other regulatory mechanisms involving the 
suppressors of cytokine signalling (SOCS) and protein inhibitors of activated STATs 
(PIAS) also exist. SOCS inactivate JAKs and STATs by a number of different 
mechanisms (Krebs and Hilton, 2001). Expression of SOCS genes can be stimulated by 
the same cytokines that enhance STAT activation and, therefore, SOCS proteins can act 
in classic feedback inhibition loops. PIAS bind to phosphorylated STAT dimers, 
thereby preventing DNA recognition (Shuai, 2000). Importantly, the steady-state and 
signal-inducible concentrations of all positive and negative regulators determine the 
intensity and duration of the signal (and thus the cellular response). This is both cell-
type and cell context-dependent.  
 
 
 
1.2.3.4. JAKS AND STATS IN TUMOUR CELL PROLIFERATION AND 
APOPTOSIS 
JAKs, whose activity is generally required for STAT activation, play critical 
roles in the pathogenesis of various diseases (reviewed by(Verma et al., 2003). Janus 
kinases have been shown to modulate activation of other pathways implicated in 
malignant transformation and cell growth, such as RAS/RAF/MEK/ERK pathways 
(Kumar et al., 1994; Mizuguchi et al., 2000). Malignant transformation by oncogenes, 
such as v-abl, which involves activation of STATs, RAS and PI3K signalling pathways, 
was also shown to be mediated by JAKs (Danial and Rothman, 2000). JAKs have been 
implicated in the regulation of p53-dependent cell cycle arrest and apoptosis (Quelle et 
al., 1998). Moreover, JAKs are able to promote cell survival through enhanced activity 
of BCL-2 family members thereby modulating apoptosis.  JAKs can also mediate the 
upregulation of anti-apoptotic proteins via STAT-independent pathways (Packham et 
al., 1998; Wen et al., 2001). For example, BCL-XL can be transcriptionally induced by 
growth factors, in a JAK/STAT-dependent fashion, to promote cell survival (Grad et 
al., 2000). For example, STAT5 can bind to the BCL-XL gene promoter and regulate its 
expression in response to IL-3 (Dumon et al., 1999). This strongly supports a role for 
STAT5 in the suppression of apoptosis elicited by cytokines. 
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A small number of JAK mutations were found in cancer (Constantinescu et al., 
2008). A unique somatic mutation in JAK2 was initially identified in patients with 
myeloproliferative disorders (MPDs) (Baxter et al., 2005; James et al., 2005; Levine et al., 
2005; Kralovics et al., 2005; Zhao et al., 2005). The gain-of-function mutation of a valine 
to a phenylalanine in the regulatory pseudo-kinase domain (residue 617) (Saharinen et 
al., 2003), leads to JAK2 constitutive activation and cytokine-independent signalling. 
The now well known valine mutation has also been found in JAK1 (V658F) and TYK2 
(V678F) (Staerk et al., 2005). The equivalent residue was also found mutated in JAK3, 
but in JAK3 the valine has been substituted with an isoleucine instead of a 
phenylalanine (V715I) (Jeong et al., 2008). JAK2 mutations, other that the V617F 
substitution, were identified in the kinase and pseudo-kinase domains in acute 
lymphoblastic leukemia (ALL) patients (Mullighan et al., 2009). Other JAK1 mutations 
were also identified in other types of acute leukemias, lung, colon and breast 
carcinomas (Lin et al., 2005; Jeong et al., 2008; Kim et al., 2009; Mullighan et al., 2009). 
JAK3 mutations have been identified in some leukaemia patients (Walters et al., 2006), 
and in patients with breast and gastric carcinomas (Jeong et al., 2008). Constitutively 
activated JAK3 has been reported in several lymphoproliferative disorders (Gee et al., 
2001; Yared et al., 2005; Lai et al., 2005; Tomita et al., 2006; Krejsgaard et al., 2006; Marzec 
et al., 2008). In addition, mutant JAK3 alleles were identified in acute myeloid leukemia 
(AML) patients, which resulted in the constitutive activation of JAK3 and a spectrum of 
downstream pathways that included STAT5, the PI3K/AKT pathway and the 
RAS/MEK/ERK pathway (Walters et al., 2006).  
Chromosomal translocations that fuse the catalytic domain of JAK2 to other 
molecules have been identified: one involves the oligomerisation domain of ETS 
translocation variant 6 (TEL), a gene encoding a member of the E26 transformation-
specific (ETS) transcription factor family, and is thus called TEL-JAK2 (Lacronique et 
al., 1997; Peeters et al., 1997); another translocation juxtapositions JAK2 to the coiled-coil 
dimerisation domain of breakpoint cluster region (BCR) gene (Griesinger et al., 2005) 
and is denoted BCR-JAK2; and another, the PCM1-JAK2, links JAK2 to the human 
autoantigen pericentriolar material (PCM1) (Reiter et al., 2005). These gene products, 
which all result in the constitutive activation of JAK2, were initially identified in 
leukaemia. 
As STATs are involved in regulating the expression of many genes that in 
normal cells control fundamental biological processes, aberrant activation of STAT-
mediated signalling can lead to cell transformation and oncogenesis (reviewed by(Yu 
and Jove, 2004). Not surprisingly, constitutive activation of several STATs has been 
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observed in a wide variety of tumours, including blood malignancies (leukaemia, 
lymphoma, multiple myeloma) and solid neoplasias (lung, head and neck, brain, 
breast, pancreas, and prostate cancers) (Buettner et al., 2002; Song et al., 2003). 
As previously mentioned (Section 1.2.3.1.2), STAT3 mediates cell cycle 
progression and prevents apoptosis and thus has an important function in the growth 
and survival of tumour cells (e.g. Catlett-Falcone et al., 1999; Kujawski et al., 2008; 
Bollrath et al., 2009; Grivennikov et al., 2009). Constitutive STAT3 activity has been 
attributed to diverse causes such as autocrine or paracrine loops of IL-6 (in myeloma, 
prostate and in lung cancer cells), transforming growth factor-β (TGF-β), EGFR (in 
some head and neck cancer cell lines) and hepatocyte growth factor (HGF) signalling in 
cooperation with SRC kinase (in leiomyosarcoma cells and breast carcinoma cells). SRC 
family kinases are, in fact, thought to induce constitutive STAT3 activation, which is 
often observed in many breast cancer, melanoma and lung cancer cell lines (reviewed 
by(Yu and Jove, 2004).  
STAT5 was also found to be deregulated in cancer and to promote cell 
proliferation (Onishi et al., 1998), particularly in leukaemias (Lewis and Ward, 2008). 
Importantly, the anti-apoptotic BCL-2 family member BCL-XL is a STAT5 target gene 
(Dumon et al., 1999; Silva et al., 1999; Socolovsky et al., 1999). Deregulated STAT5 
signalling induced by the TEL–JAK mutation has been shown to promote oncogenesis 
in a number of myelo- and lymphoproliferative diseases (Schwaller et al., 2000). 
Another oncogenic fusion protein, BCR-ABL, known as the Philadelphia chromosome 
translocation that is commonly associated with chronic myeloid leukemia (CML), has 
been shown to activate STAT5 and STAT1, thereby promoting cell survival and 
transformation of hematopoietic cells (Carlesso et al., 1996; Frank and Varticovski, 1996; 
Ilaria and Van Etten, 1996; Shuai et al., 1996; Chai et al., 1997). Activation of STAT5 was, 
in fact, shown to be essential for BCR-ABL-mediated cell transformation (de Groot et 
al., 1999; Nieborowska-Skorska et al., 1999).  
STAT2, STAT4 and STAT6 roles in oncogenesis are not as evident as those of 
STAT3 or STAT5. In breast cancer cells, STAT6 was shown to mediate IL-4-mediated 
growth inhibition and induction of apoptosis (Gooch et al., 2002). In primary B cells, 
however, it can mediate upregulation of BCL-XL in response to IL-4 and block 
apoptosis (Wurster et al., 2002). Furthermore, STAT6 signalling was implicated in 
tumour immunosurveillance (Terabe et al., 2000) and was shown to play a role in the 
regulation of cell proliferation and apoptosis in colon cancer cells (Zhang et al., 2006). 
Interestingly, STAT2-mediated signalling was shown to play a critical role in 
inflammatory responses in carcinogenesis (Clifford et al., 2003; Maher et al., 2008). 
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Most reports in the past have attributed pro-apoptotic and anti-proliferative 
properties to STAT1. It seemed, therefore, unlikely that STAT1 could promote tumour 
cell growth (Bromberg and Darnell, 2000). Indeed, there is a compelling body of 
evidence suggesting that STAT1 has properties of a bona fide tumour suppressor 
protein (Dunn et al., 2004). More recent findings, however, as previously mentioned, 
show that, under a particular set of circumstances, STAT1 can also play a role in the 
development of tumours and in mediating drug resistance (Kovacic et al., 2006; 
Patterson et al., 2006). Clearly, the cellular context in which any given set of proteins 
operates strongly determines the outcome of the response.  
Interestingly, contrary to the JAKs, no study has identified to date any 
mutations in STATs and it has thus been postulated that their constitutive activation is 
due to auto- and paracrine signalling (Constantinescu et al., 2008). 
 
 
 
1.2.3.5. TARGETING JAK/STAT PATHWAYS FOR CANCER TREATMENT 
An ideal target for cancer therapy should have amongst its properties that of 
being over-activated in a large percentage of cells in different tumour types and 
inducing gene expression patterns that determine malignant properties, such as cell 
survival and proliferation, tumour angiogenesis and immune evasion. Good 
therapeutic targets should also be susceptible to specific inhibition by drugs and, very 
importantly, tumour cells should be more dependent on the activity of the target than 
normal cells. On the basis of these criteria, and despite not being mutated in cancer 
cells, STAT proteins have been suggested as key molecular targets for cancer therapy 
(Yu and Jove, 2004). Indeed, the central role that JAK/STAT pathways play in 
transducing signals downstream of many cytokine receptors and a number of growth 
factors, and their clear involvement in oncogenesis, makes them attractive targets for 
drug development (Boudny and Kovarik, 2002; Verma et al., 2003; Yu and Jove, 2004).  
Many oncogenic signalling pathways seem to converge on a limited set of 
nuclear transcription factors (Hahn and Weinberg, 2002) and these transcription factors 
can be seen as key ‘switches’ that activate gene expression patterns that may ultimately 
lead to malignancy. Such properties make transcription factors logical choices as anti-
cancer targets (Darnell, 2002). Targeting a single transcription factor, such as STATs 
(which are both cytosolic and nuclear), can potentially block the effects of a multitude 
of signalling pathways. In fact, blocking STAT signalling is often sufficient to induce 
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growth arrest and apoptosis in many different tumour types  (reviewed by(Yu and 
Jove, 2004). Importantly, several studies have shown that blocking constitutively 
activated STAT3 signalling leads to apoptosis of tumour but not normal cells (Bowman 
et al., 2000; Battle and Frank, 2002; Buettner et al., 2002). This selective inhibition might 
reflect an irreversible dependence of tumour cells on high levels of activated STAT3 for 
growth and survival, whereas normal cells might be able to withstand low STAT3 
activity or use alternative pathways (reviewed by(Yu and Jove, 2004).  
At present, while a number of JAK inhibitors have been developed, just a few 
have been used in the clinic due to issues related to low potency, off-target effects and 
drug toxicity (reviewed by Wilks, 2008). This may be related to the scarcity in the 
information available regarding JAKs molecular structures. The crystal structures of 
the kinase domain (JH1) of JAK2 and JAK3 have already been resolved (Boggon et al., 
2005; Lucet et al., 2006), but no structure has been solved for the JAK pseudokinase 
domain, a domain that has a particularly important role in maintaining the inactive 
state of the kinase (Saharinen and Silvennoinen, 2002). Treatments with some JAK 
inhibitors, currently being tested in the clinic, are showing promising results in the 
treatment of disorders associated with JAK deregulation, such as MPDs (e.g. 
Pardanani, 2008). Accordingly, more information regarding JAK structure will allow 
better predictions for the development of more potent and likely selective JAK 
inhibitors, hopefully with reduced toxicity for the patients (Wilks, 2008). 
Constitutive activation of oncogenic STAT3 can be blocked using JAK 
pharmacological inhibitors, which have been shown to suppress, for example, the 
growth of human prostate cancer cells (Ni et al., 2000). Therefore, STAT3 seems to 
assemble a number of properties that make it a particularly well-suited target for 
cancer therapy. However, the inhibition of STAT3 can also have undesirable 
consequences. For example, it was shown that in the absence of STAT3, IL-6 can 
mediate an IFN-γ-like response, including the prolonged activation of STAT1 and the 
induction of multiple IFN-γ–stimulatable genes (ISGγ) (Costa-Pereira et al., 2002). Since 
in many cancers, including lung cancer, IL-6 is often found at elevated levels in 
patients’ serum (Yanagawa et al., 1995; Eickelberg et al., 1999; Yeh et al., 2006) the 
inhibition of STAT3 could lead to an inflammatory response with potentially adverse 
clinical outcomes. Accordingly, caution is necessary before one can safely use 
signalling inhibitors of STAT3 in the treatment of patients and more work is required 
before this can become part of routine clinical practice (Turkson et al., 2001; 
Karamouzis et al., 2007). 
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1.3. FIBROBLAST GROWTH FACTORS (FGFS), FGF RECEPTORS (FGFRS) AND 
CANCER  
Growth factors and their receptors play a critical physiological role in cellular 
growth and differentiation. In cancer, growth factor-induced pathways that mediate 
normal cellular functions are frequently deregulated leading to malignancy (e.g. 
Aaronson, 1991). Fibroblast growth factor (FGF) signalling pathways have been the 
subject of intense investigation not only because of their role in tissue patterning and 
organogenesis during embryogenesis, but also because of their important role in 
tumour development (Powers et al., 2000).  
 Most FGFs are secreted into the extracellular environment and work as 
paracrine factors, but some FGFs can also function in an autocrine manner. Autocrine 
FGF signalling seems to be particularly important for the progression of some cancers 
(reviewed by(Beenken and Mohammadi, 2009). 
The FGF family consists of a number of small polypeptide growth factors that 
have certain structural characteristics in common, most of which have a high affinity 
for heparin and heparan-like glycosaminoglycans (HLGAGs) (Burgess and Maciag, 
1989). There are at least 18 identified mammalian fibroblast growth factors (FGF-1-10 
and FGF-16-23) that are classified into 6 subfamilies according to phylogeny (Itoh and 
Ornitz, 2004).  
FGFs exert their effects by signalling via a set of high-affinity cell surface 
receptors, the FGF receptors (FGFRs 1-4) encoded by four genes (reviewed by 
Mohammadi et al., 2005). They are composed of three extracellular immunoglobulin-
like domains (D1–D3), a single-pass transmembrane domain and a cytoplasmic 
tyrosine kinase domain (Fig. 9). Between the domains D1 and D2, FGFRs have an 
acidic, serine-rich sequence (acid box) (Lee et al., 1989). The D1 domain and the acid 
box were shown to be dispensable for ligand binding and affinity, but play an 
autoregulatory role in FGFR function (Wang et al., 1995a). It was proposed that the acid 
box serves as a flexible hinge that allows the D1 domain to interact with the other 
domains D2 and D3, affecting FGFR’s affinity for the ligand and heparin. The 
immunoglobulin-like domains D2 and D3 constitute the ligand-binding domain (Wang 
et al., 1995b). 
Several FGFR isoforms exist, which are generated by the alternative splicing of 
FGFR1, FGFR2 and FGFR3 coding genes, and have different ligand-binding capacities 
and tissue distributions. Alternative splicing can involve the domain D1 and the acid 
box determining whether these domains are included in the receptors (Johnson et al., 
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1990). Another alternative splicing event occurs in the D3 domain where two 
alternative exons (exons 8 and 9) are spliced in a mutually exclusive manner, giving 
rise to the FGFR isoforms IIIb and IIIc (highlighted in green in Fig. 9) (Johnson et al., 
1991; Avivi et al., 1993; Chellaiah et al., 1994). FGFR1-3 isoforms IIIb and IIIc have 
different ligand specificities (Ornitz et al., 1996). FGFR4 has a unique exon in this 
region that is more identical to the variant IIIc than to the variant IIIb (Vainikka et al., 
1992). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Structural organisation of FGFRs. FGFRs have three extracellular immunoglobulin-like 
domains (D1–D3), a single transmembrane domain and a cytoplasmic tyrosine kinase domain. Between D1 
and D2 domains, FGFRs have a serine-rich sequence (acid box). The green highlighted region within the 
D3 domain corresponds to the region that can be alternatively encoded by two exons (corresponding to 
IIIb and IIIc). (Figure adapted from Mohammadi et al., 2005). 
 
 
 
 
FGFs not only provide pro-survival signals, but also confer broad-spectrum 
resistance to chemotherapeutic drugs (Song et al., 2000) and so have important roles in 
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cancer. Indeed, FGF/FGFR signalling has been associated with chemoresistance in 
breast cancer (Manuvakhova et al., 2006; Smaragda Angelidou and Michael Seckl, 
personal communication), metastatic prostate cancer (Song et al., 2000), and lung cancer 
(Pardo et al., 2002; Pardo et al 2003; Pardo et al., 2006). Inappropriate expression and 
secretion of FGFs can contribute to uncontrolled cell proliferation in many cancers 
including breast, prostate, and pancreatic cancer (reviewed by Dickson et al., 2000; 
Powers et al., 2000). Deregulation of FGF signalling can also occur as a result of 
alterations of the expression of their receptors and FGFR mutations have also been 
associated with tumourigenesis. For example, over-expression of FGFR1 has been 
reported in breast and prostate cancer (Penault-Llorca et al., 1995; Giri et al., 1999), and 
over-expression of FGFR2 was found in pancreatic tumours (Nomura et al., 2008). 
Gain-of-function mutations were found in many tumours. Examples of these include 
the mutation in the kinase domain of FGFR1 found in glioblastoma brain tumours 
(Rand et al., 2005), an activating mutation in the FGFR2 gene found in some primary 
uterine tumours (Pollock et al., 2007) and FGFR3 mutations detected in human bladder, 
cervical cancers and multiple myeloma (Chesi et al., 1997; Cappellen et al., 1999). A 
substitution of a glycine residue by an arginine at position 388 in the transmembrane 
domain of the receptor FGFR4 was linked to increased motility and invasion in breast 
and prostate cancer cells (Bange et al., 2002; Wang et al., 2004). Chromosomal 
translocations giving rise to various fusion genes of FGFR1 with other genes have been 
reported in leukaemia, particularly the fusion bcr-fgfr1, which can induce CML in mice 
(Roumiantsev et al., 2004). Isoform-switch was also found to be associated with 
malignant transformation, as illustrated by the isoform switch of FGFR2IIIb to R2IIIc 
that, together with an increased expression of FGFR1 and several FGF ligands, was 
found to be associated with the transformation of prostate epithelial cells (Yan et al., 
1993).  
This study focussed on FGF-2, which is described in more detail in the next 
section (Section 1.4). 
 
 
 
1.4. FGF-2  
FGF-2 is known to play a role in prostate and breast cancer (Giri et al., 1999; 
Dickson et al., 2000; Nurcombe et al., 2000; Polnaszek et al., 2003) and has been 
implicated in driving chemoresistance in a variety of cancer cells, including SCLC cells 
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(Song et al., 2000; Pardo et al., 2002; Pardo et al., 2003; Pardo et al., 2006). Several studies 
have established a significant association between expression of FGF-2 and advanced 
tumour, or poor prognosis, in lung, colon, gastric, pancreatic, liver, bladder, ovarian, 
and head and neck cancers (Yamanaka et al., 1993; Kitadai et al., 1996; Mise et al., 1996; 
Takanami et al., 1996; Ueki et al., 1996; Fujimoto et al., 1997; Dellacono et al., 1997; 
Gazzaniga et al., 1999). Moreover, elevated serum concentration of FGF-2 is an 
independent prognostic factor for an adverse outcome in SCLC (Ruotsalainen et al., 
2002). A significant correlation between serum FGF-2 levels and tumour mass and 
histological grade was also demonstrated in patients with soft tissue sarcoma (Graeven 
et al., 1999). In NSCLC, particularly when co-expressed with vascular endothelial 
growth factor (VEGF) or PDGF, FGF-2 is also associated with reduced survival rates 
(Donnem et al., 2009). Recently, autocrine signalling of FGF-2 and its receptors has been 
observed in NSCLC cell lines, in particular in those that are insensitive to the EGFR 
inhibitor gefitinib (Marek et al., 2009). 
 
 
 
1.4.1. BIOLOGICAL ROLE OF FGF-2 
FGF-2 (initially named basic FGF, bFGF, for having a basic isoelectric point) is 
the most extensively studied member of the FGF family (reviewed by Ribatti et al., 
2007). Four different FGF-2 polypeptides can be formed from the FGF-2 gene 
(Florkiewicz and Sommer, 1989) and it was suggested that the different molecular 
weight forms of FGF-2 could have distinct functions (Yu et al., 2007). FGF-2 plays key 
roles in diverse biological processes, including proliferation, differentiation, migration, 
survival and neovascularisation (Bikfalvi et al., 1997). fgf-2 knockout mice exhibit loss 
of vascular tone, indicating that fgf-2 has an important physiological role in vascular 
development and homeostasis (Zhou et al., 1998). FGF-2 was also shown to play an 
important role in astrocyte differentiation (Reuss et al., 2003; Song and Ghosh, 2004). 
Other possible physiological roles for FGF-2 include inflammation in which stress-
induced activation of caspase 1 leads to the release of FGF-2 that then mediates tissue 
repair and angiogenesis, processes that are required during and after acute or chronic 
inflammation (Keller et al., 2008). During embryonic development of the lung, FGF-2 
regulates the expression of a number of genes (Han et al., 1992). In the adult normal 
lung FGFRs seem to be expressed at low levels (Ledoux et al., 1991), but deregulated 
FGF signalling through gain- or loss-of-function mutations of the ligands or receptors 
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can contribute to many diseases, the most notable being cancer (reviewed by(Beenken 
and Mohammadi, 2009). 
 
 
 
1.4.2. ACTIVATION AND SIGNALLING IN RESPONSE TO FGF-2 
The mechanism of FGF-2 release is not clearly understood since, unlike other 
FGFs, FGF-2 does not contain a canonical signal sequence for secretion (Powers et al., 
2000). FGFs bind the receptor together with heparan sulphate glycosaminoglycan 
(HSGAG), which stabilises the ligand-receptor contact and the complex 2:2 FGF-FGFR 
dimer (Plotnikov et al., 1999; Venkataraman et al., 1999; Schlessinger et al., 2000; Stauber 
et al., 2000). Like EGF family members, which are known bind to and activate both 
EGFR homo- and heterodimers (Hackel et al., 1999), the interactions observed at the 
receptor–receptor interface in response to FGFs are compatible with FGFR homo- and 
heterodimerisation (Bellot et al., 1991; Ueno et al., 1992; Plotnikov et al., 1999; 
Schlessinger et al., 2000; Bae et al., 2010). FGFR1 homodimers and FGFR1:FGFR2 
heterodimers are the main receptor complexes for FGF-2 (Ornitz et al., 1996; Zhou et al., 
2006; Ueno et al., 1992; Plotnikov et al., 1999). Interestingly, FGFRs can also 
heterodimerise with other receptors. That is the case for FGFR1, which heterodimerises 
with PDGF receptor (PDGFR) α in response to a dual treatment with FGF-2 and PDGF 
(Faraone et al., 2006).  
Ligand-binding and FGFR dimerisation allows for the trans-phosphorylation of 
several tyrosine residues on the tyrosine kinase domains of the FGFRs’ cytoplasmic 
tails (Bellot et al., 1991). Phosphorylation sites within the catalytic domain are crucial 
for the stimulation of receptor kinase activity, while the phosphorylation of other 
tyrosine residues provides sites for direct binding of secondary messenger molecules 
with SH2 domains. Binding of SH2-binding proteins to the receptor activates several 
intracellular signalling pathways, some of which are depicted in Figure 10 (Dailey et 
al., 2005). For example, FGFR1 contains seven tyrosine residues on its cytoplasmic 
domain of which Tyr653 and Tyr654 are necessary for the receptor catalytic activity, 
while the phosphorylation of the other tyrosines likely provides binding sites for 
scaffolding proteins for further downstream signalling (Mohammadi et al., 1996).   
The two main intracellular substrates of FGFR are PLC-γ and FGFR substrate 2 
(FRS2). The main pathways activated by FGFs are schematically represented in Figure 
10. Upon FGF binding, the phosphorylation of FGFR1 provides a binding site for the 
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SH2 domain of PLC-γ (Mohammadi et al., 1991; Peters et al., 1992). Activated PLC-γ 
hydrolyses PIP2 into DAG and inositol triphosphate (IP3), which leads to the 
stimulation of PKC and intracellular calcium release, respectively (Mohammadi et al., 
1996). FRS2 is constitutively bound to the receptor and is activated after FGF 
stimulation (Mohammadi et al., 1996). FRS2 forms a complex with growth factor 
receptor bound-2 (GRB2) and son of sevenless (SOS), leading to the downstream 
activation of the RAS/RAF/MEK/ERK pathway (Kouhara et al., 1997) (Fig. 10). 
Moreover, FRS2 has also been implicated in the activation of atypical PKCs (PKCζ and 
λ) (Lim et al., 1999). Activation of PI3K and mTOR has also been observed in some cells 
downstream of FGFR and these are known to modulate the activity of S6K1/2 (Kanda 
et al., 1997; Koh et al., 1999). Of note, mTOR and S6K1/2 have been found highly over-
expressed in SCLC tumours downstream of FGF-2 (Arcaro et al., 2002; Pardo et al., 
2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Signalling in response to FGF. Binding of FGF induces FGFR dimerisation and trans-
phosphorylation of the cytoplasmic tail, providing docking sites for secondary messenger molecules. The 
main FGF-activated pathways are represented here. Grey arrows indicate direct activation. Dashed arrows 
indicate indirect activation. Red arrows indicate hydrolysis. 
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Under certain circumstances, upon activation of FGFR1, activation of SRC 
family kinases is also observed and is associated with several effects, including the 
differentiation of endothelial cells (Klint et al., 1999; Landgren et al., 1995). SRC family 
members can interact with a variety of receptors, such as receptor tyrosine kinases 
(RTKs) or GPCRs and regulate survival, proliferation, differentiation and migration 
(reviewed by Parsons and Parsons, 2004).   
Upon binding, FGF-2/FGFR complexes are internalised by endocytosis 
(Wiedlocha and Sorensen, 2004). Internalised FGF-2 was shown to cross cellular 
membranes to reach the cytosol and the nuclear compartment (Almaric et al., 1994; 
Stachowiak et al., 1996; Sperinde and Nugent, 1998). Indeed, FGF nuclear targeting was 
shown to be involved in cell proliferation and, in particular, FGF-2 entry into the 
nucleus has been reported as necessary for cell cycle progression and proliferation 
(Bouche et al., 1987; Bailly et al., 2000). Nuclear FGF-2 has also been suggested to be 
involved in the survival of carcinoma cells, which are important for the establishment 
of lung metastases (Thomas-Mudge et al., 2004). After FGF-2/FGFR endocytosis, FGF-2 
is translocated through the cytosol through a mechanism that requires PI3K activity 
(Malecki et al., 2004). The heat shock protein 90 kDa (HSP90) was shown to function as 
a chaperone required for the FGF-2 translocation from endosomes to the cytoplasm 
and nucleus (Wesche et al., 2006). Inside the cell, FGF-2/FGFR complexes trigger 
different signalling pathways from the ones triggered by cell surface receptor/growth 
factor complexes. FGF-2 in the nucleus can directly stimulate casein kinase 2 (CK2) 
activity, a ubiquitous serine/threonine kinase involved in the control of cell 
proliferation (Bonnet et al., 1996). For example, CK2 is required for the induction of 
nucleolin, a factor involved in control of ribosomal RNA (rRNA) transcription (Bouche 
et al., 1994). Although FGFR1 also does not contain a detectable NLS, a pool of FGFR1 
derived from the cell surface was detected in the nucleus upon FGF-2 binding (Maher, 
1996). The uptake of FGFR1 in the nucleus was shown to require importin β, a critical 
component of multiple nuclear import pathways (Reilly and Maher, 2001). The 
internalisation and nuclear translocation of FGFR1 does not require activation of 
receptor tyrosine kinase (Reilly et al., 2004). The same authors suggested that the 
signalling pathways that are known to be activated downstream of ligand binding are 
not the ones involved in its internalisation and thus intracellular trafficking may be 
stimulated by the binding of proteins to the transmembrane domain of FGFR. FGFR1 
was demonstrated to serve as a mediator of FGF-2 transport to the nucleus and, 
together with FGF-2, was shown to regulate the proliferation of astrocytes and glioma 
cells (Stachowiak et al., 1996; Joy et al., 1997; Stachowiak et al., 1997). Co-localisation of 
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FGFR1 with nuclear sites of RNA synthesis and processing suggested that the receptor 
could function as transcriptional regulator (Stachowiak et al., 2003). Examples of genes 
that can be induced by nuclear FGFR1 are c-JUN and cyclin D, which encode proteins 
required for cell division and proliferation (Reilly and Maher, 2001). Interestingly, 
nuclear FGFR1 transactivates the FGF-2 gene promoter and induces its expression 
(Stachowiak et al., 2003). Induction of FGF-2 expression has been previously shown in 
response to externally added FGF-2 in mouse osteoblastic cells (Hurley et al., 1994). The 
role of nuclear FGFR2 is less clear. This receptor can also be internalised and 
translocated into the nucleus but this was shown in response to FGF-9 (Kim et al., 
2007). Internalisation of FGFR also results in its degradation or recycling. Receptors 
that are destined for degradation are ubiquitinated (by virtue of ubiquitin molecules 
being attached to lysine residues on the cytoplasmic tail) and transported to lysosomes 
rather than being sorted to recycling endosomes (Haugsten et al., 2005). 
Receptor-mediated endocytosis is typically classified into two main pathways: 
the clathrin-mediated endocytosis (CME) and the clathrin-independent (CI) pathway 
(reviewed by Doherty and McMahon, 2009). The CME pathway involves the 
recruitment of clathrin from the cytoplasm to the plasma membrane. Adaptor and 
accessory proteins, such as epsin family proteins or the adaptor protein-2 (AP2), 
regulate clathrin recruitment to sites of plasma membrane that are designated to be 
internalised and promote the polymerisation of clathrin (Hinrichsen et al., 2006; Schmid 
et al., 2006). Polymerised clathrin-coated membrane pits bud and separate from the 
plasma membrane with the help of dynamin, which mediates the fission by forming a 
polymer around the pit constricted neck, thereby giving rise to clathrin-coated vesicles 
(Praefcke and McMahon, 2004). After internalisation, the vesicles are uncoated and 
undergo further trafficking within the cell. Accordingly, the receptors can be sorted to 
different sites of the cell (e.g. to the lysosomes for degradation, or back to the cell 
surface) (Grant and Donaldson, 2009). CME was for many years believed to be the 
pathway by which the internalisation of receptors occurred. Although CME is an 
extremely important endocytic pathway for receptors (including many RTKs), a 
number of reports have shown that receptor endocytosis can also occur in a clathrin-
independent manner (reviewed by Kirkham and Parton, 2005). In addition, the same 
ligand/receptor complexes can be internalised through both clathrin-dependent and -
independent pathways depending on factors, such as ligand concentration, and that 
can result in distinct signalling outcomes (Di Guglielmo et al., 2003; Sigismund et al., 
2005). The best-studied CI endocytic pathway is mediated by caveolae, flask-shaped 
plasma membrane invaginations characterised by the presence of a caveolin protein 
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family member and enriched in sphingolipids and cholesterol (reviewed by Mayor and 
Pagano, 2007). The separation of these pits from the extracellular membrane is 
dynamin-dependent. Pre-caveolae are formed in the Golgi complex where cholesterol 
and caveolin oligomerisation takes place. The specific lipid composition of caveolae 
and the function of other caveolae-associated proteins remain to be firmly established 
(reviewed by Doherty and McMahon, 2009). Caveolae seem to undergo ‘kiss-and-run’ 
fusion and fission with the plasma membrane, transporting the cargo into cellular 
compartments and then recycling it to the plasma membrane (Pelkmans and Zerial, 
2005). Other CI endocytosis can occur independently of caveolae through distinct 
pathways that require cholesterol and specific lipid compositions. An example of 
receptor endocytosis that occurs by a clathrin- and caveolae-independent mechanism is 
the internalisation of the IL-2 receptor (IL-2R) (Lamaze et al., 2001). IL-2Rs are 
constitutively associated with detergent-resistant membrane (DRM) domains (domains 
with a specific composition of glycosphingolipids and cholesterol) that were suggested 
to mediate their endocytosis. The same authors showed that the internalisation of IL-
2R is regulated by Rho family GTPases and requires dynamin. In a similar manner, the 
internalisation of FGF-2/FGFR complexes was shown to occur by a CI mechanism that 
is also independent of caveolae (Reilly et al., 2004) but it is not fully understood. FGF-2 
can also be internalised upon binding heparan sulfate proteoglycans (HSPG) 
independently of binding to FGFRs (Roghani and Moscatelli, 1992) and may have 
different intracellular destinations and functions from the internalised FGF-2 in FGF-
2/FGFR complexes (Reiland and Rapraeger, 1993). FGF-2/HSPG internalisation was 
shown to occur by a CI and caveolar-dependent mechanism (Gleizes et al., 1995). 
The signalling downstream of FGF-2 and its receptors has been shown to be 
complex and thus much remains to be fully understood. 
 
 
 
1.4.3. NEGATIVE AND POSITIVE REGULATORS OF FGF SIGNALLING 
PATHWAYS 
FGF signalling is tightly controlled through the coordinated action of both 
positive and negative regulators that function at multiple levels of the signal 
transduction cascade. The strength and duration of FGF-induced ERK signalling is 
modulated by factors such as cell-surface receptor density, expression of scaffolding 
proteins, the surrounding extracellular matrix, and the interplay between kinases and 
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phosphatases (Murphy and Blenis, 2006). Gene expression is subsequently regulated 
by the modification of transcription factors by activated ERKs. Positive modulators of 
FGF signalling include: ETS transcription factors, like ETS-related molecule (ERM) and 
polyomavirus enhancer activator 3 (PEA3), and the Xenopus homolog of the 
fibronectin-leucine-rich transmembrane protein 3 (XFLRT3). Feedback antagonists of 
FGF-induced MEK/ERK signalling include family members of Sprouty (SPRY), similar 
expression to fgf (SEF) and MAPK phosphatase (MKP) families (reviewed by(Tsang 
and Dawid, 2004). For example, SEF interacts with FGFRs and prevents the 
phosphorylation of FRS2 (Kovalenko et al., 2003), while some members of the SPRY 
family inhibit the recruitment of SOS by binding to either GRB2 or SOS itself (Hanafusa 
et al., 2002; Ozaki et al., 2005). MKPs, also known as dual specific phosphatases (DUSP), 
such as MKP3 (DUSP6) can also attenuate MAPK signalling by dephosphorylating 
critical threonine and tyrosine residues of ERK1 and ERK2 (Zhao and Zhang, 2001). 
Often key negative regulators of signalling pathways can be induced by the same 
pathway they regulate. For example, FGF was shown to induce the expression of SPRY 
family members (e.g. Ozaki et al., 2001) and genes like erm and pea3 are 
transcriptionally activated by Fgf in zebra fish (Raible and Brand, 2001). Due to the 
relevance of FGF/FGFR signalling pathways in cancer, it is no surprise that their 
regulators are also found deregulated in a variety of cancers. These genes have been 
implicated in a variety of transcriptional regulatory events controlling normal and 
abnormal cell behaviour, including proliferation, differentiation, and migration 
(Wasylyk et al., 1998). Indeed, it has been shown that the expression of SPRY family 
members is often abnormal in breast, prostate and liver cancers (Lo et al., 2004).  
The control of FGF pathways is indeed very complex and cross-talk with other 
pathways further increases the complexity of modulation. 
 
 
 
1.4.4. FGF-2 IN CANCER 
FGF-2 induces key processes that tumour cells require to successfully survive, 
proliferate and metastasise and can mediate these wide-range of functions through 
diverse signalling pathways. 
FGF-2 can promote proliferation in many cell types (Bikfalvi et al., 1997) and 
this can be achieved through different pathways. The activation of MEK/ERK has been 
shown to be required for FGF-2-induced proliferation in, for example murine lens 
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epithelial cells (Lovicu and McAvoy, 2001), bladder cancer cell lines (Tomlinson et al., 
2009) and some SCLC cell lines (Pardo et al., 2001). In SCLC cells, S6K was also shown 
to be a major regulator of FGF-2 growth promoting effect, as it can be blocked by 
rapamycin (a mTOR inhibitor) (Pardo et al., 2001). Proliferation of astrocytes and 
glioma cells was shown to be regulated by FGF-2 transported to the nucleus together 
with FGFR1 upon ligand binding and internalisation (Stachowiak et al., 1996; Joy et al., 
1997; Stachowiak et al., 1997). Nuclear FGFR1 can induce the expression of genes 
encoding proteins required for cell division and proliferation such as c-JUN and cyclin 
D (Reilly and Maher, 2001). 
Another effect of FGF-2 is to confer resistance to therapeutic drugs as 
demonstrated, for example, in human umbilical vein endothelial cells (HUVECs), 
prostate, breast and lung cancer cells (Song et al., 2000; Pardo et al., 2002; Alavi et al., 
2003; Vandermoere et al., 2005). Due to its relevance for the present study FGF-2 
mediated chemoresistance will be described in more detail in the next chapter (Section 
1.4.5). 
Recently, it was shown in mouse brain microvascular endothelial cells 
(BMVECs) that FGF-2 can mediate migration, invasion and angiogenesis though a 
mechanism that required STAT5 and involved the activation of JAK2 and ERKs (Yang 
et al., 2009). In this system, JAK2 but not SRC activity was demonstrated to be required 
for ERK1/2 phosphorylation. These findings demonstrate a cross-talk between 
JAK/STAT and MAPK pathways and suggest that this interplay is critical for the FGF-
2-mediated angiogenesis. 
In addition, FGF-2 can regulate the expression and function of E-cadherin and 
catenins, which are implicated in the proliferation, invasion and metastasis of a wide 
variety of solid tumours (El-Hariry et al., 2001). El-Hariry and colleagues (2001) showed 
that FGF-2 induced E-cadherin phosphorylation, and the expression of E-cadherin and 
catenins correlated with increased cell adhesion. This led them to suggest that FGF-2 
could induce re-localisation of E-cadherin to the plasma membrane. Other authors 
suggested a conjoint regulation of E-cadherin with FGFR1 and showed that FGF 
signalling resulted in deregulation of E-cadherin function. Over-expression of E-
cadherin, for example, blocked nuclear translocation of FGFR1 (Bryant et al., 2005). In 
addition, these authors have also shown that these two proteins were internalised in 
response to FGF-2 (and also FGF-1) stimulation and co-localised in intracellular 
compartments. Furthermore, FGF-2 can upregulate integrin receptors and potentiate 
their adhesive and signalling functions (Kinoshita et al., 1993; Miyamoto et al., 1996). 
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Importantly, FGF-2 was shown to regulate the expression of other factors that 
modulate cancer cell growth, such as IL-6 (Delrieu et al., 1998). Moreover, this growth 
factor was shown to promote angiogenesis by inducing the expression of VEGF, a 
potent mitogen for micro- and macrovascular endothelial cells (Seghezzi et al., 1998). 
The induction of VEGF expression was shown to be mediated by the 
RAS/RAF/MEK/ERK signalling pathway, at least in osteoblast cells (Tokuda et al., 
2000). Furthermore, externally added FGF-2 can also induce the expression of FGF-2 
itself and the production of FGF-2 was suggested to be important as an autocrine and 
paracrine mediator of cell division, differentiation and function (Hurley et al., 1994). 
Interestingly, FGF-2 was also shown to be capable of restoring telomerase 
activity and consequently maintaining the replicative capacity of cells, a critical 
property for successful angiogenesis (Kurz et al., 2003). Taken together, these 
observations demonstrate the pleiotropic nature of FGF-2 and highlight the 
significance that this growth factor has in cancer. 
 
 
 
1.4.4.1. FGF-2-MEDIATED CHEMORESISTANCE MECHANISMS 
Signalling downstream of FGF-2 can regulate components of the apoptotic 
machinery and consequently promote cell survival. FGF-2 has been shown to confer 
resistance to etoposide-mediated apoptosis in SCLC cells through a PI3K-independent 
mechanism that requires MEK/ERK activation (Pardo et al., 2002). In contrast, in breast 
cancer cells, FGF-2-induced survival from ceramide-induced cell death was mediated 
by PI3K but was independent of MEK/ERK signalling (Vandermoere et al., 2005). FGF-
2-protection of breast cancer cells was shown to require the activation of the anti-
apoptotic protein NF-κB by PKB. The PI3K pathway was also demonstrated to be 
required for FGF-2 protection of osteoblasts against apoptosis induced by low serum 
concentration (Debiais et al., 2004). Moreover, in HUVECs, FGF-2 also protected cells 
against apoptosis mediated by the intrinsic pathway independently of MEK/ERK 
activation (Alavi et al., 2003). In these cells, however, FGF-2 was shown to activate C-
RAF and, as a consequence, to promote its mitochondrial translocation where it binds 
and inhibits the kinase activity of the pro-apoptotic protein apoptosis signal-regulating 
kinase 1 (ASK1) (Alavi et al., 2007). Together, these reports show that FGF is able to 
protect cells from apoptosis by different pathways. 
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Seckl and colleagues have shown that in SCLC cells the mechanism by which 
FGF-2 mediated chemoresistance required, in addition to MEK activation, B-RAF, 
PKCε and S6K2 (Pardo et al., 2006). In this cell type, FGF-2 induced the 
phosphorylation of PKCε at residues Thr566 and Ser729, which are known to correlate 
with activation of this kinase (Parekh et al., 1999; Cenni et al., 2002). In addition, FGF-2 
also induced phosphorylation of residue Thr388 of S6K2, which is required for its 
activation (Phin et al., 2003). FGF-2-induced survival against etoposide was found to 
involve a translational mechanism that resulted in the upregulation of various anti-
apoptotic proteins, such as the apoptosis regulators BCL-2, BCL-XL, XIAP and the 
cellular inhibitor of apoptosis 1 (cIAP-1) (Pardo et al., 2002; Pardo et al., 2003). This pro-
survival effect was shown to involve the inhibition of SMAC/DIABLO release, but not 
of cytochrome c, from the mitochondria that is usually implicated in the activation of 
apoptosis. 
FGF-2-mediated protection from etoposide-induced cell death in H-510 cells 
involved the formation of a multiprotein complex composed by B-RAF, PKCε and 
S6K2 (Pardo et al., 2006) (Fig. 11). This is particularly interesting as it further shows that 
components of different oncogenic signalling pathways can cross-talk and synergise to 
promote cell survival and resistance to apoptosis. The specific function of each of these 
proteins in the complex is not yet completely understood. The association of PKCε 
with B-RAF was suggested to induce MEK/ERK signalling as PKCε was required for 
ERK1/2 phosphorylation and the expression of PKCε (but not of other PKC family 
members) was correlated with the ability of FGF-2 to induce MEK/ERK activation and 
upregulation of anti-apoptotic proteins in SCLC cells (Pardo et al., 2006). Interaction 
between PKCε and C-RAF had been previously shown in NIH-3T3 cells, where PKCε 
activation by phorbol esters triggered MEK/ERK signalling (Hamilton et al., 2001). In 
addition, PKC activity itself was shown to be required for PKB-induced activity of C-
RAF through a RAS-independent mechanism, a fact that prevents apoptosis in murine 
myeloid cells (Majewski et al., 1999). In the SCLC cells, a complex between PKCε and 
C-RAF was not detected (Pardo et al., 2006).  
Furthermore, in vitro kinase assays showed that PKCε can directly associate 
with and phosphorylate S6K2. It is possible that, in SCLC cells, S6K2 is a substrate of 
PKCε as other authors have shown that S6K2 is phosphorylated by several PKC 
isoforms (including PKCε), which can in turn regulate S6K2 subcellular localisation 
(Valovka et al., 2003). The downregulation of B-RAF, PKCε and S6K2 using small 
interfering RNA (siRNA) demonstrated that while in the absence of B-RAF, PKCε still 
associated with S6K2, PKCε was required for the interaction of B-RAF with S6K2. 
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These data suggested that PKCε can directly associate with S6K2, whereas B-RAF 
required the presence of PKC to join the complex. Nevertheless, other proteins may 
also bind to these three proteins and have a function in this complex. It is also 
conceivable that upon FGF-2 several different protein complexes are formed between 
these, and potentially other, proteins. 
The mechanisms by which the B-RAF, PKCε and S6K2 complex interacts with 
the translational machinery to upregulate the targets previously mentioned and 
promote FGF-2-mediated chemoresistance remain, however, unknown. It seems 
plausible that other molecules may bind to the B-RAF, PKCε and S6K2 complex but 
their molecular identity remains to be unravelled. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. FGF-2-mediated chemoresistance pathways in SCLC cells. FGF-2 signalling via MEK-
ERK induces the formation of a complex comprising at least PKCε, B-RAF and S6K2. This complex 
upregulates the expression of anti-apoptotic proteins important for promoting chemoresistance. Grey 
arrows indicate direct activation. Dashed arrows indicate indirect activation. 
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1.4.5. TARGETING FGF-2 SIGNALLING FOR CANCER TREATMENT 
The inhibition of FGF-2 signalling alone or together with other 
chemotherapeutic drugs was shown to be an effective therapy for some cancers 
(reviewed by(Beenken and Mohammadi, 2009). One example is thalidomide, an 
inhibitor of FGF-2-induced angiogenesis that was shown to have therapeutic benefits 
in prostate and renal cancer patients (Eisen et al., 2000; Figg et al., 2001). Another 
example is suramin, which interferes with FGF signalling by mimicking heparin, and 
was shown to be an efficacious treatment in bladder, kidney and prostate cancer 
patients (Motzer et al., 1992; Myers et al., 1992; Danesi et al., 1993; Eisenberger et al., 
1993; Walther et al., 1996). Another compound, sunitinib (SU011248), a tyrosine kinase 
inhibitor, has been shown to efficiently inhibit several RTKs including FGFR1, PDGFR 
and VEGFR2, and consequently inhibit tumour cell growth and tumour regression in 
mouse models of colon cancer, NSCLC, melanoma, and renal and squamous cell 
carcinomas (reviewed by Chow and Eckhardt, 2007).  
Specific FGFR inhibitors have also been developed. One example is PD173074, 
an ATP pocket inhibitor (Mohammadi et al., 1998). This compound was shown to 
inhibit FGFR-activation in several cell systems and to promote apoptosis and inhibition 
of cell growth in cancer cells with activating FGFR mutations (Bansal et al., 2003; Grand 
et al., 2004; Byron et al., 2008; Dutt et al., 2008). Moreover, recent work by the Seckl and 
Pardo groups has demonstrated that PD173074 blocks FGF2-induced proliferation and 
chemoresistance in SCLC cell lines (Pardo et al., 2009).  Importantly, treatment with this 
compound triggered tumour cell apoptosis and cured 50% of mice with H-69 SCLC 
xenografts and potentiated significantly the efficacy of cisplatin in H-510 SCLC 
xenografts (Pardo et al., 2009). Accordingly, FGFR inhibitors may provide a good 
therapeutical strategy for treatments of cancer patients. 
Other approach for targeting FGF-2 signalling might be to use MEK/ERK 
inhibitors, as MEK signalling is a crucial element of FGF-2 signalling pathways (e.g. 
Tokuda et al., 2000; Lovicu and McAvoy, 2001; Pardo et al., 2001; Pardo et al., 2002; 
Tomlinson et al., 2009) and, in addition, is a key mediator of proliferation downstream 
of multiple growth factors (reviewed by Kolch, 2000; Ballif and Blenis, 2001). Indeed, 
several small-molecule inhibitors of MEK have been developed and these are currently 
being tested in clinical trials. For example, CI-1040 was the first MEK inhibitor to enter 
clinical evaluation (Lorusso et al., 2005; Rinehart et al., 2004). Compounds like CI-1040 
prevent full activation of MEK1/2 without competing with ATP. The inhibition of 
activated MEK1/2 prevents the stimulation of ERK1/2 activity and blocks 
phosphorylation/activation of downstream substrates. CI-1040 first demonstration of 
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anti-cancer activity was the reduction of human colon cancer xenograft growth (Sebolt-
Leopold et al., 1999). This inhibitor showed promising results during a phase I clinical 
trial. Tumour tissues collected from patients treated with CI-1040 showed a significant 
reduction in activated/phosphorylated ERK. Importantly, 25% of patients with a 
variety of tumours had a stable disease for longer than 3 months (Lorusso et al., 2005). 
However, when CI-1040 advanced to a phase II trial it revealed adverse side effects and 
did not meet predetermined end points to progress to a phase III trial (Rinehart et al., 
2004). Accordingly, clinical development of CI-1040 was stopped. A second-generation 
agent, PD0325901, was introduced into the clinic but the development of this 
compound was stopped also because of toxicity-related issues (reviewed by Friday and 
Adjei, 2008). Another MEK inhibitor compound, AZD6244, was better tolerated and 
has provided encouraging results in a phase I clinical trial (Adjei et al., 2008). This 
inhibitor is still undergoing evaluation in phase II trials in combination with other 
chemotherapeutic agents (Bennouna et al., 2010). Toxicity is one of the major concerns 
when using small-molecule MEK inhibitors, but additional compounds are now being 
studied in patients. Nevertheless, early studies and reports of clinical activity are 
encouraging and put these inhibitors in the forefront of cancer therapeutics (Roberts 
and Der, 2007; Friday and Adjei, 2008) 
 
 
 
1.5. FGF-2 AND THE JAK/STAT SIGNALLING PATHWAY 
There have been reports suggesting that activation of the JAK/STAT signalling 
pathway can be triggered by FGF-2. It has been shown that FGF-2 treatment can induce 
the activation of STAT1, STAT3 and STAT5 in some cells and that blockage of JAK 
activity can inhibit FGF-2–induced proliferation (Ebong et al., 2004; Yang et al., 2009). 
Activation of STATs was also observed downstream of other FGFRs. Constitutively 
activated FGFR1, FGFR3 and FGFR4 were shown to stimulate the phosphorylation and 
activity of STAT1 and STAT3 (Hart et al., 2000). Furthermore, activation of STAT1 
downstream of FGFR3 was shown to contribute to the inhibition of chondrocyte 
proliferation and regulation of bone development (Sahni et al., 1999). In addition, 
STATs can be regulated by proteins that are activated downstream of FGF-2, such as 
ERK1/2. STAT1, STAT3, STAT4 and STAT5 all have an ERK recognition consensus 
sequence (PMSP – proline, methionine, serine, proline) located at their C-terminal 
domain (Wen et al., 1995). ERK1/2 were show to negatively regulate STAT3 
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transcriptional activity by phosphorylation of residue Ser727 (located within the PMSP 
sequence) and ERK2 was demonstrated to physically interact with STAT3 (Jain et al., 
1998; Tian and An, 2004). Depending on the cellular context, the phosphorylation of 
this residue can be induced by several other kinases but when induced by EGF it was 
shown to be ERK-dependent (Chung et al., 1997).  
To the best of our knowledge, no studies have been carried out to determine 
whether JAKs and/or STATs are involved in FGF-2-induced drug resistance. During 
my PhD, I have investigated if JAK/STAT signalling pathways impacted on FGF-2-
mediated chemoresistance mechanism(s) using lung and bone cancer cell lines as 
model cell lines. 
 
 
 
1.5.1. FGF/FGFR IN LUNG AND BONE CANCERS 
As previously mentioned, FGF/FGFR signalling has been shown to be relevant 
in organogenesis, particularly in the nervous system, the lungs and the limbs 
(reviewed by Dickson et al., 2000; Powers et al., 2000). For example, FGFR2III-null mice 
have severe defects of the limbs and lungs due to loss of the progenitor cells by 
apoptosis (De Moerlooze et al., 2000). FGFs and their receptors play a crucial role in 
lung development as FGF-10/FGFR2 signalling has been shown to be required for 
epithelial branching in the mouse lung (Abler et al., 2009). Additionally, FGF-9 has 
been implicated in the regulation of airway smooth muscle cell differentiation and 
proximal-distal patterning in the mouse lung (Perl and Gale, 2009; Yi et al., 2009). FGF 
signalling plays also an important role in the regulation of bone development (Ornitz 
and Marie, 2002). For example, while FGFR2 can act as a positive regulator of bone 
growth being essential for osteoblast proliferation and function (Yu et al., 2003), the 
disruption of the FGFR3 gene results in bone over-growth (Colvin et al., 1996; Deng et 
al., 1996). A number of studies have shown that FGF-2 induces cell proliferation and 
inhibits the differentiation of primary chondrocytes (Kato and Iwamoto, 1990; Hill et 
al., 1991; Wroblewski and Edwall-Arvidsson, 1995). 
FGF/FGFR signalling is not only vital for lung and bone cellular homeostasis, 
but is also relevant for cancer promotion/progression. Of note, FGFR1 was shown to 
promote NSCLC progression and invasion (Fischer et al., 2008). A mutation in FGFR4 
was detected in a significant number of NSCLC patients and associated with poor 
prognosis in node-positive patients (Sasaki et al., 2008). As previously described here 
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(Section 1.4.4 and 1.4.4.1), FGF-2 has been shown to confer chemoresistance in SCLC 
(Pardo et al., 2001; Pardo et al., 2002; Pardo et al., 2003; Pardo et al., 2006). Furthermore, 
FGF signalling was shown to be important for the transformed state and survival of 
bone cancer cells (Muenke and Schell, 1995; Coffin et al., 1995; Deng et al., 1996; Bodo et 
al., 2002). For example, FGF-1 expression was correlated with bone tumour growth 
(Babkina et al., 2009). In addition, FGF-8 was also shown to stimulate the proliferation 
of osteosarcoma cells (Valta et al., 2006).  
Accordingly, given the important role that FGF/FGFR signalling plays in lung 
and bone cancers, the elucidation of relevant mechanisms of chemoresistance mediated 
by these growth factors might contribute for the development of more efficient 
therapies. 
 
 
 
1.5.2. JAKS AND STATS IN LUNG AND BONE CANCERS 
 JAK/STAT signalling pathways were also shown to be critical for lung and 
bone cancer biology, participating in cell malignant transformation and 
chemoresistance (Ikuta et al., 2005; Loewen et al., 2005; Geryk-Hall and Hughes, 2009). 
For example, over-expression of RTKs like EGFR, as well as non-RTKs, such as SRC, 
are responsible for the aberrant activation of STAT3, which has been implicated in the 
development of human lung cancer (Haura et al., 2005; Song et al., 2003). In addition, 
cytokines like IL-6 have been shown to modulate lung cancer cell growth and, in fact, 
elevated levels of this cytokine seem to be an adverse prognostic factor for patients 
with this type of carcinoma (Yanagawa et al., 1995; Eickelberg et al., 1999; Yeh et al., 
2006). Patients with osteosarcoma, chondrosarcoma, Ewing's sarcoma and giant cell 
tumour of bone also have significantly elevated levels of serum IL-6 that correlates 
with a poor overall survival (Rutkowski et al., 2003). IL-6-type cytokines are, in fact, 
important regulators of bone pathophysiology (reviewed by Blanchard et al., 2009). 
Although some IL-6-type cytokines, such as OSM, can mediate anti-cancer effects in 
the bone environment they often induce bone resorption and tumour growth. 
Importantly, IL-6 has long been known to activate STAT3, which is its main 
transcription factor (Heinrich et al., 2003). Neuregulin-1 was also found to play an 
important role in lung epithelial cell proliferation by inducing JAK/STAT activation, in 
particular JAK3, TYK2, STAT3 and STAT5 (Liu and Kern, 2002).  
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STAT3 activation enhances the expression of survival proteins involved in 
preventing cell cycle arrest and senescence. Several recent studies have suggested that 
the STAT3 oncogenic pathway is not only involved in cell transformation but is also 
associated with intrinsic drug resistance (Ikuta et al., 2005; Grisko et al., 2006; Barre et 
al., 2007). In lung cancer cells, over-expression of STAT3 correlated with suppression of 
apoptotic pathways in cisplatin-resistant NSCLC cells (Ikuta et al., 2005). In addition, it 
has been shown that the growth and survival of early stage NSCLC tumours may be 
dependent on the activation of STAT3 by EGFs (Haura et al., 2005). STAT3 was also 
found to be activated in a subset of the Ewing’s sarcoma family of tumours (Lai et al., 
2006). Interestingly, activation of oncogenic STAT3 could be induced by Kaposi's 
sarcoma-associated herpesvirus (KSHV), the infectious cause of Kaposi's sarcoma, and 
it was thus suggested that it may play a critical role in KSHV pathogenesis (Punjabi et 
al., 2007). 
Somatic EGFR mutations found on NSLCL cells correlated with STAT3 
activation, a critical mediator of the oncogenic effects of this growth factor, and 
importantly STAT3 activity can be downregulated by small-molecule inhibitors 
targeting EGFR (Alvarez et al., 2006). Regarding the role of STAT3 in promoting 
survival and proliferation, these authors suggested that EGFR/STAT3 signalling 
pathway probably limits (or at least contributes to a decrease in) the efficiency of 
current chemotherapeutic treatments and that the inhibition of STAT3 is likely to be 
involved in the improved therapeutic effects of, for example, gefitinib.  
Since several types of commonly used treatments often fail in tumours where 
constitutively activated STAT proteins are found, molecular therapies leading to STAT 
signalling inhibition may increase tumour response to chemotherapy and/or 
conventional radiotherapy, and these are certainly worthwhile pursuing (reviewed 
by(Calo et al., 2003; Yu and Jove, 2004). 
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2. HYPOTHESIS AND SPECIFIC AIMS 
 
FGF-2 was shown to be an important player in promoting oncogenesis and 
driving chemoresistance (Giri et al., 1999; Dickson et al., 2000; Nurcombe et al., 2000; 
Song et al., 2000; Pardo et al., 2002; Pardo et al., 2003; Polnaszek et al., 2003). It was 
previously shown in lung cancer cell lines that FGF-2 mediated chemoresistance by 
inducing the expression of anti-apoptotic proteins via a MEK/ERK-dependent 
mechanism, which involved the formation of a multi-protein complex that contained B-
RAF, PKCε and S6K2 (Pardo et al., 2002; Pardo et al., 2006). There have been reports 
suggesting that activation of JAKs and/or STATs can occur downstream of FGF-2 
(Ebong et al., 2004; Yang et al., 2009), molecules that have been implicated in 
tumourigenesis and chemoresistance mechanisms (e.g. Verma et al., 2003; Yu and Jove, 
2004). In addition, constitutive activation of STATs is frequently observed in a variety 
of tumours (Bromberg, 2002; He et al., 2004). Despite evidence for the deregulation of 
STAT activation in lung and bone cancer cells, there is remarkably little data regarding 
the relevance of JAK/STAT signalling during lung and bone carcinogenesis. Since 
JAKs and STATs represent a point of convergence for many cytokines and, indeed, 
growth factors, they are also emerging as favoured targets for therapeutic intervention 
in human cancer therapy. We hypothesised, therefore, that JAKs and/or STATs play a 
role in FGF-2-mediated chemoresistance pathway(s). Accordingly, the main aims of 
this project were: 
 
• To investigate the generality of FGF-2-mediated chemoresistance by analysing 
additional cell types, namely NSCLC and osteosarcoma cell lines; 
• To establish the role of JAK and STAT proteins in FGF-2-mediated 
chemoresistance pathways used by different cancer cells; 
• To determine the role of mitogenic ERK2 in the regulation of the STAT3 
expression, a molecule which is increasingly recognised as a key mediator of 
tumour cell survival. 
 
 
HYPOTHESIS AND SPECIFIC AIMS
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3.1. MATERIALS 
Foetal calf serum (FCS) was purchased from FirstLink (Birmingham, UK). L-
glutamine and penicillin-streptomycin were obtained from Biowhittaker (Verviers, 
Belgium). Protease inhibitors and JAK inhibitors (JAK inhibitor I and JAK2 inhibitor II) 
were obtained from Calbiochem (Darmstadt, Germany). MEK inhibitor PD0325901 was 
provided by Pfizer (Connecticut, USA). Acrylamide was purchased from National 
Diagnostics (Hull, UK). Phosphate Buffered Saline (PBS) was purchased from OXOID 
(Hampshire, UK). Glycine, Nonidet-P40 (NP-40) and paraformaldehyde (p-FA) were 
purchased from BDH Chemicals (Poole, UK). Milk was obtained from Fluka 
BioChemika (Buchs, Switzerland). Bromophenol blue and BioRad protein assay were 
obtained from BioRad (Munich, Germany). Polyvinylidene difluoride (PVDF) 
membranes were purchased from Millipore (Bedford, USA). Ethanol, methanol and 
agarose were obtained from Fisher Scientific (Loughborough, UK). DNA 100 bp ladder 
was purchased from New England Biolabs (Hertfordshire, UK). Crystal violet was 
obtained from GURR (High Wycombe Bucks, UK). Enhanced chemiluminescence 
(ECL) detection reagents were purchased from Amersham (Buckinghamshire, UK). 
Autoradiography film was purchased from Kodak (Colorado, USA). Xylene cyanol 
was obtained from Hopkin & Williams (Essex, UK). SYBR green was purchased from 
Invitrogen (Oregon, USA). Cell viability assays were done using the Calbiochem Rapid 
Cell Proliferation Kit WST-1 (Darmstadt, Germany). All other reagents were purchased 
from Sigma-Aldrich (Steinhelm, Germany). 
Primary antibodies against JAK1 (HR 785), JAK2 (C-20), TYK2 (C-20), STAT3 
(N-terminal), STAT5A (L-20), STAT5B (G-2), ERK1 (subdomain XI), B-RAF (H145), 
BCL-2 (100), BCL-XL (H-62) and lamin B (C-20) were purchased from Santa Cruz 
Biotechnology (Heidelberg, Germany). STAT1 (N-terminal) and PY20 antibodies were 
purchased from BD Transduction Laboratories (Erembodegem, Belgium). Antibodies 
against, JAK1, phosphorylated JAK2 (pJAK2-Tyr1007/1008), phosphorylated STAT1 
(pSTAT1-Tyr701), phosphorylated STAT3 (pSTAT3-Tyr705), phosphorylated STAT5 
(pSTAT5-Tyr694), phosphorylated ERK1/2 (pERK1/2-Thr202/Tyr204), PARP and ERK5 
were obtained from Cell Signalling Technology (Hitchin, UK). Antibodies against 
MCL-1 and XIAP were from BD Pharmingen (California, USA). 4G10 and PKCε 
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antibodies were purchased from Millipore (California, USA). The antibody against β-
actin was obtained from Sigma-Aldrich (Steinhelm, Germany). The PE-conjugated 
secondary anti-mouse antibody was purchased from DAKO (Glostrup, Denmark). The 
S6K2 antibody (region between residue 430 and the C-terminus) used for 
immunoprecipitations (IPs) was obtained from Bethyl (Montgomery, USA) and the 
Western blot one was a gift from Dr Ivan Gout (University College London, London, 
UK). The gp130 antibody used for Western blot was purchased from Upstate 
Biotechnology (New York, USA) and the one used for flow cytometry (BT12) was a gift 
from Dr J. Wijdenes (Besançon, France). 
The human recombinant FGF-2 was obtained from Calbiochem (Darmstadt, 
Germany). Human IL-6 and soluble IL-6 receptor (sIL-6R) were from R&D Systems 
(Abingdon, UK). OSM was obtained from PeproTech (London, UK). Etoposide and 
cisplatin were purchased from Sigma-Aldrich (Steinhelm, Germany). IFN-γ was a gift 
from Dr G. Adolf (Ernst-Boehringer Institut für Arzneimittelforschung, Vienna, 
Austria). 
 
 
 
3.2. CELL LINES AND CULTURE 
NSCLC cell lines HCC95, HCC78, A549 and HCC193, the SCLC cell line H-510 
and osteosarcoma U2OS cells were a gift from Dr Julian Downward (Cancer Research 
UK/London Research Institute, London, UK). The JAK1-negative cell line (U4C), the 
JAK1-negative cells complemented with JAK1 (U4C.JAK1) (Leaman et al., 1998), the 
JAK2-negative cell line (γ2A), the JAK2-negative cells complemented with JAK2 
(γ2A.JAK2) (Watling et al., 1993), the TYK2-negative cells (U1A) and the TYK2-negative 
cells complemented with TYK2 (U1A.TYK2) (McKendry et al., 1991) were a gift from 
Dr. Ian M. Kerr (Cancer Research UK/London Research Institute, London, UK). Cell 
line features are summarised in Table I. 
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NSCLC, osteosarcoma and JAK-negative and -complemented cell lines are 
adherent and were grown in Dulbecco’s Modified Eagle’s medium (DMEM). The SCLC 
cell line H-510 grows in suspension and was cultured in Roswell Park Memorial 
Institute (RPMI)-1640. The cells were cultured in media supplemented with 10% (v/v) 
heat-inactivated FCS, 2 mM L-glutamine, 50 units/ml penicillin and 50 µg/ml 
streptomycin in a humidified atmosphere of 10% (NSCLC, osteosarcoma and JAK-
negative and -complemented) or 5% CO2 (SCLC) at 37 °C. Cells were typically 
passaged twice a week at a 1 in 10 dilution for U2OS, HCC95, A549, HCC193, U4C, 
U4C.JAK1, γ2A, γ2A.JAK2, U1A and U1A.TYK2, 1 in 8 dilution for HCC78 and a 1 in 2-
3 dilution for H-510. U4C.JAK1 and γ2A.JAK2 cells were grown in the presence of 0.5 
µg/ml of puromycin and U1A.TYK2 cells in the presence of 250 µg/ml of hygromycin 
B for the selection of plasmid-expressing cells. 
For experimental purposes the cells were incubated in starvation media. 
Osteosarcoma and NSCLC cell lines were grown overnight in serum-free media, or in 
Table I. Cell lines. 
Cell line Type Culture Particular features 
HCC95 NSCLC, squamous cell carcinoma Adherent - 
HCC78 NSCLC, adenocarcinoma Adherent - 
A549 NSCLC, adenocarcinoma Adherent - 
HCC193 NSCLC, adenocarcinoma Adherent - 
H-510 SCLC Suspension FGF-2-induced chemoresistance  
U2OS Bone osteosarcoma Adherent Express wild type p53 
U4C Derived from the fibrosarcoma  cell line HT1080 Adherent JAK1-deficient  
U4C.JAK1 Derived from the fibrosarcoma  cell line HT1080 Adherent 
JAK1-deficient complemented 
with JAK1 
γ2A Derived from the fibrosarcoma cell line HT1080 Adherent JAK2-deficient  
γ2A.JAK2 Derived from the fibrosarcoma cell line HT1080 Adherent 
JAK2-deficient cells 
complemented with JAK2 
U1A Derived from the fibrosarcoma cell line HT1080 Adherent TYK2-deficient  
U1A.TYK2 Derived from the fibrosarcoma cell line HT1080 Adherent 
TYK2-deficient complemented 
with TYK2 
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DMEM supplemented with 0.5% (v/v) heat-inactivated FCS, 2 mM L-glutamine, 50 
U/ml penicillin and 50 µg/ml streptomycin. The SCLC cell line was grown for 3 days 
in RPMI-1640 supplemented with 5 µg/ml insulin, 10 µg/ml transferrin, 30 nM 
sodium selenite, 0.25% (w/v) bovine serum albumin (BSA), 50 units/ml penicillin and 
50 µg/ml streptomycin. 
 
 
 
3.3. PROTEIN EXTRACTION 
Protein extractions were performed using different lysis buffers depending on 
the proteins under study, and the question being addressed experimentally. Lysis 
buffers used to extract proteins usually include a buffering agent [such as 
tris(hydroxymethyl)aminomethane (Tris)-HCl] that controls the pH of the solution, 
thus preventing denaturation or inactivation of proteins (these agents prevent the 
change in the pH of the solution by providing the corresponding conjugate acid or 
base); a salt [such as sodium chloride (NaCl)] that breaks open the cells allowing the 
release of the proteins by inducing an osmotic shock; and a detergent for lipids 
solubilisation. Detergents can be non-ionic (such as Tween-20), which solubilises 
proteins though the establishment of lipid micelles and without altering protein 
conformation, or ionic [such as sodium dodecyl sulphate (SDS)], which ionise in 
aqueous solutions and bind to the proteins, normally causing their denaturation (it is 
usually used for the complete disruption of membranes). Some buffers can also include 
a thiol compound [such as dithiothreitol (DTT)], which reduces the disulphide bonds 
of proteins and destroy intra- and inter-molecular bonds between cysteine residues of 
proteins (and consequently, their main tertiary and quaternary structure), or glycerol, 
an osmolite which stabilises protein-protein interactions, and which helps protein 
samples to sink in the loading wells of the gel after loading. Importantly, lysis buffers 
contain protease and phosphatase inhibitors that prevent protein degradation and the 
removal of phosphate groups by endogenous enzymes that are released from 
subcellular compartments during cell lysis (Deutcher, 1990). Commonly used protease 
and phosphatase inhibitors include aprotinin (a trypsin inhibitor), leupeptin (a 
lysosomal protein inhibitor), phenylmethanesulphonyl fluoride (PMSF) (a serine 
protease inhibitor), ethylenediaminetetraacetic acid (EDTA) (a metalloproteases 
inhibitor that acts by chelating metal ions such Zn2+, Ca2+ and Mg2+), sodium fluoride 
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(NaF) (a serine/threonine phosphatase inhibitor) and sodium orthovanadate (Na3VO4) 
(a tyrosine phosphatase inhibitor). 
In this work, Schindler lysis buffer was used in the vast majority of 
experiments. This buffer was initially developed to detect STATs and extracts mainly 
cytoplasmic proteins (Schindler et al., 1992). Schindler lysis buffer contains 50 mM Tris 
pH 8, 150 mM NaCl, 0.5% (v/v) NP-40 (octyl phenoxylpolyethoxylethanol), 2 mM 
DTT, 10% (v/v) glycerol, 0.1 mM EDTA pH 8, 50 mM NaF, 0.1 mM Na3VO4, 100 U/ml 
aprotinin, 10 µg/ml leupeptin and 1 mM PMSF.  
For the detection of gp130 receptor, a membrane-bound protein, extractions 
were performed using a buffer extensively used for that purpose by the Hermanns 
group (Heike Hermanns, personal communication). This buffer has been shown to 
efficiently extract gp130 from the plasma membrane. It is composed of 93.2 mM di-
sodium hydrogen phosphate [Na2HPO4(*2 H2O)], 6.8 mM sodium di-hydrogen 
phosphate [NaH2PO4(*H2O)], 0.5% (v/v) Triton X-100, 0.5 mM EDTA, 1 mM Na3VO4, 
100 U/ml aprotinin, 10 µg/ml leupeptin and 1 mM PMSF.  
For co-IPs, proteins were extracted with a lysis buffer that has been shown to 
successfully preserve protein interactions between proteins under study, and which is 
extensively used in our laboratory (Pardo et al., 2006). The co-IP lysis buffer contains 50 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 150 mM 
NaCl, 0.5% (v/v) Triton X-100, 10% (v/v) glycerol, 2 mM EDTA, 10 mM NaF, 10 mM 
β-glycerophosphate, 0.1 mM Na3VO4, 100 U/ml aprotinin, 10 µg/ml leupeptin and 1 
mM PMSF.  
Protein lysates were centrifuged at 16.2 xg for 10 minutes and the pellets were 
discarded. Protein concentrations determined by spectrophotometry using the BioRad 
protein assay according to the manufacturer’s instructions. Extracts were boiled at 
99°C for 5 minutes with a modified version of the Laemli buffer [0.5 M Tris, pH 6.8, 2% 
(w/v) SDS, 100 mM DTT, 10% (v/v) glycerol, 0.001% (w/v) bromophenol blue] before 
separation by SDS-polyacrylamide gel electrophoresis (PAGE).  
 
 
 
3.4. PROTEIN IMMUNOPRECIPITATION 
Proteins present in low abundance in cells (such as JAKs) were purified by IP 
prior to separation by SDS-PAGE. U2OS cells were plated in 15 cm plates (~4x106 
cells/plate), serum-starved overnight in DMEM supplemented with 0.5 % (v/v) of 
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FCS, penicillin and streptomycin, and then incubated in serum-free media for 2 hours 
prior to stimulation with FGF-2 (10 ng/ml). Before use beads, which were stored in 
20% (v/v) ethanol, were washed 3 times with PBS (by centrifugation at 16.2 xg for 40-
60 seconds at 4 ˚C) and re-suspended in Schindler’s buffer. After extracting the 
proteins with Schindler’s lysis buffer (chapter 3.3), 3 mg of whole cell lysates (WCL) 
were incubated rotating at 4 ˚C for 1 hour with the appropriate antibody (typically 1.6 
µg/ml), followed by 1 hour with protein A-agarose beads (25 µl of a 50% slurry 
solution). Immunoprecipitates were then washed at least 5 times (by centrifugation at 
16.2 xg for 40-60 seconds at 4 ˚C) with lysis buffer (last wash was done using 
Schindler’s buffer/PBS, 1:1) and boiled for 5 minutes with modified Laemli buffer 
before separation on a SDS-PAGE gel.  
 
 
 
3.4.1. PROTEIN CO-IMMUNOPRECIPITATION 
Co-IP was performed to detect protein-protein interactions. Co-IPs were 
conducted essentially in the same manner as the IPs albeit using a different lysis buffer 
and time of incubation of the lysate with the antibody and agarose beads. Adherent 
cells were plated and starved as described in chapter 3.4. H-510 cells were starved (in 
RPMI-1640 supplemented with insulin, transferrin, sodium selenite, BSA, penicillin 
and streptomycin) for 3 days and then aliquoted at a density of 5x104 cell/ml (1 ml per 
aliquot) in serum-free RPMI. All cells were incubated for 1 hour in serum-free media 
before treatment. After treatment, proteins were extracted using the co-IP lysis buffer 
(chapter 3.3), which has a composition adequate to perform precipitation of the target 
protein and co-precipitate binding partners/protein complexes. The antibody 
(typically 1 µg/ml) and the agarose beads (25 µl of a 50% slurry solution) were 
previously incubated in 1 ml of 3% (w/v) BSA/PBS  (per sample) overnight rotating at 
4 ˚C. Lysates were pre-cleared with agarose beads (25 µl 50% slurry solution per 
sample) for 30 minutes. After centrifugation at 0.4 xg for 20-40 seconds at 4 ˚C, the 
supernatant was transferred to another labelled eppendorf tube. Protein concentration 
was determined and 0.3-0.5 mg of protein extract was incubated with the antibody and 
beads for 3 hours, rotating at 4 ˚C. Immunoprecipitates were then washed 3 times with 
the same lysis buffer (by centrifugation at 0.4 xg for 20-40 seconds at 4 ˚C) and boiled 
for 5 minutes with modified Laemli buffer before separation on a SDS-PAGE gel. 
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3.5. SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL ELECTROPHORESIS 
AND WESTERN BLOT ANALYSIS 
Proteins were separated using a 5% acrylamide stacking gel [5% (v/v) 
acrylamide, 0.125 M Tris, pH 6.8, 0.1% (w/v) SDS, 0.075% (w/v) ammonium 
persulphate (APS) and 0.083% (v/v) Tetramethylethylenediamine (TEMED)] and a 7.5, 
10 or 12.5% acrylamide resolving gel [7.5-12.5% (v/v) acrylamide, 0.375 M Tris, pH 8.8, 
0.1% (w/v) SDS, 0.06% (w/v) APS, 0.07% (v/v) TEMED] depending on the size of 
proteins being analysed. Gels were run using a Tris-glycine running buffer [2.5 mM 
Tris, 0.2 M glycine and 0.1% (w/v) SDS] at 170 V until the dye reached the bottom of 
the gel. Proteins were transferred to a methanol-activated PVDF membrane using a 
Tris-glycine buffer [2.5 mM Tris, 0.2 mM glycine supplemented with 10% (v/v) 
methanol] at 25 V for 1 hour at 4°C using an electroblotter (Idea Scientific, Minneapolis, 
USA). Membranes were blocked in Tris-buffered saline/Tween (TBST) [0.01 M Tris, 
pH 7.4, 75 mM NaCl, 1.25 mM EDTA, pH 8.0, 0.1% (v/v) Tween 20] containing 5% 
(w/v) BSA, or 5% (w/v) milk prior to incubation with antibodies. Binding of each 
antibody was detected using ECL. After probing for the phosphorylated protein, the 
membranes were stripped of antibody using a solution of 2 M of glycine, pH 2.5 and 
0.1% (w/v) of SDS and subsequently probed for the total respective protein. β-actin 
was routinely used as an additional protein loading control. 
 
 
 
3.6. CELL DEATH / CHEMORESISTANCE ASSAYS 
Cell death and chemoresistance assays were set up similarly for all the cell lines 
used in this study: cells were plated, incubated in serum free-media the following day 
(from overnight to 3 days, depending on the cell line), pre-treated with FGF-2 for 4 
hours prior to addition of the drug and cell death assessed after 1 to 3 days. 
Adherent cells were starved (in serum-free DMEM supplemented with 
penicillin and streptomycin) overnight and then pre-treated with or without FGF-2 (10 
ng/ml) for 4 hours prior to addition of the relevant chemotherapeutic agents. 
Suspension cells were starved (in RPMI-1640 supplemented with insulin, transferrin, 
sodium selenite, BSA, penicillin and streptomycin) for 3 days and then pre-treated with 
or without FGF-2 (0.1 ng/ml) for 4 hours prior to addition of the relevant 
chemotherapeutic agents (according to Pardo et al, 2002).  
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When carrying out an assay after transfecting cells with small interfering (si) 
RNA oligonucleotides, in order to avoid variability in cell numbers due to inhibition of 
different targets, cells were trypsinised, counted and then re-plated at the same cell 
density.  
Determination of viable cells was done using the WST-1 kit (adherent cells only) 
or by cell counting by trypan blue exclusion. Cell death was also measured by 
analysing DNA loss by flow cytometry, or by analysing the cleavage of PARP and/or 
lamin-B by SDS-PAGE/Western blotting. 
 
 
 
3.6.1. CELL VIABILITY ASSAY (WST-1) 
Cells were plated in 96-well plates (3,000 cells per well) and treated as described 
in chapter 3.6. After 24 hours, 10 µl of WST-1 mixture was added to each well and cells 
incubated for 1 hour at 37 °C, essentially as indicated by the manufacturer. In this 
assay, mitochondrial dehydrogenases cleave the tetrazolium salt WST-1 reducing it 
into coloured formazan compounds. The intensity of the dye is proportional to the 
number of viable cells. The optical density (OD) of the samples was read in a 
microplate reader (Anthos 2001, Bio Whittaker, Maryland, USA) at a wavelength of 460 
nm, with a reference filter at 630 nm. Every condition was set up at least in triplicate. 
Results obtained using this assay were confirmed by manual cell counting 
(Appendix I). The results were identical and, due to its ease and higher throughput 
potential, WST-1 was thus used in most experiments set up to measure cell viability. 
Because of its low stability when in solution, the cisplatin used in this study 
was always freshly prepared, as recommended by the manufacturer. The experiments 
with U2OS, HCC95 and HCC78 in the first part of this work were performed using the 
same batch of cisplatin. Each new batch used was titrated before performing 
experiments because of concerns regarding batch-to-batch variation (Appendix II).  
 
 
 
3.6.2. CELL COUNTING 
In order to establish the reliability of the WST-1 assay, experiments have been 
set up where cell death was monitored in parallel by the WST-1 assay and manual cell 
  79 
MATERIAL AND METHODS 
counting (using a haemocytometer). The live cell number was determined using the 
trypan blue exclusion method. This method is based on the principle that in a viable 
cell most compounds do not pass through the membrane, whereas the membrane in a 
dead cell is permeable. Dead cells, therefore, show a distinctive blue colour under a 
microscope and live cells are non-permissive to trypan blue staining. After 
trypsinisation, 100 µl of cell suspension was mixed with 100 µl trypan blue. For each 
condition, cells were counted from four sets of 16 corner squares. The number of cells 
in each set of 16 corner squares is equivalent to the number of cells x 104/ ml and, thus, 
the cell concentration of cells was estimated by multiplying the average of the four 
counts by 104. Final concentration was obtained by multiplying by two (to adjust for 
the 1:2 dilution in trypan blue). 
 
 
 
3.6.3. CELL CYCLE ANALYSIS 
 Cell death can be measured by analysing DNA content using flow cytometry. 
This method is based on the principle that dying cells are characterised by 
morphological changes, and fragmentation and loss of DNA content (reviewed by 
Danial et al., 2004). After staining with a DNA-binding dye, such as propidium iodide 
(PI), cells that have lost DNA will take up less stain and this can be evaluated by flow 
cytometric analysis. Dead cells will appear on the left of the G1 peak (Sub-G1 
population, Fig. 12).  
To measure cell death by analysing loss of DNA content, osteosarcoma and 
NSCLC cells were harvested after 18 hours of drug treatment (trypsinised adherent 
cells and floating ‘corpses’) and SCLC cells were harvested after 4 days of drug 
treatment. After cells were harvested, they were washed twice with PBS by 
centrifugation at 178 xg for 5 minutes, and fixed and permeabilised in cold 70% (v/v) 
ethanol (added drop-wise while gently vortexing). After fixing at 4 °C for at least 30 
minutes, specimens were washed twice with PBS by centrifugation at 178 xg for 5 
minutes. Cells were then resuspended in 400 µl of PBS, treated with 10 µg/ml of 
ribonuclease (RNase) to destroy RNA and incubated briefly with 50 µg/ml of PI, which 
intercalates with the DNA. DNA content was measured by flow cytometry in a 
BDFacsCantoTM (BD Biosciences, Erembodegem, Belgium).  
Data mining and analysis was done using FlowJo (Tree Star Inc., Oregon, USA). 
Cell doublets were excluded using gates based on cell diameter (Appendix III). 
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Figure 12. Example of a population cell cycle profile obtained by flow cytometry. Cells were 
stained with a DNA-binding dye (PI) and DNA content was measured by flow cytometry. G1 corresponds 
to the first phase after mitosis and cells have 2n DNA content. In S phase, cells synthesise DNA. In G2/M 
phase cells are ready to complete cell division and have double DNA content of a cell in G1. The Sub-G1 
population corresponds to the percentage of cells with a DNA content of less than 2n and thus 
corresponds to cells that lost DNA and are presumably dead. 
 
 
 
 
 
 
3.6.4. APOPTOSIS ANALYSIS BY POLY-(ADP-RIBOSE) POLYMERASE AND 
LAMIN B CLEAVAGE 
One of the key initiating events of the apoptotic pathway is the activation of 
caspases (cysteine-aspartic acid proteases) followed by cleavage of caspase substrates 
(Earnshaw et al., 1999). PARP is a 116 kDa protein mainly involved in DNA repair, 
which is cleaved by members of the caspase family during early apoptosis (Herceg and 
Wang, 2001). Detection of an 85 kDa, or 31 kDa cleavage fragment of PARP has been 
shown to be a bona fide marker of apoptosis (Lazebnik et al., 1994). Another read-out for 
apoptosis is the proteolytic cleavage of lamin B (the full length protein is 67 kDa). 
Nuclear lamin, located at the inner nucleoplasmic surface, is targeted by proteases 
during the early stages of cell death (Lazebnik et al., 1993). Cleavage of lamin B by the 
caspases usually generates a fragment of 45 kDa.  
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To assess apoptosis, cells were harvested after 16 hours of drug treatment. 
Protein was extracted from all cells (adherent cells and floating ‘corpses’). Cleavage of 
PARP and lamin B was monitored by SDS-PAGE/Western blot using antibodies that 
recognise both the total and cleaved forms of these proteins. 
 
 
 
3.7. REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR) 
RT-PCR was used to determine the expression of two canonical FGF-2 
receptors. Primers were designed to amplify a fragment of the FGFR1 and FGFR2IIIc. 
Primers for FGFR2IIIc amplify only this splice variant since they amplify a segment of 
the intron 9, unique to the FGFR2IIIc variant. 
Total RNA was isolated using RNeasy (Qiagen, West Sussex, UK), as directed 
by the manufacturer, and RNA concentrations were measured using a NanoDrop 
ND1000 spectrophotometer (Labtech international, East Sussex, UK). Reverse 
transcription was performed using a one-step RT-PCR kit (QIAGEN, West Sussex, 
UK). RT-PCR reactions were carried out in a 50 µl reaction volume containing 30 ng of 
template RNA, 1x RT-PCR buffer, 1x Q-Solution, 400 µM of each dNTP, 0.6 µM of each 
primer and 2 µl of RT-PCR enzyme mix, as directed by the manufacturer. The RT-PCR 
amplification conditions were set up according to the manufacturer’s guidelines: 30 
seconds at 50 ºC, 15 minutes at 95 ºC, followed by 35 cycles of 45 seconds at 94 ºC, 1 
minute at annealing temperature (Ta), 1 minute at 72 ºC, with a final extension at 72 ºC 
(10 minutes). The specific primers and correspondent Ta used to amplify the different 
fragments are shown in Table II.  
RT-PCR products together with loading dye [5% (v/v) glycerol, 0.05% (w/v) 
bromophenol blue, 0.05% (w/v) xylene cyanol] were run on a 2% agarose gel 
containing SYBR green. Products were checked based on their size against a 100 bp 
DNA ladder. A fragment of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
was amplified from all samples as a loading control. An extra reaction without RNA 
template (blank control) was carried out for each RT-PCR mix in order to detect 
potential contaminations. No contaminations were ever detected in the blank controls. 
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3.8. CRYSTAL VIOLET STAINING 
Microscopic images from cells were obtained from cells stained with crystal 
violet. Plates were washed twice with cold PBS and cells were fixed with 4% (w/v) p-
FA overnight at room temperature (RT). Plates were then washed and the fixed cells 
stained with 0.075% (w/v) crystal violet solution prepared in 5% (v/v). Plates were 
carefully rinsed in deionised water (ddH2O) until colour was no longer coming off in 
the rinse and dried overnight at RT. Pictures were taken using a Nikon Eclipse TE2000-
U microscope (100x magnification) and images were processed using QCapture Pro 
software. 
 
Table II. Sequences and annealing temperatures for each set of PCR primers. 
mRNA Primer sequences Ta Product size 
FGFR1 
FGFR1.F  ATATTGGACATCCCCAGAAAAGATGG 
FGFR1.R  TCTGGACATAAGGCAGGTTGTCTGG 
58 470 bp 
FGFR2IIIc 
FGFR2IIIc.F  GTCGGGGAATATACGTGCTTGGCGG 
FGFR2IIIc.R CAGGGGCTTGCCCAGTGTCAGCTT 
58 455 bp 
GAPDH 
GAPDH.F  GGGAAGCTTGTCATCAATGG 
GAPDH.R  GACTTTGCCTACAGCCTTGG 
52 450 bp 
JAK1 
JAK1.F  ATGCCCATCATTACCTCTGC 
JAK1.R  GCAGGATCTGCTTCTTGAGG 
52 341 bp 
JAK2 
JAK2.F  GAAACGGTGGAATTCAGTGG 
JAK2.R  ACATTTTCTCGCTCGACAGC 
52 463 bp 
STAT1 
STAT1.F  CATTCAGAGCTCGTTTGTGG 
STAT1.R  TGGTGGAGTCAGGAAGAAGG 
52 538 bp 
STAT3 
STAT3.F  GAGAAGCCAATGGAGATTGC 
STAT3.R GATTCTCTCCTCCAGCATCG 
52 641 bp 
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3.9. RNA INTERFERENCE (RNAI) 
For siRNA transfections, cells were plated in 24-well, 6-well or in 10 cm plates. 
Transfection and knockdown conditions were already optimised in our laboratory for 
U2OS, A549 and HCC193 cells (Table III).  
 
 
 
 
 
 
 
 
 
Oligonucleotides (siGENOME and siOnTargetPlus) and transfection reagents 
(DharmaFECT®) were sourced from Dharmacon (Lafayette, CO, USA) and were used 
in all experiments. Cells were plated, 24 hours later transfected with 75 nM of the 
appropriate pool of oligonucleotides (Table IV) and incubated for 48 hours more. 
Controls used included untransfected cells, mock-transfected cells (DharmaFECT® 
only) and cells transfected with a non-specific (NS) siRNA pool (a pool of siRNA 
oligonucleotides that were individually characterised by genome-wide microarray 
analysis, which identified minimal off-target signatures). Cells were subsequently 
treated as required. 
Table III. siRNA transfection conditions. 
Cell density 
Cell line 
24-well plates 6-well plates 10 cm plates 
Transfection reagent  
(volume per 100 µl) 
U2OS 4x104 cells / well 1x105 cells / well 1x106 cells / plate DharmaFECT® II (2µl) 
A549 4x104 cells / well - - DharmaFECT® I (1µl) 
HCC193 6x104 cells / well - - DharmaFECT® I (1µl) 
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3.10. GP130 DETECTION BY FLOW CYTOMETRY 
Cell surface levels of gp130 receptor were measured by flow cytometry. Forty-
eight hours after siRNA transfection, cells were removed from the plates with trypsin-
EDTA and washed with ice-cold PBS. Cells were incubated initially with an anti-gp130 
antibody (BT12) for 1 hour and, after two washes with cold PBS, cells were incubated 
with a PE-conjugated secondary antibody for 45 minutes. Cells were subsequently 
Table IV. Sequences of each set of siRNA oligonucleotides (Dharmacon). 
Target 
Name and 
accession number  siRNA Product 
siRNA oligonucleotide target 
sequences 
ERK1 MAPK3 NM_002746 
 
siGENOME 
  
1.   GACCGGAUGUUAACCUUUAUU 
2.   AGACUGACCUGUACAAGUUUU 
3.   GAAACUACCUACAGUCUCUUU 
6.   GCUACACGCAGUUGCAGUAUU 
ERK2 MAK1 NM_002745 siGENOME 
1.   CCAAAGCUCUGGACUUAUUUU 
3.   AAACAGAUCUUUACAAGCUUU 
4.   CAAGAGGAUUGAAGUAGAAUU 
9.   GUACAGGGCUCCAGAAAUUUU 
JAK1 JAK1 NM_002227 siGENOME 
5.   CCACAUAGCUGAUCUGAAA 
6.   UGAAAUCACUCACAUUGUA 
7.   UAAGGAACCUCUAUCAUGA 
8.   GCAGGUGGCUGUUAAAUCU 
JAK2 JAK2  NM_004972 siGENOME 
6.   GAGCAAAGAUCCAAGACUA 
7.   GCCAGAAACUUGAAACUUA 
9.   GAUCCUGGCAUUAGUAUUA 
10. ACAGAAUGCUGGAACAAUA 
STAT1 
STAT1  
NM_007315 siGENOME 
1.   AGAAAGAGCUUGACAGUAAUU 
3.   UAAAGGAACUGGAUAUAUCUU 
4.   GAGCUUCACUCCCUUAGUUUU 
5.   GAACCUGACUUCCAUGCGGUU 
STAT3 
STAT3 
NM_003150 siGENOME 
1.   CCAACGACCUGCAGCAAUAUU 
2.   GGAGAAGCAUCGUGAGUGAUU 
3.   CCACUUUGGUGUUUCAUAAUU 
4.   UCAGGUUGCUGGUCAAAUUUU 
STAT5A 
STAT5A 
NM_003152 siGENOME 
1.   GCACGUGGAGGAACUCUUAUU 
2.   ACAGAACCCUGACCAUGUAUU 
5.   CUACUGUGCUGUGGGACAAUU 
6.   GUACUACACUCCUGUGCUGUU 
STAT5B 
STAT5B 
NM_012448 siGENOME 
1.   GGACACAGAGAAUGAGUUAUU 
2.   GAAGUUUGAUUCUCAGGAAUU 
3.   CCAAGUCUCUGCUCAAGAAUU 
5.   GAGAACACCCGCAAUGAUUUU 
TYK2 TYK2 NM_003331 siGENOME 
6.   GCAUCCACAUUGCACAUAA 
7.   UCAAAUACCUAGCCACACU 
8.   CAAUCUUGCUGACGUCUUG 
21. CACAAGGACCAACGUGUAU 
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washed three times with ice-cold PBS, fixed with 1% p-FA (w/v) and analysed on a 
FACSCanto machine (BD, Erembodegem, Belgium).  
Data mining and analysis was done using FlowJo. Differences between the 
geometric mean values of cells stained with BT12 antibody and cells stained with 
secondary antibody only were compared between samples. The geometric mean 
calculates the nth root of the product of n measurements and gives the average of the 
logarithmic values of a data set, converted back to a base 10 number. It estimates the 
quantity of molecules expressed per cell and is a more applicable metric for a 
logarithmically normal distribution than the percentage of cell population. 
 
 
 
3.11. STATISTICAL ANALYSIS 
Mean and standard error of the mean (SEM) of independent experiments were 
calculated. Student’s t-test was used to determine the statistical significance of the 
differences observed between conditions. A two-tailed p-value below 0.05 was 
considered significant.  
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THE ROLE OF FGF-2 IN CHEMORESISTANCE 
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4.1.1. INTRODUCTION 
Nowadays many chemotherapeutic agents are available and survival rates of 
cancer patients have slightly improved. However, development of drug resistance by 
the tumour cells limits the use of these agents and eventually leads to failure to cure 
the patients (Hanahan and Weinberg, 2000). This problem is exemplified by lung 
cancer, which is almost never cured with initial therapy and is mostly chemoresistant 
upon relapse. These two factors contribute to a very low overall survival. 
Consequently, understanding the mechanisms underlying chemoresistance is critical 
for the development of new therapeutic approaches that might extend patient survival.  
FGF-2 is a growth factor that plays an important role in cancer biology (Giri et 
al., 1999; Dickson et al., 2000; Nurcombe et al., 2000; Polnaszek et al., 2003) and, indeed, 
it has been implicated in driving chemoresistance in cancer cells, including lung and 
breast cancer cells (Pardo et al., 2002; Pardo et al., 2003; Song et al., 2000; Vandermoere 
et al., 2005; Smaragda Angelidou and Michael Seckl, personal communication). FGF-2 
has been shown to confer resistance to etoposide-mediated apoptosis in SCLC cells via 
a MEK-dependent pathway that results in the up-regulation of various anti-apoptotic 
proteins such as BCL-XL, BCL-2, XIAP and cIAP. Indeed, Seckl and colleagues (Pardo et 
al., 2006) have shown that FGF-2-mediated chemoresistance requires the formation of a 
multi-protein complex consisting of at least B-RAF, PKCε and S6K2.  
In the first part of this work, our main aim was to investigate the generality of 
the FGF-2-mediated chemoresistance mechanism by analysing additional cell types, 
namely osteosarcoma and NSCLC cells. This was done using cisplatin, a clinically 
relevant chemotherapeutic drug commonly used to treat many cancer types. To 
understand the role of FGF-2 in cisplatin-mediated cell death three cell lines were used: 
two NSCLC cell lines (HCC95 and HCC78) and an osteosarcoma cell line (U2OS). The 
HCC95 and HCC78 cell lines were derived from patients with squamous cell and 
adenocarcinoma, respectively. The U2OS cell line is morphologically classified as 
epithelial and was used to extend the original findings to other types of cancers 
commonly treated with cisplatin (Bielack et al., 2004; Ta et al., 2009) and in which FGF-2 
may also have an important role in disease progression (Graeven et al., 1999). In 
addition, the U2OS cell line has been extensively utilised by the Costa-Pereira Group, 
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and, as such, many experimental protocols were already developed/ optimised for this 
cell line.  
The first step was to determine how the three cell lines responded to FGF-2. The 
kinetics of FGF-2-induced ERK1/2 activation were initially characterised in the NSCLC 
HCC95 and HCC78 cells, and the osteosarcoma U2OS cell line by performing dose- 
and time-responses with FGF-2. The expression levels of FGF-2 canonical receptors 
were also determined in order to ensure that a defect in the response to FGF-2 was due 
to an intracellular defect rather than due to lack, or mutation, of the appropriate 
receptor(s). Subsequently, we tested whether FGF-2 could rescue these cells from 
cisplatin-induced cell death. Furthermore, major players involved in FGF-2-mediated 
chemoresistance previously described for the SCLC cell line H-510 (Pardo et al., 2006) 
were also investigated. 
 
 
 
4.1.2. FGF-2 RESPONSE IN NSCLC AND U2OS CELLS 
FGF-2 is known to activate ERK1/2 in many cell types including lung cancer 
and osteosarcoma cells (Wang et al., 2000; Pardo et al., 2001; Kuhn et al., 2006). The 
activity of these kinases can be monitored by Western blot using an antibody that 
recognises both phosphorylated ERK1 and ERK2. To investigate if FGF-2 activated 
ERK1/2 in the osteosarcoma U2OS cell line and the NSCLC cell lines HCC95 and 
HCC78, cells were incubated with increasing doses of FGF-2 for different periods of 
time. Treatments were performed after serum starvation (0.5% FCS overnight and 
serum-free media for 1 hour prior to FGF-2 treatment) in order to reduce the basal 
ERK1/2 phosphorylation potentially induced by FCS components.  
Using this approach, we observed that FGF-2 induced the phosphorylation of 
ERK1/2 in U2OS cells (Fig. 13). A statistically significant increase of ERK1/2 
phosphorylation (p<0.05-0.005 for ERK1 and p<0.05-p<0.01 for ERK2) was observed 
after treatment with all doses tested (1-50 ng/ml) (Fig. 13 A). Treatment with 10 ng/ml 
of FGF-2 induced maximal ERK1/2 phosphorylation, which was on average for ERK1 
13.2-fold and for ERK2 4.3-fold above basal levels (Fig. 13 A, 3rd bar in the graphs). 
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Figure 13. ERK1/2 phosphorylation in response to FGF-2 in U2OS cells. U2OS cells were serum-
starved (0.5% FCS) overnight and then incubated in serum-free media for 1 hour. Cells were stimulated 
with FGF-2 for 10 minutes with the indicated concentrations (A.) and with 25 ng/ml of FGF-2 for the 
indicated times (B.). Proteins were extracted and separated on a 10% SDS-PAGE gel. Western blotting 
analysis was performed on total cell lysates using antibodies against pERK1/2-Thr202/Tyr204 and total 
ERK1/2. β-actin was used as a loading control. Representative Western blots and mean ± SEM of 
densiometric values of at least three independent experiments are shown in graphs. Values are expressed 
as fold change relative to untreated controls. Statistical analysis was performed using Student’s t-test (* – 
p<0.05, ** – p<0.01, *** – p<0.005 versus untreated control). ‘ – minutes, h – hours.  
A.  B.  
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Phosphorylation of ERK1/2 increased at 5 minutes and peaked at 10 minutes (p<0.005 
and p<0.01 for ERK1 and ERK2, respectively) (Fig. 13 B, 4th and 5th bars in the graphs). 
After 10 minutes, the phosphorylation levels decreased but were sustained above basal 
for up to 24 hours (particularly that of ERK2).  
Membranes were subsequently probed for total ERK1/2 and β–actin. Some 
differences in total ERK1/2 levels could be observed between FGF-2 untreated and 
FGF-treated samples (Fig. 13). These differences may be related to the ERK1/2 band 
shift due to phosphorylation, which may be responsible for a less defined band in FGF-
2 treated samples. Alternatively, the differences may be due to incomplete stripping of 
the anti-phospho-ERK1/2 antibody (this antibody is particularly difficult to remove 
from the membrane by stripping). This could interfere with the binding of the total 
ERK1/2 antibody. Accordingly, densiometric values of all conditions were normalised 
using β–actin. 
 
FGF-2 also activated ERK1/2 in the HCC95 cell line in a dose dependent 
manner (Fig. 14 A). In these cells, peak activation of ERK1/2 was also observed at 10 
minutes, with an average 7.9-fold induction for ERK1 (p<0.005) and 5.1-fold induction 
for ERK2 (p<0.01) (Fig. 14 B, 5th bar in the graphs). Contrary to U2OS cells (Fig. 13), 
phosphorylation of ERK1/2 in response to FGF-2 was transient: induction of ERK1 
phosphorylation was not statistically significant beyond 2 hours of FGF-2 treatment 
(Fig. 14 B, 10th-12th bars in the top graph) and the increase in ERK2 phosphorylation 
was not statistically significant past 30 minutes of stimulation (Fig. 14 B, 8th-12th bars in 
the bottom graph). In particular, ERK2 phosphorylation was below the basal level after 
incubation with FGF-2 for 24 hours (p<0.005) (Fig. 14 B, 12th bar in the bottom graph).  
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Figure 14. ERK1/2 phosphorylation in response to FGF-2 in HCC95 cells. HCC95 cells were 
serum-starved (0.5% FCS) overnight and then incubated in serum-free media for 1 hour. Cells were 
stimulated with FGF-2 for 10 minutes with the indicated concentrations (A.) and with 25 ng/ml of FGF-2 
for the indicated times (B.). Proteins were extracted and separated on a 10% SDS-PAGE gel. Western 
blotting analysis was performed on total cell lysates using antibodies against pERK1/2-Thr202/Tyr204 and 
total ERK1/2. β-actin was used as a loading control. Representative Western blots and mean ± SEM of 
densiometric values of at least three independent experiments are shown in graphs. Values are expressed 
as fold change relative to untreated controls. Statistical analysis was performed using Student’s t-test (* – 
p<0.05, ** – p<0.01, *** – p<0.005 versus untreated control). ‘ – minutes, h – hours. 
 
A.  B.  
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In marked contrast to U2OS and HCC95 cells, FGF-2-induced phosphorylation 
of ERK1/2 in HCC78 cells was very modest (Fig. 15). The increase of ERK1/2 
phosphorylation observed in response to FGF-2 was not statistically significant in the 
dose-response experiments performed (Fig. 15 A). Results, however, still suggest that 
the ERK1/2 phosphorylation was slightly increased upon FGF-2 treatment, measuring 
an average of 1.4-fold for ERK1 and 1.3-fold for ERK2 (Fig. 15 B). Although the 
induction of ERK1/2 phosphorylation by FGF-2 was much smaller than that observed 
in the other cell lines studied, the effect reached statistical significance at some time 
points: at 10 and 20 minutes for ERK1 (p<0.05 and p<0.01, respectively) (Fig. 15 B, 5th 
and 6th bars in the top graph) and at 5 minutes for ERK2 (p<0.05) (Fig. 15 B, 4th bar in 
the bottom graph). The phosphorylation of ERK1/2 was reduced compared to basal 
levels after 20 minutes treatment with FGF-2 (Fig. 15 B, 7th-12th lane in the Western 
blot), presumably due to a negative control mechanism (e.g. phosphatase activity). This 
decrease, however, was not statistically significant. 
Although the increase in ERK1 phosphorylation reached statistical significance 
in the treatment with 25 ng/ml of FGF-2 for 10 minutes (p<0.05) (Fig. 15 B, 5th bar in 
the top graph), the equivalent conditions in the dose-response experiments (same 
concentration and time of FGF-2 stimulation) did not reach statistical significance (Fig. 
15 A, 4th bar in the top graph). This reflects variation between experiments. Such a 
small increase in phosphorylation is less robust than a larger increase and it could have 
been affected by many factors. Although every effort was made to standardise the 
experimental method in order to avoid variation associated with cell density, or sample 
handling, other factors such as cell cycle are more difficult to control.  
These observations suggest that in HCC78 cells, FGF-2 only led to a weak 
activation of the MEK/ERK pathway.  
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Figure 15. ERK1/2 phosphorylation in response to FGF-2 in HCC78 cells. HCC78 cells were 
serum-starved (0.5% FCS) overnight and then incubated in serum-free media for 1 hour. Cells were 
stimulated with FGF-2 for 10 minutes with the indicated concentrations (A.) and with 25 ng/ml of FGF-2 
for the indicated times (B.). Proteins were extracted and separated on a 10% SDS-PAGE gel. Western 
blotting analysis was performed on total cell lysates using antibodies against pERK1/2-Thr202/Tyr204 and 
total ERK1/2. β-actin was used as a loading control. Representative Western blots and mean ± SEM of 
densiometric values of at least three independent experiments are shown in graphs. Values are expressed 
as fold change relative to untreated controls. Statistical analysis was performed using Student’s t-test (* – 
p<0.05, ** – p<0.01 versus untreated control). ‘ – minutes, h – hours. 
 
A.  B.  
  95 
RESULTS 
4.1.3. EXPRESSION OF CANONICAL FGF-2 RECEPTORS IN NSCLC AND U2OS 
CELLS  
FGFRs 1 and 2 are the main receptors for FGF-2 (Ornitz et al., 1996). In order to 
determine the expression levels of FGF-2 receptors FGFR1 and FGFR2IIIc (a FGFR2 
isoform used by FGF-2) in U2OS, HCC95 and HCC78 cell lines, total RNA was 
extracted from cells, reverse-transcribed into cDNA and fragments from the FGFRs 
amplified by RT-PCR. Prostate cancer LNCaP cells, which are known to express both 
receptors (Susan Willis and Michael Seckl, personal communication), were used as a 
positive control. Similar RNA levels of FGFR1 were detected in all of the three cell lines 
studied (Fig. 16). FGFR2IIIc was amplified successfully in U2OS and HCC95 cells, but 
it was not detected in the HCC78 cell line even after 35 cycles of amplification. These 
results suggest that the receptor FGFR2IIIc is not expressed in HCC78 cells. This, 
together with our previous data (Fig. 15 B), suggests that FGF-2, in these cells, may 
bind to a receptor complex different from the one bound by FGF-2 in U2OS and 
HCC95 cells. The precise identity of which FGFRs might mediate FGF-2 action was 
beyond the scope of this work and was therefore not pursued.  
The detection of FGFR by RT-PCR does not reflect protein levels or cell surface 
localisation of the different receptors. This method establishes which receptors are 
transcribed and thus potentially expressed in the cells. Detection of FGFRs by Western 
blot would have made possible to determine if the receptors were effectively expressed 
in these cell lines and flow cytometric analysis of unpermeabilised cells would have 
established if they were present on the cell surface and, if so, in what abundance. 
Unfortunately, FGFR antibodies currently commercially available do not discriminate 
between the multiple FGFR isoforms and are unsuitable for flow cytometry. When 
better antibodies become available, these will be crucial experiments to determine the 
expression of canonical FGF-2 receptors. Alternatively, we could have designed siRNA 
molecules targeting a single FGFR isoform and used them to silence each of them 
independently. The cells (U2OS, HCC78 and HCC95) could then be treated with FGF-2 
and phosphorylation of ERK1/2 monitored. An inhibition/significant reduction of 
ERK1/2 phosphorylation, when compared to untransfected cells and cells transfected 
with a non-targeting siRNA molecule, would have been suggestive of the isoforms 
required for signalling in response to FGF-2. The main caveat here is that due to the 
lack of appropriate isoform-specific antibodies the specific knockdown could only be 
assessed at the RNA level. 
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Figure 16. Expression of FGF-2 receptors FGFR1 and FGFR2IIIc in NSCLC HCC95 and 
HCC78 and U2OS cell lines determined by RT-PCR. Fragments of FGFR1 and FGFR2IIIc were 
amplified by RT-PCR in U2OS, HCC95 and HCC78 cells. RT-PCR products were run on an agarose gel. 
LNCaP cells were used as a positive control. GAPDH was amplified and used as a loading control. These 
results are representative of two independent experiments. 
 
 
 
 
 
4.1.4. FGF-2 INDUCED PROLIFERATION OF U2OS CELLS BUT NOT OF NSCLC 
CELLS 
FGF-2 was shown to promote proliferation in some SCLC cell lines (Pardo et al., 
2001). This was also shown in other cells lines, such as lung, prostate and pancreatic 
cancer cells, and human embryonic stem cells (hESCs) (Yamanaka et al., 1993; Fukui et 
al., 2003; Polnaszec et al., 2003; Xu et al., 2005; Berger et al., 1999). To assess the effect of 
FGF-2 on the proliferation of the osteosarcoma cell line U2OS and the NSCLC cell lines 
HCC95 and HCC78 we used a cell viability assay (WST-1) (cf. Material and methods). 
This assay measures the cleavage of the tetrazolium salt WST-1 (light red) to formazan 
compounds (dark red) by mitochondrial dehydrogenases in living cells. The intensity 
of the dye is proportional to the number of viable cells. This cell viability assay has a 
number of clear advantages when compared to other methods [e.g. [3H]-thymidine or 
5-bromo-2’-deoxyuridine (BrdU) incorporation] such as the fact that the cells do not 
need to be washed or harvested, no radioactivity or volatile solvents are required, it is 
more sensitive than the 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) assay and the absorbance correlates with the amount of cells alive. We 
tested the correlation between the results obtained using the WST-1 assay and cell 
  97 
RESULTS 
counting using trypan blue and a light microscope by performing the experiments in 
parallel. The results obtained were identical (Appendix I) and WST-1 was thus used in 
most experiments to measure cell viability. 
HCC95, HCC78 and U2OS cells plated in 96-well plates were treated with 
increasing concentrations of FGF-2 for 24 hours after an overnight starvation in serum-
free media. Cell viability was measured using WST-1. All treated samples were 
compared to the respective untreated controls. Proliferation of U2OS cells significantly 
increased (p<0.005) with the addition of FGF-2, in a dose-dependent manner, reaching 
a peak with 10 ng/ml (Fig. 17 A and B). In contrast, under the experimental conditions 
used, increased proliferation of the two NSCLC cell lines studied (HCC78 and HCC95) 
in response to FGF-2 was not observed (Fig. 17 A and B). These results suggest that 
FGF-2 has a functional effect on the growth of U2OS cells but not on the growth of 
HCC95 or HCC78 cells. 
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Figure 17. FGF-2 induced proliferation of U2OS but not of NSCLC cells. Cells were plated in 96-
well plates (3,000 cells per well), starved overnight (in serum-free media) and then treated with FGF-2 at 
the indicated concentrations for 24 hours. Cell viability was measured using the WST-1 cell viability assay. 
A. Results from one experiment are presented as fold induction relative to untreated controls. Values 
correspond to the OD of coloured formazan compounds derived from cleavage of the tetrazolium salt 
WST-1 by mitochondrial dehydrogenases. Each condition was set up in triplicate, and the results are 
shown as mean ± standard deviation. B. Mean ± SEM of three independent experiments performed in 
triplicate are shown in a graph. Values are expressed as fold change relative to untreated controls. 
Statistical analysis was performed with Student’s t-test (*** – p<0.005 versus untreated control). 
 
A.  
B.  
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 FGF-2 treatment for longer periods of time (48 and 96 hours) had no significant 
effect on NSCLC whereas in U2OS cells, increased proliferation was still observed at 48 
hours and, to a lesser extent, at 96 hours (data not shown). At these later time points 
the cells were at a much lower density and appeared to exhibit a different morphology 
compared to the cells incubated in media supplemented with 10% FCS (Fig. 18 A). 
Cells incubated for 96 hours in FCS-supplemented media exhibited a spindle-shaped 
appearance while the cells incubated in serum-free media for the equivalent period of 
time exhibited a more elongated shape and were sparser. After 96 hours of starvation 
cell viability was also significantly reduced by 0.8-fold (p<0.005) when compared to the 
number of cells incubated in fully complemented media (Fig. 18 B). A reduction in cell 
viability could already be observed after 24 (0.5-fold decrease, p<0.005) and 48 hours 
(0.7-fold decrease, p<0.005). The differences in cell morphology and density observed 
were likely due to the long-term starvation of the cells. Therefore, all subsequent 
experiments were performed within a 24 hours window.  
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Figure 18. Effect of serum starvation on cell morphology and density of U2OS. Cells were 
plated in 96-well plates (3,000 cells per well), incubated in serum suplemented with 10% FCS or serum-free 
media (0%FCS) for 24, 48 and 96 hours. A. Cells were fixed in p-FA and stained with crystal violet. 
Samples were visualised using a Nikon Eclipse TE2000-U microscope (100x magnification) and images 
were processed using QCapture Pro software. The scale bar refers to all the pictures. B. Cell viability was 
measured using the WST-1 cell viability assay. Values correspond to the OD of coloured formazan 
compounds derived from cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases and 
are expressed as fold change over the 10% FCS condition for each time point. Mean ± SEM of three 
independent experiments performed in triplicate are shown in graphs. Statistical analysis was performed 
with Student’s t-test (*** – p<0.005 versus 10% FCS condition). h – hours.  
 
 
 
B. 
 
A. 
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4.1.5. FGF-2 PROTECTED U2OS CELLS FROM CISPLATIN-INDUCED CELL 
DEATH BUT NOT NSCLC HCC95 AND HCC78 CELLS 
In order to investigate if FGF-2 induced chemoresistance in the osteosarcoma 
cell line U2OS and the NSCLC cell lines HCC95 and HCC78 cells were treated with 
cisplatin, a clinically relevant chemotherapeutic drug commonly used to treat NSCLC 
and osteosarcoma (Bielack et al., 2004; Buter et al., 2005; Ta et al., 2009). To assess which 
doses of cisplatin induced around 50% of cell death in these cell lines, cells were 
treated with increasing concentrations of the drug for 24 hours (Fig. 19). Cell viability 
was determined using the WST-1 cell viability assay. The LD50 (lethal dose that caused 
50% killing of the cells) was approximately 120 µM for U2OS, 100 µM for HCC95 and 
400 µM for HCC78. These observations suggest that HCC95 and U2OS cells were more 
sensitive to cisplatin than HCC78 cells. Indeed, 100 µM of cisplatin reduced the 
viability of U2OS cells by approximately 20% (p<0.005) and of HCC95 cells by 
approximately 50% (p<0.005) without significantly affecting HCC78 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Cisplatin-induced cell death in U2OS, HCC95 and HCC78 cells. Cells were plated in 
96-well plates (3,000 cells/well) and incubated in serum-free media overnight. Cells were treated with 
increasing doses of cisplatin for 24 hours. Cell viability was measured using the WST-1 cell viability assay. 
Values correspond to the OD of coloured formazan compounds derived from cleavage of the tetrazolium 
salt WST-1 by mitochondrial dehydrogenases. Mean ± SEM of three independent experiments, each 
performed in triplicate, are presented as fold induction over untreated controls. Statistical analysis was 
performed with Student’s t-test (*** – p<0.005 versus untreated control).  
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 To investigate the effect of FGF-2 on cisplatin-induced cell death, cells were 
pre-treated with or without FGF-2 for 4 hours prior to addition of cisplatin (cf. Material 
and methods). Previous experiments showed that four hours were required for the 
induction of early cell survival signalling pathways necessary for inducing 
chemoresistance (Pardo et al., 2002 and our own observations, Fig. 28, Section 4.1.9). 
Henceforth, these experiments will be referred to as “rescue experiments”. Rescue 
experiments were performed with 10 ng/ml of FGF-2. This dose was chosen based on 
its activity as measured by ERK1/2 phosphorylation (Fig. 13, 14 and 15). Individual 
LD50 doses of cisplatin were chosen in order to assess whether FGF-2 could prevent 
drug-induced cell death in HCC95, HCC78 and U2OS cell lines. 
The cisplatin used in this study was always freshly prepared, as recommended 
by the manufacturer, and each batch titrated before performing experiments. This was 
because cisplatin has low stability when in solution and because of concerns regarding 
batch-to-batch variation (Appendix II). Such precautions were taken in order to reduce 
variability between experiments.  
As previously observed (Fig. 17), FGF-2 significantly induced proliferation of 
U2OS cells (p<0.005) (Fig. 20 A, 1st versus 2nd bar). Treatment of U2OS cells with 
cisplatin alone for 24 hours induced 50% of killing (p<0.005) (Fig. 20 A, 1st versus 3rd 
bar). Incubation of U2OS cells with 10 ng/ml of FGF-2 for 4 hours prior to adding 
cisplatin, substantially blocked cell killing induced by 24 hours treatment with 
cisplatin, suggesting that FGF-2 confers protection to U2OS cells against cisplatin-
induced cell killing (Fig. 20 A, 3rd versus 4th bar). The difference between cells treated 
with cisplatin alone and cells treated with FGF-2 before cisplatin was statistically 
significant (p<0.01). 
As expected, cisplatin treatment also induced 50% of killing in the NSCLC cells 
HCC95 (p<0,01) and HCC78 (p<0.005) (Fig. 20 B and C, 1st versus 3rd bar). However, in 
these cell lines, pre-treatment with FGF-2 did not block cisplatin-mediated killing as 
shown by the lack of statistical significance between cells treated with cisplatin alone 
and cells treated with FGF-2 prior to cisplatin (Fig. 20 B and C, 3rd versus 4th bar). These 
results thus suggest that, unlike U2OS cells, FGF-2 did not rescue HCC95 and HCC78 
cells from cisplatin-mediated cell death.  
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Figure 20. FGF-2 protected U2OS but not NSCLC HCC95 and HCC78 cells from cisplatin-
mediated cell killing. A., B. and C. Cells were plated in 96-well plates (3,000 cells/well) and incubated 
in serum-free media overnight. After 4 hours pre-treatment with FGF-2 (10 ng/ml), each cell line was 
treated with the LD50 of cisplatin for 24 hours. Cell viability was measured using the WST-1 cell viability 
assay. Mean ± SEM of three independent experiments performed in triplicate are presented as fold 
induction relative to untreated controls. Values correspond to the OD of coloured formazan compounds 
derived from cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases. Values are 
expressed as fold change over untreated controls. Statistical analysis was performed using Student’s t-test 
(** – p<0.01, *** – p<0.005 versus untreated control). D., E. and F. Cells were stimulated with 10 ng/ml of 
FGF-2 for 10 minutes, proteins extracted and separated on a 10% SDS-PAGE gel. Western blotting analysis 
was performed on total cell lysates using antibodies against pERK1/2-Thr202/Tyr204 and total ERK1/2. β-
actin was used as a loading control. Mean ± SEM of densiometric values from three independent 
experiments are shown in graphs. Values are expressed as fold change over untreated controls. Statistical 
analysis was performed using Student’s t-test (* – p<0.05, *** – p<0.005 versus untreated control). 
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Functionality of FGF-2 was monitored concomitantly in all rescue experiments 
by assessing the phosphorylation of ERK1/2. Whole cell extracts from cells treated 
with FGF-2 for 10 minutes were run on a 7.5% SDS-PAGE gel and the membranes were 
probed with an antibody against phosphorylated ERK1/2 (Fig. 20 D, E and F). The 
antibody was stripped of the membrane, which was subsequently probed with an 
ERK1/2 antibody that detects both the phosphorylated and unphosphorylated forms 
of ERK1 and ERK2. The Western blot membrane was also probed with an antibody 
against β-actin, which served as a loading control. In all cases, it was established that 
the FGF-2 was active. 
Using the WST-1 assay we estimated the number of viable cells by measuring 
mitochondrial activity. With this method, however, it is not possible to discriminate if a 
reduction in cell number is due to apoptosis, necrosis, or due to a decrease in cell 
division. Accordingly, we used other experimental methods to establish if the observed 
effect(s) of FGF-2 in cisplatin-mediated cell death were due to inhibition of apoptosis. 
For that purpose, the rescue experiment was performed and cell death was assessed by 
flow cytometry, which allows measuring the loss of cellular DNA content and cell 
cycle alterations. In addition, cleavage of caspase’ substrates, such as PARP and lamin 
B, which can be used as ‘read-outs’ for apoptosis (Lazebnik et al., 1993; Lazebnik et al., 
1994), was analysed by Western blot. 
 
 
 
4.1.5.1 FGF-2 BLOCKED CISPLATIN-INDUCED APOPTOSIS IN U2OS CELLS BUT 
NOT IN NSCLC HCC95 AND HCC78 CELLS 
Having shown that FGF-2 promotes chemoresistance in U2OS cells but not in 
the NSCLC cell lines HCC95 and HCC78 using the WST-1 method (Fig. 20), we 
confirmed these observations by analysing DNA content and cleavage of caspases 
substrates in cells upon cisplatin treatment. 
Cell cycle profiles were analysed by flow cytometry. Using this method we 
assessed cell death by quantifying the sub-G1 peak of the cell cycle profile, which 
corresponds to cells that have lost DNA (cf. Materials and methods). After an 
overnight starvation in serum-free media, cells were pre-incubated for 4 hours with 
FGF-2 and, subsequently, with cisplatin for 18 hours. Cells were harvested (adherent, 
alive cells and floating “corpses”), the cell membrane permeabilised and the cells 
incubated with PI, which intercalates within the DNA.  
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In U2OS cells we observed an average 2-fold increase of cells in the sub-G1 peak 
after treatment with cisplatin (p<0.005) (Fig. 21 A, top-left versus top-right histogram, 
and B, 1st versus 3rd bar), indicating that cisplatin induced apoptosis. Pre-incubation 
with FGF-2, however, substantially reduced the cell death induced by cisplatin, as 
shown by the reduction of the sub-G1 population (p<0.005) (Fig. 21 A, top-right versus 
bottom-right histogram and B, 3rd versus 4th bar). The percentage of cells within the 
sub-G1 population of cells pre-treated with FGF-2 prior cisplatin (7.1%) was very 
similar to the sub-G1 population of untreated cells (5.5%) (Fig. 21 A, top-left and 
bottom-right histograms, and Fig. 21 B, 1st and 4th bars). Importantly, “rescued cells”, 
when re-plated, survived for at least a couple of weeks but did not proliferate further 
(data not shown). It remains to be determined, however, if given fresh FGF-2, these 
cells would re-enter the cell cycle. 
Cells treated with FGF-2 alone exhibited a decrease in basal cell death when 
compared to the untreated control (p<0.005) (Fig. 21 A, top-left versus bottom-left 
histogram and B, 1st versus 2nd bar). Basal levels of apoptosis observed in the untreated 
cells were likely caused by serum starvation. Another way of analysing these data 
would be to normalise the cisplatin treatments to the respective controls (with or 
without FGF-2). However, with the current experimental settings, that would not be 
conclusive, as cells treated with FGF-2 for 24 hours will present lower levels of 
apoptosis due to protection from serum starvation-induced cell death and 
proliferation. 
These data suggest that FGF-2 was able to protect cells from apoptosis induced 
by different cues, namely cytotoxicity and serum starvation. In addition, they clearly 
demonstrated that treatment with FGF-2 induced two different biological responses: on 
one hand, it induced cell proliferation and, on the other hand, it protected the cells 
against apoptosis.  
 
To further establish that FGF-2-mediated rescue reflected protection from 
apoptosis rather than increased proliferation we have determined whether caspases, 
the main executers of apoptosis, were activated. For that purpose, cleavage of caspases 
substrates such as PARP and lamin B was analysed, as these are routinely used as 
caspase ‘read-outs’ (Lazebnik et al., 1993; Lazebnik et al., 1994). PARP is a protein that 
protects the cell from apoptosis when the cell is able to repair damaged DNA. Its 
cleavage is an indication that the cell was unable to repair the DNA (Oliver et al., 1998) 
and it is thus often used as a marker of cells undergoing apoptosis (Lazebnik et al., 
1994). Lamin B is located in the inner nucleoplasmic surface and it is targeted by 
  106 
RESULTS 
proteases during early stages of cell death (Lazebnik et al., 1993). The cleavage of these 
proteins can be monitored by Western blot using antibodies that recognise both 
uncleaved and/or cleaved forms. Cells were serum-starved overnight and pre-treated 
with or without FGF-2. After drug treatment overnight, proteins were extracted from 
all cells (adherent, alive cells and floating “corpses”), separated by SDS-PAGE gel and 
analysed by Western blot.  
In U2OS cells, cisplatin induced the cleavage of PARP, which can be seen by the 
increase of cleaved PARP (85 kDa) compared to untreated cells (Fig. 21 C, 1st versus 3rd 
lane). This was statistically significant (p<0.005) and corresponded to an average 5.2-
fold increase over basal levels (Fig. 21 D, 1st versus 3rd bar). Pre-incubation of U2OS 
cells with FGF-2 substantially reduced cisplatin-induced PARP cleavage (p<0.005) (Fig. 
21 C, 3rd versus 4th lane, and B, 3rd versus 4th bar). Pre-treatment with FGF-2 also reduced 
the basal cell death (p<0.005) (Fig. 21 C, 1st versus 2nd lane, and D, 1st versus 2nd bar). 
Similar results were obtained assessing lamin B cleavage (data not shown). These 
results establish an anti-apoptotic role for FGF-2 in U2OS cells that have been 
challenged with the cytotoxic effects of cisplatin or subjected to serum-starvation.  
As exemplified by the Western blot shown in Figure 21 C, total (116 kDa) and 
cleaved (85 kDa) forms of PARP were not the only bands detected by the PARP 
antibody. These bands could be either unspecific or could correspond to other forms of 
PARP. The different intensities observed between samples suggest that they might be 
proteins responding to the treatments performed. The identity of these bands is 
currently unknown but it could be investigated by isolating the proteins from the gel 
and examining them by using mass spectrometry. 
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Figure 21. FGF-2 rescued U2OS cells from cisplatin-induced cell death. U2OS cells were 
incubated in serum-free media overnight. A. After 4 hours pre-treatment with 10 ng/ml of FGF-2, cells 
were treated with the LD50 of cisplatin for 18 hours. Subsequently, cells were harvested, permeabilised and 
stained with PI (50 µg/ml). Cell death was assessed by flow cytometric analysis using the FACSCanto and 
the results were analysed using FlowJo. Cell cycle profiles from one experiment are shown. Numbers refer 
to the percentage of dead cells represented within the sub-G1 population. B. Mean ± SEM of five 
independent experiments are shown in a graph. Values are expressed as fold change of sub-G1 
populations over the untreated control. Statistical analysis was performed with Student’s t-test (*** – 
p<0.005). C. After 4 hours pre-treatment with 10 ng/ml of FGF-2, cells were treated overnight with the 
LD50 of cisplatin. Subsequently, cells were harvested, proteins were extracted and separated on 7.5% SDS-
PAGE gel. Western blotting analysis was performed using total cell lysates (adherent alive cells and 
floating “corpses”) and antibodies against PARP. β-actin was used as a loading control. D. Mean ± SEM of 
densiometric values (cleaved PARP) from five independent experiments are shown in a graph. Values are 
expressed as fold change over untreated controls. Statistical analysis was performed with Student’s t-test 
(*** – p<0.005). E. Cells were stimulated with 10 ng/ml of FGF-2 for 10 minutes and proteins were 
extracted and separated on 10% SDS-PAGE gel. Western blotting analysis was performed on total cell 
lysates using antibodies against pERK1/2-Thr202/Tyr204 and total ERK1/2. β-actin was used as a loading 
control. F. Mean ± SEM of densiometric values from five independent experiments are shown in a graph. 
Values are expressed as fold change over untreated controls. Statistical analysis was performed with 
Student’s t-test (*** – p<0.005 versus untreated control). 
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E. 
F. 
  
C. 
D. 
  
  108 
RESULTS 
In parallel, phosphorylation of ERK1/2 in response to FGF-2 was monitored in 
order to confirm the functionality of FGF-2 (Fig. 21 E and F). Proteins from cells treated 
with 10 ng/ml of FGF-2 for 10 minutes were run on a 7.5% SDS-PAGE gel and 
analysed by Western blot. Membranes were probed with an antibody against 
phosphorylated ERK1/2 and upon stripping re- probed with an ERK1/2 antibody. β-
actin was also probed and used as a loading control.  
 
In HCC95 and HCC78 cells, the treatment with cisplatin induced an increase of 
the sub-G1 peak (p<0.05) (Fig. 22 A, top-left versus top-right histogram, and B, 1st versus 
3rd bar, and Fig. 23 A, top-left versus top-right histogram, and B, 1st versus 3rd bar). FGF-
2, however, did not protect these cells from cisplatin-induced apoptosis (Fig. 22 A, top-
right versus bottom-right histogram, and B, 3rd versus 4th bar, and Fig. 23 A, top-right 
versus bottom-right histogram, and B, 3rd versus 4th bar). Indeed, in the case of HCC95 
cells FGF-2 appeared to have potentiated the apoptotic effect of cisplatin (Fig. 22 A, 
top-right versus bottom-right histogram). The latter was, however, without statistical 
significance (Fig. 22 B, 3rd versus 4th bar).  
A significant increase in PARP cleavage was observed in response to cisplatin 
in the HCC95 cell line (p<0.05) as shown by the increase of the 85 kDa band (Fig. 22 C, 
1st versus 3rd lane and D, 1st versus 3rd bar). In HCC78 cells, the cleavage of lamin B was 
analysed instead (Fig. 23 C) because although cisplatin treatment caused a decrease of 
the upper band of PARP, an increase in the lower band (cleaved form) was not 
detected under the conditions used (data not shown). As shown in Figure 23 C (1st 
versus 3rd lane) and D (1st versus 3rd bar), HCC78 cells treated with cisplatin exhibited an 
increase of the lamin fragment (45kDa) (p<0.005). Confirming what was previously 
observed using the WST-1 cell viability assay (Fig. 20 B and C) and cell cycle analysis 
(Fig. 22 A and B, and 23 A and B) FGF-2 was unable to prevent the cisplatin-induced 
cleavage of PARP or lamin B in these NSCLC cells (Fig. 22 C, 3rd versus 4th lane and D, 
3rd versus 4th bar, and Fig. 23 C, 3rd versus 4th lane and D, 3rd versus 4th bar).  
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Figure 22. FGF-2 failed to reduce cisplatin-induced cell death in HCC95 cells. HCC95 cells were 
incubated in serum-free media overnight. A. After 4 hours pre-treatment with 10 ng/ml of FGF-2, cells 
were treated with the LD50 of cisplatin for 18 hours. Subsequently, cells were harvested, permeabilised and 
stained with PI (50 µg/ml). Cell death was assessed by flow cytometric analysis using the FACSCanto and 
the results were analysed using FlowJo. Cell cycle profiles from one experiment are shown. Numbers refer 
to the percentage of dead cells within the sub-G1 population. B. Mean ± SEM of four independent 
experiments are shown in a graph. Values are expressed as fold change of sub-G1 populations over the 
untreated control. Statistical analysis was performed with Student’s t-test (* – p<0.05). C. After 4 hours 
pre-treatment with 10 ng/ml of FGF-2, cells were treated overnight with the LD50 of cisplatin. 
Subsequently, cells were harvested, proteins were extracted and separated on 7.5% SDS-PAGE gel. 
Western blotting analysis was performed using total cell lysates (adherent alive cells and floating 
“corpses”) and antibodies against PARP. β-actin was used as a loading control. D. Mean ± SEM of 
densiometric values (cleaved PARP) from three independent experiments are shown in a graph. Values 
are expressed as fold change relative to untreated controls. Statistical analysis was performed with 
Student’s t-test (* – p<0.05). E. Cells were stimulated with 10 ng/ml of FGF-2 for 10 minutes and proteins 
were extracted and separated on 10% SDS-PAGE gel. Western blotting analysis was performed on total 
cell lysates using antibodies against pERK1/2-Thr202/Tyr204 and total ERK1/2. β-actin was used as a 
loading control. F. Mean ± SEM of densiometric values from three independent experiments are shown in 
a graph. Values are expressed as fold change over untreated controls. Statistical analysis was performed 
with Student’s t-test (*** – p<0.005). 
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Figure 23. FGF-2 failed to reduce cisplatin-induced cell death in HCC78 cells. HCC78 cells were 
incubated in serum-free media overnight. A. After 4 hours pre-treatment with 10 ng/ml of FGF-2, cells were 
treated with the LD50 of cisplatin for 18 hours. Subsequently, cells were harvested, permeabilised and stained 
with PI (50 µg/ml). Cell death was assessed by flow cytometric analysis using the FACSCanto and the results 
were analysed using FlowJo. Cell cycle profiles from one experiment are shown. Numbers refer to the 
percentage of dead cells within the sub-G1 population. B. Mean ± SEM of three independent experiments are 
shown in a graph. Values are expressed as fold change of sub-G1 populations over the untreated control. 
Statistical analysis was performed with Student’s t-test (* – p<0.05). C. After 4 hours pre-treatment with 10 
ng/ml of FGF-2, cells were treated overnight with the LD50 of cisplatin. Subsequently, cells were harvested, 
proteins were extracted and separated on 7.5% SDS-PAGE gel. Western blotting analysis was performed 
using total cell lysates (adherent alive cells and floating “corpses”) and antibodies against lamin B. β-actin 
was used as a loading control. D. Mean ± SEM of densiometric values (cleaved PARP) from three 
independent experiments are shown in a graph. Values are expressed as fold change relative to untreated 
controls. Statistical analysis was performed with Student’s t-test (*** – p<0.005). E. Cells were stimulated with 
10 ng/ml of FGF-2 for 10 minutes and proteins were extracted and separated on 10% SDS-PAGE gel. Western 
blotting analysis was performed on total cell lysates using antibodies against pERK1/2-Thr202/Tyr204 and 
total ERK1/2. β-actin was used as a loading control. F. Mean ± SEM of densiometric values from three 
independent experiments are shown in a graph. Values are expressed as fold change over untreated controls. 
Statistical analysis was performed with Student’s t-test (* – p<0.05). 
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As previously mentioned, phosphorylation of ERK1/2 in response to FGF-2 
was also monitored by Western blotting (Fig. 22 E and F, and Fig. 23 E and F). As 
observed before (Fig. 14), FGF-2 induced a significant phosphorylation of ERK1 
(p<0.005) and ERK2 (p<0.01) in HCC95 cells. In the HCC78 cell line, FGF-2 induced a 
small (an average of 1.3-fold) but statistically significant (p<0.05) increase in ERK1, but 
not ERK2, upon 10 minutes of stimulation. 
The FGF-2 rescue experiment was also performed in SCLC H-510 cells, where 
the FGF-2 chemoprotection was initially described (Pardo et al., 2002). These cells were 
pre-treated with 0.1 ng/ml of FGF-2 and treated with etoposide for 96 hours as 
described in Pardo et al., 2002. Subsequently, the DNA content was measured by cell 
cycle analysis and Lamin B cleavage assessed by Western blotting (Appendix III). This 
experiment was carried out initially to reproduce the original observation and 
ascertain that the results obtained with additional cell lines were bona fide. 
 
FGF-2 rescue experiments have been extensively repeated in the NSCLC 
HCC95 and HCC78 cells using multiple permutations but under the conditions used in 
our study no chemoprotection was ever observed. The study of additional NSCLC cell 
lines will be crucial to establish if FGF-2 is able to mediate chemoprotection in this type 
of lung cancer cells. It is possible that had other NSCLC cell lines been chosen we 
might have observed chemoprotection. These two cell lines were originally chosen 
because one had high levels (HCC78) and the other very low levels (HCC95) of 
constitutively activated STAT3. This was relevant to this project because we wanted to 
investigate whether JAKs and STATs were involved in mediating chemoresistance and, 
in cancer cells, STAT3 is the most frequently de-regulated JAK/STAT signalling 
molecule. Had FGF-2 conferred protection against cisplatin in these cells, they would 
have been very useful to address many of the questions asked initially in this work.  
In contrast to HCC95 and HCC78 cells, treatment of U2OS cells with FGF-2 
protected them from cisplatin-induced apoptosis. This finding is particularly 
interesting given that FGF signalling was shown to have an important role in this type 
of cancer (Muenke and Schell, 1995; Coffin et al., 1995; Deng et al., 1996; Bodo et al., 
2002). In addition, because the osteosarcoma U2OS cell line had been extensively 
utilised by the Costa-Pereira Group, some experiments (such as RNAi) were already 
optimised for this cell line. This cell line was thus subsequently used in this work to 
investigate the major players in FGF-2-mediated chemoresistance pathway(s) and 
further our understanding of this complex signalling pathway. 
  112 
RESULTS 
4.1.6. FGF-2 PROTECTED U2OS CELLS FROM CISPLATIN-INDUCED CELL 
DEATH BY A MEK-ERK DEPENDENT MECHANISM 
FGF-2 was shown to confer resistance to etoposide-mediated apoptosis in SCLC 
cells via a MEK-dependent pathway (Pardo et al., 2002). Here we investigated if in 
U2OS cells the activation of MEK-ERK pathway was also required for the FGF-2 
chemoprotection from cisplatin. We used PD0325901, a MEK1/2 specific inhibitor, 
which was added to cells prior to performing the rescue experiment. This inhibitor is a 
significantly improved analogue of CI-1040, the first MEK inhibitor to enter clinical 
evaluation (Lorusso et al., 2005; Rinehart et al., 2004). Like its analogue, PD0325901 is 
non-competitive with ATP, and its specificity and high potency against activated 
MEK1 and MEK2 has been demonstrated in vitro and in vivo (Sebolt-Leopold et al., 
2004).  
To assess the functionality of PD0325901, U2OS cells were pre-treated with this 
inhibitor and then stimulated with FGF-2 for 10 minutes. Proteins were extracted, run 
on a 7.5% SDS-PAGE gel and analysed by Western blot using antibodies against 
phosphorylated ERK1/2, ERK1/2 and β-actin. Pre-treatment of U2OS with this 
inhibitor for 30 minutes was sufficient to block the phosphorylation of ERK1/2 by 
FGF-2 in a dose dependent manner (data not shown). Addition of 0.5 µM of PD0325901 
was sufficient to maximally inhibit FGF-2-induced activation of ERK1/2 in U2OS cells 
(p<0.005) (Fig. 24 A, 2nd versus 4th lane, and B, bars compared with red asterisks).  
The requirement for the MEK/ERK pathway for the FGF-2-mediated rescue 
was then investigated by performing the rescue experiment in cells previously 
incubated with 0.5 µM of the inhibitor PD0325901. As a control, cells were incubated 
with the drug vehicle [0.005% (v/v) of DMSO]. Similarly to what was observed before 
(Fig. 21 C and D), in cells incubated with the drug vehicle (untreated), cisplatin 
induced the cleavage of PARP  (p<0.005) (Fig. 24 C, 1st versus 3rd lane, and D, 1st versus 
3rd bar in the 1st graph) and this cleavage was blocked by the pre-treatment with FGF-2 
(p<0.005) (Fig. 24 C, 3rd versus 4th lane, and D, 3rd versus 4th bar in the 1st graph). In cells 
previously incubated with PD0325901, however, FGF-2 was not able to prevent 
cisplatin-induced PARP cleavage (Fig. 24 C, 7th versus 8th lane, and D, 3rd versus 4th bar 
in the 2nd graph).  
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Figure 24. Inhibition of MEK/ERK signalling blocked FGF-2-mediated rescue in U2OS cells. 
(continued on page 114) A. Cells were serum-starved (0.5% FCS) overnight and incubated in serum-free 
media for 1 hour. Cells were pre-treated with 0.5 µM of PD0325901 or with the drug vehicle [0.005% (v/v) 
of DMSO] for 30 minutes and then stimulated with 10 ng/ml of FGF-2 for 10 minutes. Proteins were 
extracted and separated on a 10% SDS-PAGE gel. Western blotting analysis was performed on total cell 
lysates using antibodies against pERK1/2-Thr202/Tyr204 and total ERK1/2. β-actin was used as a loading 
control. B. Mean ± SEM of densiometric values from three independent experiments are shown in a graph. 
Values are expressed as fold change over untreated controls (without PD0325901 and FGF-2). Statistical 
analysis was performed with Student’s t-test (*** – p<0.005, black asterisks versus untreated control, red 
asterisks compare the indicated samples). C. and E. After overnight starvation in serum-free media, cells 
were incubated with 0.5 µM of PD0325901 for 30 minutes and, after 4 hours pre-treatment with FGF-2 (10 
ng/ml) cells were treated with the LD50 of cisplatin. C. After 16 hours treatment of cisplatin, cells were 
harvested, proteins extracted and separated on 7.5% SDS-PAGE gel. Western blotting analysis was 
performed using total cell lysates and an antibody against PARP. β-actin was used as a loading control. D. 
Mean ± SEM of densiometric values (cleaved PARP) from three independent experiments are shown in 
graphs. Values are expressed as fold change over untreated controls. Statistical analysis was performed 
with Student’s t-test (** - p<0.01; *** – p<0.005). E. After 18 hours of cisplatin treatment, cells were 
harvested, permeabilised and stained with PI (50 µg/ml). Apoptotic cell death was assessed by flow 
cytometric analysis using the FACSCanto and the results were analysed using FlowJo. Cell cycle profiles 
from one experiment are shown. Numbers refer to the percentage of dead cells within the sub-G1 
population. F. Mean of three independent experiments ± SEM are shown in graphs. Values are expressed 
as fold change of sub-G1 populations over untreated control. Statistical analysis was performed with 
Student’s t-test (* – p<0.05; *** – p<0.005).  
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Figure 24. Inhibition of MEK/ERK signalling blocked FGF-2-mediated rescue in U2OS cells. 
(continued from page 113). 
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Similar results were obtained when cell cycle profiles of each sample were 
analysed (Fig. 24 E and F). Cells treated with the drug vehicle were rescued by FGF-2 
as shown by the statistically significant reduction of the sub-G1 peak (p<0.05) in the 
FGF-2 pre-treated samples (Fig. 24 E, black coloured cell cycle profiles and F, 3rd versus 
4th black bar). The inhibition of the MEK/ERK activity prevented FGF-2-induced 
rescue (Fig. 24 C, grey coloured cell cycle profiles, and F, 3rd versus 4th grey bar).  
In addition, FGF-2 was not able to reduce basal cell death or cisplatin-induced 
killing in cells pre-incubated with PD0325901 (Fig. 24 C, 5th versus 6th lane, D, 1st versus 
2nd bar, E, grey coloured cell cycle profiles, and F, 1st versus 2nd bar). These results 
highlight the importance of MEK/ERK activity in signalling pathways that mediate 
FGF-2-induced cell survival.  
Pre-treatment with the inhibitor also caused an increase in the basal cell death 
(Fig. 24 C and E). This observation was not surprising as MEK-ERK signalling plays 
such crucial roles in survival (e.g. Ballif and Blenis et al., 2001) and inhibition of its 
activity often has a negative impact on cell viability. 
We further confirmed the crucial role of ERK1/2 for the observed FGF-2 
survival effect using RNAi. Knockdown of ERK1 and ERK2 also prevented the FGF-2-
induced rescue of U2OS cells (data not shown). These results indicate that MEK/ERK 
signalling is an essential mediator of FGF-2-induced rescue from cisplatin killing in 
U2OS cells, similar to what was previously observed in SCLC cells (Pardo et al., 2002).  
 
 
 
4.1.7. FGF-2 INDUCED PROTEIN-PROTEIN INTERACTIONS BETWEEN PKCε , B-
RAF AND S6K2 IN U2OS CELLS 
It was shown in the SCLC cell line H-510 that early signalling cascades 
activated by FGF-2 involved the formation of a signalling complex comprising B-RAF, 
PKCε and S6K2 (Pardo et al., 2006). We, therefore, investigated if FGF-2 could also 
induce the interaction of these proteins in the U2OS cells. To detect potential 
interactions between B-RAF, PKCε and S6K2 in response to FGF-2, these proteins were 
independently immunoprecipitated after treatment with FGF-2 for increasing periods 
of time. H-510 cells were treated in parallel as previously described (Pardo et al., 2006) 
and used as a positive control for the complex formation (data not shown).  
Immunoprecipitation experiments included several controls, such as 
immunoprecipitations using an unspecific antibody (with the same IgG as the 
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antibodies used for immunoprecipitation) and a sample incubated with agarose beads 
only. The first was used as a control for the antibody specificity and the second to 
determine non-specific binding to the beads. It must be noted from the onset that the 
S6K2 immunoprecipitations proved challenging, presumably due to the low levels of 
expression of this protein in U2OS cells. Importantly, B-RAF, PKCε (Fig. 25 A) and 
S6K2 (Fig. 25 B) did not bind to the irrelevant IgG control antibodies or to the beads. In 
addition, cells transfected with siRNA against S6K2 were used as a further control to 
ascertain that the presumed S6K2 band seen on the Western blot was indeed S6K2 (Fig. 
25 B). These data, together with additional data from other laboratory members, re-
assured us that the reagents available to us were trustworthy and that the data 
obtained was bona fide. In any case, immunoprecipitation with beads only was included 
as a control in all co-immunoprecipitation experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Controls for PKCε , B-RAF and S6K2 immunoprecipitations. A. Cell lysates were 
subjected to immunoprecipitation with an unspecific antibody or with beads only, run in parallel with 
whole cell extracts on a 7.5% SDS-PAGE gel and analysed by Western blot. The membrane was probed for 
B-RAF and PKCε. B. Cells were transfected with 75 nM siRNA against S6K2. Forty-eight hours after 
transfection, cell lysates were subjected to immunoprecipitation with an unspecific antibody, an antibody 
against S6K2 or with beads only. Imunonoprecipitates were run in parallel with whole cell extracts on a 
7.5% SDS-PAGE gel and analysed using Western blotting. L – lysate, B – beads only, Unsp – unspecific 
antibody. 
A.  
B.  
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U2OS cells were incubated with FGF-2 for increasing periods of time and whole 
cell extracts were used to immunoprecipitate B-RAF, PKCε and S6K2, independently. 
The immunoprecipitates were run on a 7.5% SDS-PAGE gel and membranes were 
probed for the three proteins in order to detect co-immunoprecipitated molecules. 
PKCε and B-RAF co-immunoprecipitated, whether the proteins were 
immunoprecipitated using a PKCε or a B-RAF antibody (Fig. 26 A). Importantly, this 
interaction was ligand-induced. When PKCε was immunoprecipitated, co-
immunoprecipitated B-RAF increased 1.8-fold upon FGF-2 treatment.  This reached 
statistical significance at all time points analysed (p<0.05) (Fig. 26 A, 1st versus 2nd-4th 
lanes in the 1st row of the Western blot). The reverse immunoprecipitation with a B-
RAF antibody co-immunoprecipitated PKCε at the same time points, albeit with 
different kinetics. An average of 1.8-fold induction (p<0.05) was detected by 10 
minutes and a stronger interaction was detected at later time points (an average of 4.5-
fold, p<0.05) (Fig. 26 A, 1st versus 2nd-4th lanes in the 3rd row of the Western blot). By 20 
and 30 minutes, the increase of B-RAF detection on PKCε immunoprecipitates was 
weaker (1.8-fold) than the detection of PKCε in B-RAF immunoprecipitates (4.5-fold) 
(Fig. 26 A, 3rd and 4th bar in the 1st and 2nd graphs). This could be related to 
stoichiometry or reflect differences in the efficiency of immunoprecipitation by the two 
different antibodies. In addition to this, some variation was observed between 
experiments. This can be illustrated, for example, by the Western blot showing the B-
RAF immunoprecipitation, where the interaction between B-RAF and PKCε peaked at 
20 minutes and decreased at the 30 minutes time point (Fig. 26 A, 3rd row of the 
Western blot). This decrease at the 30 minutes time point was not seen in all the 
experiments performed as shown in the graph in Figure 26 A (4th bar in the 2nd graph). 
This may reflect a highly dynamic complex (that would involve a quick ”kiss and run” 
of these molecules) or may be related to low stability of the complex that could allow 
some interactions to be lost in the immunoprecipitation process. In any case, and 
though this clearly requires additional analysis, the interaction between these two 
molecules was consistently observed throughout all experiments performed. 
Unfortunately, we were not able to detect S6K2 in the B-RAF and PKCε 
immunoprecipitates. This does not necessarily reflect a lack of interaction between 
S6K2 and these proteins. Indeed, both B-RAF and PKCε were detected in S6K2 
immunoprecipitates. Low levels of expression of S6K2 in U2OS cells, as well as 
stoichiometry, may have hindered the detection of the interaction when 
immunoprecipitating B-RAF and PKCε.  
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S6K2 was immunoprecipitated from the whole cell lysates, the proteins run on a 
7.5% SDS-PAGE gel and analysed by Western blot. The membranes were then probed 
for B-RAF and PKCε. Membranes were probed first for PKCε (95 kDa), stripped 
overnight (cf. Materials and methods) and then probed for B-RAF (94 kDa). To ensure 
that the detection of B-RAF was not influenced by any residual unstripped PKCε 
antibody, some membranes were probed first for B-RAF, stripped overnight, and then 
probed for PKCε. Similar results were obtained regardless of the sequence of detection. 
Both PKCε and B-RAF co-immunoprecipitated with S6K2 upon FGF-2 treatment for 10 
minutes (p<0.05) (Fig. 26 A, 2nd lane in the 5th and 6th rows of the Western blot and 3rd 
graph). Interaction of S6K2 with B-RAF and PKCε appeared to be more transient than 
the interaction observed between B-RAF and PKCε, since the interaction of S6K2 with 
B-RAF and with PKCε decreased after 20 minutes of FGF-2 treatment.  
Although these experiments establish that, upon FGF-2 treatment, S6K2 can 
bind to PKCε and B-RAF and that PKCε and B-RAF interact, they still do not 
categorically demonstrate that these proteins are all part of the same protein complex, 
as it was shown for the SCLC H-510 cells and previously shown by Seckl and 
colleagues (Pardo et al., 2006). Conceptually, treatment of U2OS cells with FGF-2, can 
lead to the formation of three different dimers (B-RAF/PKCε; B-RAF/S6K2; 
S6K2/PKCε) and/or the formation of a trimer (B-RAF/PKCε/S6K2). The precise 
nature of the protein complexes induced by FGF-2 and the precise stoichiometry 
remain to be established. This will be addressed initially using RNAi: each protein will 
be silenced independently and the impact of each siRNA (siPKCε, siB-RAF and siS6K2) 
on these interactions analysed. FRET could also be used to address this question but 
this would require tagging each protein and transfecting them into cells, which may 
lead to over-expression artefacts and may change the dynamics of the interactions. 
In parallel with co-immunoprecipitations, whole cell extracts were also 
analysed by SDS-PAGE/Western blot. We monitored B-RAF, PKCε and S6K2 levels 
and also the phosphorylation of ERK1/2 in response to FGF-2 to monitor FGF-2 
functionality. Total protein levels and activation of ERK1/2 by FGF-2 are shown in 
Figure 26 B. As previously observed, FGF-2 induced the phosphorylation of ERK1/2. 
Interestingly, a small (1.5- to 1.7-fold) but statistically significant (p<0.05 and p<0.005) 
increase of S6K2 was detected in response to FGF-2. This increase is observed shortly 
after FGF-2 stimulation (10 to 30 minutes), which is too short a period for it to be the 
result of de novo protein synthesis. One interesting possibility is that FGF-2 signalling 
may increase the stability of this protein. This will be the subject of future studies. 
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Figure 26. FGF-2 induced interactions between PKCε , B-RAF and S6K2 in U2OS cells. U2OS 
cells were serum-starved (0.5% FCS) overnight and then incubated in serum-free media for 1 hour. After 
stimulation with 10 ng/ml of FGF-2 for the indicated times, proteins were extracted A. Cell lysates were 
subjected to immunoprecipitation with a PKCε, B-RAF or S6K2 antibody. Immunoprecipitates were 
separated on a 7.5% SDS-PAGE gel and proteins detected by Western blot. Membranes were probed for 
PKCε, B-RAF and S6K2. B. Total cell lysates were separated on a 7.5% SDS-PAGE and analysed by 
Western blot. Membranes were probed for PKCε, B-RAF, S6K2, pERK1/2-Thr202/Tyr204 and total ERK1/2. 
β-actin was used as a loading control. A. and B. Representative Western blots and mean ± SEM of 
densiometric values from at least three independent experiments are shown in graphs. Values are 
expressed as fold change over untreated controls. Statistical analysis was performed with Student’s t-test 
(* – p<0.05; *** – p<0.005 versus untreated controls). L – lysate, ‘ – minutes.  
A. 
B.  
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4.1.8. INTERACTIONS BETWEEN PKCε , B-RAF AND S6K2 IN HCC95 CELLS 
Despite activating ERK1/2, FGF-2 was not able to protect HCC95 cells from 
cisplatin-mediated cell death under the conditions studied (Section 4.1.2 and 4.1.5). We 
therefore investigated whether or not FGF-2 induced interactions between B-RAF, 
PKCε and S6K2 in this cell line as it did in SCLC (Pardo et al., 2006) and U2OS (Section 
4.1.7) cells. If FGF-2 did not induce such protein interactions this could explain why it 
did not provide chemoprotection in HCC95 cells.  
HCC95 cells were treated with FGF-2 for increasing periods of time and whole 
cell extracts were used to immunoprecipitate B-RAF, PKCε and S6K2 independently. 
The immunoprecipitates were run on a 7.5% SDS-PAGE gel and membranes were 
probed for the three proteins in order to detect co-immunoprecipitated molecules. We 
were able to detect B-RAF in PKCε immunoprecipitates upon treatment with FGF-2 
(Fig. 27 A, 1st row in the Western blot). This interaction was confirmed by performing 
the reverse immunoprecipitation with a B-RAF antibody (Fig. 27 A, 3rd row in the 
Western blot). The interaction between B-RAF and PKCε was detected in all 
experiments performed, however, the time points when these two proteins interacted 
were not consistent between experiments, a fact reflected in the statistical analysis. 
Accordingly, detection of B-RAF in PKCε immunoprecipitates from samples treated 
with FGF-2 did not reach statistical significance (Fig. 27 A, 1st graph) as it did in the 
reverse immunoprecipitation (p<0.05) at the 20 minutes time-point (Fig. 27 A, 2nd 
graph). The reason why the induction of B-RAF and PKCε interactions upon FGF-2 
stimulation varied so much is currently unknown. This may be due to either low 
stability of the complex, or due to these molecules interacting ‘intermittently’ (on-and-
off) upon FGF-2 stimulation. The variation between time points can also be related to 
other factors, such cell cycle phase of each cell population or other experimental 
factors, although the latter is unlikely as all experimental conditions had been 
optimised and standardised from the beginning. The data suggest that FGF-2 may 
induce the interaction between B-RAF and PKCε in HCC95, but the kinetics of this 
interaction are still unclear. If the interaction(s) are highly labile and if stable 
complex(es) were required for FGF-2 to induce chemoresistance, this could explain 
why FGF-2 failed to protect these cells from cisplatin-induced cell death. Like in U2OS 
immunoprecipitates, we were not able to detect S6K2 in B-RAF or PKCε 
immunoprecipitates.  
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Figure 27. Interaction between B-RAF, PKCε  and S6K2 in HCC95 cells. HCC95 cells were serum-
starved (0.5% FCS) overnight and then incubated in serum-free media for 1 hour. After stimulation with 10 
ng/ml of FGF-2 at the indicated times, proteins were extracted A. Cell lysates were subjected to 
immunoprecipitation with a PKCε, B-RAF or S6K2 antibody. Immunoprecipitates were separated on a 
7.5% SDS-PAGE gel and the proteins detected by Western blotting. Membranes were probed for PKCε, B-
RAF and S6K2. B. Total cell lysates were separated on a 7.5% SDS-PAGE and analysed by Western blot. 
Membranes were probed for PKCε, B-RAF, S6K2, pERK1/2-Thr202/Tyr204 and total ERK1/2. β-actin was 
used as a loading control. A. and B. Representative Western blots and mean ± SEM of densiometric values 
from three independent experiments are shown in graphs. Values are expressed as fold change over 
untreated controls. Statistical analysis was performed with Student’s t-test (* – p<0.05; *** – p<0.005 versus 
untreated controls). ‘ – minutes. 
A.       B. 
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S6K2 appeared to bind to B-RAF and PKCε after 10 minutes of FGF-2 
stimulation, and this interaction was maintained with less strength for at least 30 
minutes (Fig. 27 A, 5th and 6th row in the Western blot). As this immunoprecipitation 
was only performed once, this result is preliminary and needs to be further confirmed. 
Whole cell extracts of samples used for co-immunoprecipitations were analysed 
in parallel by SDS-PAGE/Western blot. Total protein levels of B-RAF, PKCε and S6K2 
and the phosphorylation of ERK1/2 in response to FGF-2 were analysed (Fig. 27 B). 
ERK1/2 were phosphorylated in response to FGF-2 (p<0.005) in a similar manner as 
previously observed (Fig. 27 B, 2nd graph). As seen in U2OS cells, there was a small 
increase of S6K2 protein levels in response to FGF-2. This increase was statistically 
significant at 10 minutes of FGF-2 stimulation (p<0.05) (Fig. 27 B, grey bars in the 1st 
graph).  
 
 
 
4.1.9. FGF-2 INDUCED THE UP-REGULATION OF ANTI-APOPTOTIC PROTEINS 
IN U2OS CELLS 
FGF-2 has been shown to confer resistance to etoposide-mediated apoptosis in 
SCLC cells via a translational mechanism that results in the up-regulation of various 
anti-apoptotic proteins (Pardo et al., 2002). FGF-2 has previously been shown to up-
regulate MCL-1 in U2OS cells (Janet Lyons-Lewis and Michael Seckl, personal 
communication). Here we investigated which other anti-apoptotic proteins were up-
regulated in response to FGF-2 in U2OS cells. For that purpose, cells were treated with 
FGF-2 for increasing periods of time, the proteins were extracted and, due to the small 
molecular sizes of the proteins of interest, separated on a 12.5% SDS-PAGE. The 
expression of BCL-2, BCL-XL, XIAP and MCL-1 was subsequently monitored by 
Western blot with the appropriate antibodies.  
The results obtained showed that, in U2OS cells, FGF-2 induced up-regulation 
of anti-apoptotic proteins (Fig. 28 A). Indeed, MCL-1 levels increased upon treatment 
with FGF-2 for 1 hour (p<0.05) and reached a maximum (an average of 1.7-fold 
increase) after 2 hours of treatment (p<0.005) (Fig. 28 B). Treatment with FGF-2 for two 
hours also induced the up-regulation of BCL-2 (p<0.005) (Fig. 28 A and C), XIAP 
(p<0.05) (Fig. 28 A and D) and BCL-XL, (p<0.05) (Fig. 28 A and E).  
The induction of BCL-2, BCL-XL, XIAP and MCL-1 observed was modest 
(around 1.5-fold). It is possible that the protein extraction lysis buffer used here was 
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not ideal for the extraction of these proteins and could account for the small differences 
observed between untreated and FGF-treated samples. Schindler lysis buffer (cf. 
Material and methods) was developed to extract mainly JAKs and STATs, which are 
cytoplasmic proteins (Schindler et al., 1992). BCL-2 family members are predominantly 
associated with the mitochondrial membrane (e.g. Breckenridge and Xue, 2004). 
Proteins associated with this organelle may be insufficiently extracted using this buffer. 
Extraction with a more stringent buffer that will disrupt membranes more efficiently 
may reveal greater differences in future experiments [e.g. radio immunoprecipitation 
assay (RIPA) buffer]. 
Whether the increase of BCL-2, BCL-XL, XIAP and MCL-1 protein expression 
results from de novo protein synthesis, protein translation or increased protein stability 
remains to be established. The prominent roles that these proteins play in apoptosis 
raise the possibility that they may be involved in the FGF-2-mediated chemoresistance 
seen in the U2OS cells. 
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Figure 28. FGF-2 induced the up-regulation of anti-apoptotic proteins in U2OS cells. A. U2OS 
cells were serum-starved (0.5% FCS) overnight and then incubated in serum-free media for 1 hour. After 
stimulation with 10 ng/ml of FGF-2 at the indicated times, proteins were extracted and separated on a 
12.5% SDS-PAGE gel. Western blotting analysis was performed using total cell lysates and antibodies 
against MCL-1, BCL-2, BCL-XL and XIAP. β-actin was used as a loading control. B., C., D. and E. Mean ± 
SEM of densiometric values from at least three independent experiments are shown in graphs. Values are 
expressed as fold change over untreated controls. Statistical analysis was performed with Student’s t-test (* 
– p<0.05; ** - p<0.01; *** – p<0.005 versus untreated controls). ‘ – minutes, h – hours. 
D.         E.  
A.  
B.         C.  
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4.1.10. DISCUSSION 
FGFs are known to provide prosurvival signals and to confer broad-spectrum 
resistance to chemotherapeutic drugs (Song et al., 2000). Accordingly, aberrant FGF 
signalling can contribute to diverse pathologic conditions, including cancer (reviewed 
by Beenken and Mohammadi, 2009). There is increasing evidence in favour of an 
important role for FGF-2 in cancer biology and, indeed, FGF-2 has been implicated in 
driving chemoresistance in cancer (Song et al., 2000; Pardo et al., 2002; Pardo et al., 2003; 
Vandermoere et al., 2005). In addition, FGF-2 is known to play a role in cell 
proliferation and tumour progression in prostate and breast cancer (Giri et al., 1999; 
Dickson et al., 2000; Nurcombe et al., 2000; Polnaszek et al., 2003). This part of the study 
provides firm evidence for a role of FGF-2 in promoting chemoresistance in 
osteosarcoma cells by inhibiting apoptosis and stimulating cell proliferation. 
FGF-2 was shown to bind preferentially to FGFRs 1 and 2 (variant IIIc) (Orniz et 
al., 1996). Upon binding, the FGF receptors become activated and trigger well-
documented early signalling events such as the activation of ERK1/2 protein kinases 
(e.g. Wang et al., 2000; Pardo et al., 2001; Kuhn et al., 2006). We started by investigating 
the activation of ERK1/2 downstream of FGF-2 in osteosarcoma (U2OS) and NSCLC 
(HCC95 and HCC78) cell lines. We observed that FGF-2 significantly activated ERK1/2 
in the osteosarcoma U2OS cell line and the NSCLC cell line HCC95 (Fig. 13 and 14). In 
contrast, the NSCLC cell line HCC78 was defective in the response to FGF-2 as 
phosphorylation of ERK1/2 was only very weakly increased in response to FGF-2 (Fig. 
15). In fact, in HCC78 cells FGF-2 increased phosphorylation of these kinases only by 
1.3-fold and, in the majority of experiments conducted, led to a reduction in the basal 
levels of ERK1/2 phosphorylation after 20 minutes of treatment (which due to some 
experimental variation that we still do not understand did not reach statistical 
significance). The decrease in ERK1/2 phosphorylation levels upon FGF-2 treatments 
observed in HCC95 (Fig. 14) and HCC78 (Fig. 15) were, presumably, due to a negative 
feedback control mechanism. For example, FGF was shown to induce the expression of 
SPRY family members (e.g. Ozaki et al., 2001) that attenuate FGF signalling. In general, 
SPRYs inhibit the recruitment of SOS by either binding GRB2, or SOS itself, thereby 
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blocking MEK/ERK signalling and FGF responses (Hanafusa et al., 2002; Ozaki et al., 
2005). 
Using RT-PCR, we successfully detected FGFR1 in all the three cell lines studied 
here (Fig. 16). FGFR2IIIc, however, was amplified in U2OS and HCC95 cells but it was 
not detected in HCC78 cells. The modest phosphorylation of ERK1/2 in response to 
FGF-2 in HCC78 cells may be associated with the lack of expression of FGFR2IIIc. The 
observation that the constitutive phosphorylation of ERK1/2 was modestly, but 
significantly, increased by treatment with FGF-2 (and subsequently downregulated) 
suggests, however, that HCC78 cells still respond to FGF-2. It suggests that FGF-2 
probably acts through receptor complex composed of FGFR1 homodimers in HCC78 
cells whereas in U2OS and HCC95 cell lines there could be contributions through both 
FGFR1 and FGFR2. It is also possible that FGF-2 could act through another FGFR 
family member as FGF-2 can also signal through other receptors such as FGFR4, 
although it binds them with lower affinity than it binds to FGFR1 and FGFR2IIIc 
(Vainikka et al., 1992; Ornitz et al., 1996). It is also possible that ERK1/2, despite being 
constitutively active, can still be further phosphorylated in response to other growth 
factors, such as EGF. This was, however, beyond the scope of this research project and 
the experiment was, therefore, not conducted at the time.  
The detection of FGFR1 and FGFR2IIIc by RT-PCR suggest that these receptors 
may be expressed in the cells and used by FGF-2. Western blot analysis would have 
allowed us to ascertain if the receptors were expressed at the protein level in these cell 
lines. In addition, flow cytometric analysis would have allowed us to determine if the 
receptor chains were present on the cell surface and would have given an indication of 
the quantity of receptor molecules available for FGF-2 signalling. Unfortunately, no 
suitable antibodies were available to us. 
FGF-2 is known to promote proliferation of many cell types (Bikfalvi et al., 
1997). In this work we observed that FGF-2 induced proliferation of U2OS cells but not 
of the NSCLC cell lines HCC95 and HCC78 (Fig. 17). The inability of FGF-2 to promote 
proliferation of these cells suggested that FGF-2 might be unable to activate some of 
the pathway(s) required for FGF-2-mediated proliferation. One such pathway could be 
the mTOR/S6K pathway. S6K was suggested to be a major regulator of the FGF-2 
growth-promoting effects, as its inhibition with rapamycin (an mTOR inhibitor) 
blocked FGF-2-induced proliferation of SCLC cells (Pardo et al., 2001). Alternatively, 
FGF-2 may promote proliferation of the NSCLC cells HCC95 and HCC78 under 
conditions that were not tested here (such as alternative starvation settings or 
incubation with FGF-2 for periods longer that 96 hours). 
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FGF-2 has been shown to mediate chemoresistance in many cell types including 
HUVECs, prostate, breast and lung cancer cells (Song et al., 2000; Pardo et al., 2002; 
Alavi et al., 2003; Vandermoere et al., 2005). Seckl and colleagues have demonstrated 
that FGF-2 could prevent etoposide killing in a SCLC cell line (Pardo et al., 2002). The 
same authors revealed key early signalling events triggered by FGF-2 that impinged on 
the apoptotic machinery, namely the activation of protein kinases ERK1/2, the 
formation of a multi-protein complex consisting of B-RAF, PKCε and S6K2 (which was 
shown using RNAi and co-IP methodologies) and the up-regulation of various anti-
apoptotic proteins (Pardo et al., 2002; Pardo et al., 2003; Pardo et al., 2006).  
Here we have investigated if FGF-2 also protected the NSCLC HCC95 and 
HCC78 cell lines and the osteosarcoma U2OS cell line from chemotherapeutic drug-
induced apoptosis, in order to extend these observations to other cell types. In U2OS 
cells we observed that FGF-2 provided protection from cisplatin killing. This was 
demonstrated using the cell viability assay WST-1 (Fig. 20 A), and further confirmed 
by analysing cell cycle profiles (Fig. 21 A and B) and PARP cleavage (Fig. 21 C and D). 
FGF-2 reduced the amount of cells in the sub-G1 peak following challenge with 
cisplatin and it prevented cisplatin-induced cleavage of caspase substrates such as 
PARP and lamin B (Fig. 21 A, B, C, D and data not shown). These observations 
suggested that FGF-2 inhibited cisplatin-mediated apoptosis rather than just 
promoting proliferation. Hence, in U2OS cells, FGF-2 not only induced proliferation 
but it also blocked apoptosis. These findings further highlighted the well-recognised 
pleiotropic nature of FGF-2 (Bikfalvi et al., 1997). Furthermore, FGF-2-rescued cells 
were able to survive for extended periods once the drug was withdrawn (data not 
shown) as observed in the SCLC cell line H-510 (Pardo et al., 2002). U2OS cells that 
survived cisplatin due to FGF-2 had a different morphology than unchallenged cells 
(they looked bigger and had a rounder shape). The reason for this altered morphology 
is yet unknown. Collectively, these data suggest that FGF-2 plays an important role in 
osteosarcoma tumour progression as it promotes cell survival in the presence of 
cytotoxic agents and allows the arising of new cell populations. 
FGF-2 failed to induce both proliferation of the NSCLC HCC95 and HCC78 cell 
lines studied here and rescue these cells from cisplatin-mediated apoptosis (Fig. 20 B 
and C, Fig. 22 and Fig. 23). FGF-2 rescue experiments have been extensively repeated 
but, under the conditions used, no chemoprotection was ever observed in these cells. 
These findings do not exclude the possibility that FGF-2 can provide protection of 
other NSCLC cell lines. It is possible that had other cell lines been chosen we might 
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have observed chemoprotection. Moreover, it is possible that in HCC95 and HCC78 
cells FGF-2 may prevent cell death induced by other chemotherapeutic agents. 
The inability of FGF-2 to protect the NSCLC HCC78 cell line might be 
associated with the modest ERK1/2 activation observed (Fig. 15). Indeed, MEK/ERK 
signalling has been shown to have a key role in cell growth and drug resistance 
(reviewed by McCubrey et al., 2007). Importantly, the activation of this pathway was 
also shown to be essential for the FGF-2-mediated chemoresistance observed in SCLC 
cells (Pardo et al., 2002). The same authors subsequently showed in a series of elegant 
experiments that MEK/ERK was uncoupled from FGF-2 signalling in the SCLC H-69 
cell line, which was refractory to the protective effect of FGF-2. In this cell line the lack 
of ERK activation was not due a dysfunctional MEK/ERK pathway, as it could be 
activated by other growth factors. The introduction of an activated version of MEK into 
H-69 cells induced phosphorylation of ERK1/2 and reverted the phenotype by 
rescuing these cells from etoposide-induced killing (Pardo et al., 2002). The inability of 
FGF-2 to protect the NSCLC HCC95 cell line remains to be explained. In this cell line, 
as in H-510 (Pardo et al., 2002) and U2OS cells (Fig. 13), FGF-2 induced the 
phosphorylation of ERK1/2 (Fig. 14). Therefore, the inability of FGF-2 to protect 
HCC95 cannot be attributed to a failure in MEK/ERK activation. The observed FGF-2-
mediated activation of ERK1/2 in these cells was more transient than the activation 
observed in U2OS (Fig. 13). Strength and duration of ERK signalling have been shown 
to have an impact on the response and to influence biological outcome (Murphy et al., 
2004). Variations of the intensity and duration of the ERK1/2 activation signal in 
response to FGF-2 may have been a significant factor for the lack of protection of 
HCC95 by FGF-2 from apoptosis. In addition, it is conceivable that the defect lies either 
with signalling downstream of ERK1/2 phosphorylation, or in a parallel signalling 
pathway that may cross-talk with the main chemoresistance pathway identified thus 
far. Preliminary data suggested that FGF-2 was able to up-regulate some anti-apoptotic 
BCL-2 family members (data not shown). Accordingly, the reason why FGF-2 was not 
able to protect HCC95 cells from cisplatin-mediated cell killing remains unknown. 
Having observed that FGF-2 rescued the osteosarcoma cell line U2OS from 
cisplatin-induced apoptosis but not the two elected NSCLC cell lines, we decided to 
focus our attention on the U2OS cells. We were particularly interested in the early 
signalling events that occur within the first four hours of treatments, which 
corresponded to the time of pre-incubation with FGF-2. This was because it was 
established previously in our laboratory that it is during this period of time that key 
anti-apoptotic molecules necessary to provide chemoprotection are up-regulated and 
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that this incubation time was sufficient to rescue cells from the noxious effects of 
drugs.. 
Many processes that lead to cell growth and drug resistance were shown to be 
dependent of MEK/ERK activation (reviewed by McCubrey et al., 2007). Here we 
investigated if in U2OS cells the activation of the MEK/ERK pathway was also 
required for the FGF-2 chemoprotection from cisplatin. In fact, inhibition of MEK1/2, 
the upstream activator of ERK1/2 (Roux and Blenis, 2004), with the specific inhibitor 
PD0325901 (Sebolt-Leopold et al., 2004) abolished the FGF-2 rescue (Fig. 24). This was 
demonstrated by analysing PARP cleavage (by Western blot) (Fig. 24 C and D) and 
loss of DNA (by flow cytometry) (Fig. 24 E and F). These data suggested that, similar to 
what was previously observed in SCLC cells (Pardo et al., 2002), the activation of the 
MEK/ERK signalling pathway was essential for the FGF-2-induced rescue from 
cisplatin killing in U2OS cells. Additionally, in the absence of MEK/ERK activity, FGF-
2 was not able to reduce the basal cell death seen in the cell cultures (Fig. 24 C, D, E 
and F). This observation emphasises the pivotal role of these molecules in protecting 
cells from various apoptotic stimuli (Bonni et al., 1999; Liu et al., 1999; Deng et al., 2000; 
Jost et al., 2001; Xu et al., 2008). 
Another early signalling event that was shown to be required for the FGF-2-
mediated protection of SCLC cells from etoposide killing was the formation of a multi-
protein complex consisting of B-RAF, PKCε and S6K2 (Pardo et al., 2006). Using co-
immunoprecipitation techniques we observed that in U2OS cells FGF-2 also induced 
interactions between these three proteins (Fig. 26). The interaction between B-RAF and 
PKCε was detected between 10 and 30 minutes upon FGF-2 stimulation (Fig. 26 A), 
which also induced the interaction of S6K2 with B-RAF and the interaction of S6K2 
with PKCε. These interactions appeared to be more transient than that observed 
between B-RAF and PKCε. These two proteins also co-immunoprecipitated with S6K2 
after 10 minutes of FGF-2 treatment but the Western blot signal representing the 
interaction was greatly reduced after 20 minutes of treatment (Fig. 26 A). Depending 
on the antibody used for co-immunoprecipitation (B-RAF or PKCε), we observed some 
variation between experiments with regards to the kinetics of the interactions between 
B-RAF and PKCε. It is possible that this interaction is very dynamic, involving 
transient interactions between these molecules, that there are multiple stoichiometric 
possibilities, or that this is due to an experimental artefact caused by instability of the 
complex under our experimental conditions. Nevertheless, and regardless of the 
precise kinetics, the results obtained here demonstrated that these molecules rapidly 
interacted with each other upon FGF-2 stimulation. Silencing B-RAF, PKCε and S6K2 
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individually using RNAi will elucidate if, in U2OS, these molecules interact in a tri-
partite multi-protein complex as previously observed in SCLC cells (Pardo et al., 2006). 
The requirement for these interactions for chemoresistance and the exact function of 
the complex(es) in U2OS cells is still unknown.  
It was observed in SCLC cell lines that B-RAF, PKCε and S6K2 were 
activated/phosphorylated in response to FGF-2 (Pardo et al., 2001; Pardo et al., 2006). 
Activation of B-RAF, PKCε and S6K2 in response to FGF-2 will be investigated in the 
future. The requirement for their activation for FGF-2-mediated chemoprotection will 
be assessed using specific inhibitors and, as previously mentioned, siRNA molecules. It 
is possible that their interaction is a requirement for the downstream activation of all or 
some of these three molecules.  
One hypothesis is that PKCε is required to phosphorylate S6K2. Indeed, it was 
shown in another context that S6K2 was phosphorylated by several PKC isoforms, 
including PKCε (Valovka et al., 2003) and in vitro kinase assays showed that PKCε can 
directly associate and phosphorylate S6K2 (Pardo et al., 2006). It is also possible that 
PKCε activity itself may be required for B-RAF activation, as it was shown that it was 
required for PKB-induced activity of C-RAF through a RAS-independent mechanism 
(Majewski et al., 1999). In addition, PKCε was required for ERK1/2 phosphorylation 
and the expression of PKCε (but not of other PKC family members) correlated with the 
ability of FGF-2 to induce MEK/ERK activation and up-regulation of anti-apoptotic 
proteins in SCLC cells (Pardo et al., 2006). One can thus envisage a chain of events 
where the activation of one kinase is required for the activation of the other kinases.  
Interestingly, we observed an increase of S6K2 protein in response to FGF-2 in 
whole cell lysates (Fig. 26 B). Ten minutes of stimulation were sufficient to observe this 
up-regulation. In such a short period of time, it is unlikely that this increase is due to de 
novo protein synthesis. It may be that S6K2 degradation rate was decreased in response 
to FGF-2. Ubiquitination was shown to be important for the regulation of S6K protein 
levels (Wang et al., 2008) and it is possible that this process may be a target of FGF-2 
signalling. This obvious possibility will be the subject of future studies in our laboratory. 
A transient interaction between B-RAF and PKCε upon FGF-2 stimulation was 
also detected in the HCC95 cell line (Fig. 27 A). Although the intensity and kinetics of 
this interaction varied amongst different experiments it was detected in all experiments 
performed. FGF-2 also induced the interaction of S6K2 with B-RAF and PKCε (Fig. 27 
A). This interesting observation requires further confirmation as, due to technical 
difficulties and time restrains, it was only carried out once. Although FGF-2 
chemoprotection mechanism in the HCC95 cell line needs a more thorough 
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investigation our data suggests that the inability of FGF-2 to protect these cells against 
cisplatin is likely related to the absence of particular signalling molecules other than 
MEK/ERK, B-RAF and PKCε. Alternatively, it may be due to altered kinetics and/or 
signal intensity. It is now widely accepted that proteins rarely act as individual entities 
and that the cellular context is pivotal to a particular cellular response. It is our view 
that FGF-2-mediated chemoprotection is no exception to this rule. Other pathways that 
may also be involved and required for the FGF-2 protection against apoptosis induced 
by drugs such as cisplatin may be impaired in this cell line. For example, protection 
from apoptosis through inactivation of BAD (by phosphorylation) was seen in 
leukemia (Zhao et al., 2004) and in response to growth factors such as EGF (She et al., 
2005; Sastry et al., 2006) and FGF-10 (Smaragda Angelidou and Michael Seckl, personal 
communication). Another way by which FGF-2/FGFR could be regulating cell survival 
is through direct regulation of transcription. Interestingly, upon ligand binding FGF-2 
is internalised and it was shown that it is transported to the nucleus together with 
FGFR1, thereby regulating the proliferation of astrocytes and glioma cells (Stachowiak 
et al., 1996; Joy et al., 1997; Stachowiak et al., 1997). Indeed, nuclear FGFR1 induce the 
expression of genes, which encode proteins required for cell division and proliferation, 
such as c-JUN and cyclin D (Reilly and Maher, 2001).  
Growth factors promote cell survival by modulating various components of the 
apoptotic machinery and they can regulate these components by regulating protein 
expression levels and/or their activation status (phosphorylation or 
dephosphorylation). For example, increased expression of the anti-apoptotic protein 
BCL-XL was observed downstream of EGF (Jost et al., 2001) and FGF-2 (Pardo et al., 
2003) and it was implicated in promoting cell survival. Another example is the 
phosphorylation of BAD in response to EGF and FGF-10 (She et al., 2005; Sastry et al., 
2006; Smaragda Angelidou and Michael Seckl, personal communication). In our work, 
we observed that in U2OS cells FGF-2 induced the up-regulation of several anti-
apoptotic proteins such as MCL-1, BCL-2, BCL-XL and XIAP (Fig. 28). These proteins 
are likely to be involved in the chemoresistance provided by FGF-2. To verify the direct 
cause-effect of this up-regulation on FGF-2-induced chemoresistance, their up-
regulation will be inhibited using RNAi. It will have to be taken into consideration that 
the use of siRNA against those proteins will also knockdown their endogenous levels 
and will probably contribute to a reduction in cell viability. The inclusion of 
appropriate controls will allow to take this into consideration and to normalise the 
data. The use of inhibitors of protein synthesis such as cycloheximide is not ideal, as 
they would also inhibit the synthesis of many other proteins. Proteasome inhibitors 
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(e.g. MG132 and lactacystein) could be used to artificially increase these anti-apoptotic 
proteins. The cells could then be challenged with cisplatin. If these anti-apoptotic 
molecules are stabilised (by blocking their degradation), and assuming that they are 
key inhibitors of cisplatin-induced death, then the cells should survive even in the 
absence of FGF-2. In any case, up-regulation of these proteins may not be due to de 
novo protein synthesis. The use of proteasome inhibitors will help to establish this 
assumption.  
The up-regulation of anti-apoptotic proteins required in FGF-2-mediated 
chemoprotection of the SCLC H-510 cell line was found to occur via increased protein 
translation (Pardo et al., 2002; Pardo et al., 2003). Thus, another possibility is that in 
U2OS cells the increase in protein expression could also result from an increase in 
translation. This could be examined by looking at polysome fractions of cells treated 
with cisplatin in the presence or absence of FGF-2. 
Collectively, the results from this part of the study showed that FGF-2 mediated 
chemoresistance in the osteosarcoma cell line U2OS, but not in the two NSCLC cell 
lines, HCC95 and HCC78. The failure of FGF-2 to protect these NSCLC cell lines 
remains to be understood. Presumably, the lack of robust ERK1/2 activation in HCC78 
cells impaired FGF-2-mediated chemoprotection, as this pathway has been previously 
shown to require MEK/ERK activity. The inability of FGF-2 to protect HCC95 cannot, 
however, be attributed to this. Thus, it seems likely that other components of the rescue 
pathway, downstream of, or in parallel to, MEK/ERK signalling, may be missing. FGF-
2 rescued U2OS cells from cisplatin-induced cell death in a MEK/ERK-dependent 
fashion. Furthermore, in this cell line, FGF-2 induced the interaction of proteins such as 
B-RAF, PKCε and S6K2, and the up-regulation of anti-apoptotic proteins thought to be 
required to protect cells from cisplatin-induced apoptosis. Although some molecular 
aspects of the anti-apoptotic mechanism involved here need to be clarified, U2OS 
chemoprotection by FGF-2 appears to be mediated through a mechanism similar to 
that previously observed in SCLC cells (Pardo et al., 2003). Common players in 
chemoresistance mechanisms between tumour types make these attractive molecular 
targets and potential candidates for the development of novel therapies. 
 
Activation of JAKs and/or STATs can occur downstream of FGF-2 (Ebong et al., 
2004; Yang et al., 2009) and these molecules have been implicated in tumourigenesis and 
chemoresistance (reviewed by Verma et al., 2003; Yu and Jove, 2004). We next investigated, 
therefore, if JAKs and/or STATs also played a role in FGF-2-mediated chemoresistance 
pathway(s) 
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4.2.1. INTRODUCTION 
JAKs and STATs are involved in regulating the expression of many genes that 
in normal cells control fundamental biological processes (Horvarth, 2000). 
Deregulation of JAK/STAT-mediated signalling can lead to cell transformation and 
oncogenesis and, indeed, aberrant activation of JAKs and/or STATs has been observed 
in many human cancer cells (Bowman et al., 2000). JAKs have been shown to modulate 
the activation of signalling pathways implicated in malignant transformation and cell 
growth and were also shown to modulate apoptosis via regulation of anti-apoptotic 
proteins (reviewed by Verma et al., 2003). Constitutive activation of STAT1, STAT3 and 
STAT5 has been observed in a wide variety of human cancer cell lines and primary 
tumours (reviewed by Yu and Jove, 2004). In particular, recent studies have suggested 
that STAT3 oncogenic pathways are not only involved in cellular transformation but 
are also associated with intrinsic drug resistance (Barre et al., 2007; Grisko et al., 2006; 
Ikuta et al., 2005). Although a compelling body of evidence suggests that STAT1 has 
properties of a tumour-suppressor protein (Dunn et al., 2004), recent findings have 
shown that STAT1 can also play a prominent role in the development of tumours and 
in mediating drug resistance (Kovacic et al., 2006; Patterson et al., 2006). STAT5A and 
STAT5B are also found constitutively activated in many cancers, particularly in 
leukaemias (Lewis and Ward, 2008). 
 Some reports have suggested that activation of JAK/STAT signalling pathways 
can occur downstream of FGF-2 but not much work has been done in this area. It was 
shown that FGF-2 can activate STAT1, STAT3 and STAT5 in murine lens cells and 
BMVECs and, in addition, inhibition of JAK activity was demonstrated to impair FGF-
2–induced proliferation (Ebong et al., 2004; Yang et al., 2009). We hypothesised, 
therefore, that JAKs and/or STATs may play a role in FGF-2-mediated 
chemoresistance pathway(s). 
In this part of the work, we aimed to establish a role for JAK and/or STAT 
proteins in FGF-2-mediated chemoresistance pathways. We have investigated the 
requirement for these molecules in this pathway by assessing the ability of FGF-2 to 
protect U2OS cells from cisplatin-mediated cell death when the levels of these proteins 
were reduced by RNAi or their activity blocked by chemical inhibition. FGF-2 rescue 
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experiments (Section 4.1.5) were performed in cells where JAK1, JAK2, TYK2, STAT1, 
STAT3 or STAT5 were independently silenced by RNAi using siRNA oligonucleotides 
molecules. Modulation of JAKs and STATs by FGF-2 was characterised in the U2OS 
cell line by performing extensive dose- and time-response experiments. Subsequently, 
having identified a role for the JAKs but seemingly not for the STATs, we investigated 
the requirement for the JAKs in FGF-2-mediated chemoresistance. 
 
 
 
4.2.2. JAK1, JAK2 AND TYK2 BUT NOT STAT1, STAT3 AND STAT5 WERE 
REQUIRED FOR FGF-2-MEDIATED CHEMORESISTANCE IN U2OS CELLS 
In the osteosarcoma cell line U2OS, FGF-2 prevented cisplatin killing by 
blocking death-inducing signalling pathways activated by this drug (Section 4.1.5). We 
asked, therefore, whether JAKs and/or STATs were involved in this process. To 
address this, the FGF-2 rescue experiment (Section 4.1.5) was performed in cells with 
reduced levels of JAK1, JAK2, TYK2, STAT1, STAT3 or STAT5A/B.  
 
 
 
4.2.2.1. KNOCKDOWN OF JAK1, JAK2, TYK2, STAT1, STAT3 AND STAT5 
IN U2OS CELLS 
Knockdown of JAK1, JAK2, TYK2, STAT1, STAT3 and STAT5A/B was 
achieved by independently transfecting cells with siRNA oligonucleotide pools against 
each one of these molecules. U2OS cells were transfected with siSMART pools 
(provided by Dharmacon), which consist of four different oligonucleotides each 
targeting different regions of the same mRNA. Although siRNA oligonucleotides are 
designed to specifically silence specific targets, there is always the possibility that any 
given siRNA oligonucleotide may silence molecules other than the specific target (“off-
target” effect). Exclusion of obvious ”off-target” effects has been previously extensively 
done by members of the Costa-Pereira group. Validation of each one of the siRNA 
pools is routinely done in our laboratory by deconvoluting each siSMART pool into its 
four constituents, followed by the analysis of the phenotypes of each and by utilising 
siRNAs designed using a different algorithm and technology (OnTargetPlus, 
Dharmacon). If two out of the four individual oligonucleotides give the same 
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phenotype as the original siSMARTpool, then the siRNA pool is validated (Echeverri 
and Perrimon, 2006).  
The levels of knockdown and the specificity of the siRNA pools were assessed 
by Western blot and RT-PCR (Fig. 29). Whole cell extracts from cells transfected with 
siRNA were run on 7.5% SDS-PAGE gels (Fig. 29 A and E). Figure 29 A shows the 
expression of JAK1, JAK2 and TYK2 in U2OS cells upon transfection with siRNA 
against each one of them. Untreated cells and cells transfected with a non-specific 
siRNA control (NS) were included in order to establish the basal levels of these 
proteins (untransfected control) and to determine the impact of transfecting cells with 
double-strand RNA (NS control). Because JAKs have similar molecular weights (JAK1 
is 130 kDa, JAK2 is 125 kDa and TYK2 is 140 kDa), two Western blot membranes were 
used to ensure there was no cross-reactivity of antibodies and to avoid probing a 
membrane stripped twice. The Western blot membranes were probed for with 
antibodies against JAK1, JAK2 and TYK2. Both membranes were probed for β-actin, 
which was used as a loading control. siRNA against JAK1 significantly reduced the 
levels of JAK1 protein (p<0.005) without affecting the other two JAK family members, 
JAK2 and TYK2 (Fig. 29 B). siRNA against JAK2 also caused a significant reduction of 
JAK2 protein levels (p<0.005) and siRNA against TYK2 significantly reduced TYK2 
proteins (p<0.005) without affecting the other JAKs (Fig. 29 C and D). Because STAT1, 
STAT3 and STAT5 are highly homologous and have similar molecular weights (STAT1 
is 91 kDa, STAT3 is 86 kDa, STAT5A is 92 kDa and STAT5B is 94 kDa), three Western 
blot membranes were used. The Western blot membranes were probed for with 
antibodies against STAT1, STAT3, STAT5A/B and β-actin, the latter used as a loading 
control. siRNA against STAT1, STAT3 and STAT5A/B significantly reduced the levels 
of STAT1 (p<0.005), STAT3 (p<0.005) and STAT5A and B (p<0.005) proteins, 
respectively, without affecting other STAT family member probed here (Fig. 29 F, G, H 
and I).  
Knockdown of some targets (JAK1, JAK2, STAT1 and STAT3) was also 
confirmed by RT-PCR. Total RNA was extracted from cells, reverse-transcribed into 
cDNA and fragments of JAK1, JAK2, STAT1 and STAT3 amplified by PCR. 
Untransfected cells and cells transfected with a non-specific siRNA were used as 
controls. The fragments were successfully amplified in untransfected cells and in cells 
transfected with the non-specific siRNA but not in cells transfected with a specific 
siRNA pool (Fig. 29 J). 
Protein knockdown levels were monitored concomitantly by Western blot in all 
experiments involving siRNA. 
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Figure 29. siRNA oligonucleotides can specifically knockdown JAK1, JAK2, TYK2, STAT1, 
STAT3 and STAT5A/B in U2OS cells. (Continued on page 138). U2OS cells were transfected with 75 
nM siRNA using DharmaFECT II. Untransfected cells (Unt), or cells transfected with a non-specific siRNA 
(NS) were used as controls. A. and E. Forty-eight hours after transfection, proteins were extracted and 
separated on a 7.5% SDS-PAGE gel. Total cell lysates were Western blotted as indicated. A. Cells were 
transfected with siRNA against JAK1, JAK2 or TYK2. The Western blot membranes were probed for JAK1, 
JAK2 and TYK2. β-actin was also probed and used as a loading control. E. Cells were transfected with 
siRNA against STAT1, STAT3 or STAT5A/B. The Western blot membranes were probed for STAT1, 
STAT3, STAT5A and STAT5B. β-actin was also probed and used as a loading control. B., C., D., F., G., H. 
and I. Mean ± SEM of densiometric values of at least three independent experiments are shown in the 
graphs. Values are expressed as fold change relative to untransfected controls. Statistical analysis was 
performed with Student’s t-test (*** – p<0.005). J. RNA was isolated 48 hours post-transfection and used as 
a template for the amplification of fragments of JAK1, JAK2, STAT1 and STAT3. GAPDH was amplified 
for the same samples and used as a loading control. Unt – untransfected, NS – non-specific siRNA, J1 – 
JAK1, J2 – JAK2, T2 – TYK2, ST1 – STAT1, ST3 – STAT3, ST5 – STAT5A/B. 
A. 
E.  
C.       G. 
B.       F. 
I.  
D.       H. 
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Figure 29. siRNA oligonucleotides can specifically knockdown JAK1, JAK2, TYK2, STAT1, 
STAT3 and STAT5A/B in U2OS cells. (Continued from page 137). 
 
 
 
 
 
 
4.2.2.2. JAK1, JAK2 AND TYK2 WERE REQUIRED FOR FGF-2-MEDIATED 
CHEMORESISTANCE 
JAKs have been shown to play a role in oncogenesis and to modulate apoptosis 
via regulation of anti-apoptotic proteins (reviewed by Verma et al., 2003). Here we 
investigated if the JAKs were required for the FGF-2-mediated chemoresistance 
mechanism that was identified in U2OS cells (Section 4.1.5). We used RNAi to reduce 
protein levels of JAK1, JAK2 and TYK2, which enabled us to investigate the impact of 
their knockdown on FGF-2-mediated rescue from cisplatin. After verifying that JAK1, 
JAK2 and TYK2 could be efficiently silenced by RNAi (Fig. 29), FGF-2 rescue 
experiments were performed on these cells.  
Following two days of siRNA transfection, cells were trypsinised, counted, and 
re-plated in 6-well plates (2x105 cells per well). This was important to ensure that the 
rescue experiment was initiated with an equal number of cells in every sample, as 
transfection with different siRNA pools induced different levels of cell death. Twenty-
four hours later, period after which all cells should have adhered to the plates, cells 
were incubated in serum-free media overnight and treated as previously described: 
they were pre-incubated for 4 hours with FGF-2 and then treated with cisplatin. The 
J. 
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rescue experiment was also performed in untransfected cells and cells transfected with 
a non-specific siRNA (NS), both used as controls, as described before. Protein 
extractions were performed in parallel with all experiments involving siRNA to 
monitor the knockdown levels of each protein targeted. Protein extractions were 
performed at the moment of FGF-2 addition (72 hours after RNAi), as we were 
particularly interested on the impact of the absence of JAKs on early signalling 
cascades induced by FGF-2 occurring. One example of knockdown levels typically 
observed is shown in Figure 29 A.  
Loss of DNA content was measured by flow cytometry. Cell cycle profiles were 
analysed after 18 hours of cisplatin treatment (Fig. 30). In untransfected cells pre-
incubation with FGF-2 significantly blocked cisplatin-mediated cell death as previously 
observed (Fig. 21, Section 4.1.5.1). This was translated in a reduction of the sub-G1 
population of cells previously incubated with FGF-2 when compared to cells treated 
with cisplatin only (Fig. 30 A, black coloured cell cycle profiles, compare 3rd versus 4th 
histograms in the 1st column). In these cells FGF-2 also significantly reduced the basal 
levels of cell death (p<0.005) (Fig. 30 B, 1st versus 2nd bar in the 1st graph) and treatment 
with cisplatin induced a significant increase of cell death (p<0.005) (Fig. 30 B, 1st versus 
3rd bar in the 1st graph). Pre-incubation with FGF-2 substantially blocked cisplatin-
induced killing (p<0.05) (Fig. 30 B, 3rd versus 4th bar in the 1st graph). Similar results 
were obtained in cells transfected with a non-specific siRNA  (Fig. 30 A, brown 
coloured cell cycle profiles and Fig. 30 B, last graph). 
In contrast, cells with reduced levels of JAK1 (Fig. 30 A, light pink coloured cell 
cycle profiles), JAK2 (Fig. 30 A, dark pink coloured cell cycle profiles), or TYK2 (Fig. 30 
A, purple coloured cell cycle profiles) were not protected by FGF-2 from cisplatin-
mediated cell death (Fig. 30 A, compare 3rd versus 4th histograms in each of the 2nd-4th 
columns). In these cells, the sub-G1 population of cells treated with FGF-2 and cisplatin 
was not significantly different from cells treated with cisplatin only (Fig. 30 B, 3rd 
versus 4th bar in 2nd-4th graphs). Interestingly, in cells with decreased levels of JAK1, 
JAK2 and TYK2, FGF-2 significantly reduced the basal levels of cell death (p<0.005, 
p<0.005 and p<0.05, respectively) (Fig. 30 B, 1st versus 2nd bar in 2nd-4th graphs) but not 
the cisplatin-induced cell death (Fig. 30 B, 3rd versus 4th bar in 2nd-4th graphs). This 
observation can have more than one explanation. It may be that JAKs are specifically 
required for protection from cisplatin killing, but not essential for protection from 
death in general. In this particular case basal cell death was probably caused by 
starvation and/or other experiment-related factors. Alternatively, it may be that when 
only a small percentage of cells died, FGF-2 could still mediate survival because the 
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knockdown of a particular JAK may be compensated by the presence of another JAK. 
In addition, although siRNA significantly reduced protein levels, the knockdown 
efficiency was never 100% (cf. Fig. 29). The presence of residual JAK molecules may be 
enough for FGF-2 to block basal cell death. These data suggested that JAK1, JAK2 and 
TYK2 were integral components of the mechanism by which FGF-2 protected cells 
from cisplatin-induced apoptosis. 
The experiment illustrated in Figure 30 A is representative of several 
independent experiments. In this particular experiment there were differences between 
untransfected cells and cells transfected with siRNA molecules with regards to the 
percentage of apoptosis following an overnight treatment with cisplatin (Fig. 30 A, 3rd 
histogram of each column). This may suggest that the knockdown of JAKs itself 
protected, to a certain extent, U2OS cells from cisplatin killing. However, this was also 
seen for the non-specific control (NS) and it was not observed in all experiments 
performed as demonstrated by the mean of three independent experiments shown in 
Figure 30 B (an average of 2.9-, 2.7- and 2.8-fold for JAK1, JAK2 and TYK2, respectively 
compared to 2.6- and 3.0-fold for untransfected and NS, respectively).  
Results from three independent experiments showed that transfection of 
siTYK2 rendered cells more susceptible to death even in the absence of any obvious 
apoptosis-inducing stimuli. This was reflected by the fact that there was more 
background apoptosis in these cells than in the untransfected cells (p<0.05) and in cells 
transfected with siJAK1, siJAK2 or a non-specific siRNA (Fig. 30 C, 4th bar). This 
suggests that TYK2 may have a role in cell survival or proliferation. In siTYR2-
transfected cells, cisplatin did not induce more cell death (an average of 2.8-fold) than 
untransfected cells or cells transfected with a non-specific siRNA (an average of 2.6- 
and 3.0-fold, respectively) (Fig. 30 B, 3rd bar, 4th versus 1st and 5th graphs). This suggests 
that siRNA against TYK2 affected the basal survival of U2OS cells, but did not confer 
sensitivity to cisplatin treatment. 
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Figure 30. Knockdown of JAK1, JAK2 or TYK2 affected the ability of FGF-2 to protect U2OS 
cells from cisplatin-induced cell death. (Continued on page 142). U2OS cells were transfected with 75 
nM of siRNA against JAK1, JAK2 or TYK2 using DharmaFECT II. After 48 hours, cells were plated in 6-
well plates (2x105 cells/well) and incubated in serum-free media overnight. Cells were pre-treated with 
FGF-2 (10 ng/ml) for 4 hours and then treated with the LD50 of cisplatin for 18 hours. Cells were stained 
with PI and apoptotic cell death was assessed by flow cytometry using the FACSCanto. Results were 
analysed using FlowJo. Untransfected and non-specific (NS) transfected cells were used as controls. A. 
Cell cycle profiles from one experiment are shown. Numbers refer to the percentage of dead cells 
represented within the sub-G1 population. B. Mean ± SEM of three independent experiments are shown in 
the graphs. Numbers correspond to the fold change of sub-G1 populations over untreated control. 
Statistical analysis was performed with Student’s t-test (* – p<0.05; ** – p<0.01; *** – p<0.005). C. Mean ± 
SEM of basal cell death from three independent experiments are shown in the graph. Numbers correspond 
to the fold change of sub-G1 populations over untransfected control. Statistical analysis was performed 
with Student’s t-test (* – p<0.05 versus untransfected control). 
B. 
 
A. 
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Figure 30. Knockdown of JAK1, JAK2 or TYK2 affected the ability of FGF-2 to protect U2OS 
cells from cisplatin-induced cell death. (Continued from page 141). 
 
 
 
 
 
The requirement for JAK1, JAK2 and TYK2 in the mechanism by which FGF-2 
protected cells from cisplatin-induced apoptosis was confirmed by analysing cleavage 
of PARP. FGF-2 rescue experiments were performed in cells transfected with siRNA 
against that JAK1, JAK2 and TYK2. As a control, the rescue experiment was performed 
in untransfected cells and cells transfected with a non-specific siRNA. Two days after 
siRNA transfection cells were trypsinised, counted and replated in 6-well plates (2x105 
cells per well). Twenty-four hours later, cells were incubated in serum-free media 
overnight and pre-incubated for 4 hours with FGF-2. They were then treated with 
cisplatin. After 16 hours of cisplatin treatment proteins were extracted from all cells 
(adherent alive cells and floating “corpses”) and run on a 7.5% SDS-PAGE gel.  
In untransfected cells, pre-incubation with FGF-2 significantly blocked 
cisplatin-mediated PARP cleavage as previously observed (Fig. 21 C, Section 4.1.5.1). 
This was shown by the reduction of cleaved PARP in cells pre-incubated with FGF-2 
compared to cells treated with cisplatin only (Fig. 31, 1st Western blot panel, 3rd versus 
4th lane). In these cells, FGF-2 significantly reduced the basal levels of PARP cleavage 
(p<0.005) and treatment with cisplatin induced a significant increase PARP cleavage 
(p<0.005). Pre-incubation with FGF-2 substantially blocked cisplatin-induced killing 
(p<0.01). The pattern of PARP cleavage in cells transfected with a non-specific siRNA 
was identical to that seen in the untransfected cells (Fig. 31, 5th Western blot panel). 
C. 
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In accordance to what was observed by cell cycle analysis (Fig. 30), FGF-2 did 
not rescue cells with reduced levels of JAK1, JAK2 or TYK2 from cisplatin-mediated 
cell death (Fig. 31, 2nd-4th Western Blot panel, compare 3rd with 4th lane). In these cells 
treatment with cisplatin induced a significant increase of PARP cleavage (p<0.05, 
p<0.005, p<0.005 for JAK1, JAK2 and TYK2, respectively), which was not prevented by 
pre-treatment with FGF-2 (Fig. 31, 3rd versus 4th bar in 2nd-4th graphs). In siJAK1- and 
siJAK2- (but not siTYK2-) transfected cells, FGF-2 significantly reduced the basal levels 
of PARP cleavage (p<0.05) (Fig. 31, 1st versus 2nd bar in 2nd and 3rd graphs). This 
confirms the results obtained for JAK1 and JAK2 previously shown in Figure 30. The 
results obtained with the analysis of PARP cleavage showed that, for cells transfected 
with siTYK2, the difference between cell death in cells treated with FGF-2 only and 
untreated cells was not statistically significant (Fig. 31, 1st versus 2nd bar in 4th graph). 
The lack of significance was due to one particular experiment, where we did not 
observed a difference, which impacted on the statistical significance of the results. 
Further repeats should enable us to determine the truly representative result.  
Together, these data suggest that the presence of JAK1, JAK2 and/or TYK2 is 
required for efficient FGF-2-mediated protection of cells from cisplatin-induced 
apoptosis. 
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Figure 31. Knockdown of JAK1, JAK2 or TYK2 affected the ability of FGF-2 to block 
cisplatin-induced PARP cleavage in the U2OS cells. U2OS cells were transfected with 75 nM of 
siRNA against JAK1, JAK2 or TYK2 using DharmaFECT II for 48 hours. Untransfected cells and cells 
transfected with a non-specific siRNA were used as control. Subsequently, cells were plated in 6-well 
plates (2x105 cells/well) and incubated in serum-free media overnight. After 4 hours pre-treatment with 
FGF-2 (10 ng/ml), cells were treated with the LD50 of cisplatin for 16 hours. Subsequently, cells were 
harvested; proteins were extracted and separated on 7.5% SDS-PAGE gel. Western blotting analysis was 
performed using total cell lysates and the membrane probed with antibodies against PARP. β-actin was 
also probed and used as a loading control. Representative Western blots and mean ± SEM of densiometric 
values (cleaved PARP) from three experiments are shown in graphs. Values are expressed as fold change 
over untreated controls. Statistical analysis was performed with Student’s t-test (* – p<0.05, ** - p<0.01, *** 
– p<0.005). 
  145 
RESULTS 
Although, to the best of our knowledge, JAK3 is not generally expressed in 
osteosarcoma cells, it would be interesting to investigate if it is expressed in U2OS cells 
and, if so, whether it plays a role in FGF-2-mediated chemoresistance. In general, 
constitutively activated JAK3 and mutant JAK3 alleles can be found in 
lymphoproliferative disorders (Gee et al., 2001; Yared et al., 2005; Lai et al., 2005; Tomita 
et al., 2006; Krejsgaard et al., 2006; Walters et al., 2006; Marzec et al., 2008). Indeed, JAK3 
has been associated with tumourigenesis and since cancer cells have de-regulated gene 
expression, it is not inconceivable that U2OS cells may, against our expectations, 
express JAK3. For example, JAK3 activation was found to contribute to the oncogenesis 
of colon and breast cancers (Lin et al., 2005; Kim et al., 2009). The potential participation 
of JAK3 in FGF-2-mediated chemoresistance will be investigated further in the future. 
 
 
 
4.2.2.2.1. JAK2 ACTIVITY WAS REQUIRED FOR FGF-2-MEDIATED 
CHEMORESISTANCE 
We next investigated if JAK activity was required for FGF-2 chemoprotection. 
For this purpose, we used JAK2 inhibitor II (1,2,3,4,5,6-hexabromocyclohexane). This 
inhibitor interacts with a solvent-accessible pocket near the activation loop of JAK2 and 
acts as a specific and direct inhibitor of its autophosphorylation (Sandberg et al., 2005). 
Pre-treatment with this inhibitor for 45 minutes was sufficient to block the activation of 
STAT3 by IL-6, which requires JAK2 activity (Stahl et al., 1995), in a dose dependent 
manner (data not shown). The addition of 50 µM of JAK2 inhibitor II blocked the 
activation of STAT3 without affecting the basal levels of activated ERK1/2.  
We also tested JAK inhibitor I (Pyridone 6) that inhibits all JAKs (Thompson et 
al., 2002). This ATP-competitive inhibitor of JAKs, however, was shown to have 
profound effects on ERK1/2 basal phosphorylation (phosphorylated ERK1/2 was 
elevated in cells treated with the inhibitor) (data not shown) and was therefore 
considered inappropriate for this study. The requirement of JAK2 activity for the FGF-
2-mediated rescue was then investigated by performing the rescue experiment in the 
presence or absence of JAK2 inhibitor II.  
Rescue experiments previously described were performed in cells that were 
incubated with 50 µM of JAK2 inhibitor II for 45 minutes before adding FGF-2. 
Cisplatin was added four hours after FGF-2. The rescue experiment was also 
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performed in cells incubated with the drug vehicle [0.5% (v/v) DMSO] as a control. 
Cell cycle profiles and PARP cleavage patterns were then analysed. 
Both cells pre-incubated with JAK inhibitor II and cells incubated with the drug 
vehicle (control) underwent significant cell death upon cisplatin treatment (p<0.01 and 
p<0.005, respectively) as measured by the increase of the sub-G1 peak and PARP 
cleavage (Fig. 32 B and D, 1st versus 3rd bar in both graphs). In cells treated with the 
drug vehicle only, pre-incubation with FGF-2 significantly reduced cisplatin-induced 
cell death (p<0.05) (Fig. 32 A, 3rd versus 4th black histograms and B, 3rd versus 4th black 
bar). This was also seen by PARP cleavage analysis (Fig. 32 C, 3rd versus 4th lane and D, 
3rd versus 4th bar in the graph on the left).  
Incubation with JAK inhibitor II precluded FGF-2 rescue of cisplatin-treated 
cells from apoptosis. Indeed neither the sub-G1 peak population was reduced, nor was 
PARP cleavage prevented in FGF-2 pre-treated cells (Fig. 32 A, 3rd versus 4th grey 
histograms and C, 7th versus 8th lane). Accordingly, in these cells the difference between 
the sub-G1 populations (or PARP cleavage) after treatment with cisplatin and FGF-2 
was not statistically significant from treatment with cisplatin only (Fig. 32 B, 3rd versus 
4th grey bar and D, 3rd versus 4th bars in the graph on the right). 
Interestingly, in the presence of the JAK2 inhibitor, FGF-2 was also not able to 
significantly reduce the basal cell death (Fig. 32 B and D, 1st versus 2nd bar in the graphs 
on the right). Knockdown of JAK2 was previously shown to prevent the FGF-2 rescue 
from cisplatin but it did not impair the reduction of background cell death seen in 
response to FGF-2 (Fig. 30 and 31). This could be related to the fact that the chemical 
inhibitor blocks the kinase activity but does not affect JAK2 protein levels (data not 
shown), whereas siJAK2 reduces the amount of JAK2 in these cells without specifically 
affecting its potential for activation. The chemical inhibitor may thus be more efficient 
than siJAK2.  Although JAK2 inhibitor is supposedly specific, having low impact on 
the activity of other family members, one cannot exclude the possibility that, in these 
cells and under our experimental conditions, the inhibitor may also reduce the activity 
of other JAKs, which may be required for FGF-2 to block background cell death. Only 
in vitro kinase assays would clarify this issue. 
Together, these data suggested that in U2OS cells FGF-2 chemoprotection 
required JAK2 kinase activity.  
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Figure 32. Inhibition of JAK2 activity impaired FGF-2-mediated rescue in U2OS cells. 
(Continued on page 148). 
A. 
 
B. 
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Figure 32. Inhibition of JAK2 activity impaired FGF-2-mediated rescue in U2OS cells. 
(Continued from page 147). U2OS cells were starved in serum-free media overnight and incubated with 
50 µM of JAK2 inhibitor II for 45 minutes, or with the drug vehicle [0.5% (v/v) DMSO] (untreated). After 4 
hours of pre-treatment with FGF-2 (10 ng/ml), cells were treated with the LD50 of cisplatin. A. After 18 
hours of cisplatin treatment, cells were harvested, permeabilised and stained with PI (50 µg/ml). 
Apoptotic cell death was assessed by flow cytometric analysis using the FACSCanto and the results were 
analysed using FlowJo. Cell cycle profiles from one representative experiment are shown. Numbers refer 
to the percentage of dead cells represented within the sub-G1 population. B. Mean ± SEM of three 
independent experiments are shown in graphs. Values are expressed as fold change of sub-G1 populations 
over untreated control (* – p<0.05; ** – p<0.01; *** – p<0.005). C. After 16 hours of cisplatin treatment cells 
were harvested, proteins extracted and separated on a 7.5% SDS-PAGE gel. Western blotting analysis was 
performed using total cell lysates and antibodies against PARP. β-actin was used as a loading control. D. 
Mean ± SEM of densiometric values (cleaved PARP) from three experiments are shown in graphs. Values 
are expressed as fold change over untreated controls. Statistical analysis was performed with Student’s t-
test (* – p<0.05; ** – p<0.01; *** – p<0.005). 
C. 
 
D. 
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Reduction in the levels of JAK1, JAK2 and TYK2 had a significant impact on 
FGF-2-mediated protection against cisplatin. The use of a pharmacological inhibitor 
that targets JAK2 activity suggested that its enzymatic activity was required for 
efficient chemoprotection. We have, therefore, investigated the impact of reducing the 
levels of STAT1, STAT3 and STAT5, the main signal transducers downstream of JAKs, 
in FGF-2-mediated chemoresistance in the U2OS cells. 
 
 
 
4.2.2.3. STAT1, STAT3 AND STAT5A/B WERE NOT REQUIRED FOR FGF-2-
MEDIATED CHEMORESISTANCE 
Over-activation of STAT1, STAT3 and STAT5 has been observed in many 
cancers (reviewed by Yu and Jove, 2004). These three STATs were shown to contribute 
to oncogenesis and, in particular, STAT3, by virtue of its anti-apoptotic and growth-
promoting properties, was associated with intrinsic drug resistance (Kovacic et al., 
2006; Patterson et al., 2006; Barre et al., 2007; Grisko et al., 2006; Ikuta et al., 2005; Lewis 
and Ward, 2008). As JAKs were required for FGF-2-mediated chemoresistance in U2OS 
cells, we investigated if within this context STATs, the main targets of JAKs, were also 
required to mediate FGF-2 response(s).  
We used RNAi to reduce the protein levels of STAT1, STAT3 and STAT5 so that 
the impact of their knockdown on FGF-2-mediated rescue from cisplatin-induced cell 
death could be investigated. After verifying that STAT1, STAT3 and STAT5 could be 
efficiently silenced by using siRNA molecules, the FGF-2 rescue was attempted. The 
rescue experiment was also performed on untransfected cells and cells transfected with 
a non-specific siRNA (NS) that were used as controls, as previously explained. Two 
days post-transfection, cells were trypsinised, counted and replated in 6-well plates 
(2x105 cells per well). Twenty-four hours later cells were incubated in serum-free media 
overnight and treated as previously described with FGF-2 (4 hours) and cisplatin (18 
hours). Cell cycle profiles were analysed by flow cytometry (Fig. 33) and the levels of 
knockdown for each protein targeted were monitored in parallel (e.g. Fig. 29).  
FGF-2 significantly rescued untransfected cells from cisplatin-induced death. 
This was shown by a reduction in the sub-G1 population seen in cells that were treated 
with FGF-2 and cisplatin when compared to cells treated with cisplatin only (Fig. 33 A, 
black coloured cell cycle profiles, 3rd versus 4th histogram). Pre-incubation with FGF-2 
significantly blocked cisplatin-induced killing (p<0.01) (Fig. 33 B, 3rd versus 4th bar in 
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the 1st bar graph). In these cells FGF-2 also significantly reduced the basal levels of cell 
death (p<0.005) (Fig. 33 B, 1st versus 2nd bar in the 1st graph). Similar results were 
obtained in cells transfected with a non-specific siRNA (cf. Fig. 30). 
Like in untransfected cells, treatment with cisplatin induced a significant 
increase (p<0.005) of cell death in cells transfected with STAT1, STAT3 and STAT5A/B 
siRNAs (Fig. 33 B, 1st versus 3rd bars in 2nd-4th graphs). To our great surprise, despite the 
obvious requirement for the JAKs (Fig. 30 and 31), FGF-2 could rescue cells with 
reduced levels of STAT1, STAT3 or STAT5 (Fig. 33 A, yellow, orange and red coloured 
cell cycle profiles, 3rd versus 4th histograms). This was further confirmed by statistical 
analysis which established a significant difference between sub-G1 populations of cells 
treated with FGF-2 before cisplatin and cells treated with cisplatin alone (p<0.005 for 
siSTAT1, p<0.05 for siSTAT3 and p<0.05 for siSTAT5A/B) (Fig. 33 B, 3rd versus 4th bars 
in 2nd-4th graphs). These results suggest that, independently, each of these three 
proteins were not essential to the mechanism used by FGF-2 to protect cells against 
cisplatin. It remains to be established any possible redundancy between these three 
proteins and whether STAT2, STAT4 and/or STAT6 are also dispensable. In addition, 
in cells with decreased levels of STAT1, STAT3 and STAT5A/B FGF-2 also significantly 
reduced the background levels of cell death (p<0.05, p<0.01 and p<0.005, respectively) 
(Fig. 33 B, 1st versus 2nd bar in 2nd-4th graphs). 
In cells with reduced levels of STAT5A/B proteins, cisplatin induced less cell 
death (an average of 1.4-fold over the respective untreated control) compared to the 
untransfected cells (2.3-fold over the respective untreated control), cells transfected 
with siRNA against STAT1 (2.8-fold over the respective untreated control) and cells 
transfected with siRNA against STAT3 (2.1-fold over the respective untreated control) 
(Fig. 33 B, 3rd bar of all graphs). This was unexpected, as STAT5 is thought to have, in 
general, an mitogenic role (e.g. Lewis and Ward, 2008).  
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Figure 33. FGF-2 was able to rescue U2OS cells from cisplatin-induced cell death in the 
absence of STAT1, STAT3 or STAT5. (Continued on page 152). U2OS cells were transfected with 
75 nM of siRNA against STAT1, STAT3 or STAT5A/B using DharmaFECT II. After 48 hours, cells were 
plated in 6-well plates (2x105 cells/well) and incubated in serum-free media overnight. Cells were pre-
treated with FGF-2 (10 ng/ml) for 4 hours and then treated with the LD50 of cisplatin for 18 hours. Cells 
were stained with PI and apoptotic cell death was assessed by flow cytometry using the FACSCanto. 
Results were analysed using FlowJo. Untransfected cells were used as controls. A. Cell cycle profiles from 
one experiment are shown. Numbers refer to the percentage of dead cells represented within the sub-G1 
population. B. Mean ± SEM of at least three independent experiments are shown in graphs. Numbers 
correspond to the fold change of sub-G1 populations over untreated control. Statistical analysis was 
performed with Student’s t-test (* – p<0.05; ** – p<0.01; *** – p<0.005). C. Mean ± SEM of basal cell death 
from three independent experiments are shown in the graphs. Numbers correspond to the fold change of 
sub-G1 populations over untransfected control. Statistical analysis was performed with Student’s t-test (* – 
p<0.05 versus untransfected control). 
A. 
B. 
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Figure 33. FGF-2 was able to rescue U2OS cells from cisplatin-induced cell death in the 
absence of STAT1, STAT3 or STAT5. (Continued from page 151). 
 
 
 
 
In addition, results from three independent experiments showed that siSTAT5-
transfected cells also had lower levels of basal death than untransfected cells (p<0.05) 
(Fig. 33 C, 4th bar). It is possible that, like STAT1 (Stephanou et al., 2005; Kovacic et al., 
2006; Patterson et al., 2006), STAT5 may have both anti-apoptotic and pro-apoptotic 
properties according to the cell type and cellular environment. The average 
background cell death in siSTAT3-transfected cells was higher than untransfected cells 
(2-fold) (Fig. 33 C, 3rd bar), which is in accordance with STAT3 being required for cell 
growth and cell survival (Bromberg et al., 2000; Yu and Jove, 2004). This observation 
was not, however, statistically significant.  
 
The results obtained by cell cycle analysis were confirmed by examining PARP 
cleavage. The FGF-2 rescue experiment was performed in cells transfected with siRNA 
against STAT1, STAT3 and STAT5. Untransfected cells and cells transfected with a 
non-specific siRNA were once again used as controls. Following two days of siRNA 
transfection cells were trypsinised, counted and re-plated in 6-well plates (2x105 cells 
per well). Twenty-four hours later cells were incubated in serum-free media overnight 
and pre-incubated for 4 hours with FGF-2 followed by cisplatin treatment. After 16 
hours of cisplatin treatment proteins were extracted from all cells (adherent alive cells 
and floating “corpses”) and run on a 7.5% SDS-PAGE gel. 
By analysing PARP cleavage we noted that pre-incubation with FGF-2 blocked 
cisplatin-mediated apoptosis in untransfected cells as well as in cells transfected with 
C. 
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siRNA against STAT1, STAT3 and STAT5 (Fig. 34), confirming the results obtained 
while analysing the cell cycle (Fig. 33). This is demonstrated by the significant 
reduction in PARP cleavage in cells previously incubated with FGF-2 when compared 
to cells treated with cisplatin alone (p<0.005 in untransfected, and p<0.05 in siSTAT1-, 
siSTAT3-, si-STAT5- and NS-transfected cells) (Fig. 34, 3rd versus 4th lane in all Western 
blots and 3rd versus 4th bar in the all graphs). For all conditions, treatment with cisplatin 
induced a significant increase in PARP cleavage (p<0.005 in untransfected, siSTAT1 
and siSTAT3, and p<0.01 in siSTAT5 and p<0.05 in NS) (Fig. 34, 1st versus 3rd bar in all 
graphs).  
FGF-2 also significantly reduced the basal levels of PARP cleavage, indicative of 
background apoptosis, in untransfected cells (p<0.005) and in cells transfected with 
siRNA against STAT3 (p<0.05), STAT5 (p<0.05) and NS (p<0.05) (Fig. 34, 1st versus 2nd 
bar in 1st and 3rd-5th graphs). However, this was not observed in siSTAT1-transfected 
cells (Fig. 34, 1st versus 2nd bar in the 2nd graph). This may be related to the low levels of 
basal cell death observed in these cells. We noted during the course of these 
experiments that the levels of cleaved PARP in siSTAT1-transfected cells were low and, 
indeed, a higher exposure of the X-ray films was needed to detect this form. This not 
only makes it more difficult to detect the PARP fragment by Western blot, but it also 
makes the quantification less robust. An alternative explanation is that STAT1 was not 
required for the FGF-2 rescue from cisplatin-induced cell death, but was somehow 
needed for the effect of FGF-2 on basal levels of apoptosis. 
In most Western blots, as for example in Figure 34, the total (116 kDa) and 
cleaved (85 kDa) forms of PARP were not the only bands detected with the PARP 
antibody. We have noticed that these bands were detected when a freshly prepared 
primary antibody solution was used, suggesting that they might be unspecific. The fact 
that some bands appear to vary with the treatments performed suggested, however, 
that they might correspond to other forms of PARP. For example, PARP can be cleaved 
into a smaller fragment of 55 kDa that has been described in necrotic cells (Gobeil et al., 
2001). That fragment was never detected in our experiments though. These bands were 
also more evident in X-ray films that were exposed for longer periods of time in order 
to detect lower levels of PARP cleavage (e.g. siSTAT1 Western blot, Fig. 34).  
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Figure 34. FGF-2 was able to reduce cisplatin-induced PARP cleavage in U2OS cells with 
reduced levels of STAT1, STAT3 or STAT5. U2OS cells were transfected with 75 nM of siRNA 
against STAT1, STAT3 or STAT5A/B using DharmaFECT II for 48 hours. Untransfected cells and cells 
transfected with a non-specific siRNA were used as controls. Subsequently, cells were plated in 6-well 
plates (2x105 cells/well) and incubated in serum-free media overnight. After 4 hours pre-treatment with 
FGF-2 (10 ng/ml), cells were treated with the LD50 of cisplatin for 16 hours. Subsequently, cells were 
harvested, proteins were extracted and separated on 7.5% SDS-PAGE gel. Western blotting analysis was 
performed using total cell lysates and the membrane was probed with antibodies against PARP. β-actin 
was also probed and used as a loading control. Representative Western blots and mean ± SEM of 
densiometric values (cleaved PARP) from three independent experiments are shown in the graphs. Values 
are expressed as fold change over untreated controls. Statistical analysis was performed with Student’s t-
test (* – p<0.05, ** - p<0.01, *** – p<0.005). 
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Together, these data suggested that the absence of STAT1, STAT3 or STAT5 did 
not impede FGF-2-mediated protection of cells from cisplatin-induced apoptosis. 
Nevertheless, one cannot exclude the hypothesis that each STAT may play a non-
essential role in FGF-2 signalling and that the loss of a particular STAT may be 
compensated by another STAT. 
In addition, the fact that the knockdown of STAT1, STAT3 or STAT5 did not 
affect the ability of FGF-2 to protect U2OS cells from cisplatin-mediated cell death does 
not exclude the possibility that other STATs may play a role in chemoresistance. 
Accordingly, the potential participation of STAT2, STAT4 and STAT6 in FGF-2-
mediated chemoresistance will be investigated in the future. The role that STAT1, 
STAT3 and STAT5 may have in protecting cells from the cytotoxic effects of other 
chemotherapeutic drugs will also be addressed. 
 
 
 
4.2.3. ACTIVATION OF STAT1, STAT3 OR STAT5A/B BY FGF-2 WAS NOT 
OBSERVED IN U2OS CELLS 
Cells with decreased levels of STAT1, STAT3 and STAT5 were protected by 
FGF-2 from cisplatin-induced cell death. Although this suggested that these particular 
STATs were not essential for FGF-2-mediated chemoresistance, as mentioned above, 
there was still the possibility that they may have been involved in FGF-2 signalling.  
STATs are mainly activated after stimulation of cytokine receptors but can also 
be activated by some growth factors and G protein-coupled receptors (Levy and 
Darnell, 2002; Bowman et al., 2000; Mellado et al., 1998; Wong and Fish, 1998; Vila-Coro 
et al., 1999). Their activity is predominantly regulated by PTMs, such as tyrosine and 
serine phosphorylation of well-characterised residues (reviewed by Levy and Darnell, 
2002). Ligand binding stimulates the rapid activation of STATs. In some cell lines 
(murine lens and BMVECs), FGF-2 induces tyrosine phosphorylation of STAT1, STAT3 
and STAT5 and this was shown to occur within 5 to 15 minutes of stimulation (Ebong 
et al., 2004; Yang et al., 2009). Accordingly, we have investigated if the early signalling 
cascades activated by FGF-2 also involved the activation of STAT1, STAT3 or STAT5.  
To determine if FGF-2 could induce STAT1, STAT3 and/or STAT5 activation, 
U2OS cells were treated for different periods of time within the first four hours 
window. This corresponded to the period of time that cells were routinely incubated 
with FGF-2 in order to protect them from the toxic effects inflicted by cisplatin. Levels 
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of phosphorylated STAT1 (Tyr701), STAT3 (Tyr705) and STAT5A/B (Tyr694) were 
assessed by Western blot. The effectiveness of FGF-2 was determined by monitoring 
the phosphorylation of ERK1/2 in parallel with all the experiments (data not shown). 
Cells treated with IFN-γ, IL-6 and OSM were used as positive controls for the activation 
of STAT1, STAT3 and STAT5, respectively. The conditions for these treatments had 
been previously optimised in the Costa-Pereira laboratory and have been extensively 
described also by other groups. 
Figure 35 is a representative example of several experiments performed to show 
that, under the conditions used, FGF-2 did not induce STAT1, STAT3 or STAT5 
phosphorylation in U2OS cells. Using an antibody against STAT3 phosphorylated 
Tyr705, we observed that STAT3 was constitutively activated in this cell line (Fig. 35 B, 
1st lane) and the basal levels of phosphorylated STAT3 were not significantly affected 
by the treatment with FGF-2 for different time points within four hours (Fig. 35 C). We 
did not detect constitutive tyrosine phosphorylation of STAT1 (Tyr701) and STAT5 
(Tyr694) (Fig. 35 A and D, 1st lane on each Western blot) and treatment with FGF-2 did 
not induce it either (Fig. 35 A and D, lanes 2-6 of each Western blot). The lack of 
phosphorylation on these particular residues did not reflect a failure of the antibodies, 
as IFNγ, IL-6 and OSM treatments induced very robust phosphorylation of STAT1, 
STAT3 and STAT5, respectively (Fig. 35 A, B and D, last lane of each Western blot). 
One distinct possibility is that FGF-2 induced phosphorylation of these molecules on 
residues other than the key tyrosines on the C-terminal, which are recognised by the 
phospho-specific antibodies used here. This could be addressed by immunoprecipitating 
each STAT and probing the Western blot membranes with the widely used and 
extensively characterised anti-pan-phosphotyrosine antibodies, PY20 and 4G10. 
Several time points were analysed, which included the time points at which 
STATs are usually activated by cytokines and growth factors, including FGF-2 (Ebong 
et al., 2004; Yang et al., 2009) (Fig. 35). One cannot exclude that phosphorylation may 
have occurred transiently and was thus not easily detected here. Indeed, the duration 
and degree of STAT activation are under strict regulation by a series of negative 
regulators, which can elicit specific inhibitory signals that lead to decreased tyrosine 
phosphorylation (Aaronson et al., 2002; Krebs and Hilton, 2001). Longer time points 
were not routinely analysed for two main reasons: firstly, it is know that incubations 
with FGF-2 for periods longer than four hours do not lead to increased 
chemoprotection and, secondly, any activation/phosphorylation seen past that period 
was likely to be a secondary, if not tertiary response, unlikely to be a key event in 
triggering the cell survival mechanisms that protect the U2OS cells from cisplatin.  
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Figure 35. FGF-2 did not activate STAT1, STAT3 or STAT5A/B in U2OS cells. U2OS cells were 
serum-starved (0.5% FCS) overnight and, subsequently, incubated in serum-free medium for 1 hour. Cells 
were then stimulated with 25 ng/ml of FGF-2 for the indicated times. Cells treated with IFN-γ (500 
IU/ml), IL-6 (200 ng/ml)/ sIL-6R (250 ng/ml) and OSM (50 ng/ml) were used as positive controls for 
activation of STAT1, STAT3 and STAT5, respectively. Proteins were extracted and separated on a 7.5% 
SDS-PAGE gel. Western blotting analysis was performed on total cell lysates using antibodies against (A) 
phosphorylated STAT1 (Tyr701), (B) phosphorylated STAT3 (Tyr705) and (D) phosphorylated STAT5 
(Tyr694) and antibodies against total proteins. β-actin was also probed for and used as a loading control. C. 
Mean ± SEM of densiometric values from three experiments are shown in graphs. Values are expressed as 
fold change relative to untreated control. Statistical analysis was performed with Student’s t-test (*** – 
p<0.005 over untreated control). ‘ – minutes, h – hours.  
B. 
 
A. 
 
D. 
 
C. 
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Importantly, recent studies have shown that unphosphorylated STATs can 
dimerise and be functional by inducing the transcription of a different subset of genes 
than that induced by phosphorylated dimers (Wenta et al., 2008; Brown et al., 2008). 
Accordingly, the participation of unphosphorylated STATs in parallel pathways 
downstream of FGF-2 should also not be excluded. 
These data suggest that FGF-2 did not induce the activation of STAT1, STAT3 
and STAT5 in U2OS cells. These observations, together with a functional rescue 
observed in cells transfected with siRNA against STAT1, STAT3 and STAT5 suggest 
that these STATs are unlikely to be involved in FGF-2-mediated chemoresistance. The 
fact that RNAi was not performed against combinations of these proteins, however, 
still precludes the firm conclusion that STAT1, STAT3 and STAT5 are dispensable for 
mediating FGF-2 anti-apoptotic functions. 
 
 
 
4.2.4. FGF-2 INDUCED THE PHOSPHORYLATION OF TYK2 AND POTENTIALLY 
OF JAK1 AND JAK2 IN U2OS CELLS  
JAK1, JAK2 and TYK2 were shown to be required for FGF-2 chemoresistance 
(Section 4.2.2.2). JAKs are typically the first kinases of the JAK/STAT pathway to be 
activated upon ligand binding (reviewed by Heinrich et al., 1998). Upon cytokine 
binding, membrane-proximal immediate signalling is initiated through the activation 
of JAKs, which are associated with the receptors via their FERM domains (Chen et al., 
1997; Gauzzi et al., 1997; Yamaoka et al., 2004). Rapid phosphorylation and activation of 
JAKs has been observed in response to many cytokines and growth factors (Novak et 
al., 1995; Leaman et al., 1996; Vignais et al., 1996; Gual et al., 1998). For example, IFN-γ-
induced activation of JAK1 and JAK2 was observed within 5-15 minutes of treatment 
(Silvennoinen et al., 1993a; Silvennoinen et al., 1993b; Watling et al., 1993; Muller et al., 
1993). JAK2 phosphorylation downstream of FGF-2 occurred within 20 minutes of 
stimulation in BMVECs (Yang et al., 2009). We investigated, therefore, if JAK1, JAK2 
and TYK2 were activated by FGF-2 in U2OS cells at early time points. 
It is generally recognised that JAKs are expressed at very low levels in human 
cells. Accordingly, throughout this work, detection of JAK phosphorylation in whole 
cells extracts by Western blot was particularly difficult to achieve. We circumvented 
this problem by immunoprecipitating each JAK individually. Using this approach, we 
investigated if FGF-2 led to JAK phosphorylation in U2OS cells. To that end, cells were 
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treated with 10 ng/ml of FGF-2 for increasing periods of time. Whole cell lysates were 
prepared using Schindler’s lysis buffer and used to immunoprecipitate each JAK 
individually. The immunoprecipitates were run on a 7.5% SDS-PAGE gel and, 
following transfer, membranes were probed with two different antibodies that 
recognise phosphorylated tyrosine residues (PY20 and 4G10). We reasoned that this 
would certify we would pick up any possible tyrosine phosphorylation event 
regardless of the residue that was modified. In order to ensure that the antibodies were 
specific, protein samples from JAK-negative cells and cells transfected with siJAK1, 
siJAK2 or siTYK2 were also analysed in parallel (Fig. 36, 37 and 38, and data not 
shown). The functionality of FGF-2 was also monitored concomitantly by assessing the 
phosphorylation of ERK1/2 (data not shown). 
Immunoprecipitation of endogenous JAK1 was performed in U2OS cells. 
Although the results presented here are preliminary (this particular experiment was 
only performed twice), we observed that FGF-2 induced an increase of tyrosine 
phosphorylation in JAK1 immunoprecipitates (Fig. 36 A, 3rd and 4th lanes versus the 2nd 
lane). Phosphorylation of JAK1 in response to FGF-2 peaked at 5 minutes (2.7-fold 
increase) and returned to basal levels at 30 minutes (Fig. 36 B, 2nd and 4th bars, 
respectively). As controls, an ”immunoprecipitation” reaction was set up with beads 
without antibody and another with beads and an irrelevant antibody of the same 
isotype of anti-JAK1 (Fig. 36 A, 1st and 6th lanes). We did not detect any phospho-
tyrosine signal corresponding to JAK1 on the IgG control and, reassuringly, the lane 
corresponding to the beads control was totally empty (Fig. 36 A, 6th and 1st lanes, 
respectively). An additional control for the specificity of anti-JAK1 was the 
immunoprecipitation of JAK1 from JAK1-negative cells (U4C) (Leaman et al., 1998) and 
cells over-expressing JAK1 (U4C.JAK1, which are U4C cells complemented with JAK1) 
treated with IFN-γ, a well characterised activator of this kinase (Fig. 36 C). As 
anticipated, JAK1 was not detected in U4C cells (Fig. 36 C, 3rd lane) and there was an 
increase of tyrosine phosphorylation of JAK1 in samples from the complemented 
U4C.JAK1 cells treated with IFN-γ (Fig. 36 C, 1st versus 2nd lane). The constitutive 
phosphorylation of JAK1 in the complemented cells was almost certainly due to the 
over-expression of JAK1: this could be trivially ascertained by including in a repeat 
experiment the 2C4 parental cell line, from which U4C cells were derived (Muller et al., 
1993; Watling et al., 1993).  
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Figure 36. FGF-2 potentially activated JAK1 in U2OS cells. A. U2OS cells were starved (0.5% 
serum) overnight and incubated for one hour in serum-free media prior the experiments. Cells were 
incubated with FGF-2 (10 ng/ml) for the times indicated. JAK1 was immunoprecipitated from 3 mg of 
whole cell lysates and Western blotting analysis was performed using antibodies against phosphorylated 
tyrosines (PY20 and 4G10) and total JAK1. B. Mean of densiometric values from the experiment 
performed are shown in graphs. Values are expressed as fold change relative to untreated control. C. JAK1 
was immunoprecipitated from UC4.JAK1 cells treated with IFN-γ (500 IU/ml), which were used as a 
positive control for the activation of JAK1. U4C (JAK1-negative) cells were used as a control for the 
antibodies used here. Western blotting analysis was performed as before. ‘ – minutes, h – hours, B – beads 
only, Unsp - unspecific. (I am indebted to Dr Ana Costa-Pereira for the experiment in Fig. 27 A). 
 
A. 
 
B. 
 
C. 
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In addition, in parallel, whole cell lysates corresponding to the samples used for 
the immunoprecipitation reactions and from siJAK1-transfected cells were run on a 
7.5% SDS-PAGE gel, which was probed with antibodies raised against JAK1, pERK1/2 
(to monitor FGF-2 functionality), ERK1/2 and β-actin (loading control) (data not 
shown). These experiments re-assured us about the suitability of 4G10 and PY20 in our 
studies and suggested that JAK1 is likely phosphorylated in response to FGF-2. This is 
currently a research priority in the Costa-Pereira group. 
 
Numerous attempts were done to immunoprecipitate JAK2 from U2OS cells. 
Although we were able to immunoprecipitate JAK2 from these cells, for reasons that 
are not yet known, no reliable phospho-signal was detected in the positive control (i.e. 
cells treated with IFN-γ). Another approach was therefore taken: JAK2 was 
immunoprecipitated from cells over-expressing JAK2 (γ2A.JAK2) (Fig. 37). γ2A.JAK2 
are JAK2-negative cells (γ2A cells) stably transfected with a plasmid containing JAK2 
(Watling et al., 1993). JAK2 was immunoprecipitated from these cells upon treatment 
with FGF-2 for increasing periods of time. Cells treated with IFN-γ were used as 
positive controls for the activation of JAK2, as done before for JAK1. These preliminary 
results suggest that FGF-2 induced JAK2 tyrosine phosphorylation (Fig. 37 A, 1st lane 
versus 2nd-5th lanes). A modest increase of tyrosine-phosphorylated JAK2 (1.5-fold) was 
observed at 5-10 minutes of FGF-2 treatment (Fig. 37 B). As controls, a beads only 
immunoprecipitation was set up (Fig. 37 A, 8th lane) and JAK2 was also 
immunoprecipitated from γ2A (JAK2 negative cells) (Fig. 37 A, 7th lane): no band was 
detected with the phospho-tyrosine antibodies or with a phospho-specific JAK2 
antibody (pJAK2-Tyr1007/1008), which indicated that the band detected by this antibody 
in the other samples, corresponded to phosphorylated JAK2. This suggested that FGF-2 
has the potential to activate JAK2 in this cell line, as it does in BMVECs (Yang et al., 
2009). Optimisation of JAK2 immunoprecipitations will be carried out (initially using a 
different antibody and/or increasing the protein amount) so that the phosphorylation 
of JAK2 by FGF-2 can be further investigated in U2OS cells. This is highly relevant 
because enzymatic activity of JAK2 was required for FGF-2 rescue, as shown using an 
inhibitor of JAK2 (Section 4.2.2.2.1).  
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Figure 37. FGF-2 potentially activated JAK2 in γ2A.JAK2 cells. A. Cells were starved (0.5% serum) 
overnight and incubated for one hour in serum-free media prior to experiments. Cells were incubated with 
FGF-2 (10 ng/ml) for the times indicated. JAK2 was immunoprecipitated from γ2A.JAK2 cells (JAK2-
negative cells (γ2A) stably transfected with a plasmid containing JAK2). IFN-γ treatment (500 IU/ml) was 
used as a positive control for activation of JAK2. JAK2 was also immunoprecipitated from γ2A cells that 
was used as a negative control. Western blotting analysis was performed with antibodies against 
phosphorylated tyrosines (PY20 and 4G10), phosphorylated JAK2 (Tyr1007/1008) and total JAK2. B. 
Densiometric values of one single experiment are shown in graphs. Values are expressed as fold change 
relative to untreated controls. ‘ – minutes, h – hours, B – beads only. 
 
 
A. 
 
B. 
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Immunoprecipitation of TYK2 was also performed in U2OS cells. Cells were 
treated with FGF-2 for increasing periods of time and Western blotting analysis was 
performed using 4G10 and PY20 antibodies, as previously described. We observed that 
FGF-2 induced an increase of tyrosine phosphorylation of TYK2 (Fig. 38 A). This 
increase was significant after 5 minutes of incubation with FGF-2 (p<0.005) (Fig. 38 B, 
1st versus 2nd bar). The activation of TYK2 by FGF-2 in these cells seems to be transient 
as it returns to basal levels at the 30 minutes time point (Fig. 38 B, 1st versus 4th lane). As 
controls, immunoprecipitation with beads only and with an irrelevant antibody were 
performed. We did not detect any phospho-tyrosine signal or TYK2 in these samples 
(Fig. 38 A, 1st and 6th lanes). In parallel, whole cell lysates corresponding to the samples 
used for the immunoprecipitation reactions and from siTYK2-tranfected cells were 
analysed by Western blot. Analysis of expression of TYK2, pERK1/2, ERK1/2 and β-
actin (loading control) (data not shown), re-assured us that that FGF-2 was fully 
functional, that the results obtained using the 4G10 and PY20 antibodies were bona fide 
and that TYK2 was phosphorylated in response to FGF-2. Furthermore, experiments 
performed using TYK2-negative cells (U1A) (McKendry et al., 1991) and U2OS cells 
treated with IFN-α (Fig. 38 C) also confirmed the suitability of the reagents used here. 
Indeed, there was an increase of tyrosine phosphorylation in samples from U2OS cells 
treated with IFN-α (a well characterised inducer of TYK2) (Fig. 38 C, 1st versus 2nd lane). 
No signal was detected in the TYK2-negative U1A cells. Interestingly, endogenously 
expressed TYK2 appears to be constitutively phosphorylated in U2OS cells and this 
was further inducible by ligands such as IFN-α and FGF-2. Like JAK1, this is now one 
of the Costa-Pereira group’s research priorities. 
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Figure 38. FGF-2 induced the phosphorylation of TYK2 in U2OS cells. A. U2OS cells were 
starved (0.5% serum) overnight and incubated for one hour in serum-free media prior the experiments. 
Cells were incubated with FGF-2 (10 ng/ml) for the times indicated. TYK2 was immunoprecipitated and 
Western blotting analysis was performed using antibodies against phosphorylated tyrosines (PY20 and 
4G10) and total TYK2. B. Mean ± SEM of densiometric values from four independent experiments are 
shown in graphs. Values are expressed as fold change relative to untreated control. Statistical analysis was 
performed with Student’s t-test (*** – p<0.005 over untreated control). C. TYK2 was immunoprecipitated 
from U2OS cells treated with IFN-α (500 IU/ml) as a positive control for the activation of TYK2. U1A 
(TYK2-negative) cells were also used as a control for the antibodies. Western blotting analysis was 
performed as before. ‘ – minutes, h – hours, B – beads only, Unsp - unspecific. (I am indebted to Dr Ana 
Costa-Pereira for the experiments showed in Fig. 29 A and B). 
 
A. 
 
B. 
 
C. 
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4.2.5. A REQUIREMENT FOR JAKS IN FGF-2-MEDIATED CHEMORESISTANCE 
MECHANISM IN U2OS CELLS 
FGF-2 was shown to protect U2OS cells from cisplatin-mediated cell death by a 
mechanism that also required JAK1, JAK2 and/or TYK2 (Section 4.2.2.2). We, 
therefore, investigated the requirement for these proteins in the early signalling 
cascades activated by FGF-2. 
As ERK1/2 activity was necessary for FGF-2 rescue (Section 4.1.6) we 
investigated if JAKs were required for the activation of these proteins. Because FGF-2-
mediated chemoresistance involved interactions between B-RAF, PKCε and S6K2 
(Section 4.1.7), we hypothesised that JAKs were also required for, or at least part of, 
these interactions. If this were the case, then it would be feasible that JAK1, JAK2 or 
TYK2 may be required for the up-regulation of anti-apoptotic proteins following FGF-2 
treatment (Section 4.1.9). 
 
 
 
4.2.5.1. KNOCKDOWN OF TYK2 AFFECTED FGF-2 INDUCED ACTIVATION OF 
ERK1/2  
In U2OS cells, treatment with 10 ng/ml of FGF-2 for 10 minutes was shown to 
induce full activation of ERK1/2 (Section 4.1.2). To ascertain if JAKs mediated FGF-2-
induced ERK1/2 phosphorylation, U2OS cells were transfected with siRNA against 
JAK1, JAK2 or TYK2 and subsequently treated with FGF-2. Treatments were done 
upon serum starvation (0.5% FCS overnight and serum-free medium for one hour prior 
to the experiment). ERK1/2 phosphorylation was monitored by Western blot as 
previously described using an antibody that recognises both phosphorylated ERK1 and 
ERK2. Using this approach, we established that the activation of ERK1/2 by FGF-2 was 
affected by the knockdown of TYK2 (Fig. 39 A, 8th versus 2nd and 10th lanes). 
Phosphorylation of ERK1 was reduced by an average of 40% (p<0.01) and ERK2 by an 
average of 25% (p<0.005) (Fig. 39 B, 4th black and grey bars, respectively). Knockdown 
of JAK1 also seemed to affect FGF-2 induced phosphorylation of ERK2 (p<0.005), but 
the decrease observed was only approximately 10%. Transfection of U2OS cells with 
siRNA against JAK2 did not affect the induction of ERK1/2 in response to FGF-2.  
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Figure 39. TYK2 knockdown in U2OS led to decreased ERK1/2 phosphorylation in response 
to FGF-2. A. U2OS cells were transfected with siRNA (75 nM) against JAK1, JAK2 or TYK2 using 
DharmaFECT II. Untransfected cells were used as a control. After 48 hours, cells were serum-starved (0.5% 
FCS) overnight, incubated in serum-free media for one hour and stimulated with 10 ng/ml of FGF-2 for 10 
minutes. Proteins were extracted and separated on a 10% SDS-PAGE gel. Western blotting analysis was 
performed using total cell lysates and antibodies against p-ERK1/2 (Thr202/Tyr204) and total ERK1/2. β-
actin was also probed and used as a loading control. B. Mean ± SEM of densiometric values of four 
independent experiments are shown in graphs. Values correspond to phospho-ERK1 and 2 levels and are 
expressed as fold change relative to untransfected controls. Statistical analysis was performed with 
Student’s t-test (** – p<0.01, *** – p<0.005 versus untransfected FGF-2 treated control). Unt – untransfected. 
 
 
 
 
Such small reductions warrant further investigation. Detection of phospho-ERK1/2 
with alternative methods such as the Odyssey IR imaging system  (LI-COR 
Biosciences), or flow cytometry (as in Ricciardi et al., 2005) could further validate this 
observation. In the laboratory we have several cell lines that lack TYK2: MEFs kindly 
A. 
 
B. 
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provided by Dr Mathias Müller (Vienna, Austria) and human HT1080-derived U1A 
cells (McKendry et al., 1991). We also have the corresponding wild-type and 
complemented cells. The use of these cells will be used to further confirm the effect that 
the lack of TYK2 has in FGF-2-induced ERK1/2 phosphorylation. 
ERK1/2 Western blots showed differences between FGF-2 untreated and 
treated samples (Fig. 39 A, second row). This was also previously observed in other 
experiments (e.g. Fig. 13 in Section 4.1.2, Fig. 20 D in Section 4.1.5 and Fig. 24 A in 
Section 4.1.6). This difference is related to the fact that phosphorylation causes a 
mobility shift on the gel, which is often translated in less defined bands in FGF-2 
treated samples. This is particularly noticeable in Figure 24 A were the band shift was 
not observed in samples pre-treated with a MEK inhibitor. In addition, these 
differences may also be due to incomplete stripping of the anti-phospho-ERK1/2 
antibody. This antibody usually binds very strongly and it is particularly difficult to 
remove by membrane stripping. To avoid this, total ERK1/2 could have been studied 
in samples run on a separate parallel gel. 
 
 
 
4.2.5.2. JAK1 AND TYK2 MAY BE REQUIRED FOR THE INTERACTION 
BETWEEN PKCε  AND B-RAF INDUCED BY FGF-2 
FGF-2 induced interactions between B-RAF, PKCε and S6K2 (Section 4.1.7). To 
investigate if JAKs were required for the interaction between these proteins in U2OS 
cells, JAK1, JAK2 and TYK2 were silenced by RNAi. Forty-eight hours later, cells were 
serum starved (0.5% FCS overnight and serum-free medium for one hour) and then 
treated with FGF-2. Proteins were isolated and B-RAF, PKCε and S6K2 were 
independently immunoprecipitated. The immunoprecipitates were run on SDS-PAGE 
gels and, after Western blotting, the membranes were probed with antibodies against 
the three proteins. Due to time constrains, this experiment was only done once and the 
results are thus preliminary. In addition, additional controls should have been 
included in this experiment, such as cells transfected with a non-specific siRNA. In 
untransfected cells FGF-2 induced the interaction between B-RAF and PKCε, as well as 
the interaction between S6K2 and B-RAF and S6K2 and PKCε (Fig. 40 A and B). Taking 
it at face value, this particular experiment suggests that knockdown of JAK1, JAK2 and 
TYK2 impacted on the interactions between PKCε, B-RAF and S6K2. It would appear 
that the knockdown of JAK1 induced the interaction of B-RAF with PKCε in the 
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absence of growth factor (Fig. 40 A, 2nd versus 5th lane), that silencing JAK2 delayed the 
interaction upon FGF-2 stimulation (Fig. 40 A, 3rd versus 9th lane) and that reduced 
TYK2 levels blocked the interaction (Fig. 40 A, lanes 11-13). Interaction between S6K2 
and B-RAF or, less convincingly, S6K2 and PKCε was detected in untransfected cells 
and in cells transfected with siRNA molecules against JAK1, JAK2 or TYK2 (Fig. 40 B). 
Although the Western blots quality is poor it would appear that downregulation of 
JAK1 increased the interaction(s) between S6K2 and B-RAF and PKCε (Fig. 40 B, 2nd 
versus 5th lane) and silencing of JAK2 and TYK2 transiently permitted interaction(s) 
between S6K2, B-RAF and PKCε (Fig. 40 B, 2nd versus 8th and 11th lanes). 
Total protein levels and activation of ERK1/2 by FGF-2 are shown in Figure 40 
C. As previously observed (Fig. 26 B, Section 4.1.7) S6K2 increased in response to FGF-
2 in untransfected cells. Variations on B-RAF, PKCε and S6K2 protein levels induced 
by knockdown of JAK1, JAK2 or TYK2 are difficult to evaluate in a single experiment. 
Accordingly, this experiment will be repeated and, importantly, repeats will include 
samples from cells transfected with a non-specific siRNA as an additional control. In 
this particular experiment basal levels of phosphorylated ERK1/2 increased in cells 
transfected with siRNA against JAK1 (Fig. 40 C, 1st lane versus 4th lane in the 4th row). 
This was, however, not observed in all experiments (like the experiment shown in 
Figure 39). Such variations in basal levels of phosphorylated ERK could have an 
impact on the FGF-2 response. It is conceivable that increased phosphorylation of 
ERK1/2 could be related to the higher basal interaction of B-RAF with PKCε, and of 
those molecules with S6K2 (Fig. 40 A, 5th lane and B, 4th lane). As observed before 
(Section 4.2.5.1), when TYK2 protein levels were reduced by RNAi, the activation of 
ERK1/2 in response to FGF-2 was lower compared to the untransfected cells (Fig. 40 C, 
2nd and 3rd versus 11th and 12th lanes, respectively in the 4th row). In this particular 
experiment, siRNA against other JAKs also affected the phosphorylation of ERK1/2. 
However, we cannot exclude the possibility that the activation of ERK1/2 may have 
been affected by the siRNA transfection itself, as an unspecific control was not 
performed this time. These results warrant a more detailed investigation. 
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Figure 40. JAK1 and TYK2 may be required for the interaction between B-RAF and PKCε  
induced by FGF-2 in U2OS cells. (Continued on page 170). Cells were plated in 10 cm plates and 
transfected with siRNA (75 nM) against JAK1, JAK2 or TYK2 for 48 hours. Subsequently, cells were plated 
in 15 cm plates (~4x106 cells/plate), serum-starved (0.5% FCS) overnight and incubated in serum-free 
medium for one hour. After stimulation with 10 ng/ml of FGF-2 at the indicated times, proteins were 
extracted, separated on a 7.5% SDS-PAGE gel and analysed by Western blot. Untransfected cells were used 
as a control. Cell lysates were subjected to immunoprecipitation with antibodies against B-RAF (A.) or 
S6K2 (B.) and membranes were probed as indicated in the figure. C. Total cell lysates were Western 
blotted as indicated. β-actin was used as a loading control. Densiometric values from one experiment are 
represented in graphs. Values are expressed as fold change over untransfected untreated controls. Unt – 
untransfected, ‘ – minutes, B – beads only, L – lysate. 
A.  
 
B.  
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Figure 40. JAK1 and TYK2 may be required for the interaction between B-RAF and PKCε  
induced by FGF-2 in U2OS cells. (Continued from page 169). 
C.  
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4.2.5.3 JAK1, JAK2 AND TYK2 INTERACTED WITH PKCε  AND B-RAF IN 
RESPONSE TO FGF-2 
We sought to study the involvement of JAK1, JAK2 and TYK2 in FGF-2 
mediated chemoresistance mechanism by investigating if these JAKs interacted with B-
RAF and PKCε or S6K2. Because JAKs are expressed at low levels in these cells, it was 
not trivial to detect them in the S6K2, B-RAF and PKCε protein complex(es), when 
either of these molecules was immunoprecipitated. To address this, JAK1, JAK2 and 
TYK2 were independently immunoprecipitated after treatment with FGF-2 for 
increasing periods of time and the immunoprecipitates were run on SDS-PAGE gels. 
After Western blotting, membranes were probed for B-RAF, PKCε and S6K2  (Fig. 41). 
Immunoprecipitated JAKs were used for normalisation. In U2OS cells, FGF-2 induced 
interactions of JAK1, JAK2 and TYK2 with B-RAF and PKCε (Fig. 41 A).  
In untreated cells, JAK1 was constitutively bound to PKCε and B-RAF (Fig. 41 
A, 1st lane, rows 2 and 3), as was JAK2 (Fig. 41 A, 1st lane, rows 5 and 6). FGF-2 induced 
a transient increase of the interaction between JAK1 and PKCε and between JAK1 and 
B-RAF within 5 minutes of FGF-2 stimulation (p<0.005 and p<0.05, respectively), 
which after 10 minutes was not as evident (Fig. 41 A, 1st versus 3rd lane in rows 2 and 3, 
and B). In the experiment illustrated in Figure 41 A, the interaction between PKCε and 
JAK1 was completely lost after 30 minutes of FGF-2 stimulation (Fig. 41, 5th lane in the 
2nd row). This was not observed in one of the three experiments performed and this 
impacted on the statistical analysis (Fig. 41 B, 5th grey bar). It thus remains to be 
established whether this dissociation is real.  
JAK2 interacted with PKCε with kinetics identical to those observed for JAK1 
(p<0.005) (Fig. 41 A, 1st versus 2nd and 3rd lanes in the 5th row). JAK2 interacted with B-
RAF more weakly than it did with PKCε (an average of 1.5- versus 2-fold) but 
seemingly for a longer period, as shown by the statistical analysis at the 5, 10 and 20 
minutes time points (p<0.05) (Fig. 41 A, 2nd to 5th lanes in the 6th row, and C). 
Interestingly, no constitutive interaction(s) could be detected between TYK2 and PKCε 
and/or B-RAF (Fig. 41 A, 1st lane, rows 8 and 9). Analysis of protein complex(es) 
induced in response to FGF-2 indicated that TYK2 interacted with PKCε and B-RAF 
with different kinetics than those for JAK1 and JAK2 (Fig. 41 A). FGF-2-induced 
interaction between TYK2 and B-RAF was more gradual and prolonged than those 
observed for JAK1 and JAK2. Indeed, the interaction(s) could be observed between 5 
and 20 minutes of stimulation (p<0.05) (Fig. 41 A, 2nd to 4th lanes in the 9th row and D, 
black bars). The interaction between TYK2 and B-RAF reached a peak at 20 minutes (an 
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average of 2.7-fold induction) and was lost after 30 minutes incubation with FGF-2 
(Fig. 41 A, cf. 5th lane in the 9th row, and D, black bars). PKCε was only found to 
transiently interact with TYK2 at 20 minutes of FGF-2 stimulation (p<0.05) (Fig. 41 A, 
4th lane in the 8th row, and D, grey bars).  
Although these experiments showed that JAKs interacted with B-RAF and 
PKCε, they did not conclusively prove that JAK molecules bind B-RAF and PKCε 
whitin the same complex. In addition, they did not rule out the possibility that several 
JAKs may bind B-RAF or PKCε in the same complex. Experiments using siRNA will be 
conducted to further elucidate these points. 
Membranes were probed first for PKCε (95 kDa), after which the antibody was 
stripped of overnight (cf. Materials and methods) and then probed for B-RAF (94 kDa). 
To ascertain that the detection of B-RAF was not influenced by any residual unstripped 
PKCε antibody some membranes were probed in reverse order. Similar results were 
obtained regardless the sequence of detection. 
We were not able to detect S6K2 in any JAK immunoprecipitates. It is 
conceivable that low levels of S6K2 and JAKs, as well as stoichiometry, could have 
made these interactions in response to FGF-2 particularly difficult to detect. In 
addition, the binding of these proteins may be unstable and/or transient, in which case 
the interaction is likely to be ‘lost’ in the immunoprecipitation process, or particularly 
difficult to capture. The time points at which these experiments are performed may 
thus be crucial. Another less attractive hypothesis is that JAKs and S6K2 simply do not 
interact. All these possibilities are being currently investigated in the laboratory.  
Routinely, in parallel with all co-immunoprecipitations, whole cell extracts 
were run on 7.5% SDS-PAGE gels and analysed by Western blot (Fig. 41 E). We 
monitored the levels of JAK1, JAK2, TYK2, B-RAF, PKCε and S6K2 levels in samples 
used for the co-immunoprecipitation studies. As previously observed (Fig. 26 B, 
Section 4.1.7), treatment with FGF-2 increased S6K2 protein levels by an average of 1.5-
fold (p<0.005), which further suggests that FGF-2 can, somehow, affect S6K2 protein 
expression (Fig. 41 E, 8th row, and G, grey bars). JAK1, JAK2, PKCε, B-RAF and TYK2 
protein levels were not affected by treatment with FGF-2 (Fig. 41 E, 1st, 5th, 6th, 7th and 
10th rows, respectively, F and G). We also monitored total and phosphorylated ERK1/2 
in response to FGF-2 to ensure the functionality of the growth factor (Fig. 41 E, 2nd row, 
and H).  
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Figure 41. FGF-2 induced interaction of JAK1, JAK2 and TYK2 with PKCε  and B-RAF in 
U2OS cells. (Continued on page 174). U2OS cells were serum-starved (0.5% FCS) overnight, incubated in 
serum-free media for 1 hour and then stimulated with 10 ng/ml of FGF-2 at the indicated times. A. Cell 
lysates were subjected to immunoprecipitation with JAK1, JAK2 or TYK2 antibodies. Immunoprecipitates 
were separated on a 7.5% SDS-PAGE gel and analysed by Western blot. Membranes were probed for PKCε 
and B-RAF. JAK1, JAK2 and TYK2 were also probed for and used as a loading controls for the respective 
immunoprecipitations. E. Total cell lysates were separated on a 7.5% SDS-PAGE gel and after Western 
blot, membranes were probed for PKCε, B-RAF, S6K2, JAK1, JAK2, TYK2, p-ERK1/2 and ERK2. β-actin 
was used as a loading control. B., C., D., F., G. and H., Mean ± SEM of densiometric values of three 
independent experiments are shown in graphs. Values are expressed as fold change over untreated 
controls. Statistical analysis was performed with Student’s t-test (* – p<0.05, ** – p<0.01, *** – p<0.005 
versus control). L – lysate.  
A. 
C.  
D.  
B.  
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Figure 41. FGF-2 induced interaction of JAK1, JAK2 and TYK2 with PKCε  and B-RAF in 
U2OS cells. (Continued from page 173). 
 
E.  F.  
G.  
H.  
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4.2.5.4. TYK2 WAS REQUIRED FOR FGF-2-INDUCED UP-REGULATION OF THE 
ANTI-APOPTOTIC PROTEIN MCL-1 
Having shown that JAKs were required for FGF-2-mediated chemoresistance in 
U2OS we then investigated whether up-regulation of anti-apoptotic proteins by FGF-2 
was impaired upon silencing of JAKs. U2OS cells were transfected with siRNA against 
JAK1, JAK2 and TYK2 and subsequently treated with FGF-2 for 4 hours. Proteins were 
separated by SDS-PAGE and the expression of MCL-1 was monitored by Western blot. 
Untransfected cells and cells transfected with non-specific siRNA (NS) were used as 
controls. In untransfected cells, or cells transfected with a non-specific control FGF-2 
induced a significant increase in MCL-1 protein levels (p<0.01 and p<0.005, 
respectively) (Fig. 42 A, 2nd and 12th lanes and B, 2nd and 12th bars). In the experiment 
shown in Figure 42 this increase is not particularly evident for the NS control because 
the FGF-2-treated sample was under-loaded (Fig. 42 A, 12th lane).  
Cells transfected with siRNA against ERK1/2 were also used as a control. The 
inhibition and knockdown of ERK1/2 impaired the FGF-2-mediated chemoprotection 
(Fig. 24, Section 4.1.6 and data not shown), therefore, siRNA against ERK1/2 should 
impact on the upregulation of anti-apoptotic proteins in response to FGF-2. 
Reassuringly, silencing of ERK1/2 inhibited the up-regulation of MCL-1 protein (Fig. 
42 A, 9th and 10th lanes, and B, 9th and 10th bars). Interestingly, JAK1 and JAK2 
downregulation did not impair up-regulation of MCL-1 levels upon FGF-2 treatment 
(p<0.05) (Fig. 42 A, 3rd-6th lanes and B, 3rd-6th bars).  In cells with reduced levels of 
TYK2, however, MCL-1 expression did not increase in response to FGF-2 suggesting 
that this particular JAK is required for the up-regulation of MCL-1 (Fig. 42 A, 7th and 
8th lanes and B, 7th and 8th bars). It remains to be established if this is also true for other 
proteins up-regulated in response to FGF-2 (Fig. 28, Section 4.1.9).  
As previously observed (Fig. 28, Section 4.1.9), FGF-2-induced up-regulation of 
MCL-1 was modest (around 1.5-fold). This may have been due to proteins not being 
fully extracted from intracellular compartments with Schindler lysis buffer (cf. Material 
and methods). This buffer was developed mainly to extract cytoplasmatic proteins 
(Schindler et al., 1992) and BCL-2 family members are predominantly associated with 
the mitochondria membrane (e.g. Breckenridge and Xue, 2004). Extraction with a more 
stringent buffer containing for example SDS (0.1%) and sodium deoxycholate (0.5%) 
(e.g. RIPA buffer) will disrupt membranes and potentially allow for a better, more 
efficient, protein extraction.  
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Figure 42. TYK2 is required for the up-regulation of the anti-apoptotic protein MCL-1 
induced by FGF-2 in U2OS cells. A. U2OS cells were transfected with 75 nM of siRNA against JAK1, 
JAK2 or TYK2 using DharmaFECT II. After 48 hours, cells were serum-starved (0.5% FCS) overnight and 
incubated in serum-free media for 1 hour. Cells were stimulated with 10 ng/ml of FGF-2 for 4 hours. 
Proteins were extracted and separated on a 12.5% SDS-PAGE gel. Western blotting analysis was 
performed using total cell lysates and an antibody against MCL-1. β-actin was used as a loading control. 
B. Mean ± SEM of densiometric values of three independent experiments are shown in graphs. Values are 
expressed as fold change relative to untransfected controls. Statistical analysis was performed with 
Student’s t-test (* – p<0.05, *** – p<0.005 versus untreated controls).  
 
 
A. 
B. 
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4.2.6. DISCUSSION 
Results from the previous chapter showed that FGF-2 protected the 
osteosarcoma cell line U2OS from cisplatin-mediated apoptosis (Section 4.1.5) through 
a MEK-ERK-dependent mechanism (Section 4.1.6). Early signalling events 
downstream of FGF-2 in this cell line involved the phosphorylation of ERK1/2 
(Section 4.1.2), the interaction between B-RAF and PKCε and those with S6K2 (Section 
4.1.7), and the up-regulation of a number of anti-apoptotic proteins (Section 4.1.9). 
Here, we investigated the requirement for JAKs and/or STATs in FGF-2 
chemoprotection in U2OS cells. The requirement for JAK1, JAK2, TYK2, STAT1, STAT3 
and/or STAT5 was investigated using RNAi. After verifying that these molecules were 
specifically silenced using siRNA (Fig. 29), we evaluated the impact of the knockdown 
each of these proteins on FGF-2-mediated chemoresistance mechanism.  
Knockdown of JAK1, JAK2 or TYK2 in U2OS cells profoundly affected FGF-2-
mediated protection from cisplatin killing of U2OS cells. In cells with reduced levels of 
JAK1, JAK2 or TYK2, FGF-2 was not able to protect cells from cisplatin’s noxious 
effects (Fig. 30 and 31) suggesting that these three proteins were required for the 
mechanism by which FGF-2 drives chemoresistance. These results were confirmed by 
analysis of DNA loss by flow cytometry (cell cycle analysis) (Fig. 30) and analysis of 
caspases’ cleaved substrates, such as PARP (Western blot) (Fig. 31). These findings 
further strengthen the notion that JAKs play critical roles in tumour progression 
(Verma et al., 2003). Interestingly, in cells with decreased levels of JAK1, JAK2 and 
TYK2, FGF-2 reduced basal levels of cell death (Fig. 30). This may be related to FGF-2 
being able to protect cells from reduced levels of cell death in the absence of JAKs, or 
JAK-dependent FGF-2 protection being specific to cisplatin-induced cell death. We 
confirmed these observations for siJAK1- and siJAK2-transfected cells using additional 
experimental approaches such as PARP cleavage analysis (Fig. 31). In siTYK2-
transfected cells, there was no significant difference in PARP cleavage due to one 
particular experiment, which skewed the statistical analysis. Accordingly, this should 
be studied further. The use of JAK-negative cells will also be useful to confirm these 
observations. 
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JAK3, another JAK family member was not yet studied in this context. Unlike 
the other three JAK family members, which are ubiquitously expressed, JAK3 is 
preferentially expressed in leukocytes (reviewed by Schindler et al., 2008). It is 
currently unknown if U2OS cells express JAK3. Constitutive activation of this JAK has 
been reported in several lymphoproliferative disorders (Gee et al., 2001; Yared et al., 
2005; Lai et al., 2005; Tomita et al., 2006; Krejsgaard et al., 2006; Marzec et al., 2008). In 
addition, mutant JAK3 alleles were identified in AML patients and resulted in the 
constitutive activation of JAK3 and a spectrum of downstream pathways that include 
STAT5, PI3K/AKT pathway and RAS/MAPK pathway (Walters et al., 2006). JAK3 
activation was also found to contribute for the oncogenesis of other types of cells such 
as colon cancer (Lin et al., 2005) and breast cancer (Kim et al., 2009). Accordingly, we 
will investigate if the osteosarcoma cell line U2OS expresses JAK3 and if this JAK also 
participates in FGF-2-mediated chemoresistance. 
Inhibition of JAK2 activity with a specific inhibitor of JAK2 
autophosphorylation (Sandberg et al., 2005) also blocked FGF-2-mediated 
chemoresistance (Fig. 32), indicating that the activity of this particular JAK may be 
required for FGF-2 signalling. Interestingly, in the presence of the inhibitor, FGF-2 did 
not reduce basal cell death (Fig. 32 B and D). In contrast, in siJAK2-transfected cells, 
FGF-2 significantly reduced the basal cell death (Fig. 30 and 31). This may be due to a 
more efficient inhibition of JAK2 activity by this inhibitor in comparison with the 
incomplete knockdown by siRNA (which was never 100%) (Fig. 29). In addition, 
although this is a specific JAK2 inhibitor, it may also block the activity of other JAKs 
that may be required for FGF-2 survival. Studies with additional JAK inhibitors will be 
useful to confirm this observation and to investigate the requirement of the activity of 
other JAK family members for FGF-2 responses. It would be interesting to investigate if 
JAKs are required in additional types of cancer cell lines in which FGF-2 was 
demonstrated to play a role in chemoresistance such as SCLC and breast cancer cell 
lines (Pardo et al., 2002; Pardo et al., 2003; Vandermoere et al., 2005; Smaragda 
Angelidou and Michael Seckl, personal communication). 
Activation of JAKs has been previously shown to occur downstream of growth 
factors. For example JAK1, JAK2 and TYK2 can be activated by PDGF (Vignais et al., 
1996) and JAK2 was shown to be activated by FGF-2 (Yang et al., 2009). This is the first 
report showing that JAKs were required for FGF-2 mediated chemoresistance. In 
accordance with what many authors have proposed, our work provides further 
evidence that supports the notion that the inhibition of JAKs may be helpful for the 
successful treatment of cancer.  
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STATs, in particular STAT1, STAT3 and STAT5, were shown to contribute to 
oncogenesis (reviewed by Yu and Jove, 2004). STAT3 was also associated with intrinsic 
drug resistance (Kovacic et al., 2006; Patterson et al., 2006; Barre et al., 2007; Grisko et al., 
2006; Ikuta et al., 2005; Lewis and Ward, 2008). Surprisingly, we have observed that the 
STATs were not absolutely required for the mechanism by which FGF-2 protects cells 
against cisplatin (Fig. 33 and 34). Furthermore, under the conditions tested, FGF-2 did 
not induce STAT1, STAT3 or STAT5A/B phosphorylation/activation in U2OS cells 
(Fig. 35) in contrast to data shown in murine lens epithelial cell lines and BMVECs 
(Ebong et al., 2004; Yang et al., 2009). Our observations suggested that STAT1, STAT3 
and STAT5A/B were not activated by FGF-2 in the osteosarcoma cell line U2OS, and 
therefore, are unlikely to be involved in FGF-2-mediated chemoresistance mechanism. 
The possibility that the loss of a particular STAT is compensated by another member of 
the STAT family cannot, nevertheless, be excluded at this time.  
Other STAT family members (STAT2, STAT4 and STAT6) can also potentially 
play a role in chemoresistance. STAT2 signalling was shown to play a critical role in 
inflammatory responses in carcinogenesis (Clifford et al., 2003; Maher et al., 2008). 
STAT6 signalling was also implicated in tumour immuno-surveillance (Terabe et al., 
2000) and it was shown to play a role in the regulation of cell proliferation and 
apoptosis in colon cancer cells (Zhang et al., 2006). However, in breast cancer cells, 
STAT6 was required for IL-4-mediated growth inhibition and the induction of 
apoptosis (Gooch et al., 2002). Although these STATs do not seem to have as a 
prominent role in cancer biology as STAT1, STAT3 and STAT5, one cannot exclude the 
possibility that they may also be involved in chemoresistance. The requirement for 
STAT2, STAT4 and STAT6 for the FGF-2-mediated chemoresistance will be 
investigated further in the future. 
Here we showed that FGF-2 induced the phosphorylation of TYK2 in U2OS 
(Fig. 38). This phosphorylation was rapid and transient like it is in response to many 
cytokines and growth factors (Novak et al., 1995; Leaman et al., 1996; Vignais et al., 
1996; Gual et al., 1998). Preliminary data indicate that FGF-2 potentially induce the 
phosphorylation of JAK1 in this cell line and of JAK2 in another cell line (γ2A.JAK2) 
(Fig. 36 and 37). These data suggest that TYK2, and potentially JAK1 play roles 
downstream of FGF-2 in U2OS cells. The activation of JAK2 by FGF-2 in U2OS cells is 
currently unknown and will be investigated in the future. Considering that the 
enzymatic activity of JAK2 seemed to be required for efficient FGF-2 chemoprotection 
(Fig. 32), we hypothesised that JAK2 may also be phosphorylated in response to FGF-2 
in U2OS cells. The activation of TYK2 downstream of FGF-2 receptors may be direct or 
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indirect. As for cytokine receptors (Rane and Reddy, 2000), JAKs might physically 
interact with FGF-2 receptors. Usually, JAKs associate with membrane-proximal 
receptor motifs via the FERM domain located in their N-terminal region (Chen et al., 
1997; Gauzzi et al., 1997; Yamaoka et al., 2004). FGFRs have tyrosine residues on the 
tyrosine kinase domains of their cytoplasmic tail that become phosphorylated upon 
activation (Bellot et al., 1991), which provide sites for the direct binding of secondary 
messenger molecules with SH2 domains (Dailey et al., 2005). JAKs have a predicted 
SH2-related domain and they might use this region to bind to FGFRs. The possible 
interaction of JAKs with FGF-2 canonical receptors will be, therefore, investigated. 
Activation of ERK1/2 by FGF-2 in U2OS cells was not abrogated by lack of 
JAK1, JAK2 or TYK2. This activation was, however, significantly reduced (p<0.01 for 
ERK1 and p<0.005 for ERK2) in cells transfected with siRNA against TYK2 (Fig. 39). 
Despite not being a dramatic reduction (approximately 40% for ERK1 and 25% for 
ERK2), it was significant and consistently observed. Such a reduction is likely to impact 
on FGF-2 response, as the strength and duration of ERK signalling can determine 
distinct biological outcomes (Murphy and Blenis, 2006). For example, lowering ERK 
signal strength and duration was shown to have an impact on the expression of genes 
such as Jun and Myc, and consequently on the proliferative response in mouse 
fibroblasts (Murphy et al., 2004). Decreased phosphorylation of ERK1/2 in response to 
FGF-2 observed in siTYK2-transfected cells suggested that TYK2 was likely to act 
upstream of MEK/ERK signalling pathway and may be required for ERK1/2 full 
activation. Alternatively, in the absence of TYK2, ERK1/2 activation by FGF-2 may be 
more transient (happening at a time point earlier than 10 minutes and rapidly 
decreasing) or be delayed. Treatment of siTYK2-transfected cells with FGF-2 for 
additional periods of time will be useful to clarify this issue. TYK2 can also have a 
structural role in the response and may be required for stabilising FGF-2 receptor(s), as 
was shown for the IFN-α receptor 1 (IFNAR1) (Ragimbeau et al., 2003). Indeed, cells 
that lack TYK2 also have reduced levels of IFNAR1, the receptor chain to which TYK2 
binds. In this case, it was shown that TYK2 has a scaffolding role. The fact that 
knockdown of JAK1 and JAK2 had no such effect on the activation of ERK1/2 by FGF-
2 suggested that these two JAKs likely play roles either downstream, or in parallel to 
MEK/ERK signalling pathway(s). 
Preliminary data obtained here suggested that JAK1 and TYK2 might be 
required for the interaction between B-RAF and PKCε in response to FGF-2 in U2OS 
cells (Fig. 40 A). However, the knockdown of JAK1, JAK2 and TYK2 did not affect the 
ability of S6K2 to interact with B-RAF or PKCε in response to FGF-2 (Fig. 40 B). These 
  181 
RESULTS 
preliminary data suggest that these three JAKs are not required for the binding of S6K2 
to B-RAF and PKCε. Although these results need to be confirmed, they suggest that 
JAK1 and TYK2 may be required for the interaction and/or stability of interaction of B-
RAF with PKCε in response to FGF-2. It is also possible that direct interaction between 
B-RAF and PKCε is essential for efficient FGF-2-mediated chemoprotection explaining 
why FGF-2 is not able to rescue siJAK1- and siTYK2-transfected cells. It needs to be 
established if B-RAF, PKCε and S6K2 are in the same complex formed upon FGF-2 
stimulation in U2OS cells. It may be possible that S6K2 molecules that bind B-RAF are 
not the same molecules that bind PKCε. Accordingly, we will investigate if FGF-2 
induces the interaction between B-RAF and PKCε in the absence of S6K2.  
It is possible that B-RAF, PKCε and S6K2 are phosphorylated/activated in 
U2OS in response to FGF-2, as observed in SCLC cells (Pardo et al., 2001; Pardo et al., 
2006). The activation of B-RAF requires the phosphorylation of a threonine (Thr598) and 
a serine (Ser601) residue located within its activation segment (Zhang and Guan, 2000). 
PKCε kinase activity correlates with the phosphorylation of a threonine residue within 
the activation loop of the kinase domain (Thr566) and of a serine residue (Ser729) within 
the C-terminal loop (Parekh et al., 1999; Cenni et al., 2002), which is critical for 
stabilising the kinase core in an active conformation (Newton, 2003). S6K2 activation is 
absolutely dependent on phosphorylation of a threonine located within the catalytic 
domain (Thr228) and a threonine located within the linker domain (Thr388) (Phin et al., 
2003). The phosphorylation of a serine residue located within the linker domain site 
(Ser370) also plays a role in the activity of the shorter form of S6K2 (Minami et al., 2001; 
Phin et al., 2003). Because JAKs are tyrosine kinases (Levy and Darnell, 2004; Yamaoka 
et al., 2004) it is unlikely that they catalyse the phosphorylation of B-RAF, PKCε or 
S6K2. However, we observed that JAK1, JAK2 and TYK2 interacted with B-RAF and 
PKCε upon FGF-2 stimulation (Fig. 41). JAK1 and JAK2 interacted with these proteins 
after 5 minutes of stimulation with FGF-2 and TYK2 seemed to interact in a different 
fashion. Indeed, B-RAF interacted with TYK2 after 5 minutes of incubation with FGF-2 
and this interaction was still evident at 20 minutes, whereas PKCε significantly bound 
to TYK2 only after 20 minutes of FGF-2 stimulation. Interaction of JAK1 and JAK2 with 
B-RAF and PKCε at a different time point than that of TYK2 suggested that different 
JAKs (at least TYK2 compared to JAK1 and JAK2) do not play redundant roles in the 
early signalling events triggered by FGF-2 in U2OS cells. It would be interesting to 
know if JAKs also interact with S6K2, a protein that we were not able to detect in JAK 
immunoprecipitates. Low levels of S6K2 and JAKs, as well as stoichiometry of the 
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interaction, may have hindered the detection of these interactions in response to FGF-2. 
Another possibility is that JAKs and S6K2 do not interact.  
JAKs may be required for bringing at least B-RAF and PKCε together, 
functioning as chaperone proteins. These interactions may facilitate their activation 
and/or function or establishment of their intracellular localisation. Alternatively, JAKs 
may be required for the interaction of B-RAF and PKCε (and possibly S6K2) with the 
translation machinery that led to up-regulation of anti-apoptotic proteins. It will be 
crucial to determine if JAKs are required for the activity of B-RAF, PKCε and S6K2, and 
consequently for their function. The hypothetic roles that JAKs could have in this 
mechanism will be studied further in the future. 
FGF-2 was shown to up-regulate MCL-1 in U2OS cells (Janet Lyons-Lewis and 
Michael Seckl, personal communication and Fig. 28, Section 4.1.9). This may be of 
particular importance, as MCL-1 was found highly expressed in osteosarcoma patients 
and its down-regulation induced apoptosis in osteosarcoma cell lines (Pignochino et al., 
2009). In cells with reduced levels of TYK2 FGF-2 did not significantly increase the 
expression of MCL-1 (Fig. 42). This may be related to reduced ERK1/2 activation by 
FGF-2 in siTYK2-transfected cells. Indeed, inhibition of ERK activity by MEK inhibitors 
was shown to result in down-regulation of MCL-1 in H-510 and U2OS cells (Janet 
Lyons-Lewis and Michael Seckl, personal communication and data not shown), human 
pancreatic cell lines (Boucher et al., 2000), and melanoma cell lines (Wang et al., 2007b). 
It remains to be established if this is also true for other proteins up-regulated in 
response to FGF-2. The knockdown of JAK1 and JAK2 did not affect the up-regulation 
of MCL-1 by FGF-2 (Fig. 42). Interestingly, JAK2 and JAK3 were reported to be 
involved in the activity of members of the BCL-2 family such as BCL-2 and BCL-XL, in 
some cases through STAT-independent pathways (Packham et al., 1998; Wen et al., 
2001). Accordingly, the knockdown of JAK1 and JAK2 may affect other anti-apoptotic 
proteins that might also be required for the FGF-2-mediated mechanism. 
The results obtained thus far suggest that JAK1, JAK2 and TYK2 are required 
for the FGF-2-mediated chemoresistance. These three JAKs are likely involved in the 
regulation of proteins such ERK1/2, B-RAF, PKCε and S6K2 and may thus be 
important modulators of the FGF-2 response. More importantly, our study has 
provided evidence for a key role of JAKs in FGF-2 anti-apoptotic pathway(s).  
 
Whilst analysing a negative control for an RNAi experiment, we observed that 
the ERK2 knockdown caused a concomitant reduction in STAT3 protein levels, a fact 
that, to the best of our knowledge, has not been previously described. This was an 
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unexpected result, but one that due its novelty and relevance to cancer was further 
pursued (Section 4.3). 
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4.3.1. INTRODUCTION 
In U2OS cells FGF-2 was shown to mediate chemoresistance to cisplatin by a 
MEK/ERK-dependent mechanism. We observed that STAT1, STAT3 and STAT5 were 
not absolutely required for the mechanism by which FGF-2 protects cells against 
cisplatin because in their absence FGF-2 was able to protect cells from cisplatin-
mediated cell death (Fig. 33 and 34, Section 4.2.2.3). While analysing these data, we 
identified a novel interplay between STAT3 and ERK2. Curiously, ERK2 (but not 
ERK1) knockdown in U2OS cells caused a concomitant reduction in STAT3 levels. This 
suggested that ERK2 might be involved in the regulation of STAT3 protein levels, a fact 
that, to the best of our knowledge, had not been described yet. Our finding brings 
potentially new perspectives to the regulation of STAT3, a STAT family member with a 
prominent role on oncogenic signalling pathways (Yu and Jove, 2004). In addition, 
during the course of investigation, we observed that the knockdown of ERK2 also 
affected IL-6 signalling. Our hypothesis is that the ERK2 is a regulator of STAT3 and 
gp130, the later the signal transducing unit of IL-6-type cytokines receptors.  ERK2 may 
be acting at the level of transcription, translation or post-translational by, for example, 
stabilising these proteins. In this part of the work we aimed to further characterise the 
impact of ERK2 knockdown on STAT3, gp130 and IL-6 signalling and to determine 
the nature of the requirement for ERK2 in the control of STAT3 and gp130 
expression. 
One of the regulators of the STAT3 gene is STAT3 protein itself (Ichiba et al., 
1998). Indeed, in response to IL-6, STAT3 activity is required for transcription of the 
STAT3 gene and subsequent STAT3 protein synthesis, thereby generating a positive 
signalling loop. Although ERK2 has not been previously shown to transcriptionally 
regulate the STAT3 gene per se, it is known that ERK1/2 can regulate STAT3 
transcriptional activity (Jain et al., 1998; Tian and An, 2004). STAT3 phosphorylation on 
residue Ser727 was shown to be ERK-dependent when induced by EGF (Chung et al., 
1997) and, in this context, negatively modulated its tyrosine phosphorylation, which 
resulted in the inhibition of STAT3 DNA binding and transcriptional activity in COS 
cells. Serine phosphorylation of STAT3 induced by IL-6, however, was shown to be 
ERK-independent (Chung et al., 1997). In addition to MAPK, many other kinases have 
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now been shown to phosphorylate STAT3 Ser727, and it is generally accepted that the 
kinase involved is highly cell type- and context-dependent (Decker and Kovarik, 2000). 
ERK1 and ERK2 are very similar proteins, with a sequence homology of 83% 
(Chen et al., 2001). They are activated by the same upstream kinases (MEK1 and 
MEK2), display identical kinetics of action and seem to have the same substrate 
specificities (for example RSK family members) (reviewed by Roux and Blenis, 2004). 
The observation that ERK2 but not ERK1 affected STAT3 protein levels strongly 
suggest that ERK1 and ERK2 have, in fact, non-overlapping functions. This further 
strengthens reports that indicate that ERK1 and ERK2 do not have exclusively cellular 
redundant roles. Importantly, mutation of the erk2 gene in mice leads to early 
embryonic lethality (Saba-El-Leil et al., 2003), while erk1-/- mice are viable and 
reproduce normally, presenting just small defects such as a deficit in thymocyte 
maturation (Pages et al., 1999). It has been suggested that erk2 can compensate for most 
of the functions of erk1, but the contrasting phenotypes could in fact indicate that the 
two erk isoforms may also have distinct functions (Aouadi et al., 2006).  
Here we have established a role for ERK2 (but not ERK1) in the regulation of 
STAT3. We excluded the possibility of a siRNA off-target effect by deconvolution of 
the ERK2 siRNA pool, and extended this observation to other cell lines other than 
U2OS cells. We then investigated if the kinase activity of ERK2 was required for STAT3 
expression. We also studied how IL-6/gp130 signalling was affected by reduced ERK2 
cellular levels. 
 
 
 
4.3.2. KNOCKDOWN OF ERK2 BY SIRNA REDUCED STAT3 PROTEIN LEVELS 
IN U2OS CELLS 
The knockdown of ERK2 by siRNA used as an experimental control in this 
study revealed a very interesting and intriguing result: ERK2 knockdown appeared to 
affect STAT3 protein levels. Cells were transfected with siRNA oligonucleotides 
against ERK2, and protein levels were assessed by SDS-PAGE/Western blot. Figure 43 
A shows the expression of STAT3 and STAT1 in U2OS cells upon transfection with 
siERK2. As a control for the STAT3 antibody, cells were also transfected with siSTAT3 
oligonucleotides (Fig. 43 A, 2nd lane and B, 3rd lane). Because STAT3 and STAT1 are 
highly homologous and have the similar molecular weights (both are 91 kDa), two 
parallel SDS-PAGE gels were run. The Western blot membranes were probed for with 
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antibodies against STAT3, STAT1 and ERK1/2, the latter as a read-out for silencing 
efficiency of siERK2. Both membranes were probed for β-actin, which was used as a 
loading control. Cells with reduced levels of ERK2 showed a concomitant 50% decrease 
in STAT3 protein (p<0.005) (Fig. 43 D, 5th bar) without any apparent effect on STAT1 
levels (Fig. 43 C, 3rd bar).  
Having observed this, the initial experiment (Fig. 43 A) was repeated and, from 
this point on, cells were also transfected with siERK1 so that the impact of silencing 
ERK1 on STAT3 levels could also be investigated (Fig. 43 B, 4th lane). ERK1 silencing 
was highly efficient (p<0.005) (Fig. 43 F, 4th bar), but without effect on STAT3 and 
ERK2 protein levels (Fig. 43 D and E, 4th bars). In contrast, siERK2-transfected cells had 
approximately 50% less STAT3 than untransfected cells, which was highly statistically 
significant (p<0.005) (Fig. 43 D, 5th bar). ERK2 was very efficiently silenced by siERK2 
(p<0.005) and ERK2 expression was not affected by transfection with siERK1, or 
siSTAT3 as compared to the untransfected and mock-transfected controls (Fig. 43 E, 5th 
bar versus 1-4th bars). Interestingly, there was a statistically significant increase (p<0.05) 
in ERK1 levels upon downregulation of ERK2 (Fig. 43 F, 5th bar). Controls used 
included untransfected and mock-transfected cells (cells transfected with the 
transfection reagent DharmaFECT II only). Ideally, a non-specific siRNA control 
should also have been included. Indeed, at the time these experiments were conducted, 
the controls provided by Dharmacon affected a variety of signalling pathways and cell 
systems. They were thus deemed inappropriate. We now have siRNA against 
luciferase, which has proven to be a more appropriate ‘non-specific’ siRNA control and 
is routinely used by the Costa-Pereira Group in all RNAi experiments. 
It would be interesting to investigate the impact of the knockdown of ERK2 
(and, indeed, ERK1) on the expression of other STAT family members. This is currently 
being addressed by Ms Nair Bonito, a new PhD student, who is continuing work on 
this aspect of my PhD research work.  
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Figure 43. siRNA against ERK2 (but not ERK1) reduced STAT3 protein levels in U2OS cells. 
U2OS cells were transfected with 75 nM of siRNA using DharmaFECT II. After 48 hours, proteins were 
extracted and separated on a 7.5% SDS-PAGE gel. Total cell lysates were Western blotted as indicated. A. 
Cells were initially transfected with siRNA against STAT3 and ERK2. The Western blot membranes were 
probed for ERK1/2, STAT1 and STAT3. β-actin was also probed and used as a loading control. B. Cells 
were transfected with siRNA against STAT3, ERK1 or ERK2 as described previously. Untransfected and 
mock-transfected cells were used as base-line controls. β-actin was used as a loading control. The Western 
blot membranes were probed for ERK1/2 and STAT3. β-actin was also probed and used as a loading 
control. C., D., E., F. Mean ± SEM of densiometric values of four independent experiments are shown in 
graphs. Values are expressed as fold change relative to untransfected controls. Statistical analysis was 
performed with Student’s t-test (* – p<0.05, *** – p<0.005 versus untransfected control). Unt – 
untransfected, M – mock transfected, ST3 – STAT3, E1 – ERK1, E2 – ERK2. 
A. B. 
C. D. 
E. 
F. 
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To rule out the possibility of off-target effects elicited by the siRNA 
oligonucleotides against ERK2, we deconvoluted the ERK2 siRNA pool and analysed 
the phenotype induced by the transfection with each oligonucleotide independently. 
Out of the four oligonucleotides, two had an identical effect to that induced by the 
siRNA pool, and these correlated to ERK2 protein knockdown levels (Fig. 44 A, 2-5th 
lanes). Transfection with oligonucleotides number 1 and 9 provided the best ERK2 
knockdown (at similar levels to the knockdown in cells transfected with the siRNA 
pool) (Fig. 44 C, 2nd and 5th bars), and in these cells we observed a significant reduction 
of STAT3 protein levels (Fig. 44 B, 2nd and 5th bars). siRNA against ERK2 was also 
carried out with a different pool of oligonucleotides (ON-TARGETplus from 
Dharmacon) and identical results were obtained (data not shown).  
Overall, the results strongly suggested that the diminished STAT3 protein 
levels were a consequence of a decrease in ERK2 and not the result of an off-target 
effect.  
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Figure 44. Decrease of STAT3 protein levels in cells transfected with individual siRNA 
oligonucleotides against ERK2 correlated with the degree of ERK2 knockdown. A. U2OS cells 
were transfected with 75 nM of siRNA against ERK2 (oligonucleotides 1, 3, 4 and 9, or a pool of these four) 
and STAT3 using DharmaFECT II. After 48 hours, proteins were extracted and separated on a 7.5% SDS-
PAGE gel. Western blotting analysis was performed using total cell lysates and the membrane was probed 
with antibodies against ERK1/2 and STAT3. β-actin was also probed and used as a loading control. B. and 
C. Mean ± SEM of densiometric values of four independent experiments are shown in graphs. Values are 
expressed as fold change relative to untransfected controls. Statistical analysis was performed with 
Student’s t-test (** – p<0.01, *** – p<0.005 versus untransfected control). Unt – untransfected, ST3 – STAT3.  
 
A. 
C. 
B. 
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4.3.2.1 KNOCKDOWN OF ERK2 ALSO REDUCED STAT3 PROTEIN LEVELS IN 
OTHER CELL LINES 
In order to determine whether this was a cell type-specific phenomenon we 
investigated if the effect of ERK2 knockdown on the levels of STAT3 protein observed 
in U2OS could also be seen in other cell lines. Here we used two NSCLC cell lines 
(A549 and HCC193). These NSCLC cell lines were different from the ones used in the 
first part of this study (Section 4.1) because when performing siRNA experiments we 
observed that HCC95 cells were not efficiently transfected, and the transfection of 
HCC78 cells led to the up-regulation of STAT1. Accordingly, HCC95 and HCC78 were 
considered unsuitable for these experiments. 
A549 and HCC193 cells were transfected with siRNA against ERK2 and STAT3. 
The levels of STAT3 were analysed by SDS-PAGE/Western blot (Fig. 45 A). Similarly 
to what was observed in U2OS cells, decreased levels of ERK2 (Fig. 45 C and E, 3rd 
bars) caused a concomitant decrease in STAT3 protein levels in these cell lines (Fig. 45 
A, 3rd and 6th lanes in the 1st row). We observed an average 33% reduction (p<0.01) in 
STAT3 protein levels in A549 cells transfected with siRNA against ERK2 (Fig. 45 B, 3rd 
bar), and an average of 46% reduction (p<0.05) in STAT3 protein levels in HCC193 cells 
transfected with siRNA against ERK2 (Fig. 45 D, 3rd bar). siSTAT3-transfected cells 
were used as an antibody control (Fig. 45 B and D, 2nd bars). 
This suggests that the decrease in STAT3 levels in siERK2-transfected cells was 
a general phenomenon, not exclusively observed in the U2OS cell line, and may thus 
have far-reaching biological implications. It would be interesting to analyse the levels 
of STAT3 in ERK2-negative cells. This would be useful to further confirm the results 
obtained with siRNA (upon which the knockdown efficiency was never 100%). 
  192 
RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45. siRNA against ERK2 reduced STAT3 protein levels in lung cancer A549 and 
HCC193 cells. A. U2OS cells were transfected with 75 nM siRNA against STAT3 and ERK2 using 
DharmaFECT II. After 48 hours, proteins were extracted and separated on a 7.5% SDS-PAGE gel. Western 
blotting analysis was performed using total cell lysates, and the membrane was probed with antibodies 
against ERK1/2 and STAT3. β-actin was also probed and used as a loading control. B., C., D. and E. 
Mean ± SEM of densiometric values of three independent experiments are shown in graphs. Values are 
expressed as fold change relative to untransfected controls. Statistical analysis was performed with 
Student’s t-test (* – p<0.05, ** – p<0.01, *** – p<0.005 versus untransfected control). Unt – untransfected, ST3 
– STAT3, E2 – ERK2.  
C.            E. 
B.            D. 
A. 
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4.3.3. THE INHIBITION OF ERK1/2 ACTIVITY BY MEK INHIBITORS DID NOT 
AFFECT STAT3 PROTEIN LEVELS IN U2OS CELLS 
Since the knockdown of ERK2 caused a decrease in STAT3 levels we next asked 
whether this was due to the lack of ERK2 enzymatic activity or due to reduced levels of 
ERK2 protein itself. 
Accordingly, U2OS cells were treated with PD0325901, a MEK1/2 specific 
inhibitor, and the levels of STAT3 measured by SDS-PAGE/Western blot (Fig. 46). 
Treatment of U2OS cells with this inhibitor for 6, 18 or 24 hours blocked the basal 
activation of ERK1/2 (Fig. 46 C and D). Under the conditions used here, inhibition of 
MEK-ERK activity did not affect STAT3 protein levels (Fig. 46 B). This suggests that 
the requirement for ERK2 in maintaining STAT3 protein levels was independent of its 
enzymatic activity.  
ERK2 has been previously shown to regulate several transcription factors and 
consequently gene expression (e.g. Whitmarsh et al., 1995). It is thus possible that it 
may regulate STAT3 transcription. Although transcription normally requires ERK 
enzymatic activity (e.g. Chen et al., 2001) we cannot exclude the possibility that ERK2 
may do it independently of its activation status as seen in the yeast Saccharomyces 
cerevisiae (Bardwell et al., 1998). STAT3 protein levels may also be regulated by ERK2 in 
other ways. For example, ERK2 may regulate STAT3 translation or may have a 
scaffolding role, stabilising it or protecting it from degradation.  
The transfection of cells with a negative-dominant ERK2 plasmid will be an 
additional approach to address this question and further confirm this observation. If 
the activation of ERK2 is not needed for the maintenance of STAT3 protein levels, we 
would expect that the transfection with such a plasmid would not affect STAT3 
expression levels. An inactive ERK2 plasmid is currently available in the Costa-Pereira 
Group together with additional plasmids containing wild type ERK2, inactive ERK1 
and wild type ERK1, which will be use as controls. 
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Figure 46. Inhibition of MEK/ERK did not affect STAT3 protein levels in U2OS cells. U2OS 
cells were pre-treated with the indicated doses of PD0325901 for 6, 18 or 24 hours. Proteins were extracted 
and separated on a 10% SDS-PAGE gel. A. Western blotting analysis of STAT3 levels was performed using 
total cell lysates and the membrane was probed with antibodies against STAT3, pERK1/2 (Thr202/Tyr204) 
and total ERK1/2. β-actin was used as a loading control. B., C., D. Mean ± SEM of densiometric values of 
three independent experiments are shown in graphs. Values are expressed as fold change relative to 
untransfected controls. Statistical analysis was performed with Student’s t-test (** – p<0.01, *** – p<0.005 
versus control). h – hours. 
B. 
C. 
D. 
A. 
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4.3.4. KNOCKDOWN OF ERK2 AFFECTED IL-6 SIGNALLING IN U2OS CELLS 
STAT3 is the main transcription factor in the IL-6 pathway (Heinrich et al., 
2003). IL-6 can also activate STAT1 but only transiently and to a much lesser extent 
than it activates STAT3 (Stahl et al., 1995). We have hypothesised, therefore, that if 
STAT3 protein levels were sufficiently diminished as a consequence of the reduced 
levels of ERK2 then the IL-6 pathway should also be affected. It was shown previously 
that in the absence of STAT3, IL-6 can mediate a completely different cytokine 
response (Costa-Pereira et al., 2002). Indeed, in cells that lack STAT3 IL-6 mediates an 
IFN-γ-like response, including the prolonged activation of STAT1 and the induction of 
multiple ISGγ. We thus investigated whether the IL-6-induced STAT1 phosphorylation 
was in any way affected by the ERK2 knockdown.  
U2OS cells were transfected with siRNA against ERK2 as described before. 
Cells transfected with siRNA against ERK5, another ERK family member and cells 
transfected with siRNA against STAT3 were used as controls (ERK5 as a ‘non-specific’ 
siRNA control and siSTAT3 as an antibody control). After incubation with siRNA for 
48 hours cells were treated with 200 ng/ml of IL-6 together with 250 ng/ml of sIL-6R 
for 15 minutes. sIL-6R is a receptor subunit that together with gp130 form the receptor 
complex by which IL-6 binds and signals in cells devoid of the sIL-6R chain (e.g. 
Heinrich et al., 1998). This subunit is normally found in human plasma and is mainly 
expressed by hepatocytes, monocytes and some lymphocytes (Honda et al., 1992; 
Muller-Newen et al., 1996). sIL-6R can also be secreted by some cancer cells, such as 
myeloma (Gaillard et al., 1993). In this experiment, sIL-6R was added together with IL-
6 because U2OS cells do not express it (Ana Costa-Pereira, personal communication). 
Cells treated with 500 IU/ml of IFN-γ were used as a control for a robust, prolonged, 
STAT1 activation. Proteins were extracted, run on a SDS-PAGE gel and analysed by 
Western blotting.  
We observed that in untransfected cells, STAT1 was activated differently by 
IFN-γ and IL-6, being stronger in response to IFN-γ than in response to IL-6 (Fig. 47 A, 
2nd and 3rd lanes in the 1st row and 47 D, 2nd and 3rd bars). In accordance with what was 
observed by other authors (Qing and Stack, 2004) IFN-γ also induced a weak but 
significant activation of STAT3 (p<0.05) (Fig. 47 A, 2nd lane in 3rd row and 47 D, 2nd 
bar). In contrast, in siSTAT3-transfected cells the activation of STAT1 by IL-6 was 
stronger (p<0.05) and almost comparable to that induced by IFN-γ (Fig. 47 B, 3rd versus 
6th bar). This observation was expected and is in agreement with previously published 
data by our laboratory (Costa-Pereira et al., 2002). The knockdown of ERK5 did not 
affect the ability of IL-6 to activate STAT1 or STAT3 and these cells behaved effectively 
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as if they were untransfected (Fig. 47 B and D, 9th bars). Surprisingly, phosphorylation 
of STAT1 in response to IL-6 in siERK2-transfected cells was significantly lower than 
IL-6-induced phosphorylation in untransfected cells (p<0.01) (Fig. 47 B, 3rd versus 12th 
bar) or in cells transfected with siSTAT3 (p<0.01) or siERK5 (p<0.05) (Fig. 47 B, 6th and 
9th versus 12th bar). It was, in fact, undetectable by the naked eye (Fig. 47 A, 12th lane in 
the first row). STAT1 protein levels were not affected by siRNA against STAT3, ERK5 
and ERK2 (Fig. 47 C). STAT3 phosphorylation by IL-6 in cells with reduced ERK2 was 
also significantly reduced comparing to IL-6-induced STAT3 phosphorylation in 
untransfected (p<0.005) or siERK5-transfected cells (p<0.01) (Fig. 47 D, 3rd and 9th 
versus 12th bar). This was presumably because total protein levels of STAT3 were 
decreased in these cells (Fig. 47 E, 12th bar). ERK2 protein levels were significantly 
decreased by the siERK2 transfection (p<0.005) but were not affected by siRNA against 
STAT3 and ERK5 (Fig. 47 F, 10-12th versus 1-9th bar). 
ERK5 total protein levels seemed to be decreased in cells transfected with 
siRNA against STAT3 (Fig. 47 G). This was significant in cells subsequently treated 
with cytokines (p<0.05) (Fig. 47 G, 5th and 6th bars). ERK5, also called big MAPK (BMK) 
for being more than twice the size of the other MAPK family members is one of the less 
well-characterised MAPKs (Wang and Tournier, 2006). To the best of our knowledge, 
there are no reports suggesting that STAT3 regulates, directly or indirectly, ERK5 
protein levels. This observation could represent an unknown role for STAT3, a fact that 
merit future investigation. The specificity of STAT3 siRNA oligonucleotides has been 
extensively investigated in the laboratory (Ana Costa-Pereira and Diane Watling, 
personal communication) by deconvolution and use of additional siRNA 
oligonucleotides and it is unlikely that the impact on ERK5 levels by siSTAT3 
transfection was due to off-target effects. This needs, nevertheless to be fully 
established in this particular context. Alternatively, the immunodetection of ERK5 
could have been hindered by a change of protein mobility (a band shift) caused by 
possible PTMs induced by IFN-γ and IL-6. In particular, IL-6 was shown to activate 
ERK5 in myeloma cells (Carvajal-Vergara et al., 2005). Preliminary data from our group 
established that IL-6 activated ERK5 in the absence of STAT3 (data not shown). 
Although the ERK5 Western blot shown here is not very “clean”, it is possible to see a 
band shift in siSTAT3-transfected cells treated with IFN-γ and IL-6 (Fig. 47 A, 5th and 
6th lanes in the 6th row). These may correspond to ERK5 PTMs but further work is 
necessary to confirm this assumption.  
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Figure 47. IL-6-induced activation of STAT1 and STAT3 was impaired in U2OS cells with 
reduced levels of ERK2. (continued on page 198). U2OS cells were transfected with 75 nM of siRNA 
targeting STAT3, ERK5 or ERK2 using DharmaFECT II. After 48 hours, cells were stimulated with IFN-γ 
(500 IU/ml) or IL-6 (200 ng/ml) together with sIL-6R (250 ng/ml) for 15 minutes. Proteins were extracted 
and separated on a 7.5% SDS-PAGE gel. A. Western blotting analysis was performed using total cell 
lysates and the membrane was probed with antibodies against ERK1/2, ERK5, phosphorylated STAT1 
(Tyr701), STAT1, phosphorylated STAT3 (Tyr705) and STAT3. β-actin was used as a loading control. B., C., 
D., E., F., G. Means ± SEM of densiometric values from three independent experiments are represented in 
graphs. Values are expressed as fold change relative to untransfected controls. Statistical analysis was 
performed with Student’s t-test (* – p<0.05, ** – p<0.01, *** – p<0.005, black asterisks versus untransfected 
untreated control, red asterisks compare the indicated samples). Unt – untransfected cells, γ – IFN-γ.  
C. 
B. 
A. 
  198 
RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. IL-6-induced activation of STAT1 and STAT3 was impaired in U2OS cells with 
reduced levels of ERK2. (continued from page 197). 
D. 
E. 
F. 
G. 
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The inability of IL-6 to activate STAT1 in cells transfected with siRNA against 
ERK2 was an unexpected and surprising observation. One plausible hypothesis to 
explain this observation might be that ERK2 knockdown might affect the expression or 
localisation gp130, the signal transducing receptor chain that all IL-6-type cytokines 
utilise. We therefore next examined if ERK2 silencing affected this receptor. 
 
 
 
4.3.4.1. KNOCKDOWN OF ERK2 REDUCED GP130 RECEPTOR EXPRESSION 
To determine if the inability of IL-6 to activate STAT1 was due to reduced levels 
of the receptor gp130 on the cell surface, cells were transfected with siRNA against 
ERK2 and cell surface levels of gp130 measured by flow cytometry. Controls used here 
included untransfected cells, siSTAT3-transfected cells and cells transfected with a 
non-specific siRNA (NS). After 48 hours, cells were stained for gp130 (cf. Materials and 
methods) and analysed using a FACSCanto. siRNA oligonucleotides specificity and 
protein knockdown levels were assessed by SDS-PAGE/Western blotting, as 
previously described (data not shown). The amount of gp130 present on the cell 
surface was determined by comparing cells stained with an anti-gp130 antibody to 
cells stained with the secondary antibody only (shadowed coloured peaks) (Fig. 48 A).  
We detected similar levels of gp130 on the cell surface of untransfected and cells 
transfected with siRNA against STAT3, or with a non-specific siRNA pool (Fig. 48 A, 
1st, 4th and 5th histograms and B, 1st, 4th and 5th bars). In siERK2-transfected cells 
detection of gp130 on the cell surface was significantly reduced to around 20% 
(p<0.005) (Fig. 48 B, 2nd bar). The absence of gp130 on the cell surface could certainly 
explain the lack of signalling in response to IL-6 observed upon knocking down ERK2 
using RNAi (Fig. 47). Interestingly, in cells transfected with siRNA against ERK1 a 
significant reduction (p<0.005) of around 25% of gp130 in the cell surface was also 
observed (Fig. 48 B, 3rd bar).  
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Figure 48. siRNA against ERK2 reduced the levels of the gp130 receptor on the surface of 
U2OS cells. A. U2OS cells were transfected with 75 nM siRNA against ERK2, ERK1, STAT3 or a non-
specific target using DharmaFECT II, and 48 hours later, were stained for gp130. Levels of gp130 in the cell 
surface were assessed by flow cytometric analysis using a FACSCanto. Results were analysed using 
FlowJo. Shadowed coloured peaks represent cells stained with the secondary antibody only and 
transparent peaks represent cells stained with the anti-gp130 antibody together with the secondary 
antibody. The different colours correspond to different transfections: black: untransfected, dark green: 
ERK2, light green: ERK1, orange: STAT3 and brown: non-specific. Numbers correspond to the geometric 
means of florescence in stained samples. B. Mean ± SEM values of three independent experiments are 
shown in graphs. Values are expressed as fold change relative to untransfected controls. Statistical analysis 
was performed with Student’s t-test (*** – p<0.005 versus untransfected control). Unt – untransfected cells, 
E2 – ERK2, ST3 – STAT3, E1 – ERK1, NS – non-specific. 
 
 
 
 
 
 
The decrease of gp130 levels on the cell surface following siRNA against ERK1 
or ERK1 could be due to i) a reduction of protein levels in the cell, or ii) a defect on cell 
surface presentation (transport to the plasma membrane), or iii) increased endocytosis. 
Therefore, gp130 total protein levels in cells were assessed by SDS-PAGE/Western 
blotting after transfection with siRNA against ERK2.  
B.
. 
A.
. 
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Using an antibody that recognises total gp130 we were able to detect two bands 
(approximately 150 and 130 kDa) in untransfected and siSTAT3-transfected cells (Fig. 
49 A, 1st and 3rd lanes in the 1st row). These two bands presumably correspond to the 
gp130 precursor form (130 kDa) and the processed form (150 kDa) that contains 
complex-type oligosaccharides (Gerhartz et al., 1994). The expression of gp130 receptor 
was significantly reduced in siERK2-transfected cells (p<0.005) (Fig. 49 B, 2nd bar). The 
hypothesis of an off-target effect elicited by the siERK2 oligonucleotides on gp130 was 
excluded by performing RNAi against ERK2 using a different pool of oligonucleotides 
(ON-TARGETplus from Dharmacon), which gave similar results to those described 
above (data not shown).  
The defect in gp130 expression in siERK2-transfected cells might thus be due to 
either shorter protein half-life, or to a defect in transcription or translation. Or perhaps 
the gp130 receptor has a different conformation (due to incorrect protein folding) in 
siERK2-transfected cells. This could impair its recognition by the anti-gp130 antibody 
used for Western blotting.  
Interestingly, ERK1 silencing also affected gp130 and this effect was distinct 
from ERK2 knockdown. In siERK1-transfected cells, this receptor was detected (Fig. 49 
B, 4th bar). Instead of reducing total gp130 levels, ERK1 silencing resulted in a selective 
reduction in the 150 kDa processed form of gp130 (p<0.05) (Fig. 49 C, 4th bar) and the 
predominant form was the lower molecular weight form (130 kDa) (Fig. 49 D, 4th bar), 
which may correspond to the immature receptor. These results suggest that the 
knockdown of ERK1 may impair the maturation of gp130 thereby affecting its cellular 
localisation. This is currently being investigated. 
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Figure 49. siRNA against ERK2 and ERK1 altered gp130 protein expression pattern in U2OS 
cells. U2OS cells were transfected with 75 nM siRNA against ERK2, STAT3 and ERK1 using DharmaFECT 
II. After 48 hours, proteins were extracted and separated on a 7.5% SDS-PAGE gel. A. Western blotting 
analysis was performed using total cell lysates and the membrane was probed with antibodies against 
ERK1/2, gp130 and STAT3. β-actin was also probed and used as a loading control. B., C., D., E., F., G. 
Means ± SEM of densiometric values from three independent experiments are represented in graphs. 
Values are expressed as fold change relative to untransfected controls. Statistical analysis was performed 
with Student’s t-test (* – p<0.05, ** – p<0.01, *** – p<0.005 versus untransfected control). Unt – 
untransfected cells, E2 – ERK2, ST3 – STAT3, E1 – ERK1.  
D.            G. 
C.            F. 
B.            E. 
A. 
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4.3.5. DISCUSSION 
The inhibition of ERK2, used in this work initially as a control, has revealed a 
fascinating result. ERK2 knockdown reduced the levels of STAT3 protein levels by 50% 
(Fig. 43). In contrast, cells transfected with siRNA against ERK1 express STAT3 protein 
to similar levels of untransfected cells. STAT1 levels remained unaffected by the 
knockdown of ERK2 (Fig. 43). The reduction of STAT3 protein expression was not due 
to an off-target effect elicited by the siRNA oligonucleotides against ERK2, since 
deconvolution of the siRNA pool yielded a similar phenotype to those observed with 
the siRNA pool in two out of four oligonucleotides (Fig. 44). Cells transfected with the 
two oligonucleotides that gave the best ERK2 knockdown were the cells that showed 
the most reduction in STAT3 protein levels. In addition, siRNA against ERK2 carried 
out with a different pool of oligonucleotides showed identical results. Overall, the 
results strongly suggest that the diminished STAT3 protein levels were a consequence 
of decreased ERK2 and not the result of an off-target effect. This observation suggests a 
novel interplay between ERK2 and STAT3 and maybe a new mechanism for the 
regulation of STAT3, the member of a STAT family believed to play a major role in 
cancer (Yu and Jove, 2004). 
The reduction of STAT3 protein levels upon the silencing of ERK2 was initially 
observed in the osteosarcoma cell line U2OS but this observation was further extended 
to other cell lines, the NSCLC A549 and HCC193 lines (Fig. 45). These results suggest 
that ERK2 plays a role in the regulation of STAT3 in different cell lines, suggesting that 
this is a more generalised phenomenon.  
ERK2 can be regulating STAT3 expression in diverse ways. ERK2 may be 
involved in the regulation of STAT3 transcription. This MAPK is known to induce the 
expression of many genes by directly activating gene promoter-bound transcription 
factors (Whitmarsh et al., 1995), which suggest that ERK2 could be acting as a 
transcription factor for STAT3. ERK signalling was also shown to be involved in 
translational machinery (Roux et al., 2007). In fact, ERKs can regulate the translation of 
various proteins through MKs (reviewed by Roux and Blenis, 2004). It is plausible that 
ERK2 may thus be a modulator of mRNA translation of STAT3. ERK kinase activity 
was, however, required for the induction of translation, which makes this a less likely 
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explanation for the result described here. STAT3 protein levels reduction in the absence 
of ERK2 may also be related to lack of STAT3 activity. Indeed, STAT3 protein regulates 
the STAT3 gene, a process that requires STAT3 activity (Ichiba et al., 1998). It is possible 
that ERK2 is required for STAT3 activity (for example, by virtue of being an inhibitor 
of PIAS): knockdown of ERK2 would thus reduce STAT3 protein activity, which would 
then result in reduced STAT3 expression. Lastly it is also a possibility that ERK2 is not 
involved in de novo STAT3 protein synthesis per se, but is instead required for the 
stabilisation and protection of STAT3 from protein degradation and/or cleavage. 
Indeed, activation of MEK/ERK2 signalling pathway is associated with inhibition of 
caspase activation (Erhardt et al., 1999; Rytomaa et al., 2000; Tashker et al., 2002). It was 
shown that ERK1/2 can inhibit caspase-9 activity by directly phosphorylating and 
subsequently inhibiting caspase-3 (Allan et al., 2003). Under certain circumstances, 
STAT3 is known to undergo proteolytic processing by caspases (Darnowski et al., 
2006). Perhaps ERK2 inhibit such caspases and the knockdown of ERK2 may lead to 
STAT3 cleavage and degradation. 
We observed that inhibition of MEK activity did not affect STAT3 expression 
(Fig. 46), suggesting that enzymatic activity was not required for the stabilisation of 
STAT3. Although the activation of ERKs was shown to be required for the 
transcription and translation of many genes (e.g. Chen et al., 2001) we cannot exclude 
the possibility that ERK2 may also regulate transcription or translation independently 
of its enzymatic activity. A kinase inactive form of the yeast Saccharomyces cerevisiae 
MAPK, the kinase suppressor of Sst2 (Kss1), was shown to negatively regulate gene 
expression by directly binding to the transcription factor Ste12 thereby inhibiting 
invasive growth (Bardwell et al., 1998). Moreover, MAPKs were shown to be able to 
translocate into the nucleus independently of their phosphorylation state (Gonzalez et 
al., 1993; Lenormand et al., 1993; Meili and Ballmer-Hofer, 1996; Matsubayashi et al., 
2001). Accordingly, it is possible that ERK2 may be regulating STAT3 expression 
through a mechanism independent of its kinase activity.  
The reduction of STAT3 protein levels in the absence of ERK2 was expected to 
affect the response to IL-6. This cytokine activates STAT3 (Heinrich et al., 2003), and 
STAT1 transiently (Stahl et al., 1995). In cells that lack STAT3, IL-6 can mediate an IFN-
γ-like response that involves the induction of a strong and prolonged STAT1 
phosphorylation (Costa-Pereira et al., 2002). Accordingly, because transfection with 
siRNA against ERK2 caused a decrease in the STAT3 protein levels, a stronger STAT1 
phosphorylation was expected to be seen in siERK2-transfected cells. This, however, 
was not observed (Fig. 47). Instead of increased IL-6-induced STAT1 phosphorylation 
  205 
RESULTS 
we observed that IL-6 was unable to activate STAT1, which was unexpected. STAT3 
phosphorylation by IL-6 in cells with reduced ERK2 was also significantly reduced 
compared to IL-6-induced STAT3 phosphorylation in untransfected or siERK5-
transfected cells, but this was no surprise as STAT3 total protein levels were also 
reduced. The most straightforward explanation would be that, somehow, reduced 
ERK2 led to reduced levels of the receptor gp130, or to reduced binding of STAT1 to 
the recruitment motifs in gp130 molecule.  
Indeed, transfection of U2OS cells with siRNA against ERK2 resulted in the 
near obliteration of gp130 on the cell surface of these cells (Fig. 48). This receptor is 
required for STAT1 and STAT3 recruitment to the IL-6 receptor complex, whereupon 
these molecules become phosphorylated and activated (Stahl et al., 1995; Heinrich et al., 
1998). Interestingly, in cells transfected with siRNA against ERK1 gp130 was also 
reduced on the cell surface, although this reduction was not as dramatic as that 
observed in siERK2-transfected cells (25% versus 80%). The decrease of gp130 on the 
cell surface could be due to a reduction in protein levels in the cell, due to a defect in 
cell surface presentation caused by deficient transport to the membrane and/or defects 
in the maturation of the receptor. Increased gp130 endocytosis could also affect the 
levels of gp130 at the plasma membrane.  
By Western blot analysis of total cell lysates we were able to detect gp130 in 
untransfected cells but not cells transfected with siRNA against ERK2 (Fig. 49). This 
explained the dramatic reduction of gp130 on the cells surface and suggested that 
ERK2 was regulating transcription, translation, or had a scaffolding role that protected 
gp130 from degradation.  
Similarly to what was mentioned for STAT3, ERK2 may be a transcription 
factor for gp130 or it may be required for mRNA translation of gp130. Alternatively, 
ERK2 may be a protein that protects gp130 from degradation. Lysosomal degradation 
of gp130 upon IL-6 binding has been previously reported, leading to a rapid and 
critical translocation of the receptor from the cell surface to endosomal compartments 
(Dittrich et al., 1994; Blanchard et al., 2001). Like for many other receptors, 
ubiquitination plays a key role in gp130 endosomal trafficking (Tanaka et al., 2008). 
Down-regulation of the receptor was suggested to play an important role as a means of 
protecting cells against over-stimulation. A di-leucine motif (Leu786 and Leu787) located 
in the intracellular domain of gp130 was shown to be crucial for efficient receptor 
endocytosis (Dittrich et al., 1994). Interaction of the adaptor protein AP2 with this motif 
was observed to enable the transfer of receptors to clathrin-coated pits, and 
intracellular targeting to lysosomal degradation (Dittrich et al., 1996; Thiel et al., 1998). 
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In addition, phosphorylation of the Ser782 residue located immediately next to the di-
leucine motif of gp130 regulates its turnover (Dittrich et al., 1996; Gibson et al., 2000) 
and is a requisite for receptor degradation via ubiquitin-proteasome pathway 
(Mitsuhashi et al., 2005). CamKs, such as CaMKII, which phosphorylate gp130, can 
phosphorylate this particular residue (Gibson et al., 2005). ERK2 may be a repressor of 
a kinase such as CamKII and regulate gp130 trafficking and degradation. The 
requirement for ERK2 kinase activity for the maintenance of gp130 protein levels is still 
unknown. This will be investigated using MEK inhibitors. Another possibility is that, 
in the absence of ERK2, gp130 is cleaved. A previous report showed that gp130 can be 
cleaved by caspase 3 at position 800-806 (Graf et al., 2008). Cleavage in this region 
would impair gp130 recognition by the antibody used here for Western blotting since it 
recognises the region 713-918. The use of other antibodies against gp130 that recognise 
other residues will be useful to detect cleaved forms of the receptor, if this is the case. If 
this proves true, the involvement of caspases in this process will be investigated using 
specific caspase inhibitors. 
A connection between the decrease of STAT3 and gp130 cannot be excluded 
and will be taken into consideration in future studies. On one hand, the reduction in 
STAT3 protein levels caused by the knockdown of ERK2 could be the reason why there 
is decreased expression of gp130. The 5’-flanking region of the human gp130 gene 
functions as a constitutively active transcriptional promoter and can be stimulated by 
IL-6-type cytokines (O'Brien and Manolagas, 1997). These authors showed that STAT3 
and STAT1 homo and heterodimers bind STAT-binding elements (SBEs) identified in 
this region. This was suggested to stimulate the production of new gp130 molecules to 
replenish receptors consumed upon ligand activation. This is unlikely to be the case 
here as we observed that knockdown of STAT3 by siRNA did not affect gp130 
expression (Fig. 48 and 49). On the other hand, lack of gp130 protein may affect STAT3 
protein levels. One possibility is that the reduction of gp130 protein may cause a 
decrease STAT3 signalling and this could have an impact on STAT3 itself because, as 
previously mentioned, one of the regulators of the STAT3 gene is STAT3 itself (Ichiba 
et al., 1998). The main point thus pertains to how ERK2 levels can influence both STAT3 
and gp130 expression and, presumably, regulate signalling pathways involving these 
molecules.  
Total levels of gp130 protein in the cells were not significantly affected by the 
knockdown of ERK1 (Fig. 49 B). However, we observed a reduction (of around 25%) of 
this receptor on the cell surface of siERK1-transfected cells. The anti-gp130 antibody 
(Upstate, against residues 713-918) used on Western blots detected two bands in 
  207 
RESULTS 
untransfected and siSTAT3-transfected cells (Fig. 49). These two bands presumably 
correspond to the gp130 precursor form (130 kDa) and the processed form (150 kDa) 
(Gerhartz et al., 1994; Wang and Fuller, 1995). gp130 molecules are produced as 
precursors of 130 kDa and are processed within 45-60 minutes in the endoplasmic 
reticulum (ER) into mature forms that weight 150 kDa (Gerhartz et al., 1994). This 
receptor was shown to be N-glycosylated at 9 out of 11 asparagine potential residues 
for glycosilation (Moritz et al., 2001). N-glycosylation of gp130 is essential for the 
stability and localisation of the receptor (Waetzig et al., 2009). By mutating the 
asparagines of all 9 functional N-glycosylation sites of gp130, these authors showed 
that gp130 molecules without N-glycans are inherently unstable and are mostly 
degraded in the proteosome before reaching the cell surface (Waetzig et al., 2009). In 
siERK1-tranfected cells the gp130 processed (150 kDa) form decreased and the lower 
molecular weight (130 kDa) was the predominant form. This raises the intriguing 
possibility that ERK1 may be required to efficiently process gp130. This could be 
addressed using endoglycosidase H, which would allow us to confirm that the 
accumulation of the 130 kDa form in siERK1-transfected cells is indeed due to a lack of 
glycosylation. If this proves to be the case then the effects of ERK1 knockdown on the 
maturation and/or function of gp130 will be studied in great detail. First, the 
requirement for ERK1 in the maturation of gp130 will be investigated. The requirement 
for ERK kinase activity will be determined using MEK inhibitors. Furthermore, it will 
be investigated if ERK1 can function as a chaperone required for the transport of 
gp130. It will be important to investigate if the gp130 receptor is functional in the 
absence of ERK1. This could be addressed by knocking down ERK1 using siRNA and 
monitoring the phosphorylation of STAT1 and STAT3 in response to IL-6. 
Glycosylation of gp130 was shown to be required for receptor function in rat 
hepatocytes (Wang and Fuller, 1995). N-glycosylation was, however, suggested to be 
dispensable for ligand binding as the small quantities of non-glycosylated gp130, 
which do reach the cell surface, were are still able to induce stat3 activity upon IL-6 
binding in BAF3 (murine) cells (Waetzig et al., 2009). In mouse neuroepithelial cells N-
glycans are required for the activation but not for the localisation of gp130 
(Yanagisawa and Yu, 2009). If ERK1 is required for the maturation of gp130 it is almost 
certain that the knockdown of ERK1 will somehow affect the function receptor. 
Although these results warrant a more detailed investigation the data establish 
a novel role for ERK1 that is not shared by ERK2. Besides ERK1 and ERK2 being very 
similar proteins with analogous activities, kinetics and substrates (Chen et al., 2001; 
Roux and Blenis, 2004), our findings corroborate the idea that ERK1 and ERK2 have, in 
  208 
RESULTS 
fact, non-overlapping functions (Aouadi et al., 2006; Vantaggiato et al., 2006; Bessard et 
al., 2008; Fremin et al., 2009). Here we have established a role for ERK2 in the regulation 
of STAT3 and gp130 levels. Our data also suggests that whilst gp130 expression or 
stability is dependent on ERK2, its maturation is dependent on ERK1. These are totally 
novel observations.  
 
 
Together these findings further strengthen the relevance of ERK1/2 in cancer, 
as these molecules regulate the expression of gp130 and STAT3, two important players 
in pathways relevant to cancer cells, in addition to their already well described and 
recognised mitogenic role. 
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5.1. GENERAL DISCUSSION 
Chemoresistance is probably the main obstacle for the successful treatment of 
many tumour types. As a prime example, lung cancer has an extremely low cure rate 
mainly due to innate or acquired resistance to chemotherapy (Spiro and Silvestri, 2005). 
Activation of various survival signalling pathways has been related to the induction of 
chemoresistance. This work has focused on a signalling pathway induced by FGF-2 which 
has been shown to play an important role in driving chemoresistance in lung, prostate 
and breast cancer cells (Song et al., 2000; Pardo et al., 2002; Pardo et al., 2003; Vandermoere 
et al., 2005). Here, we have extended these findings to another type of tumour, namely 
bone cancer. In the osteosarcoma U2OS cell line, FGF-2 induced cell proliferation and 
provided protection from cell death induced by the chemotherapeutic agent cisplatin, 
refelecting well-recognised multiple functions of FGF-2 (Bikfalvi et al., 1997). Using a 
variety of assays and read-outs we have confirmed that rescue from cisplatin-induced 
death by FGF-2 reflected a bona fide inhibition of apoptosis rather than just an increase in 
cell proliferation. In U2OS cells, FGF-2 induced the expression of anti-apoptotic proteins 
(MCL-1, BCL-2, BCL-XL and XIAP) that are likely to be involved in the chemoprotection 
mechanism. Given that FGF signalling has an important role in bone growth and cancer 
(Muenke and Schell, 1995; Coffin et al., 1995; Deng et al., 1996; Bodo et al., 2002) our 
findings might help to develop additional ways of circumventing common medical 
problems arising from chemoresistance in osteosarcoma. This is particularly relevant for 
this type of cancer (and potentially for many other cancers) in which the development of 
resistance to chemotherapy is associated with a lower survival rate (Bacci et al., 2000). 
The RAS/RAF/MEK/ERK signalling pathway has been demonstrated to control 
several fundamental cellular processes that lead to cell growth, cell survival and drug 
resistance (reviewed by Kolch, 2000; Ballif and Blenis, 2001; McCubrey et al., 2007). In 
particular, MEK/ERK activation was shown to be indispensable for FGF-2-mediated 
protection from etoposide in SCLC cells (Pardo et al., 2002). Here, we observed that FGF-2 
rescues U2OS cells through a mechanism that also requires MEK/ERK activation. Indeed, 
in this cell line, FGF-2 was unable to rescue cells from cisplatin-induced cell death in the 
presence of a MEK chemical inhibitor, or siRNA molecules that target ERK1 or ERK2. 
Accordingly, this finding adds further evidence for the notion that this pathway plays a 
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central role in chemoresistance in different cancer types. Moreover, it is possible that 
additional pathways may be activated in this context. For example, the PI3K pathway was 
shown to mediate FGF-2-induced survival in breast cancer cells and osteoblasts (Debiais et 
al., 2004; Vandermoere et al., 2005). PI3K was, however, dispensable in FGF-2-mediated 
chemoresistance in SCLC cells (Pardo et al., 2002). Future work focusing on other 
pathways downstream of FGF-2 in U2OS cells will help to elucidate further the 
mechanisms by which this growth factor confers protection from apoptosis in this cell 
line. 
We have also investigated the FGF-2-mediated chemoresistance in NSCLC cells, 
the most common lung cancer cell type (Spiro and Porter, 2005). Under the conditions 
used here, FGF-2 failed to induce proliferation in the two NSCLC cell lines studied 
(HCC95 and HCC78) and was also unable to rescue them from cisplatin-mediated cell 
death. In HCC78, this may be due to a defective ERK1/2 activation in response to FGF-2. 
While maximum induction of ERK1/2 phosphorylation was on average 13.2-/4.3- and 
7.9-/5.1-fold for U2OS and HCC95 cells, respectively, FGF-2 increased the 
phosphorylation of ERK1/2 only by 1.4-/1.3-fold in HCC78 cells. One possible reason 
why ERK1/2 is only modestly activated in response to FGF-2 is that HCC78, in contrast to 
U2OS and HCC95 cells, lack the expression of FGFR2IIIc, one of the two main canonical 
FGF-2 receptors (FGFR1 and FGFR2IIIc) (Ornitz et al., 1996). The reason for the inability of 
FGF-2 to protect the NSCLC cell line HCC95 from cisplatin-induced killing is less obvious 
and remains to be explained. It is possible that other pathways potentially activated 
downstream of FGF-2 may be impaired in HCC95 cells. Nevertheless, FGF-2 may provide 
chemoprotection in other NSCLC cell lines, which have not been studied here. Therefore, 
analysing additional NSCLC cell lines will be crucial to establish if FGF-2 is able to 
mediate chemoprotection in this type of lung cancer. 
Furthermore, our work not only provides additional evidence for the crucial role 
played by ERKs in chemoresistance (reviewed by McCubrey et al., 2007), but also unravels 
novel functions for these proteins in oncogenic pathways. We discovered that the 
knockdown of ERK2 caused a reduction in STAT3 protein levels in the osteosarcoma cell 
line U2OS. Consequently, we investigated if the knockdown of ERK2 by siRNA had the 
same effect on STAT3 in another cell type (i.e. NSCLC cells). Here, we used two NSCLC 
cell lines (HCC193 and A549) that were different from the ones used in the first part of 
this study because optimisation of siRNA experiments previously performed in the Costa-
Pereira laboratory revealed that HCC95 cells were not efficiently transfected and because 
transfection of HCC78 cells with siRNA led to the upregulation of STAT1. For these 
reasons, we selected the HCC193 and A549 cells for the experiments involving RNAi. 
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Similarly to what was observed in U2OS cells, STAT3 protein levels were reduced in 
HCC193 and A549 cells transfected with siRNA against ERK2, suggesting that ERK2 may 
play a role in maintaining STAT3 protein levels in different cell types. Treatment with 
MEK inhibitors suggested that the enzymatic activity of ERK2 was not essential for the 
maintenance of STAT3 levels. In addition, the knockdown of ERK2 also led to the 
downregulation of the gp130 receptor in U2OS cells. The knockdown of ERK1 did not 
affect the protein levels of gp130 but appeared to promote the accumulation of its 
unglycosylated form (130 kDa) suggesting that it may block the maturation of this 
receptor. The results obtained here thus demonstrate a role for ERK2 in the regulation of 
STAT3 and gp130 levels, and also suggest that ERK1 might be required for the maturation 
of gp130. These observations corroborate the idea that although ERK1 and ERK2 are very 
similar proteins with analogous activities, kinetics and substrates (Chen et al., 2001; Roux 
and Blenis, 2004), they can also perform distinct functions (Aouadi et al., 2006; Vantaggiato 
et al., 2006; Bessard et al., 2008; Fremin et al., 2009). Furthermore, these findings strengthen 
the relevance of ERK1/2 in cancer, as we provided evidence that they regulate the 
expression of STAT3 and gp130, two important players in pathways relevant to 
proliferation, survival and drug resistance in cancer cells. 
MEK/ERK signalling plays a pivotal role in cancer progression and, accordingly, 
this pathway has been targeted by several researchers aiming to develop more efficient 
anti-cancer therapies (Roberts and Der, 2007; Friday and Adjei, 2008). New small-
molecule inhibitors of MEK recently developed are currently being evaluated in the clinic, 
where they are showing encouraging results (Adjei et al., 2008; Bennouna et al., 2010). Our 
work reinforces the idea that the inhibition of MEK in conjunction with traditional 
chemotherapy may prevent the occurrence of chemoresistance and contribute to a more 
successful cancer treatment. 
In this study, novel players in FGF-2-induced resistance have been revealed. 
Similarly to what was previously observed in SCLC cells (Pardo et al., 2002; Pardo et al., 
2006), FGF-2 protected U2OS osteosarcoma cells from cisplatin-mediated apoptosis 
through a mechanism that required the activation of MEK/ERK and involved the physical 
interaction of B-RAF, PKCε and S6K2. Here we demonstrated that FGF-2-mediated 
chemoresistance also required the JAK family members JAK1, JAK2 and TYK2. We 
observed that the knockdown of JAK1, JAK2 or TYK2 by siRNA, as well as chemical 
inhibition of JAK2 impaired the ability of FGF-2 to rescue U2OS cells from cisplatin-
induced cell death. We did not explore the requirement for JAK3 in the FGF-2-mediated 
chemoresistance because JAK3 is preferentially expressed in leukocytes unlike the other 
three JAKs that are ubiquitously expressed (reviewed by Schindler et al., 2008). In this 
  213 
GENERAL DISCUSSION 
study, we showed that FGF-2 induced the phosphorylation of TYK2 in U2OS cells and 
preliminary data suggested that FGF-2 may also phosphorylate JAK1 and JAK2. These 
data indicate that JAK proteins are likely activated downstream of FGF-2. This is also 
supported by results from other authors, who observed phosphorylation of JAKs 
downstream of this growth factor in BMVECs, contributing to their migration, invasion, 
and angiogenesis (Yang et al., 2009). In our study we demonstrated that JAK1, JAK2 and 
TYK2 interacted with B-RAF and PKCε upon FGF-2 stimulation in U2OS cells. In 
particular, TYK2 was required for the full activation of ERK1/2 and for the upregulation 
of the anti-apoptotic protein MCL-1 in response to FGF-2. Although the participation of 
JAKs in this mechanism is still not fully elucidated, the data obtained here strongly 
supports our initial working hypothesis that JAKs play a role in FGF-2-mediated 
chemoresistance. 
Interestingly, FGF-2-mediated chemoresistance did not require the STAT family 
members STAT1, STAT3 and STAT5, which are commonly deregulated in many cancers 
(Yu and Jove, 2004). Furthermore, under the conditions tested, FGF-2 did not induce 
STAT1, STAT3 or STAT5A/B phosphorylation/activation in these cells. This suggests that 
these STATs are unlikely to play a role in the pathway downstream of FGF-2 studied here.  
We still do not known if other STAT family members (STAT2, STAT4 and STAT6) play a 
role in FGF-2-mediated chemoresistance. Although JAKs commonly exert their effects 
through STATs, it was shown by other authors that some responses are mediated by JAKs 
independently of STATs (Packham et al., 1998; Wen et al., 2001; Dawson et al., 2009). Taken 
at face value, our data is consistent with the notion that the regulation of cell death in 
U2OS cells upon cisplatin treatment involves JAKs but not STAT1, STAT3 or STAT5. At 
this stage, we cannot, however, rule out the possibility that there may be compensatory 
roles amongst these STATs in this particular context. 
Our findings strongly suggest that JAKs are potential targets for treatment of 
chemoresistant cancers, as their inhibition blocked FGF-2-mediated survival in 
osteosarcoma cells. Targeting these molecules may be particularly relevant in cancer 
treatments also because JAK family members have been shown to modulate activation of 
several other pathways (such as MEK/ERK or p53 pathways) that are implicated in 
malignant transformation, cell growth and apoptosis (Kumar et al., 1994; Quelle et al., 
1998; Mizuguchi et al., 2000). Furthermore, JAK mutations were found to contribute to 
tumourigenesis in MPDs (Constantinescu et al., 2008). At present, while a number of JAK 
inhibitors have been developed, just a few have been used in the clinic due to problems 
related to low potency, off-target effects and drug toxicity (reviewed by Wilks, 2008). But 
some JAK inhibitors that are currently being tested in clinic are showing promising results 
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mainly in the treatment of MPDs (e.g. Pardanani, 2008). Our findings support the 
inhibition of JAKs in additional tumour types. Indeed, this may be a potentially good 
strategy to overcome chemoresistance and improve the survival of cancer patients. 
 
 
 
In summary, the results presented here assign to FGF-2 an important role in the 
survival of osteosarcoma cells and pave the way to further studies for the elucidation of 
relevant mechanisms of chemoresistance. Our study has provided compelling evidence 
for a key role played by JAKs in the anti-apoptotic pathways triggered by FGF-2 in 
addition to previously identified molecules (i.e. ERK1/2, B-RAF, PKCε and S6K2). In 
addition, these results suggest that targeting JAKs may provide a novel therapeutic 
strategy for cancer treatment, particularly in osteosarcoma. Our findings are also 
consistent with the notion that the signalling downstream of FGF-2 is complex and that 
the main oncogenic signalling pathways cross-talk and synergise to promote cell survival 
and resistance to apoptosis. Moreover, our observations further highlight the relevance of 
ERK1/2 in cancer, as they regulate the expression of many important players in pathways 
relevant to cancer cells, in addition to their well-described and recognised mitogenic roles.  
  215 
GENERAL DISCUSSION 
 
 
 
 
5.2. FUTURE DIRECTIONS 
The present work brings new perspectives on the context of chemoresistance, one 
of the major obstacles in the successful treatment of cancer. Although a more thorough 
investigation will be needed to better understand and clarify the mechanisms involved, 
our findings clearly establish the previously unrecognised importance of JAKs in FGF-2-
mediated chemoresistance signal transduction pathways. 
The results presented here show that FGF-2 can drive chemoresistance in a bone 
cancer cell line in a similar manner to that previously observed in lung cancer cells (Pardo 
et al., 2002; Pardo et al., 2006). In fact, in the osteosarcoma U2OS cell line, FGF-2 conferred 
protection from cisplatin-induced cell death via a MEK-ERK-dependent mechanism, 
which involved interactions between B-RAF, PKCε and S6K2, and induced the expression 
of anti-apoptotic proteins, such as XIAP and several BCL-2 family members. This 
emphasises the generality of this phenomenon and it highlights the importance of this 
pathway in chemoresistance and, by inference, in tumour progression. 
In U2OS cells, FGF-2 likely signals through FGFR1 and FGFR2IIIc. We would like 
to confirm by Western blotting analysis that these receptors are expressed in U2OS using 
specific antibodies but the antibodies commercially available are not ideally suited. The 
use of siRNA against the different FGFRs will confirm the requirement for these receptors 
in FGF-2 signalling in this cell line. Because we observed that HCC78 cells responded to 
FGF-2, it would also be interesting to know if, in these cells, FGF-2 signal trough FGFR1 
only or can use other receptors (i.e. FGFR3 and FGFR4). 
Based on what was observed in the SCLC cells (Pardo et al., 2002; Pardo et al., 2006) 
we hypothesise that the proteins B-RAF, PKCε and S6K2 and their interaction are 
required for the upregulation of anti-apoptotic proteins, and are thus also relevant for 
chemoresistance in the U2OS cells line. Importantly, we will need to clarify if B-RAF, 
PKCε and S6K2 are in the same complex formed upon FGF-2 stimulation in U2OS cells as 
was observed in SCLC (Pardo et al., 2006). The use of siRNA against these proteins and 
the expression of mutant proteins will be used in the future to confirm these assumptions. 
The activation of B-RAF, PKCε and S6K2 in response to FGF-2 will also be 
investigated in U2OS cells. Western blot analysis using antibodies that recognise specific 
phosphorylated sites will be used to determine the activation of these proteins in response 
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to FGF-2. Since these proteins are kinases it is likely that one, or more, may phosphorylate 
other components of the complex and that their interaction is a requirement for their 
activation. We will investigate this using specific inhibitors, in vitro kinase assays, 
immunoprecipitations and co-immunoprecipitations. These experiments will likely help 
to understand the complex’s dynamics, and to establish and identify crucial steps in the 
pathway.  
We observed an increase of S6K2 protein upon stimulation with FGF-2 for a short 
period of time (ten minutes). Accordingly, it is unlikely that this increase is due to de novo 
protein synthesis. Because S6K protein levels can be regulated by ubiquitination (Wang et 
al., 2008), we will investigate if the S6K2 degradation rate is decreased in response to FGF-
2, for example, by Western blot analysis using antibodies that recognise ubiquitin 
residues. This very interesting, and potentially important, observation has not been 
reported yet and will be further pursued. We could also perform pulse chase experiments 
to assess how the absence or presence of FGF-2 treatment alters the protein half-life of 
S6K2. 
Here, we observed that in U2OS cells FGF-2 induced the upregulation of anti-
apoptotic proteins (MCL-1, BCL-2, BCL-XL and XIAP). Using Western blotting, we 
detected approximately a 1.5-fold increase in these proteins in response to FGF-2. We will 
repeat these experiments and extract proteins with a more stringent buffer that may allow 
a better extraction of BCL-2 family members, which are predominantly associated with 
the mitochondria membrane (e.g. Breckenridge and Xue, 2004). We will also confirm that 
these proteins are involved in the chemoresistance provided by FGF-2 using siRNA 
against these molecules. We will try as well to inhibit their upregulation by inhibiting 
protein synthesis (using cycloheximide) and observing if this impairs FGF-2-mediated 
rescue from cisplatin-induced cell death.  
The upregulation of anti-apoptotic proteins in response to FGF-2 reported in SCLC 
H-510 cells was shown to be via a translation mechanism (Pardo et al., 2002; Pardo et al., 
2003). We will investigate how FGF-2 induces the upregulation of these anti-apoptotic 
proteins in U2OS. Using real-time PCR we will assess if treatment with FGF-2 induces an 
increase in mRNA transcripts coding for MCL-1, BCL-2, BCL-XL and XIAP. Pulse-chase 
experiments will be conducted to ascertain if the increase in protein levels results from de 
novo protein synthesis or as a consequence of an increase in the proteins’ half-lives.  
Under the conditions used here, FGF-2 did not rescue the NSCLC cell lines HCC95 
and HCC78 from cisplatin-mediated cell death. Rescue experiments will be performed on 
additional NSCLC cell lines. These experiments will be crucial to establish if FGF-2 is able 
to also mediate chemoprotection in this type of lung cancer cells. 
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This work provides the first direct evidence for the involvement and requirement 
of JAKs in FGF-2-mediated chemoresistance. These proteins were previously associated 
with tumourigenesis in MPDs by virtue of mutations which affect JAK kinase activity 
(reviewed by Verma et al., 2003). Here, we have established that they also regulate drug 
resistance in tumour cells. We have access to a number of cell lines deficient in JAK1, 
JAK2 or TYK2 (both human and murine) and to matched cell lines complemented with 
wild type JAKs, or kinase-dead JAKs. These will be utilised in the future to confirm the 
results obtained using siRNA and further delineate the requirement of JAKs.  
Inhibition of JAK2 activity with an inhibitor of its autophosphorylation (Sandberg 
et al., 2005) also blocked FGF-2-mediated chemoresistance. Studies with additional JAK 
inhibitors will be useful to confirm the results obtained with the JAK2 inhibitor II and to 
establish whether the activity of other JAK family members is also required for this 
process. The use of these inhibitors will be important to understand the requirement of 
JAK1 and TYK2 activity for FGF-2-mediated chemoresistance mechanism(s). 
A more thorough investigation will be needed to understand the precise molecular 
mechanism of action of JAKs downstream of FGF-2. In response to FGF-2, TYK2 and 
possibly JAK1 and JAK2 become phosphorylated (albeit more weakly than what is 
typically observed for the IFNs and other cytokines), a fact which is entirely consistent 
with a role in FGF-2 signalling. We will confirm the preliminary results regarding JAK1 
and JAK2 in U2OS by immunoprecipitation using larger amounts of protein extracts. The 
possible interaction of JAKs with FGF-2 canonical receptors should also be investigated. 
In particular, it should be determined if JAKs are recruited to FGF receptors and/or are 
required for the stability, or expression of these molecules [as seen, for example for TYK2 
and IFNAR1 (Ragimbeau et al., 2003)]. Co-immunoprecipitation assays will be conducted 
to investigate if JAKs bind to FGFRs. The use of in vitro kinase assays would be useful to 
firmly establish that FGF-2 not only leads to JAK phosphorylation/activation.  
Preliminary data obtained here suggested that JAK1 and TYK2 were required for 
the interaction between B-RAF and PKCε (but not the interaction of S6K2 with B-RAF or 
PKCε) in response to FGF-2 in U2OS cells. These experiments need to be repeated so that 
the effects can be quantified and statistical significance established. In addition, the 
requirement for JAK enzymatic activity in the formation of B-RAF/ PKCε/ S6K2 
complex(es) will be investigated using specific JAK inhibitors.  
We showed that JAK1, JAK2 and TYK2 interacted with B-RAF and PKCε upon 
FGF-2 stimulation. It remains to be established if they also interact with S6K2. Co-
immunoprecipitation using a higher concentration of cell lysate may allow the detection 
of co-immunoprecipitated proteins. Because JAKs are tyrosine kinases it is unlikely that 
  218 
GENERAL DISCUSSION 
they catalyse the phosphorylation of B-RAF, PKCε or S6K2 (Levy and Darnell, 2004; 
Yamaoka et al., 2004) as these three proteins become activated upon phosphorylation of 
threonine and serine residues (Parekh et al., 1999; Zhang and Guan, 2000; Minami et al., 
2001; Cenni et al., 2002; Phin et al., 2003). Many scenarios can be proposed to interpret the 
interaction between these proteins. It is possible that these interactions are a requirement 
for the activation and/or function of these molecules, their intracellular localisation or 
interaction with the translation machinery. It is also plausible that JAKs may function as 
chaperone proteins required for bringing at least B-RAF and PKCε together. It will be 
crucial to determine if B-RAF, PKCε and S6K2 become phosphorylated upon FGF-2 
stimulation and if the knockdown of JAKs impairs these molecular events. Clearly, it 
remains central to determine if JAKs bind to S6K2, if they have compensatory roles, or if 
they have specific functions. The fact that the kinetics of recruitment were not identical for 
all the JAKs suggests a complex interplay between these molecules. This will be 
addressed in greater detail in future studies. 
We established that MCL-1 upregulation in response to FGF-2 required TYK2 and 
it would, therefore, be extremely interesting to establish if the upregulation of other anti-
apoptotic proteins by FGF-2 are also affected by the absence of JAK1, JAK2 or TYK2. It 
remains a possibility that JAKs are modulators that are only required for the expression of 
a subset of target molecules. 
The role for JAK3, another JAK family member, in FGF-2-mediated 
chemoresistance has not been studied yet. This JAK family member was found to be 
deregulated in several lymphoproliferative disorders (Gee et al., 2001; Yared et al., 2005; 
Lai et al., 2005; Tomita et al., 2006; Krejsgaard et al., 2006; Walters et al., 2006; Marzec et al., 
2008) and to contribute to the oncogenesis of other types of cells, such as colon cancer (Lin 
et al., 2005) and breast cancer (Kim et al., 2009). Therefore, we will investigate if the 
osteosarcoma cell line U2OS expresses JAK3 and if so, if this kinase also participates in 
FGF-2-mediated chemoresistance. 
We observed that STAT1, STAT3 and STAT5 were not required for FGF-2-
mediated chemoresistance in U2OS cells. We choose to investigate these particular STAT 
family members because they are the most commonly deregulated STATs in many cancer 
types (Yu and Jove, 2004), making them prime candidates for playing a role in 
chemoresistance. Although STAT2, STAT4 and STAT6 do not seem to have such a 
prominent role in cancer biology, one cannot exclude their involvement in FGF-2-induced 
chemoresistance. Accordingly, the requirement of STAT2, STAT4 and STAT6 for the FGF-
2-mediated chemoresistance will be investigated in the future. 
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The involvement of other pathways in FGF-2-mediated chemoresistance in U2OS 
cells will be determined. Accordingly, specific chemical inhibitors will be used in this 
context. Since JAKs and SRC family kinases (SFK) can work together to activate many 
signalling molecules (Ingley and Klinken, 2006), the study of SRC within this context 
remains an obvious possibility and it may contribute to further understanding of the 
mechanism by which JAKs participate in FGF-2-induced chemoresistance.  
It would be interesting to determine if JAKs are required for FGF-2-mediated 
chemoresistance in SCLC cell lines, where this phenomenon was initially described. This 
will be carried out using JAK inhibitors prior to the “rescue experiment” as these cells are 
particularly difficult to transfect with siRNA (Michael Seckl and Olivier Pardo, personal 
communication). In addition, understanding why FGF-2 was not able to protect the 
NSCLC HCC95 and HCC78 cell lines from cisplatin-mediated killing will likely provide 
information regarding functional molecules and/or signalling pathways that are required 
for FGF-2-induced chemoresistance. Based on our data, we hypothesise that the JAKs may 
be the ‘missing link’ in these cells and this is something that should be investigated in the 
future.  
Importantly, our work has also unravelled novel roles for ERK2 and ERK1, which 
appear non-redundant. These proteins have been extensively associated with several 
oncogenic pathways and are almost universally recognised as potent mitogens. During 
the course of this work we have found that ERK2 regulates the expression of STAT3 and 
gp130. These molecules are important players not only in cancer-related pathways, but 
are also vital players in cytokine responses. Although these results were made possible by 
the advent of RNAi we are confident that they reflect bona fide molecular requirements, as 
we have used several different siRNA molecules and have also observed these 
phenomena in other cell lines.  
Currently, there is another PhD student in the Costa-Pereira group already 
investigating how ERK2 regulates STAT3 and gp130 protein levels. ERK2 can be i) a 
regulator of the their transcription, ii) a modulator of mRNA translation of these proteins, 
or iii) a molecule required for the stabilisation and protection from protein degradation 
and/or cleavage. Real-time PCR will be used to verify if STAT3 and gp130 transcripts are 
also reduced in cells transfected with siRNA against ERK2. If they are, then it will be 
investigated if ERK2 binds to the promoters of these proteins using chromatin IP (ChIP). 
If ERK2 does not regulate the expression of STAT3 and/or gp130 genes, it will 
investigated if ERK2 is required for the translation of these proteins. Pulse-chase 
experiments will be conducted to ascertain if the translation of these proteins is affected 
by the siRNA. Additionally, polysome analysis can be conducted to ascertain if decreased 
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levels of ERK2 lead to a decrease in ribosomal binding to mRNA molecules. If none of 
these processes is being controlled by ERK2, it will be assessed if the decrease in ERK2 is 
causing a decrease in the proteins’ half-lives. Proteasomal degradation will be blocked 
using proteosomal inhibitors such as MG132 and protein ubiquitination using antibodies 
that recognise ubiquitin modifications. In addition, also it will be interesting to investigate 
if STAT3 is cleaved by caspases and if so, if ERK2 is involved in the inhibition of caspases, 
such as caspase-9 and -3 as previously reported (Allan et al., 2003). For this purpose, 
caspase inhibitors will be used. 
Since inhibition of ERK kinase activity did not impact on STAT3 levels, it seems 
likely that ERK2 may have a non-enzymatic role as yet unidentified. These observations 
could be further investigated by transfecting cells with plasmids containing inactive 
ERK2, as well as plasmids containing wild type ERK2. Inactive and wild type ERK1-
palsmids could be used as controls. The prediction is that the transfection of cells with 
plasmids containing dominant forms of inactive ERK2 will not affect STAT3 protein 
levels. A connection between the decrease of STAT3 and gp130 will also be investigated in 
the future. Indeed, it remains to be established if ERK2 modulates STAT3 and gp130 
levels by the same mechanism. siRNA could be used to determine if the knockdown of 
one protein affects the expression of the other. 
In contrast, we have observed that inhibition of ERK1 led to modification of gp130 
(as assessed by Western blotting) but did not affect STAT3 levels. The data are consistent 
with ERK1 being required for the processing of gp130 and, presumably, for its transport 
from the Golgi to the plasma membrane. If our hypothesis is correct, then experiments 
using endoglycosidase H will confirm that the 150 kDa band detected in untransfected 
cells corresponded to the glycosilated form of gp130 and the 130 kDa band detected in 
siERK1-transfected cells corresponded to the unprocessed form. It will be critical to 
investigate if, in the absence of ERK1, the gp130 receptor is functional. For that purpose, 
cells could be transfected with siRNA against ERK1, treated with IL-6 or OSM, and 
phosphorylation of STAT3 and STAT1 detected by Western blotting. In addition, 
detection of gp130 by immunofluorescence would help clarify if the knockdown of ERK1 
affected the cellular localisation of the receptor.  
Taken together, these data not only demonstrate that ERK1 and ERK2 have 
cellular non-redundant roles but also that, as amply recognised, they cross-talk with many 
other important signalling pathways. Our results emphasise the importance of thoroughly 
understanding differential functions of ERK1 and ERK2, which are likely to impact on the 
design of targeted therapies for cancer. 
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In conclusion, our findings highlight the importance of JAKs in chemoresistance 
and contribute to the further understanding of the regulation of STAT3 and gp130. These 
molecules are all essential mediators of cytokine responses and are thus vital for the 
appropriate maintenance of fundamental biological processes that include immune and 
acute phase responses. The ‘JAK/STAT field’ was born just over 10 years ago. Since then, 
many more functions have been attributed to JAKs and STATs and it is now clear that 
they also play key roles in cancer biology. The proposed future directions aim to expand 
our understanding of such molecular processes: much remains to be done, many 
questions remain to be answered but the proposed work will likely provide new 
promising perspectives for the development of more effective cancer therapies. 
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ABBREVIATIONS 
 
  
 
 
 ‘ Minutes 
µg Microgram 
µl Microliter 
µM Micromole 
AIDS Acquired immune deficiency syndrome 
ALL Acute lymphoblastic leukemia 
AMKL Acute megakaryoblastic leukemia 
AML Acute myeloid leukemia 
AP2 Adaptor protein-2 
APAF-1 Apoptotic protease activating factor-1 
APS Ammonium persulphate 
ASK1 Apoptosis signal-regulating kinase 1 
ATM Ataxia Talangiectasia-Mutated 
ATP Adenosine tri-phosphate 
BAD BCL2-associated agonist of cell death 
BAK BCL2-antagonist/killer 
BAX BCL2-associated X protein 
BCL-2 B-cell leukaemia/lymphoma-2 
BCL-XL BCL-2-like 1 protein 
BCR Breakpoint cluster region 
BH BCL-2 homology domains 
BIK BCL2-interacting killer 
BMVECs Brain microvascular endothelial cells 
BrdU 5-bromo-2’-deoxyuridine 
BSA Bovine serum albumin 
CamKII Calcium/calmodulin kinase II 
Caspases Cysteinyl-aspartic acid proteases 
CBP CREB-binding protein 
ChIP Chromatin IP 
CI Clathrin-independent 
cIAP-1 Cellular inhibitor of apoptosis 1 
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APPENDIX I – COMPARISON BETWEEN THE WST-1 ASSAY AND CELL COUNTING 
 
 
The results obtained with the cell viability assay WST-1 used in this work in some 
experiments were compared with the ones obtained using cell counting (cf. Material and 
methods). The results obtained with these two methods were identical (Fig. 50). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50. Results obtained with the cell viability assay WST-1 are identical to the results 
obtained with cell counting. Cells were plated in 96-well plates (3,000 cells per well) or in 6-well plates 
(2x105 cells per well), incubated overnight in serum-free media and then treated with FGF-2 (10 ng/ml) (A.) or 
with the LD50 of cisplatin (B.) for 24 hours. Cell viability was measured using the WST-1 cell viability assay 
(graphs on the left panel). Values correspond to the OD of coloured formazan compounds derived from 
cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases. Cell number was determined by 
cell counting using trypan blue exclusion (graphs on the right panel). Mean ± SEM from three independent 
experiments are shown in graphs. Values are expressed as fold change over untreated controls. Statistical 
analysis was performed using Student’s t-test (*** – p<0.005 versus untreated control). 
A. 
 
B. 
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APPENDIX II – CISPLATIN BATCH-TO-BATCH VARIATION  
 
 
The titration of the batch of cisplatin used in the first part of this work is shown in 
Figure 19 (Section 4.1.5). The second part of this study was done in U2OS cells with a new 
batch of cisplatin. The LD50 in U2OS using the new batch was approximately 60 µM for 
this cell line (p<0.005) (Fig. 51). Denis Akan performed these experiments. 60 µM of 
cisplatin was therefore used routinely to perform the rescue experiment in U2OS cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51. Cisplatin-induced cell death in U2OS cells. Cells were plated in 96-well plates (3,000 
cells/well) and incubated in serum-free media overnight. Cells were treated with increasing doses of cisplatin 
for 24 hours. Cell viability was measured using the WST-1 cell viability assay. A. Results from one experiment 
are presented as fold induction relative to untreated controls. Each condition was set up in triplicate, and the 
results are shown as mean ± standard deviation. B. Mean ± SEM of three independent experiments performed 
in triplicate are shown in a graph. Values correspond to the OD of coloured formazan compounds derived 
from cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases. Values are expressed as fold 
change relative to untransfected controls. Statistical analysis was performed with Student’s t-test (*** – 
p<0.005 versus untreated control). (I am indebted to Denis Akan for these data). 
B.  
A.  
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APPENDIX III – CELL CYCLE DATA ANALYSIS  
 
 
The DNA content of cells was measured by flow cytometry after staining cells with 
PI, a DNA-binding dye. Data mining and analysis was done using FlowJo (Tree Star Inc., 
Oregon, USA). Gates were used to exclude cell doublets and cell fragments from the 
analysis. The gating used was hierarchical (gate 3 is contained within gate 2 and gate 2 is 
contained within gate 1) (Fig. 52).  
The values of PE (phycoerythrin) are the values measured by the red channel and 
correspond to the amount of PI (proportional to the DNA content) inside the cells. By 
plotting a graph with PE-A (pulse area) versus PE-H (pulse height) and drawing a gate 
(gate 1) that included the cells with PE-A proportional to PE-H, we excluded the doublet 
cells (Fig. 52 A). The number of events recorded during the acquirement was 10000 within 
gate 1. To further exclude potential doublet cells we drew a second gate within gate 1. For 
that purpose we plotted a graph with forward scatter-area (FSC-A), a measurement 
related to cell size versus side scatter-width (SSC-W), a measurement related to the 
granularity of the cells (Fig. 52 B). A third gate within gate 2 was drawn to exclude cell 
fragments. This was achieved by plotting a graph with FSC-A versus SSC-A (Fig. 52 C). 
Gate 3 comprises all cells contained within gate 1 and 2 to include all sizing variables 
except small fragments. The histogram was obtained with cells within gate 3 and shows a 
typical cell cycle profile (Fig. 52 D). Figure 52 E shows the single cells that were used in 
the analysis (blue dots) and the ungated population that was excluded (black dots).  
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Figure 52. Flow cytometric cell cycle analysis. Cells were harvested, fixed and permeabilised with 70% 
ethanol and stained with propidium iodide (PI), a DNA-binding dye. DNA content was measured by flow 
cytometric analysis using a FACSCanto and results were analysed using FlowJo software. Hierarchical gating 
was done to exclude doublets and cell fragments from the analysis. A. Gate 1 selects single cells. The number 
of events recorded was 10000 within this gate. B. Gate 2, contained within gate 1, was drawn to exclude any 
potential doublet cells not excluded from the analysis using gate 1. C. Gate 3, contained within gate 2, was 
drawn to exclude cell fragments (debris). D. Cell cycle profile of the cell population within gate 3. G1 
corresponds to the first phase after mitosis when cells have 2n DNA content. In S phase, cells synthesise DNA. 
In G2/M phase cells are ready to complete division and have the double of DNA content of a cell in G1. The 
Sub-G1 population corresponds to the percentage of cells with a DNA content of less than 2n and represents 
cells with fragmented DNA. E. Graph showing gated (blue dots) and ungated (black dots) events. PE – 
phycoerythrin, A – area, H – height, FSC – forward scatter, SSC – side scatter W – width. Numbers correspond to 
the percentage of cells within each gate. 
A. 
 
B. 
 
C. 
 
D. 
 
E. 
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APPENDIX IV – FGF-2-MEDIATED RESCUE IN H-510 CELLS 
 
 
In this work, the FGF-2-mediated rescue experiment was also done in SCLC cells, 
where the phenomenon was initially described (Pardo et al., 2002). The purpose of these 
experiments was to reproduce the rescue previously observed ensuring that the 
experimental settings were properly conducted and to ascertain that the results obtained 
with additional cell lines were bona fide. 
H-510 cells were treated using the conditions described by Pardo and colleagues 
(2002). Cells were starved in RPMI-1640 medium supplemented with insulin, transferrin, 
sodium selenite, BSA, penicillin and streptomycin for 3 days. Cells were then aliquoted at 
a density of 5x104 cell/ml (1 ml per aliquot) in serum-free RPMI. After 1 hour of 
incubation in serum-free media, cells were pre-treated with 0.1 ng/ml of FGF-2 for four 
hours and treated with etoposide for 96 hours. Cells were harvested, fixed and 
permeabilised with 70% ethanol and stained with PI. DNA content was measured by flow 
cytometry and cell cycle analysis. We observed an increase of the sub-G1 peak after 
treatment with etoposide, which was substantially reduced following pre-incubation with 
FGF-2. This reduction of the sub-G1 population indicates a reduction in cell death induced 
by etoposide (Fig. 53 A). After 96 hours of drug treatment proteins were extracted from 
cells, run on a SDS-PAGE gel and analysed by Western blot. Lamin B cleavage was 
assessed. In H-510 cells, etoposide induced the cleavage of lamin B, which can be seen by 
the increase on the lower band (45 kDa) and preincubation with FGF-2 reduced this effect 
(Fig. 53 B). These results indicate that, as previously shown (Pardo et al., 2002), FGF-2 
protected H-510 cells from etoposide-mediated cell death. 
In parallel with the rescue experiments performed, phosphorylation of ERK1/2 in 
response to FGF-2 was monitored in order to confirm the functionality of FGF-2 (Fig. 53 
C). Proteins extracted from cells treated with 0.1 ng/ml of FGF-2 for 5 minutes (as 
indicated in Pardo et al., 2002) were run on a 7.5% SDS-PAGE gel extracted and analysed 
by Western blot. Membranes were probed with an antibody against phosphorylated 
ERK1/2 and upon stripping of the antibody the membrane was re-probed with an 
ERK1/2 antibody which detects total levels of these proteins. β-actin was also probed and 
used as a loading control. We observed that FGF-2 induced the activation of ERK1/2 in H-
510 cells, clearly demonstrating that the FGF-2 used in the rescue experiment was active. 
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Figure 53. FGF-2 reduced etoposide-induced cell death in H-510 cells. H-510 cells were starved for 
three days and incubated in serum-free media for one hour. A. After 4 hours pre-treatment with 0.1 ng/ml of 
FGF-2, cells were treated with 1 µM of etoposide for 96 hours. Subsequently, cells were harvested, fixed, 
permeabilised and stained with PI (50 µg/ml). Cell death was assessed by flow cytometric analysis using a 
FACSCanto and the results were analysed using FlowJo software. Cell cycle profiles from one experiment are 
shown. Numbers refer to the percentage of dead cells represented within the sub-G1 population. These results 
are representative of two independent experiments. B. After 4 hours pre-treatment with 0.1 ng/ml of FGF-2, 
cells were treated with increasing doses of etoposide for 96 hours. Subsequently, cells were harvested; proteins 
were extracted and separated on a 7.5% SDS-PAGE gel. Western blotting analysis was performed using total cell 
lysates and antibodies against lamin B. β-actin was used as a loading control. This experiment was performed 
once. C. Cells were stimulated with 0.1 ng/ml of FGF-2 for 5 minutes and proteins were extracted and separated 
on a 10% SDS-PAGE gel. Western blotting analysis was performed on total cell lysates using antibodies against 
pERK1/2-Thr202/Tyr204 and total ERK1/2. β-actin was used as a loading control. These results are representative 
of two independent experiments. 
A.  
B.  
C.  
